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THE HOLISTIC ASSESSMENT AND CARE PLANNING IN PARTNERSHIP 
(HAPPI) STUDY  
HELEN LYNDON 
Aim 
This mixed-methods feasibility study aimed to identify and to develop consensus on 
the components of a holistic assessment and care planning intervention for frail older 
people in primary care and to conduct a feasibility cluster randomised, controlled trial 
with an embedded qualitative study to assess potential trial methods for a definitive 
trial. 
Background 
Frailty is a serious but not inevitable consequence of ageing that can be managed as 
a long-tern condition. Frail older people are more at risk to adverse health outcomes 
than the non-frail, yet many do not receive evidence based management including a 
comprehensive geriatric assessment (CGA); a holistic assessment and care planning 
approach. This is because the impact of CGA is well evidenced in a hospital setting, 
but less so with community-dwelling frail older people who receive the majority of their 
healthcare and support in primary care. It is not clear if this approach can be 
successfully delivered in primary care and whether a holistic assessment and care 






Firstly, a patient and public involvement consultation informed the design of this mixed-
methods feasibility study. Then a three-round e-Delphi study was carried out to gain 
consensus on the content of the intervention. A multi-site, feasibility, cluster 
randomised controlled trial (fRCT) with embedded qualitative study was conducted. 
Findings 
The e-Delphi survey provided consensus on the important and feasible components of 
the intervention. This was then further refined by research stakeholders to produce the 
Holistic Assessment and care Planning Intervention (HAPPI) assessment pack to be 
used in the fRCT. The fRCT demonstrated that it was possible to conduct a randomised 
controlled trial of the intervention in primary care, all feasibility criteria relating to 
recruitment and retention were achieved, outcome measures evaluated, and 
recommendations made for a definitive trial. The qualitative study determined that the 
intervention was acceptable to participants and judged as feasible to deliver by the 
nurses. Trial processes and procedures were feasible with some changes.  
Conclusions  
The study adds new knowledge having developed a nurse-led intervention for older 
people with frailty that can be delivered in primary care. It has demonstrated that the 
intervention is feasible and provided information to inform the conduct of the definitive 
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Chapter 1: Introduction 
1.1 Thesis Aim  
Frailty is a clinical syndrome associated with older age, which features deterioration 
across multiple body systems and is accompanied by increased vulnerability to 
adverse health outcomes (Clegg et al., 2013). Frailty can be a devastating 
consequence of ageing, with older people who live with frailty experiencing higher 
death rates, hospitalisations, falls, and care home admissions than the non-frail, with 
poorer quality of life and more loneliness (Kojima et al., 2016). This thesis reports the 
development of a nurse-led assessment and care planning intervention for 
community-dwelling frail older people and evaluates the feasibility of conducting a 
randomised controlled trial (RCT) of the implementation of this intervention in primary 
care. 
To meet the challenges of a growing older population with a high prevalence of frailty, 
proactive, holistic, person-centred primary and community-based care is needed, and 
yet there is no accepted model or ideal intervention in these settings (Gardner et al., 
2017). Community-based frailty interventions should be clinically rigorous and time-
effective and include appropriate screening methods, which enable resources to be 
targeted at patients who will benefit most (Fougere et al., 2017).The content of this 
thesis adds to the existing evidence and addresses the methodological limitations of 
current research into complex interventions for older people who live with frailty.  
1.2 Structure of the Thesis 
This thesis presents the research journey from the initial co-production of the study 
and design of the intervention, the conduct of the mixed-methods feasibility study, 
through to conclusions and implications of this work. Chapter one sets the context for 
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the research with the background, literature review and significance of this work. 
Chapter two describes the co-production of the Holistic Assessment and care Planning 
in Partnership Intervention study (HAPPI), including the patient and public involvement 
(PPI) consultation, which informed the study design. Chapter three outlines the study 
methodology and theoretical paradigm that underpinned the research. The 
development of the HAPPI intervention, by means of an e-Delphi survey and research 
stakeholder consultation, is reported in chapter four. Chapter five details the methods 
of the feasibility randomised controlled trial (fRCT) with its embedded qualitative study. 
The results of the fRCT are reported in chapter six and the qualitative study findings in 
chapter seven; results are split into two chapters for ease of reading. Study results are 
discussed in chapter eight and chapter nine presents overall conclusions and 
recommendations for future practice and research.  
In addition to illustrating the research process, the thesis captures the author’s 
personal journey as an early career researcher and progression through a National 
Institute for Health Research (NIHR) career pathway. This began with a clinical 
academic internship, where the topic of frailty was extensively researched and the 
study objectives formulated. Broad patient and public involvement activity then led to 
the design of the study, and progressed to the Clinical Doctoral Research Fellowship, 
during which the study was conducted, leading to completion of the PhD. This is 




Figure 1.1: The research journey 
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1.3  Background: our ageing society and living with frailty 
The UK population is ageing and, whilst this is undoubtedly a success for improved 
public health and welfare leading to longer life expectancy, it brings with it the challenge 
of meeting the health and social care needs of higher numbers of older people. Figures 
published by the Office for National Statistics in 2018 predict that, by 2066, there will 
be an additional 8.6 million UK residents aged sixty-five years and over, taking the total 
number in this group to 20.4 million or 26% of the population (Office for National 
Statistics, 2018a). Numbers of people aged eighty-five years and over are rising most 
rapidly. In mid-2016, there were 1.6 million people in this age group (2% of the total 
population) however, by mid-2041, this is expected to double to 3.2 million (4% of the 
population). Numbers are due to treble by 2066, to 5.1 million people, comprising 7% 
of the total UK population. In contrast, the population aged sixteen to sixty-four years 
is predicted to grow by just 2% over the next twenty-five years, leaving a significant 
gap between those contributing to pension and national insurance costs and the 
numbers of people who will require support from these funds. 
Remaining life expectancy at aged sixty-five is currently eighteen years for men and 
twenty-one years for women. However, on average, we can expect to experience 
about ten years of diminished quality of life at the end of life, due predominantly to 
limiting disability and illness (Mortimer, 2015). Much of this disability and loss of 
function can be attributed to the development of frailty. In 2019, the UK Government 
launched its “Grand Challenge for Ageing” with a goal of enabling its population to 
experience at least five extra healthy, independent years of life by 2035 by helping 
people to remain independent and addressing risk factors for adverse events such as 
social isolation (UK Government, 2019). Funding has been allocated and projects 
commenced in some areas of the UK, but the impact is yet to be determined. If 
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initiatives such as these are not successful, it is possible that prolonged life expectancy 
of frail adults may result in expanded morbidity and disability and resultant decreases 
in healthy life expectancy (Kingston et al., 2018). Therefore, frailty is an important 
public health issue for society, both now and in the future.  
The term frailty has long been accepted in daily language, 2500 years ago, Buddha 
contemplated “How easily the wind overturns a frail tree” (Byrom, 2012, p.3). Recently, 
a UK geriatrician likened frailty to a paper boat; brightly painted and sailing happily on 
still waters, but one that will quickly sink without trace once the rain starts and the wind 
gets up (Cantley, 2018). Nonetheless, it is only in the last 40 years that frailty has 
become a recognised disorder in the field of research and more recently accepted as 
a treatable syndrome in clinical practice (Sieber, 2017). Frailty was first described in 
research literature in the 1970s as “failure to thrive” (Hodkinson, 1973, p.94) and 
throughout four decades of research, definitions have been evolving. Frailty does not 
yet have an internationally recognised standardised definition (Dent, Kowal & 
Hoogendijk, 2016), however, most definitions focus on frailty as an age-related clinical 
syndrome associated with loss of resilience:  
“A multidimensional syndrome of loss of reserves (energy, physical ability, cognition, 
health) that gives rise to vulnerability.” (Rockwood et al., 2005, p.489) 
 
Frailty is associated with a multitude of adverse outcomes such as debility, falls, 
fractures, loneliness, poor quality of life, depression, cognitive decline, hospitalisation, 
loss of independence and care home admission (Hoogendijk et al., 2019). These poor 
outcomes are costly to older individuals and to the health and social care system. In 
order to minimise cost and meet the needs and preferences of older people, there has 
been a policy move towards “ageing in place” (World Health Organization, 2015, p.36). 
This concept proposes that older people, irrespective of age, income and level of 
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disability should be supported to live safely, independently and comfortably at home if 
this is their preference. Not only is this viewed as the preferred option for individuals, 
it is thought to reduce health care expenditure (Beard et al., 2016). This ethos has 
been adopted by the UK and other countries with policies and clinical practice aimed 
at providing frailty care away from hospitals and closer to people’s homes (Imison et 
al., 2017). However, it is not yet clear how this move from hospital-based, specialist 
care to generalist services delivered in low-intensity settings can be achieved, what 
the care models should encompass and which clinicians are skilled to lead and provide 
care (Hoogendijk et al., 2019). 
1.4 Current evidence 
The following sections set the context for the remainder of this thesis, and highlight the 
current lack of evidence for nurse-led management of frailty in older people within 
primary care in the UK.  Firstly, the impact of frailty is presented and secondly, its 
pathophysiology is explored. Thirdly, the established and emerging models of frailty 
are introduced and fourthly, the management of frailty is discussed. Finally, frailty 
management in primary care is presented with a focus on the role of nurses working 
in partnership with frail older people.  
1.4.1 The Impact of Frailty. 
As individuals age, their mortality risk escalates, according to Gompertz’s law 
(Gompertz, 1825). However, people do not die of old age, rather they amass a variety 
of age-related conditions and so become increasingly susceptible to dying from various 
internal and external stressors. Ageing is normal in all species and is characterised by 
catabolism, degeneration and functional loss in body organs leading to progressive 
reliance on reserves to maintain homeostasis (Sieber, 2017). Physiological changes 
of ageing are exacerbated by co-existing disease and deterioration is progressive but 
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heterogeneous with a variable rate of decline (Navaratnarajah & Jackson, 2017). This 
means that individuals age differently, but generally, in older age, impaired physical 
and mental function leads to limitations in activities of daily living and ultimately loss of 
independence.  
Ageing, accompanied by a loss of physiological resilience, manifests as the clinical 
syndrome of frailty (Clegg et al., 2013). Accurate estimates of global frailty prevalence 
are not available. The majority of frailty research has been conducted in higher-income 
countries, with a paucity of research in poorer countries and a variety of definitions of 
frailty used (Hoogendijk et al., 2019). This means there are no globally accurate 
prevalence figures. However, one systematic review combined findings from 61,500 
older participants (minimum age sixty-five and no maximum age) and found a weighted 
average estimate of 11% for frailty, but noted a variation of between 4% and 59% 
across studies (Collard et al., 2012).  In England, overall prevalence of frailty is 14%, 
6.5% in those aged 60-69 years and rising to 65% in those aged 90 years and above 
(Gale, Cooper & Aihie Sayer, 2015).  
Over decades, ill health has been reducing in older age, mainly because of healthcare 
quality improvement and health behaviour change (Cutler, 2001), however, this trend 
is changing (Martin et al., 2010).  Higher-income countries are now experiencing an 
increase in early disability among mid-adulthood (ages fifty to sixty-four) due to lifestyle 
factors and the earlier development of long-term conditions such as ischaemic heart 
disease and diabetes. This situation raises an important economic challenge. This 
cohort of new older people with moderate to severe functional limitation is expected to 
live for a longer period of time and consume proportionally larger amounts of 
healthcare resource. Consequently, there is a policy drive to develop new models of 
care, usually in non-acute settings, aimed at meeting the needs of this population at 
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lower cost to ensure that sufficient funds are available to provide services for the larger 
numbers of people who will be living with frailty (Beard et al., 2016). 
In high-income populations, numbers of frail people are expected to rise as life 
expectancy continues to increase in these countries (Kingston et al., 2018). Studies 
show increased healthcare expenditure for older people with higher levels of frailty due 
to greater in-patient use including admissions and bed days, post-acute care, and 
outpatient care (Ensrud et al., 2018; García-Nogueras et al., 2017; Sirven & Rapp, 
2017). A recent UK study calculated the extra annual cost to the healthcare system 
associated with frailty (Han et al., 2019) as £561.05 per person for mild frailty, 
£1,208.60 for moderate frailty and £2,108.20 for severe frailty. This equates to a total 
additional cost of £5.8 billion per year across the UK.  Thus, despite frailty having a 
negative impact on longevity and quality of life for individuals and it’s cost to society as 
a whole, it remains a poorly managed clinical syndrome (Harrison et al., 2015).  
Harrison et al (2015) called for frailty to be conceptualised as a long-term condition to 
promote earlier identification, prevention and effective management, however, robust 
clinical knowledge of the pathophysiology of the syndrome is lacking, leading to 
ongoing debate about its management in different healthcare sectors. 
1.4.2  The Pathophysiology of Frailty 
Frailty is thought to result from cumulative cellular damage over the life course (Cesari, 
Vellas & Gambassi, 2013; Rockwood & Mitnitski, 2007). Although its specific 
pathophysiology is not fully understood, it is known to follow similar mechanisms to 
sarcopenia (muscle weakness) (Jeejeebhoy, 2012) and malnutrition (Cesari et al., 
2014b) accompanied by de-regulation of inflammatory processes (Li, Manwani & Leng, 
2011). Frailty is not natural ageing; rather it develops when multiple body systems fail. 
As individuals age, the more systems that fail, the more likely it is that the person will 
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become frail (Clegg et al., 2013; Morley et al., 2013). Recent literature has focussed 
on a continuum of change, from healthy ageing to the development of long-term 
conditions, then to multimorbidity (defined as the presence of two or more long-term 
conditions) and lastly to frailty, predominantly towards the end of life (Franceschi et al., 
2018). In this model, frailty is a “multisystem ageing syndrome”  (Thillainadesan, Scott 
& Le Couteur, 2020, p.758) that represents the later stages of ageing that occur in 
people who have not died of other causes earlier in life.  
As people move along this continuum, there is a loss of physiological reserve in all 
body systems. Normally, there is an intrinsic reserve buffer, thought to be about 30%, 
which enables homeostasis to be maintained and good function preserved. Once this 
threshold is breached, then frailty will result as repair mechanisms can no longer 
maintain homeostasis (Lang, Michel & Zekry, 2009). This leads to loss of resilience, or 
loss of ability to “return to basal state” (Woo, 2019, p.68) when faced with a stressor. 
Clinically, this means that a frail person will not recover in a timely manner compared 
to a non-frail person from a stressor such as minor illness or change to social 
circumstances. Over time, this leads to functional deterioration and loss of 
independence. In addition, pre-frailty can be described as the “silent precursor” (Dent, 
Kowal & Hoogendijk, 2016, p.4), which converts to frailty in seemingly robust 
individuals when certain external factors are present, such as acute illness, injury or 
stress (Clegg et al., 2013). Other independent risk factors for frailty development have 
been identified including loneliness (Gale, Westbury & Cooper, 2018), deprivation 
(Hoogendijk et al., 2014), depression (Vaughan, Corbin & Goveas, 2015), low physical 
activity and polypharmacy (Heuberger, 2011). With its plethora of risk factors affecting 
all body systems, frailty is clearly a multifactorial syndrome that can be challenging to 
address. This has led to the development of several models describing causation and 
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proposing clinical management strategies which will be discussed in the next section 
of this thesis. 
1.4.3 Models of Frailty 
Given its pathophysiology, contributory risk factors for frailty can be clinical, functional, 
behavioural, biological, psychological, emotional and social, consequently, a broad 
range of expertise is needed to identify relevant risks and support the older person to 
manage them (Dent, Kowal & Hoogendijk, 2016). Risk factors are not always obvious 
and older persons, who do not tend to perceive themselves as frail, may not recognise 
or acknowledge the risks (Nicholson, Gordon & Tinker, 2017). Frailty is unpredictable, 
it can fluctuate and there can be sudden deterioration and so the potential to be 
proactive can be lost (Stolz, Mayerl & Freidl, 2019). In order to better comprehend, 
research and clinically manage frailty, several biomedical models have been proposed 
including those that are rules-based using the presence of defined symptoms (Fried et 
al., 2004) or those that total numbers of impairments (Rockwood et al., 2005). These 
biomedical models have dominated the literature of the past forty years, however, 
newer models acknowledge a more holistic approach integrating a broad range of risk 
factors and their management. In recent years, clinical and nonprofessional definitions 
of frailty have diverged, the former focusing on biomedical risks and the latter on the 
social consequences (Morden, Jinks & Ong, 2012; Nicholson, Gordon & Tinker, 2017). 
Both the established and the emerging models will be discussed in sections 1.4.3.1 
and 1.4.3.2. 
1.4.3.1 Established Models 
Two models of frailty have dominated research and clinical (predominantly medical) 
practice; Fried’s phenotype model (Fried et al., 2004) and Rockwood’s cumulative 
deficit model (Rockwood et al., 2005). Both models have been extensively utilised in 
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research studies but were originally developed for different purposes. The phenotype 
model claimed to diagnose frailty whilst the cumulative deficit model calculates frailty 
risk (Cesari et al., 2014a). 
Fried’s phenotype model offers five descriptors: self-reported exhaustion; reduced 
muscle strength; low physical activity; slow walking speed; and unintentional weight 
loss. If a person displays three or more of these symptoms they are considered to be 
frail (Fried et al., 2004). This model can be used in clinical practice during a 
consultation with a patient and is useful for prognostication as it strongly predicts 
adverse outcomes of falls, hospitalisation, disability and death.  Rockwood’s model 
takes a quantitative approach to describing frailty as the accumulated sum of a number 
of problems or deficits; the greater the number of deficits, the higher the probability that 
adverse outcomes are likely (Rockwood et al., 2005). Both models have been criticised 
in that they do not take into account psychological or cognitive domains of frailty (Berrut 
et al., 2013) and consequently do not provide a holistic framework for its management. 
1.4.3.2 Emerging Models  
In acknowledgement of the need for a more holistic approach to frailty management, 
there has been a move towards life-course and assets-based conceptualisations of 
frailty. This change has grown out of evolving research in which older people have 
rejected the term “frailty” as irrelevant or stigmatising based on its focus on the negative 
aspects of ageing (Britain Thinks, 2015). It would appear that people resent the term 
frailty and perceive that it signals a self-perpetuating cycle into decline (Warmoth et al., 
2016). Participants in Warmouth’s study, who objectively met frailty criteria, willingly 
portrayed their health conditions and physical limitations but did not self-identify as 
frail. Other researchers have found that reasons given for limitations and loss of 
independence were often perceived as relating to psychological and social factors 
12 
 
rather than physical conditions (Grenier, 2006). Understanding older peoples’ 
perspectives on frailty is important when delivering an appropriate person-centred 
approach to frailty assessment and management, as using inappropriate terminology 
can provoke an emotional reaction and may lead to older people rejecting services 
(Puts et al., 2017).   
Taking into account older people’s views on using frailty as a diagnostic label, it could 
be argued that taking a wholly biomedical approach has caused clinicians to neglect 
personhood and disregard existing strengths and assets. In this context, assets can 
include the person’s own resources, abilities and capabilities (National Institute for 
Health and Care Excellence, 2019a). Ignoring these assets can miss opportunities for 
health improvement and lead to tension in the person-clinician relationship (Rahman, 
2018). Identifying assets means there is a recognition and inclusion of the full range of 
available resources that can be used to protect individuals against negative health 
outcomes and it takes a more holistic, multidimensional approach to managing these 
outcomes. This concept has been adopted by the World Health Organisation who have 
promoted intrinsic capacity as a quantifiable measure of healthy ageing (World Health 
Organization, 2015) and a composite measure of all physical and mental capabilities 
of an older person (Woo, 2019). The construct of intrinsic capacity moves away from 
the biomedical approach of diagnosing and treating diseases, and towards 
assessment of body functions as a “holistic entity” (Cesari et al., 2018, p.3), supporting 
prevention or managing deterioration, aiming always to preserve function and 
independence. This is more in tune with older people’s perceptions of becoming frail 
in terms of everyday tasks and how it feels if these tasks start to become difficult to 
complete, thus eroding independence and wellbeing (Britain Thinks, 2015). 
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Another conceptualisation of frailty promotes a life course approach (Gill et al., 2006). 
Frailty is viewed as a dynamic trajectory, which progresses and recedes over the life-
course (Trevisan et al., 2017). Progress along this trajectory is influenced by 
individualised factors from earlier life that can predict age-related health and morbidity. 
These include wider determinants of health such as education, ethnicity, gender, 
geography, financial hardship, occupation, physical activity, smoking and body mass 
index (Hale, Shah & Clegg, 2019). This means that there are opportunities for 
prevention and prognostication at all stages of the life-course and that mid-life social, 
behavioural and biomedical risk factors can be modified altering the frailty trajectory 
thus avoiding adverse outcomes.  
In 2015, the National Institute for Health and Care Excellence (NICE) published a 
guideline entitled “Dementia, disability and frailty in later life – mid-life approaches to 
delay or prevent onset” (National Institute for Health and Care Excellence, 2015) . This 
encouraged health and local government organisations to develop population-level 
initiatives to address lifestyle issues, with the aim of preventing frailty and promoting 
healthy ageing. However, as previously discussed, the majority of older people are not 
frail and so a systematic method of identifying the frail cohort is required to target 
prevention and management strategies effectively. Multiple studies have attempted to 
address this deficit by developing frailty screening instruments. The next section of this 
review examines the evidence for their use.  
1.4.4 Screening for frailty 
The combination of increasing prevalence of frailty and its association with adverse 
health outcomes would seem to make screening for frailty appropriate, particularly in 
primary care, where the majority of older people access health services. In addition, 
early identification of frailty enables the design of population-based preventative 
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interventions to target known risk factors (Santos-Eggimann & Sirven, 2016). 
However, population screening for frailty poses significant challenges. There is low 
awareness of frailty among older people who may view it as natural ageing and 
among some clinicians who may not have access to specialist treatment options 
(Ambagtsheer et al., 2019). Although early frailty has the potential for treatment and 
reversibility (Travers et al., 2019), response to treatment is variable and there is less 
evidence of response as frailty becomes more severe. Furthermore, primary care is 
already overburdened with screening activity, so a simple, validated tool or method to 
identify and stratify frailty is needed. 
Multiple studies have proposed instruments to screen for and measure frailty (Pialoux, 
Goyard & Lesourd, 2012), some are simple and some more complex. Two common 
approaches are questionnaires that assess frailty characteristics or the use of physical 
markers for frailty, such as gait speed and hand grip strength. A systematic review by 
Clegg at al (2015) evaluated screening tools that had been validated in clinical trials 
for their application in primary care. These included four metre gait speed 
measurement (Castell et al., 2013), timed-up-and-go-test (TUGT) (Savva et al., 2013), 
the use of questionnaires such as the Groningen Frailty Indicator (Hoogendijk et al., 
2013) and the PRISMA-7 tool (Raiche, Hebert & Dubois, 2008). This review found that 
four metre gait speed, PRISMA-7 and the TUGT had the highest sensitivity for frailty 
identification, but all tests displayed limited specificity resulting in high numbers of false 
positives. They concluded that no one test is accurate enough to diagnose frailty in 
primary care. A later study by Lee at al (2017a), found that a combination of 
measurement of gait speed and grip strength was sensitive and specific as a proxy for 
the Fried frailty phenotype (Fried et al., 2004) with a higher positive predictive value 
than either gait speed or grip strength alone. Ideally, a simple investigation such as a 
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blood test could be a viable solution, however, a review of biological markers for frailty 
did not find one single marker that would be diagnostic (Lee et al., 2017b). 
Given concerns about primary care capacity and workload (Shaw et al., 2018), there 
has been a move in recent years to provide easy and rapid approaches to frailty 
identification (Ruiz et al., 2020). This has led to the development of automated tools 
that can be populated by information from the clinical record and provide lists of frail 
people within a general practice population. The most developed tool is the electronic 
frailty index (eFI) (Clegg et al., 2016). The eFI is a computerised algorithm developed 
using data from 900,000 older people’s UK primary care records. It is based on the 
principles of the cumulative deficit model of frailty (Rockwood et al., 2005) and 
calculates a frailty score based on the occurrence of up to 36 deficits, taking 
information from the primary care clinical record (Alharbi et al., 2020). Frailty scores 
are then categorised into four levels of frailty severity; fit, mildly frail, moderately frail 
and severely frail (Table 1.1). The eFI has an advantage over other tools in that it is 
fully automated and, therefore, is time-efficient and does not require any clinical 
knowledge to produce a full list of frail patients within a general practice population. 
Table 1.1: eFI scores to categorise severity of frailty 
Severity of frailty Score range 
Fit 0.00 - 0.12 
Mild 0.13 – 0.24 
Moderate 0.25 – 0.36 




The eFI has been shown to have robust predictive validity for mortality, hospitalisation 
and care home admission (Clegg et al., 2016) and convergent validity (Brundle et al., 
2019) with a strong correlation with other frailty screening tools including the Clinical 
Frailty Scale (Rockwood et al., 2005) and the Edmonton Frail Scale (Rolfson et al., 
2006). Nonetheless, the eFI is a risk stratification tool that is known to result in false 
positives, therefore, it is recommended that frailty diagnosis is confirmed either by 
using another screening tool or clinical judgement (NHS England, 2017). The eFI has 
been embedded into clinical records systems in the majority of general practices in 
England. The general practice contract mandates the requirement to identify 
moderately and severely frail patients and employ limited clinical interventions. These 
interventions include yearly medication reviews (severely frail only), annual falls risk 
identification and to promote the use of the additional information in Summary Care 
Record. 
Whatever tool is used, once frail people have been screened for and identified, frailty 
requires management and treatment as with any other long-term condition (Harrison 
et al., 2015). The following section of this review examines the current approaches to 
the management of frailty and their evidence base. 
1.4.5 Managing Frailty 
As evidenced in section 1.4.3, frailty can be managed by interventions addressing 
individualised, relevant risk factors (Clegg et al., 2013). Many of the symptoms of frailty, 
which lead to loss of independence, can be improved and even reversed with relatively 
simple measures.  For example, exercise and addressing visual impairments can 
prevent falls (Chan et al., 2017; Morley, 2017). Weight loss and malnutrition that 
accompany frailty can be managed using nutritional supplementation (Landi et al., 
2016). Polypharmacy and adverse effects of medication are common causes of 
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cognitive decline, which can be addressed by an effective medication review (Morley 
et al., 2015).  
This holistic, individualised approach is the founding principle of a comprehensive 
geriatric assessment (CGA), which is described as the gold standard intervention for 
the management and prevention of deterioration in frailty (Gladman, 2016). The most 
widely accepted definition of CGA is: 
“a multidimensional, multidisciplinary process which identifies medical, social and 
functional needs, and the development of an integrated/co-ordinated care plan to meet 
those needs.” (Parker et al., 2018).  
CGA is part of routine care and is well evidenced in the acute hospital setting within 
the speciality of geriatric medicine. A systematic review by Ellis et al (2011) found that 
patients who experienced CGA in hospital were more likely to be alive and in their own 
homes at up to six months following discharge, were less likely to be institutionalised 
or suffer deterioration and death. However, the efficacy of CGA is not well established 
in other healthcare settings, such as primary care, despite the shift of international 
policy direction towards ageing in place with care and support close to home (World 
Health Organization, 2015). 
It has been proposed that the provision of coordinated, person-centred care is 
preferable to support the older person in managing complex health needs at home 
(Goodwin, 2013). The National Coalition on Care Coordination (2018) developed a 
blueprint for care coordination that includes: being patient centred; taking a multi-
professional approach connecting health and social services; using a comprehensive 
assessment; and executing and monitoring a flexible care plan in partnership with the 
patient. Thus, there is a largely consensual understanding of what successful 
approaches to person-centred care outside of hospital for frail older people should look 
like (Goodwin, 2013).  However, lack of research in this area means there is insufficient 
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evidence to support a positive association between this care model and improved 
patient experiences, clinical outcomes and financial savings (Imison et al., 2017). The 
following section will explore the evidence to date and identify the research 
deficiencies. 
1.4.6 Frailty Management in Primary Care 
In the UK, risk management of frailty to prevent future deterioration leading to 
secondary care usage has been encouraged (La Grouw, Bannink & van Hout, 2020).  
With its ease of accessibility, established relationships between general practitioners 
and their patients and access to a multidisciplinary team, primary care has been seen 
as a suitable setting for the management of frailty (Drubbel et al., 2013). The British 
Geriatrics Society (BGS) in 2014 suggested that a primary care led ‘holistic review’ by 
a GP or specialist nurse may enable more frail older people to access services out of 
hospital (British Geriatrics Society, 2014). Despite this guidance, implementation of 
primary care frailty management remains problematic with reports that general 
practitioners view frailty screening as a burden within an already challenging workload 
(Reeves et al., 2018). Concerns have been raised across Europe about the time taken 
for identification of the frail population, conducting a CGA and the additional cost in 
time and resources to primary care (Shaw et al., 2018). 
Notwithstanding these concerns, there is no evidence to indicate that the acute hospital 
CGA framework is immediately transferable or that primary care clinicians possess the 
specialist skills and knowledge to deliver this care. Furthermore, there is no one 
specific, validated CGA model for use in primary care. The delivery of complex 
interventions for older people at home can reduce care home and hospital admissions 
and falls, however, there is less certainty around the benefit of any specific type or 
intensity of intervention (Beswick et al., 2008). In addition, Beswick et al’s systematic 
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review revealed that there was a lack of identification and recruitment of frail older 
people to studies and, therefore, the additional benefits of targeting the frail population, 
as opposed to all older people, are not known.  
A systematic review of one primary care CGA tool noted a lack of an agreed 
implementation model and concerns of workforce capacity in UK primary care (Craig 
et al., 2015). A review that attempted to identify short, validated approaches to CGA in 
primary care found several tools but identified the need for more research into 
approaches addressing the implementation of an integrated, holistic CGA in a primary 
care setting, including what is feasible for large numbers of the population (Morley et 
al., 2017). It seems possible that whilst the principles of CGA are appropriate for 
primary care delivery, the practicalities of its implementation, including which clinicians 
should lead the process, require further exploration. Interest in this topic has gained 
traction with the James Lind Alliance naming optimal delivery of CGA in different 
healthcare settings as one of the top ten research priorities for older people (James 
Lind Alliance, 2018). 
1.4.7 Nurse-led Frailty Interventions in Primary Care. 
Some authors have evaluated health care clinicians’ attitudes to frailty assessment and 
management and found more positive engagement among nurses than other clinicians 
(Moffatt et al., 2018). In the UK, The Royal College of General Practitioners have 
advocated the use of a broader skill mix in primary care where nurses and other 
clinicians deliver care coordination (NHS England, Royal College of General 
Practitioners & Health Education England, 2016). It would appear that the BGS 
recommendation that holistic assessment of frail older people in primary care should 
be led by nurses would seem appropriate. However, the nursing contribution to the 
management of frailty is poorly developed. A literature search conducted to inform this 
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review (Appendix 1) revealed that studies assessing nurse-led interventions have 
shown mixed results. Five studies reported positive effects of nurse-led interventions 
(Berglund et al., 2015; Bleijenberg et al., 2017b; Kono et al., 2016; Melis et al., 2008; 
Rockwood et al., 2000), four reported both positive and negative effects (Bleijenberg 
et al., 2017a; Schein et al., 2005; Stijnen et al., 2014a; Taube et al., 2018) and seven 
reported no effect on outcomes (Bouman et al., 2008; Godwin et al., 2016; Hoogendijk 
et al., 2016b; Metzelthin et al., 2010; Suijker et al., 2016b; Van Hout et al., 2010; van 
Lieshout et al., 2018). It is clear that there are some methodological challenges that 
may have affected results, including heterogeneity of participants, which the authors 
acknowledge and recommend are addressed in future research.  
As discussed in section 1.4.4, identifying and targeting the frail population is 
problematic as there is no definitive definition of frailty and a variety of screening tools 
and other methods of case finding have been used. Furthermore, there is no 
consistency of screening methods across the studies and, indeed, some made no 
attempt to target frail people within the older population (Godwin et al., 2016; van 
Lieshout et al., 2018). Authors acknowledge that including the non-frail population may 
leave little room for improvement in some outcomes (Bleijenberg et al., 2017a). In 
addition, there may be benefit in selecting groups of the frail population including the 
oldest-old i.e. those aged eighty years and over (Bleijenberg et al., 2017b). 
Other authors, in critiquing the studies above, reported that there was a lack of 
specialist older persons’ knowledge and skills amongst the nurses, as well as a need 
for possession of more advanced assessment skills to ensure effective delivery and 
fidelity to the intervention (Hertogh & Bastiaans, 2016; Hoogendijk, 2016b). Some 
authors have suggested that primary care teams require the support of specialist 
services, such as geriatricians (Hertogh & Bastiaans, 2016), whilst others have 
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employed nurses with advanced assessment and case management skills and 
reported more positive effects on outcomes (Kono et al., 2016; Rockwood et al., 2000). 
In addition to advanced clinical skills, several studies have highlighted the importance 
of a goal-orientated intervention focussing on person-centeredness and self-
management. This approach should be built on a caring, supportive relationship 
between nurse and patient (Imhof et al., 2012). 
Studies focussed on a variety of outcome measures, including function and 
independence, quality of life, care needs and mortality (Berglund et al., 2015; Kono et 
al., 2016; Melis et al., 2005; Rockwood et al., 2000). Despite this multiplicity of outcome 
measures, evidence is lacking in relation to which outcomes are important to frail older 
people themselves or which might be amenable to a person-centred intervention. This 
makes comparison across studies problematic. Health-related quality of life is an 
important outcome measure for this population group, however, study methods need 
to address the issue of demonstrating quality of life improvement when frailty is a 
declining trajectory. Imhof et al (2012) suggest the need to combine quality of life 
outcome measures with assessment of function to provide a more holistic picture of 
independence. 
Highlighting the need for holistic, person-centred outcome measures, some studies 
have suggested that care is needed in the choice of intervention components in order 
for them to have maximum effect. These include assessment of falls, medications, pain 
and long-term conditions management (Stijnen et al., 2014a). However, other studies 
emphasise the importance of non-medical solutions including environmental, social 
support and housing to ensure a holistic, multidimensional assessment process 
(Hoogendijk et al., 2016b; Schein et al., 2005). This provides an additional challenge 
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to ensure primary care nurses are able to access wider social and environmental 
support as part of the assessment process. 
Finally, the majority of the research carried out into the efficacy of nurse-led and 
coordinated care for frail older people has been conducted in The Netherlands; in this 
case eleven out of the seventeen studies reviewed. Nine of the Dutch studies 
demonstrated no effect, or mixed effects of the intervention (Bleijenberg et al., 2017a; 
Bouman et al., 2008; Hoogendijk et al., 2016b; Metzelthin et al., 2010a; Stijnen et al., 
2014a; Stijnen et al., 2014b; Suijker et al., 2016; van Hout et al., 2010; van Lieshout et 
al., 2018). Emiel Hoogendijk provided critique of some of these studies which formed 
part of the Dutch National Care for the Elderly Programme and considered the difficulty 
of demonstrating the effect of these interventions (Hoogendijk, 2016). He concluded 
that the Netherlands already had a strong primary care approach to supporting older 
people and, therefore, these new care models offered little advantage over the existing 
care and support. He advocated that more research was needed to determine whether 
these findings from the Netherlands differ from other countries whose primary care 
systems, while strong, are not necessarily focussed on older people, such as the UK 
and Finland.  
In 2019, NHS England published “The NHS Long Term Plan”, which set out plans to 
ensure appropriate funding for services, including those in primary care (NHS England, 
2019). It specifically highlighted the needs of frail older people suggesting there should 
be a systematic method to allow early detection of frailty and the development of 
integrated services to work with older people to maintain their independence. Under 
the terms of the NHS England General Practice Contract 2017/18, to facilitate the 
identification of frail older people, general practices were required to identify patients 
aged 65 years and over, who are living with moderate or severe frailty using an 
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appropriate, evidenced based tool such as the electronic frailty index (eFI). Building on 
the UK policy direction, the BGS issued a Position Statement on Primary Care for Older 
People (British Geriatrics Society, 2018), proposing a multi-professional approach to 
supporting frail patients once they are identified, and highlighted evidence that nurses 
and allied health professionals can successfully lead and input into the assessment 
and care planning process (Schadewaldt et al., 2013). 
1.5 Significance of this research 
This review of the literature has demonstrated the challenges of evaluating primary 
care interventions for frail older people. Evidence to date concludes that mechanisms 
of effect are unclear, outcome measures are multiple and confused and interventions 
often poorly reported and, therefore, not replicable (Gardner et al., 2017). In examining 
the evaluation of complex healthcare interventions, Greenhalgh and Papoutsi note that 
much of what is named as complexity research does not in fact engage with complexity 
and that there is a need for “in-depth, mixed-methods studies” (Greenhalgh & Papoutsi, 
2018, p.1092) and process-based approaches to understand dynamic, real-life 
healthcare. This study aims to address this deficiency though the use of mixed-
methods to gain a deeper and richer understanding of the potential barriers and 
enablers to nurse-led primary care for frail older people. 
Other gaps in the evidence base have been revealed. Studies have concluded that 
some frailty interventions are ineffective, when in reality, flaws in study design may 
have impacted on their ability to show an effect. Such issues include a lack of 
identifying and targeting the frail population (Christensen et al., 2017; Fougère et al., 
2017); ineffective components of the intervention (Li et al., 2017); lack of clinician skills 
and knowledge in delivery of the intervention (Hertogh & Bastiaans, 2016); poor fidelity 
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to the intervention (Bleijenberg et al., 2016b; Suijker et al., 2016b) and use of 
inappropriate outcome measures (Bleijenberg et al., 2016a; Gardner et al., 2017). 
Utilising a mixed-methods approach, the research presented in this thesis addresses 
these limitations in a number of ways. Through the HAPPI feasibility study, the use of 
an automated, systematic method of frailty diagnosis and participant identification 
using the electronic frailty index (eFI) has been evaluated. Furthermore, it has been 
possible to implement and test, for the first time, the acceptability of a unique person-
centred intervention, which has not been prescribed or regimented but instead, 
developed iteratively based on the needs and aspirations of frail older persons. Finally, 
extensive testing of feasibility parameters to maximise recruitment and retention and 
to determine the acceptability of the intervention allowed further exploration of the 
views of participants, carers and clinicians. The phases of this study and methods used 




Figure 1.2: Study phases and research aims 
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1.6 Chapter Summary 
Whilst conceptualisation and definition of frailty continues to evolve, it is clear that it is 
a complex syndrome, existing not only as a clinical state but also as a lived experience. 
It requires researchers and clinicians to understand that the health and psychosocial 
problems that accompany it are inseparable. Therefore, any intervention introduced to 
treat and manage frailty should, ideally, be holistic and wholly person-centred. There 
is currently no standardised treatment protocol and any future approach should ensure 
that all interventions are developed in partnership with the frail person. Clinicians too 
must take a multi-dimensional approach to assessment and planning care.  
The evidence has indicated that, to meet the challenges of frail older people and to 
provide proactive, holistic care close to home, there is a need for a person-centred 
intervention to be developed, which could be implemented in primary care. It must be 
feasible to be delivered in this setting and have a high level of specificity to enable 
primary care resources to be targeted at patients who will most benefit from the 
intervention. It is not yet clear if this intervention can successfully be delivered by 
nurses.  
The HAPPI study has been designed to address the identified research gaps and to 
fully explore the issues of feasibility and acceptability. The next step involved frail older 
people and their carers working with the researcher to co-design the feasibility study. 




Chapter 2: Co-production of the research study 
The HAPPI study was co-produced in partnership with older people, carers and 
clinicians. The National Institute for Health Research (NIHR) guidance defines patient 
and public involvement (PPI) in research as: 
 “… an approach in which researchers, practitioners and the public work together, 
sharing power and responsibility…”  
(National Institute for Health Research, 2018, p.4).  
One of the key principles, of effective PPI as defined by the NIHR, is to include the 
perspectives and skills of  all those who can make a contribution, and so authentic 
consultation with stakeholders was seen to be a vital step in the design of this study. 
The concept of frailty may have emotive and negative connotations for older people 
and carers, with  research noting that older people did not always relate to the term 
‘frailty’ but do articulate clinical features relating to loss of independence and ability to 
cope at home (Britain Thinks, 2015).  
In order to increase the likelihood of a successful study, it was important to involve 
older people and their carers from the outset. This included understanding their 
perspectives of living with frailty to ensure sensitive methods of recruitment and 
retention designed to maximise participation in the study. Similarly, as a feasibility 
study, involving clinicians who would be delivering the intervention was essential in 
ensuring the design was rigorous and fit for purpose. The content below has been 
submitted as a manuscript for publication to BMC Family Practice and the format of 
this chapter reflects the submitted manuscript. The manuscript is currently under 
review. An estimated percentage of contribution (%) of each author is as follows: 
Lyndon, H. (85%), Latour, J.M. (5%), Marsden, J. (5%), Kent, B. (5%). The 
percentages of contributions have been agreed among all authors. 
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Background: Frailty is a clinical syndrome associated with older age and 
characterised by loss of reserves and functional capability. This patient and public 
involvement (PPI) consultation aimed to explore views of older people with frailty, their 
carers and health care professionals on the importance of developing and 
implementing a nurse-led holistic assessment and care planning intervention and a 
proposed study design to test the intervention and its delivery including, outcome 
measures, recruitment and retention methods.   
Methods: A consultation with frail older people, their carers and health care 
professionals using involvement frameworks as advocated for patient and public 
involvement by the National Institute for Health Research (NIHR). Data was collected 
through six individual face-to-face interviews with moderately and severely frail older 
people and, where possible, their carers. A semi-structured interview guide was 
developed and used to facilitate a conversation around the main topics of the proposed 
study design.  Data was collected from health care professionals using a focus group 
and questionnaire. 
Results: Older people and carers communicated their experiences of living with frailty 
and the difficulties presented. These challenges were categorised into four main 
themes; (1) the characteristics of frailty (2) the challenge of managing multiple long-
term conditions, (3) organising care and support and (4) concerns about losing 
independence and the links to social isolation and loneliness. Health care 
professionals identified current barriers to effective frailty management in community 
care including an increased focus on acute care in the community with less time to 
complete thorough assessments and plan care. They highlighted having less time to 
be proactive and preventative. 
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Conclusions: This consultation reinforces the importance of early involvement of older 




2.2 Plain English summary 
Frailty can be a distressing but not inevitable part of getting older. People who are frail 
may feel more tired and weak than normal, have trouble getting around, lose weight 
and feel that they are slowing down. Frailty may lead to losing independence, hospital 
admissions and moving to a care home. Previous research has suggested that it may 
be possible to support older people to manage frailty like any other long term condition. 
If recognised early, we can provide care and support that may delay or prevent 
negative effects of frailty so that older people can retain their independence and quality 
of life. To do this, people need effective support at home from health services such as 
doctors and community nurses.  
Our research aims to explore how community nurses can provide individualised 
support to older people who live with frailty. In order to ensure the study meets the 
needs of older people we have involved them in developing this research. We have 
consulted via interviews with older people who live with frailty and their carers. They 
felt that our proposed research was an important priority for them and suggested 
outcomes that were significant to them. They told us that they would want co-ordinated 
care led by a doctor or a nurse delivered close to home. We also spoke to general 
practitioners and community nurses who agreed with the suggestions of the older 
people and suggested we explore any barriers to providing care for frail older people 





Patient and Public Involvement (PPI) in Research is essential to inform all stages of 
the research process (National Institute for Health Research, 2012). The term ‘public’ 
includes patients, carers and people who use health services as well as other 
stakeholders. Involving patients and the public in the design of a research study is 
important to make studies more effective, credible and relevant to the population group 
(Iliffe, McGrath & Mitchell, 2013). It can be seen as a core democratic principle that 
people who are affected by research have a right to influence what and how publicly-
funded research is undertaken (National Institute for Health Research, 2012). Public 
involvement in research can lead to empowering people who use health and social 
care services, providing a route to influence change and improvement in issues that 
concern people most. 
Evidence suggests that older people are often under-recruited in clinical trials 
(McMurdo et al., 2011).   Therefore, effective PPI at the early stages of studies that 
explore frailty management might provide insight into their needs and improve 
recruitment. Increasing the participation of older people in research can improve the 
generalisability of research findings and inform best practice. This paper describes the 
process undertaken to involve older people and health care professionals in the 
development of a study investigating how community health services can best support 
older people living with frailty to improve their quality of life  
The research team planned to carry out a mixed methods feasibility study with the aim 
of developing and testing a nurse-led holistic assessment and care planning 
intervention and to determine important parameters for the design of a definitive 
randomised controlled trial (RCT). Prior to initiating the study, the research team 
identified important stakeholders as frail older people themselves, their carers and the 
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health care professionals who support them in primary care. This highlighted the 
importance of undertaking a consultation with older people who live with frailty and 
other stakeholders to further comprehend the challenges experienced by them to 
provide information on whether frailty and support to manage it was a priority for 
research and if so, how best to engage participants in the study.  Frail older people, 
carers and health care professionals in primary care were approached as Specialist 
Advisors and the PPI consultation undertaken with them is described in this paper.  
2.4 Aim 
The aim of this PPI consultation was to: 
a. Explore the views of frail older people and other stakeholders on the importance 
of frailty as a research topic. 
b. Listen to older people and other stakeholders about their views of the proposed 
study design to increase the quality of the study protocol.   
2.5 Methods 
The NIHR INVOLVE Briefing Notes for Researchers: public involvement in NHS, public 
health and social care research (National Institute for Health Research, 2012) were 
used as a framework for the involvement process. The research team used qualitative 
methods, including interviews, a focus group and questionnaires, with subsequent data 
analysed using content analysis.  
Eight moderately or severely frail older people, and forty-five health care professionals 
were approached to act as Specialist Advisors to be involved in the consultation round. 
One of the older people had a carer who also agreed to participate. Six older people 
agreed to be interviewed. The approach was made via their primary health care 
professional in this case the Community Matron (CM) who identified moderately and 
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severely frail older people from their existing caseloads who were interested in fulfilling 
the Specialist Advisor role and put them in touch with the research team. CMs were 
issued with an information leaflet to share with patients and carers (Figure 2.1) and 
were briefed on how to make the initial approach. Once initial agreement to participate 
was given, the investigator contacted the older person and/or their carer to give more 
information, answer any questions and offer a face-to face interview in their home. This 
method of original approach via the older person’s usual care team is borne out by 
evidence demonstrating that this approach to identification of potential study 
participants is associated with high recruitment rates (Bugeja, Kumar & Banerjee, 
1997).  Interviews were offered in the home to minimise the impact of travelling on frail 
older people and their carers. Six older people and one carer agreed to participate in 






Figure 2.1: Information Sheet for Potential Participants 
 
Frailty in Primary Care Study  
Background: As people get older they may become frail. Frailty can be described 
as a set of symptoms which result from a combination of the natural effects of getting 
older with the impact of developing a number of long term conditions. People who 
are frail may feel more tired and weak than normal, have trouble getting around, lose 
weight and feel that they are slowing down. Frailty progresses over a period of 5-15 
years and for some people may lead to losing independence, having more hospital 
admissions and moving to a care home. Previous research has suggested that it may 
be possible to support older people to manage frailty like any other long term 
condition. If recognised early, we can provide care and support that may delay frailty 
so that patients can retain their independence and quality of life. To do this people 
need effective support at home from health services such as their GP and community 
and practice nurses. This may include carrying out an assessment of the frail 
person’s needs and working in partnership with them to develop a plan to address 
these needs which will be individual to them. 
The Study: This study aims to explore how frail people can be best supported at 
home and how GP surgeries and community teams need to work to provide this 
support. We want to explore if carrying out the assessment and developing a care 
plan will improve certain measures for patients.  These measures are; being 
independent, better quality of life, less hospital admissions and living in preferred 
place of care. 
Why we would like your help: We are applying to the National Institute for Health 
Research for funding to carry out this research study. A very important part of the 
application is the involvement of people and patients in developing plans for the 
study. We would value your opinion on the study and to understand if the subject 
and the outcomes seem important to you. 
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Thirty-five Community Matrons (CMs) and ten General Practitioners (GPs) were 
approached to act as Specialist Advisors. CMs were contacted through their local 
forum and a focus group organised as part of a regular meeting. All thirty-five CMs 
were invited to attend the focus group and twenty-five participated. GPs were identified 
through the UK NIHR South West Clinical Research Network as having a particular 
interest in the care of older people. They were sent a questionnaire based on the 
conversation guide used for the focus group (Figure 2.2). This method was employed 
to engage with GPs as, due to time constraints, they would be unlikely to participate in 
interviews or attend a focus group. Four GPs responded.  
Figure 2.2: Conversation Guide for CM Focus Group  
2.5.1 Data Collection 
The consultation with the older people and the carer was completed in six individual 
face-to-face interviews. The duration of the interviews was between 15 and 45 minutes. 
A semi-structured interview guide (Figure 2.3) was developed and used to facilitate a 
conversation around the main topics of the proposed study design.  In order to ease 
the people with frailty and their carers at the beginning of the interview, the first 
1. How do you currently identify and support frail patients? 
2. Are there any barriers to delivering effective assessment and care planning 
in primary/community care? 
3. How do you think we could address some of those barriers? 
4. Do you think this study would be useful in planning for the future care of 
our ageing population? If not, what are the topics you would like to see 
addressed relating to older people living with frailty? 
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question was always a general question about their experience of living with frailty. 
After this, the conversation continued with four questions regarding design of the 
proposed study, maximising recruitment and retention and appropriateness and 
importance of the proposed outcome measures.  The interviews were recorded and 
permission gained for the recording with the understanding that the data would be 





Figure 2.3: Semi-structured interview guide for older people and carers 
Data collection from the CMs was completed in one focus group meeting. A brief 
background and outline of the proposed study was provided to the focus group 
participants prior to attending. The focus group discussion was guided by four 
questions addressing the aim of the consultation round with CMs. The focus group was 
recorded and notes taken. Permission for the recording was sought with the 
understanding that the data would be safely stored and not identifiable. After the focus 
group with CMs a questionnaire with the same three focus group questions and 
accompanying information sheet with information about the proposed study was sent 
to General Practitioners (GPs).  The GPs were able to return the completed 
questionnaire via email.  
1. What are your experiences of frailty?   
 
2. What do you think of our proposed measurements of the study – 
independence, quality of life, number of hospital admissions, and 
living in preferred place of care?  
 
3. What information would you want to know if you were participating in 
the study? 
 
4. How can we best approach people to ask if they would like to 
participate in the study? 
 
5. Do you have any concerns about this study and if so, what are they? 
 
Prompts: 
Why do you say this? 
Can you explain this a bit more? 
Why do you think this is important? 
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2.5.2 Data Analysis  
All data were transcribed and anonymised and original recordings destroyed. After 
transcription, the data were analysed by the investigators using inductive content 
analysis (Hsieh & Shannon, 2005). Authors HL and JML completed this process, which 
involved organising of data through open coding by in-depth and repeated reading and 
gathering into main categories based on the interview questions. Data were then 
further grouped, reducing the number of categories by combining similar headings into 
broader categories. Finally, the third author (BK) reviewed the data to ensure there 
were coherent patterns and no categories were missed. 
2.5.3 Ethical Considerations 
Formal ethical approval was not required as part of this involvement process. The 
NIHR advise that ethical approval is not needed where people are involved in planning 
or advising on research. In their INVOLVE Guidance they state that: 
“Members of the public actively involved in research are acting as specialist advisors, 
providing valuable knowledge and expertise based on their experience of a health 
condition or public health concern. Therefore ethical approval is not needed for the 
active involvement element of the research (even when people are recruited via the 
NHS), where people are involved in planning or advising on research, for example 
helping to develop a protocol” (NIHR INVOLVE, 2020, p.1). 
2.6 Results  
Content analysis of the interviews with frail older people and the carer identified a broad 
category concerning experiences of frailty that were then further analysed to reveal 
four sub-categories concerning the characteristics of frailty, the challenge of managing 
multiple long term conditions, organising care and support and worries about losing 
independence and the links to social isolation and loneliness. Further categories 
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included advisors’ views on content of the proposed intervention, recruitment to a 
research study and appropriateness and importance of outcome measures. 
2.6.1 Experiencing Frailty 
Older people and carers described the characteristics of frailty as tiredness, feeling 
weak and loss of mobility: “Weakness and everything makes him tired” (C1). For some, 
these characteristics were viewed with dismay “I don’t know how this has happened to 
me…they say I have heart failure, my legs won’t work and the nerves in my arm are 
gone” (P1). Some participants expressed fear of the impact of frailty on their lives and 
independence: “It’s very frightening as you get older and can’t do as much” (C1). 
Others acknowledged the gradual functional deterioration and demonstrated 
acceptance: “Getting to the state I am in now comes so gradually you learn to cope 
with it…you find ways to do things” (P5). Other people’s perceptions of their frailty were 
discussed by the patients and they expressed satisfaction in the way others view their 
difficulties and their ability to cope: “My brother says he couldn’t live like I did…but we 
said to him, if you had the same things wrong you would have to put up with it” (P1). 
There is also a feeling that others don’t always recognise the impact increasing frailty 
can have: “People don’t see me as frail…my nephew said to me ‘you’re not frail, you 
are as tough as old boots’” (P4). 
Frail older people told us that they struggled with having “so many things wrong at 
once” (P1). They talked about how each long term condition impacted on the others 
and how this presented challenges for their on-going treatment and care: “I’m terrified 
I will need my other hip done because of my heart…and I’ve had three operations on 
my spine already” (P2) “I take eleven tablets every morning, they give me terrible dizzy 
spells but I know I need them” (P2). Strong sub- themes were the importance of 
determination, coping strategies and developing resilience: “I can’t go out but I use my 
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computer to look around the world…you can go anywhere…I watch the surfers on the 
beach…I don’t know of any beach that doesn’t have a webcam.” (P5).  The older 
people were aware of the impact of their mood on those around them and talked about 
how the importance of cheerfulness and staying positive: “I joke with the carers as I 
don’t want them to be miserable, they all love coming here, but I am in so much pain 
24/7.” (P1). 
All older people and the carer talked about the challenges of navigating and 
understanding health and social care systems: “I don’t understand the system…I’m not 
asking for the world.” (P1). They talked about a lack of continuity, which accompanies 
working with multiple health and social care professionals: “We’ve had four different 
Occupational Therapists for different things; one for the chair, one for the bed, one for 
the hoist” (P1). “If only there was a single number to call” (C1). 
Access to equipment and services was discussed and there was a perceived 
unfairness associated with charges for care and a perception that previous 
contributions are not recognised. Carers’ time is unpaid and there is little recognition 
for this contribution when assessments for financial contributions towards care are 
made: “If he was in a home it would cost a lot more…it makes you wonder what you’ve 
done wrong but my help has kept other help away for a long time.” (C1).  Financial 
burden was highlighted, particularly the cost of care and necessary adaptations to the 
home. This caused anxiety to both the older people and their carers: “We have to pay 
£5000 for a ramp, we just don’t have this as we have to pay towards my daughters bills 
– she moved to this house so we could come and live here…this is not taken into 
account” (C1). “I dread the water bills – that washing machine is never off…we’ve tried 




All older people and carers were supported by a Community Matron who provides long 
term case management for frail patients and those with multiple long term conditions. 
The older people and their carers highlighted the importance of this role and it was felt 
to have improved coordination of care and integration of services. They particularly 
appreciated having a knowledgeable single point of contact that is responsive to their 
needs: “S…. is the best medic I have ever come across…whenever I ask her a 
question she gives me the right answer…anything, no matter what I ask” (P4).  “If I 
need help I ring K…. first of all…I seem to feel so comfortable with her…I know she 
will do her best for me” (P5). Another key aspect of the role is that of coordination of 
services and care: “We only have to ask C…… and she says ‘Well what about so and 
so’…by having her come in it all got put together and treated like a person not just a 
name.”(C1). 
Frail older people placed high importance on staying independent and remaining in the 
home for as long as possible: “We want to stay at home…we really don’t want to go 
into a home” (P2).  They expressed dismay at how they are viewed by wider society 
and the loss of control over their own lives they have experienced: “People don’t tell 
me the things that are going to happen” (P4). They expressed frustration when care-
givers do not respect their independence and may schedule visits which then limit this 
independence further: “Timing of district nursing visits is important…they come and do 
my legs every day…one day I was able to go out with my friend but they (the district 
nurses) could have come at any time and that’s a day out of my life when I’ve had no 
social contact.” (P4). This links to the need to remain engaged with society and playing 
an active role within it: “I’m fed up with looking at the walls…I feel like a prisoner…I’d 
like to go out and see the other world” (P1). This statement was reinforced by the 
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patient’s carer who stated “They forget older people like to go out…four walls are very 
hard to take”. (C1).  
A strong sub-category was the subject of social isolation which accompanied 
increasing frailty and loss of independence. All older people and the carer highlighted 
this as an important issue which impacted on quality of life. Several of the patients 
talked about how they had tried to retain their links to society and how their attempts 
eventually fail: “ When I had to give up my car I bought a scooter…I used it to go out 
regularly, but then it got that it was getting too much for me…that was my 
independence gone.” (P3). All patients were housebound and they expressed feelings 
of frustration and sadness caused by loneliness: “The only time we get out is to see a 
specialist” (P2). “The winter seemed endless to me…like today I put on my jacket to sit 
outside…I used to do my own garden…I want to get outside and do my tubs.” (P5). 
2.6.2 Views on the content of the proposed intervention 
Patient and Carer Perspectives 
This part of the consultation involved gaining the perspectives of older people, carers 
and clinicians on the content of the proposed intervention. The intervention is a nurse-
led holistic assessment and care planning process which would identify the needs of 
older people living with frailty and work in partnership with them to develop a care plan 
to address these needs with an overall aim of maximising independence and quality of 
life.  All older people and carers thought that the proposed study topic was an important 
one particularly given the ageing population and increasing numbers of older people 
needing care and support. Some expressed that the needs of older people can be 
ignored and were pleased to see this issue was being prioritised: “You don’t change 
inside…I might be 72 but I don’t feel 72…and there will be many more of us.” (P1). 
“No, it’s nice to know someone is thinking about older people who are frail” (C1). 
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When asked about the importance of the intervention to them, the older people talked 
about having one person who led coordination of the complex care plan and was easily 
accessible. The carer also said that they would value “…someone to fall back on…” 
(C1), information on who to call for help and what to do in different circumstances: 
“There should be a booklet explaining how to do things…who to approach for different 
things and who to approach in different circumstances…” (C1). Once again the issue 
of independence was emphasised but with the need for adequate support to retain that 
independence.  
Clinicians’ Perspectives 
Data collected from GPs and CMs revealed that they currently identified frail people 
using a screening tool or by clinical assessment, or they had no systematic 
identification method. Current barriers to effective frailty management in community 
care were discussed and main themes identified were;  an increased focus on  more 
acute care in the community with less time on the caseload to complete full 
assessments and plan care, the existence of a “firefighting culture” (CM4) with  less 
time to be proactive and preventative. Concerns were expressed about the current 
skills level in primary care with a lack of knowledge about frailty and its management.  
Some suggested enablers to address these barriers were to streamline referral 
processes and assessment, to ensure the essentials of assessment were covered and 
then shared to avoid duplication. The focus of the proposed study should be to 
determine the ‘essentials of a Community Geriatric Assessment’ (GP4) that are 
feasible in primary care and will make a difference to patients. Coordination and 
continuity of care was seen as vital and time to develop a relationship with the patient 
and carer is needed.    
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2.6.3 Views on Recruitment  
The older people and carers addressed some important considerations for recruitment 
to the study involving participants who are frail. When asked about measures that could 
support recruitment to the proposed study and how best to approach frail older people 
to gain their engagement, opinions were varied. Some older people and the carer felt 
it would be best to approach through a known primary care clinicians rather than 
receiving a letter in the post: “If you got a letter you might think oh that’s something 
official, what’s that about, whereas my Community Matron coming in to explain to us, 
I was like ‘oh yeah that’s no problem’” (C1). Others commented that they would be 
happy to receive an initial invitation to participate in the post, some were not concerned 
about which way they were contacted: “A letter or a phone call…whichever is easiest” 
(P5). There were varying opinions on the information leaflet that introduced the study, 
some felt it was helpful in understanding the topic and as background to the proposed 
study; one patient thought it was not helpful 
2.6.4 Views on Outcome Measures. 
When asked about the outcome measures that were important for the study, quality of 
life and staying out of hospital were the most important outcomes for the older people 
and the carer: “It’s important for us…he doesn’t want to go into hospital again and he 
doesn’t want resuscitating, we’ve got the forms for all that…” (C1). “Anything that keeps 
old people in their own homes can only be good.” (P5). Several older people talked 
about how quality of life is very individual and could be achieved with relatively simple 
interventions.  
Whilst ‘hard’ outcomes such as prevention of admission to hospital, reduction in 
general practice contacts etc. were seen as important, all advisors stressed the 
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importance of meaningful outcomes that led to improved quality of life and functional 
independence. 
2.7 Discussion 
The importance of early involvement of older people who were also patients, their 
carers and other stakeholders in designing and planning research studies has been 
reinforced by this consultation. It has demonstrated that older people and carers valued 
the research topic and gave important insights into how to maximise recruitment into 
the trial. The proposed methodology has been designed to answer some of the 
questions and issues raised by older people, carers and clinicians and the research 
protocol has been adapted to ensure patients are approached in a sensitive way that 
will maximise recruitment to the trial based on the data from this consultation.  
Valuable insight was gained into the lived experience of older people living with frailty 
and their carers. The theme detailing the characteristics of frailty and how the clinical 
syndrome is experienced in reality is borne out by earlier research (Britain Thinks, 
2015). This found that the term frailty isn’t part of older people’s vocabulary when 
describing themselves and their lives; but that older people describe frailty and 
wellbeing in terms of everyday tasks and how it feels if these tasks start to become 
difficult. Older people within the consultation emphasised how it felt to them to struggle 
with activities of daily living and the feelings of frustration and sadness they 
experienced, but were also keen to show their resilience and coping strategies when 
presented with these challenges. This has highlighted the importance of the 
researchers in explaining frailty to participants in terms of its effect on health and 
wellbeing and to focus on support to maintain independence.  
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A strong theme that had not been considered in the original research proposal was the 
older peoples’ anxieties regarding losing independence and the links to social isolation 
and loneliness. This has been acknowledged in the frailty literature in recent times with 
social isolation becoming increasingly recognised as an independent risk factor for 
frailty (Herrera-Badilla et al., 2015). Guidance published by the National Institute for 
Clinical Excellence (NICE) on prevention of frailty and dementia emphasises that age-
related physiological changes can be impacted by personal, social and environmental 
circumstances which may limit social interaction (National Institute for Health and Care 
Excellence, 2015). In addition, there is emerging evidence on the importance of 
psychosocial risk factors throughout life such as loneliness, isolation and depression. 
These factors may reduce resilience to disease onset and progression. NICE highlights 
that psychosocial factors may be as important as physical factors in reducing the risk 
of dementia and frailty. Changes will be made to the proposed study design to include 
the risk factors of social isolation and loneliness in the development of the assessment 
and care planning tool.  
Using the feedback from the participants, recruitment to the trial will be led by the 
General Practice who will send out the initial recruitment letter and participant 
information sheet to ensure the potential participants can ask questions and gain 
support from their primary care clinicians. This is aimed at addressing any potential 
barriers to recruitment and ensuring targets for recruitment are met. 
It was encouraging to see that the proposed outcome measures for the study were 
seen as important and relevant to the patients and carers. Most importance was placed 
on remaining at home with a reasonable quality of life. It is recognised that measuring 
quality of life in older people who live with multiple complex conditions can be 
challenging and that many validated tools are not tested in populations of older people 
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(Diener, 2012; Neve et al., 2013; Steptoe, Deaton & Stone, 2015). The proposed study 
design has been altered to consider specific tools which measure quality or life and 
overall well-being in older people such as the SF-36 (Ware & Gandek, 1998) which 
has evidence for measurement of emotional health and mood in older people (Akpan 
et al., 2018). The advisors all stressed the importance of a person-centred approach 
with outcomes and goals based on individual patient preferences and needs. The 
research team have considered this when designing study outcome measures and 
included measurement of quality of life, functional independence and remaining in 
preferred place of care.  
The major limitation of the consultation was the small numbers of patients and carers 
who participated; however, there were larger numbers of clinicians. This combination 
did provide a rich source of data, which enabled the study protocol to be reviewed and 
improved. This ensures that the design meets the aims and objectives of the study and 
that we will be able to implement appropriate measures to maximise recruitment of 
participants. 
2.8 Conclusion  
Completion of this PPI consultation has reinforced the importance of early involvement 
of patients and the public in study design. It enables researchers to understand the 
topic from the patient’s perspective and to ensure relevance and importance. This 
should, in turn, enable high quality study design and relevance to the wider population. 
This is particularly important when carrying out research involving vulnerable, hard to 
reach groups such as older people and their carers who live with frailty. In relation to 
this proposed study, one of the challenges is related to recruiting adequate participants 
who are moderately or severely frail. Our PPI work has enabled us to test some of the 
proposed methods including face-to-face interviews and focus groups but we may 
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need to consider more novel ways in which frail older people can be engaged in 
consultation work.  Despite these challenges, we would strongly advocate the benefits 




Chapter 3: Study Design 
3.1 Chapter introduction 
Informed by the PPI consultation described in Chapter Two and in line with the Medical 
Research Council guidance on developing and evaluating complex interventions 
(Cathain et al., 2019; Craig et al., 2008), it was clear that the use of one research 
method would not be effective in developing the content of the intervention and 
determining the feasibility of conducting a trial in primary care. Survey methods with 
the aim of achieving consensus would enable development of the intervention and 
qualitative research would enable a deeper exploration of clinicians and participants’ 
experiences of participating in a trial. Consequently, a mixed-methods design 
comprising of three phases, including a Delphi survey, feasibility RCT and embedded 
qualitative study, was agreed on and further developed.  
This chapter explores the theoretical conceptual paradigms for mixed-methods 
research and describes, and justifies, the chosen study methods. It demonstrates how 
each method contributes to meeting the research aims and objectives and how the 
mixed-methods approach contributes to a holistic approach to integrating and 
interpreting findings. This enables more comprehensive conclusions to be drawn when 
evaluating complex healthcare interventions (Cathain et al., 2019). In this case, this 
includes exploring how this feasibility trial will inform the conduct of a full trial, involving 
stakeholders in iterative intervention development and providing intelligence to support 
the implementation of the intervention in real world clinical practice. 
3.2 Mixed-methods research 
Plano Clark and Ivankova (2016) describe mixed-methods research as  
“…the intentional integration of qualitative and quantitative research methods to best 
address a problem”. (p.4)  
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Since the 1980s, mixing research methods has become increasingly accepted as a 
legitimate approach, notwithstanding differing views on the integration of quantitative 
and qualitative methods (Greene, 2008; Johnson, Onwuegbuzie & Turner, 2007). 
Greenhalgh and Papoutsi (2018) argue that many evaluation studies testing complex 
interventions fail to embrace the concept of complexity fully. They suggest that 
complex health systems have blurred boundaries where clinicians operate internal 
rules and adapt and evolve those systems iteratively. It can be argued that randomised 
controlled trials alone will not fully answer questions as much of real life healthcare 
cannot be controlled for (Greenhalgh & Papoutsi, 2018). Therefore, more in-depth, 
mixed-methods approaches are needed to explore the dynamic nature of testing 
feasibility of an intervention and its implementation. The original Medical Research 
Council Framework for the development and testing of complex interventions (Craig et 
al., 2008) was updated in 2015 (Moore et al., 2015) and in 2019 (Cathain et al., 2019) 
and emphasised the need for more mixed-methods and process-based studies to 
explore the challenges of non-linearity and iterative local adaptations. 
The HAPPI study sought to apply the principles of mixed-methods research throughout 
the research process using an integrated approach to conceptualising and interpreting 
findings. To ensure this approach was incorporated at each stage of the study, it was 
necessary to appraise the underpinning philosophical principles of mixed methods 
research and their application. This theoretical paradigm will be explored in section 
3.3. 
3.3 The theoretical paradigm 
Mixing research methods poses a dilemma in that the underpinning philosophies of 
quantitative and qualitative research appear to be at odds with each other. The 
traditional philosophical foundation for quantitative research is positivism, which states 
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that all reliable knowledge can be verified by scientific enquiry. This scientific, 
experimental method was introduced by August Comte (1798–1857), who is regarded 
as the first philosopher of modern science (Crotty, 1998). In the early 19th century 
philosophers such as Karl Popper introduced the philosophy of post-positivism, which, 
while continuing to value objectivity, recognised that researchers’ values and 
background can influence their research and that this potential source of bias should 
be acknowledged and managed (Popper, 1959). The postpositive movement set the 
context for the development of qualitative methodologies and for the mixing of research 
methods in the 1980s (Giddings & Grant, 2007). Qualitative research is rooted in the 
paradigm of constructivism where the study aims to describe multiple realities, 
including that of the researcher, to interpret meaning and contexts from the 
experiences of individuals (Lincoln & Guba, 1985).  
Some writers claim there is no need for tangible connections between specific 
philosophies and certain research methods (Cook, 1979; Greene, Caracelli & Graham, 
1989). In order to move the knowledge base forward, Greenhalgh proposed a break 
from traditional paradigms and questioned “prevailing assumptions and 
methodological rules” (Greenhalgh, 2013, p.92). The integration of research methods 
in mixed-methods research and their founding conventions can be challenging as the 
researcher may be operating from or attempting to combine differing paradigms within 
one study. Furthermore, the investigator will operate within his or her personal and 
professional context. This reflexivity is acknowledged and viewed as an essential and 
valued contribution in qualitative research ontology (Giddings & Grant, 2007). The 
concept of reflexivity is given less importance in quantitative methods where objectivity 
is prized (Dodgson, 2019). Reflexivity describes the perspectives and interconnecting 
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relationships between the researcher and participants and the influences the 
researcher’s personal standpoint and values may have on the research (Berger, 2013).  
The author of this thesis is a nurse and, as such, draws on both quantitative and 
qualitative research data to inform clinical practice. It has been argued that nursing can 
be considered both an art and a science (Jasmine, 2009) with its roots in caring, whilst 
also acknowledging the need for scientific, evidence based research on which to base 
practice. In the HAPPI study, the use of quantitative data may offer a high level of 
accuracy and objectivity of results, whereas qualitative data can provide an effective 
way of exploring attitudes, feelings and behaviours in depth and detail.   
In order to provide clarity and transparency, I acknowledged my personal position in 
relation to the study and the ethical challenges which might arise. As a nurse and a 
researcher, I occupied a dual role where my clinical background and the desire to 
support and respond to participants in a caring capacity could be at odds with the 
objectivity required as a Chief Investigator and an interviewer in the qualitative phase. 
There was also the potential for blurring of role boundaries, where participants might 
view me as a clinician rather than an independent researcher. During supervision 
sessions, ethical and practical issues were reviewed and discussed so that there was 
a constant awareness of the tension between the privileged relationship with and 
access to participants and maintaining my responsibility for rigour in the conduct of the 
study (Hiller & Vears, 2016).  
In designing the study, ultimately, a pragmatic stance was taken in order to value the 
practicality of a wide range of designs and their applicability to the world of complex 
healthcare evaluation. There was an awareness of underpinning ideologies so that in 
mixing methods, they were not at odds and that each method and their results were 
given equal weighting, so avoiding domination of one method over the others. If there 
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was a disparity in findings across methods, then, as a feasibility study, this provided 
the opportunity to refocus the research questions and original research assumptions. 
Lather argues for “disjunctive affirmation” where paradigm disagreement is neither a 
“cause for war nor requires reconciliation” (Lather, 2006, p.52). Maxwell (2011, p.28) 
suggested adopting a “bricolage” approach where philosophies can be viewed as 
practical tools and the researcher can assemble their own toolkit to fit their personal 
perspective and the purpose of their research. This justification aligns fully with the 
aims and objectives of this study. 
3.4 Study methods 
A holistic picture of findings from both qualitative and quantitative elements of a study 
can be achieved by the integration of statistical and thematic data analytic techniques. 
This approach can allow a deeper insight by aiming to achieve complementarity, where 
quantitative and qualitative methods are combined leading to a more complete and 
multifaceted understanding of a phenomenon (Greene, Caracelli & Graham, 1989). 
This is particularly relevant when testing the feasibility of a complex intervention where 
the processes and the outcomes of the intervention and its implementation are 
explored. In mixed-methods research, integration of methods and findings to complete 
the whole picture should be the aim; the process by which this was achieved will now 
be presented. 
The study was designed using sequential timing. Initial quantitative data were gained 
using e-Delphi survey methods to develop the content of the intervention then further 
quantitative data collected from results of the fRCT, which tested implementation. 
Embedded within the trial, qualitative data were used to understand experiences of the 
intervention and to explain its implementation. Mixing of the data occurred when results 
were interpreted together to obtain the holistic picture. There are strengths and 
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limitations of this approach (Plano Clark & Ivankova, 2016). Sequential timing is 
convenient for the planning and organising of a study. It allows for exploration of the 
quantitative results in more detail and aligns with the recommendations for evaluating 
complex interventions (Moore et al., 2015). However, a sequential design can prove 
lengthy to complete and, therefore, the qualitative study was embedded within the 
fRCT to fit within the timeframe of the NIHR fellowship. Figure (3.1) details the research 










The primary aim of the HAPPI study was to determine the feasibility of delivering a 
nurse-led assessment and care planning intervention in primary care to older people 
with frailty and to test potential trial methods to inform the design of a definitive 
randomised controlled trial (RCT). Specific objectives were achieved within the three 
phases of the study using quantitative and qualitative methods. Development of the 
intervention was completed in the first phase of the study using an e-Delphi survey and 
research stakeholder involvement. The fRCT enabled assessment of feasibility of the 
intervention and delivery of the trial including compliance with the HAPPI intervention, 
verification of proposed outcome measures and their collection and determining 
achievable targets for recruitment and follow-up. Further objectives were met within 
the embedded qualitative study including determining acceptability of the intervention 
to patients, carers and clinicians in primary care, assessment of barriers to delivery of 
the HAPPI intervention and acceptability of trial processes and collection of outcome 
measures to participants. This mixed-methods research approach was thus designed 
to achieve complementarity and provide a structure for the evaluation of a complex 
intervention examining all aspects of its development in addition to the feasibility of its 
implementation.  
Subsequent chapters of this thesis present the methods, findings and discussion of the 




Chapter 4: Development of the Intervention  
4.1 Introduction 
Building on the information from the PPI consultation, in the next phase of the study, 
an e-Delphi survey was conducted to gain consensus on the detailed content of the 
HAPPI intervention with an expert panel made up of specialist nurses for older people, 
community and primary care.  In order to ensure wider stakeholder involvement, the 
results of the survey were then shared with a group of older people, carers and senior 
clinicians to verify and confirm the content and delivery of the intervention. This chapter 
describes the methods and results of the e-Delphi survey and the research stakeholder 
group leading to the finalisation of the intervention to be tested in the fRCT. The content 
below has been submitted as a manuscript for publication to the International Journal 
of Older Peoples Nursing and the format of this chapter reflects the submitted 
manuscript which is currently under review. An estimated percentage of contribution 
(%) of each author is as follows: Lyndon, H. (85%), Latour, J.M. (5%), Marsden, J. 
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Aim: The aim of this study was to obtain expert consensus on important and feasible 
components of a primary care, nurse-led, comprehensive geriatric assessment (CGA)-
based approach. 
Background: To meet the challenge of a growing frail, older population, there is a 
need to provide proactive care using a person-centred, CGA-based approach in 
primary care. Currently, there is no evidence for which components of a CGA can be 
effectively delivered in this healthcare setting. 
Methods: A three-round e-Delphi survey was conducted with an expert panel of 75 
UK specialist older people and primary healthcare nurses. In round one, experts gave 
their opinions on the important components of a CGA-based approach. In round two 
the experts rated the components for importance and feasibility. In round three, in order 
to achieve consensus, experts re-rated the components based on group opinion.  Data 
were analysed using thematic analysis of the content in round one and descriptive 
statistics in later rounds to indicate convergence of opinion and, ultimately, consensus.  
Findings: In round one, 36 CGA components were identified by the experts and based 
on a literature review. These were clustered into six domains: frameworks/care 
structures; home/family/safety assessment; personalised care and support planning; 
long-term condition management; physical health assessment; mental health 
assessment. In rounds two and three rating scores for importance were high across all 
domains, with lower scores for feasibility. The 36 components achieved consensus on 
importance, but only 11 out of the 36 components reached consensus on feasibility.  
Conclusions: Of the 36 identified CGA-based components, 11 were deemed to be 
feasible in delivering optimised person-centred care to frail older people in community 
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settings. Results of the study will inform the development of a nurse-led CGA-based 
approach which will be evaluated within a randomised controlled trial. 
Keywords: older people; frailty, comprehensive geriatric assessment; care planning; 






Frailty is a clinical syndrome associated with ageing, which develops through 
cumulative cellular damage over the life course and leads to progressive disability and 
loss of independence (Clegg et al., 2013). Frailty assessment has been biomedical in 
nature, focusing on the diagnosis and treatment of the clinical syndrome (Hoogendijk 
et al., 2019). However, this approach fails to capture individuals’ differences and can 
cause clinicians to neglect peoples’ abilities to participate in their own care and support 
(Rahman, 2018). An asset-based model of assessment and support takes a more 
holistic, multidimensional approach to managing frailty and has been promoted by the 
World Health Organisation as a means of preserving function, personhood and 
independence (World Health Organization, 2015).  
In the UK and other countries, assessment of frailty is most commonly undertaken in 
acute hospitals using a Comprehensive Geriatric Assessment (CGA) which is led by a 
geriatrician (Clegg et al., 2013). This assessment and care planning process is 
acknowledged as the gold standard approach for the management and prevention of 
deterioration in frailty (Gladman, 2016). It is a multidimensional, interdisciplinary 
diagnostic process to determine the medical, psychological and functional capabilities 
of a frail older person in order to develop an individualised care plan for treatment and 
long-term follow up in partnership with the patient and their families (Ellis et al., 2011). 
The British Geriatrics Society (BGS) have suggested an alternative to hospital-based, 
geriatrician-led CGA, proposing that, in primary care, a ‘holistic review’ by a general 
practitioner (GP) or specialist nurse may enable more frail older people to access 
services out of hospital (Turner & Clegg, 2014). Unfortunately, there is no evidence to 
indicate that the acute hospital CGA is immediately transferable and achievable, or 
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that primary care clinicians (including nurses) possess the specialist skills and 
knowledge to deliver this care model.  
To support the movement of CGA from secondary to primary care, the BGS has 
published a Comprehensive Geriatric Assessment Toolkit for Primary Care 
Practitioners (Turner et al., 2019). This toolkit is 48 pages in length and takes a 
minimum of two hours to complete. The BGS themselves acknowledge that its 
completion by GPs may not be possible due to short appointment times and lack of 
capacity in the current UK model of primary care. Additionally, its full completion may 
not ensure a person-centred approach as not all components may be appropriate for 
all frail older people. Consequently, there remains a need for a more holistic, flexible 
approach that can be delivered by primary care professionals other than GPs and 
adapted for the individual and their needs, whilst being practical to implement. In 
addition, evaluation of the role of nurses in leading this care model is required 
Beswick et al (2008) found that the delivery of complex interventions (based on CGA) 
for older people at home can reduce care home and hospital admissions and falls. A 
systematic review investigating the implementation of one primary care CGA-based 
approach noted a lack of an agreed implementation model and concerns of workforce 
capacity in UK primary care (Craig et al., 2015). Another review attempted to identify 
approaches to CGA in primary care and found several in existence. However, the 
review identified the need for more research into what is feasible for large numbers of 
the population (Morley et al., 2017).  With growing numbers of older, frail people, this 
topic has gained interest in the UK and abroad. How best to deliver CGA to frail older 
people in a range of healthcare settings was one of the top ten research priorities 
identified by the UK priority setting organisation (James Lind Alliance, 2018). 
64 
 
The BGS issued a Position Statement on Primary Care for Older People (British 
Geriatrics Society, 2018), which proposes that there should be a multi-professional 
approach and pointed to some evidence that nurses and allied health professionals 
can successfully lead and input into the assessment and care planning process 
(Schadewaldt et al., 2013). However, the nursing contribution to frailty management is 
poorly developed, with studies assessing nurse-led approaches showing mixed results 
(Bleijenberg et al., 2017a; Schein et al., 2005; Stijnen et al., 2014a; Stijnen et al., 
2014b; Taube et al., 2018).   
Whilst a CGA-based approach may be appropriate for primary care delivery, the 
practicalities of its implementation require further exploration, including which 
components can and should be led by nurses rather than doctors. The use of 
alternative clinicians to lead CGA may, in itself, provide additional capacity to support 
more frail older people closer to home. 
4.4  Aim  
To meet the challenges of an increasingly frail, older population, there is a need to 
provide proactive, holistic, person-centred care led by nurses that is clinically effective. 
However, it is not yet clear what the content of that approach should be or if a nurse-
led model if feasible. Therefore, the aim of this study was to identify and reach 
consensus on components of a primary care, nurse-led CGA-based care delivery 
model.  
4.5 Methods 
4.5.1 The e-Delphi process 
The Delphi method is an iterative process comprised of repeated rounds of voting and 
is effective for determining expert group consensus where there is little or no definitive 
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evidence and where opinion is important (Babak et al., 2019). This Delphi survey was 
conducted as the first phase of a mixed-methods feasibility study to develop and test 
a nurse-led assessment and care planning approach for frail older people in primary 
care.  
Methods and results are reported in line with the “Guidance on Conducting and 
Reporting Delphi Studies” (CREDES) (Jünger et al., 2017) which promotes 
consistency and quality in conducting Delphi studies. Figure 1 summarises the Delphi 
process. In order to provide rigour and transparency in methods, study procedures 









4.5.2 Survey Preparation 
The study consisted of a three-round electronic Delphi (e-Delphi) method, which was 
conducted between September 2017 and January 2018. The study followed a modified 
Delphi technique (Foth et al., 2016) using literature review, opinion and the judgment 
of experts. It aimed to reach consensus on an issue from an expert panel (Keeney, 
Hasson & McKenna, 2011). The use of an electronic survey provided advantages over 
paper versions, including high quality data collection, ease and speed of 
administration, direct communication with individual panel members, and rapid 
collation of feedback allowing data collection to be undertaken in a limited time period 
(Gill et al., 2013). Ethical approval was provided by the University of Plymouth Faculty 
Research Ethics and Integrity Committee (Reference Number: 18/19-1027).  
4.5.3 Literature review 
A review of the literature was completed to identify what was already known regarding 
the content of nurse-led CGA-based approaches in primary care. A search of PubMed 
and CINAHL English language journals from 1990 to 2017 was undertaken to identify 
articles on the topic. The search strategy combined headings and keywords for 
“comprehensive geriatric assessment”, “CGA”, “primary care”, “community care”, 
“nursing assessment”, “care plan” “frail”, “older people”. Information on components of 
an intervention were extracted and listed. This information was not shared with the 
expert panel in round one so as not to influence panel members’ judgements and 
prevent bias in the first open-ended opinion round. 
4.5.4 Development of the e-Delphi surveys 
The round one survey was designed by three research team members. Subsequently, 
the survey was piloted with two clinicians for ease of use, understanding of content 
and amendments were made prior to the first round. The round one survey began with 
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information on the purpose of the study and an informed consent form. Consent 
included panel members agreeing to the use of email addresses to contact with 
subsequent survey rounds. Initial questions related to the demographic characteristics 
of the experts including years qualified as a nurse, specialist area of practice and any 
specialist qualifications. There was one open-ended question; “Please give your ideas 
about the components of a CGA intervention that you think are important and will 
improve clinical outcomes for frail older people in a primary/community setting. Please 
list as many as you can for example; multidisciplinary team involvement, agreeing a 
plan of care and support, medication review, environmental assessment, etc.” 
The round two survey consisted of 36 components of CGA suggested by the panel 
members and the results of the literature review. Panel members were asked to rate 
each component on two issues; importance and feasibility. Importance was rated on a 
five-point Likert scale ranging from one is ‘not important at all’ to five is ‘extremely 
important’. The feasibility scale was a five-point Likert scale ranging from one is “not 
feasible” to five is “extremely feasible”. The last question in this survey was an open-
ended question asking if there were any missing components that could be included in 
the next round. 
The round three survey consisted of 36 components. The aggregated results 
(frequency and percentage) for each component from round two were presented back 
to the panel along with the same rating scales so that panel members had the 
opportunity to re-rate based on the group response in round two.  
4.5.5 The expert panel 
The research team aimed to recruit at least 20 expert panel members from across the 
country in order have a national panel with expertise in the care of older people in 
primary care. Expert nurses were contacted through the British Geriatrics Society 
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Nurses Council, the Royal College of Nursing Older Peoples Forum Steering 
Committee and the National Health Service (NHS) National Community/Primary Care 
Nurses Forum. Participating organisations were asked to provide letters of approval 
and confirm that they would share the survey with their members. Panel members were 
sent an invitation to participate and a participant information sheet. The surveys were 
administered via an online survey platform, “SurveyMonkey”. They were directed to 
SurveyMonkey (http://www.surveymonkey.com/) with a URL specific to this survey. 
Panel members were asked to confirm consent through the completion of an online 
consent form as part of the first round survey. 
4.5.6 Confidentiality and Anonymity 
Panel members were assured of anonymity in the participant information sheet. 
Internet protocol addresses were used to contact panel members who could not be 
identified in the process and individual responses were unknown to other panel 
members.  
4.5.7 Statistical analysis 
Statistical analysis and definition of consensus were planned and agreed prior to data 
collection. Panel members’ demographic characteristics were reported by descriptive 
statistics; frequencies and percentages. Data from the open-ended question in round 
one was qualitative and analysed using content analysis (Hasson, Keeney & McKenna, 
2000). In round two, frequencies and percentages for all ranking scales were 
calculated prior to being presented back to the panel in round three. In addition to 
frequencies being derived, means and standard deviations for ranking scores were 
calculated to assess convergence of opinions from round two to round three. Final 
consensus figures (percentage consensus for each component) were calculated for 
reporting after round three. 
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4.5.8 Response rate 
There is no specific guidance available for acceptable response rates in Delphi studies. 
Some Delphi studies relating specifically to older people’s care have not reported 
response rates (Goldberg et al., 2016; Mahoney et al., 2017). However, others have 
reported between 75% (Rodríguez-Mañas et al., 2013) and 92% (Jeffs et al., 2017). 
Due to the iterative process of Delphi studies there is the potential for panel members 
to withdraw after subsequent rounds, which can lead to response bias if attrition is 
significant (Evans, 1997). Some authors recommend that a 70% response rate is 
necessary for each round to maintain rigour (Sumison, 1998). In this study, a response 
rate of 70% was anticipated to the rounds two and three. In order to encourage 
consensus, three reminders to complete the survey were sent to the panel members. 
4.5.9 Definition of consensus 
An a priori definition of consensus was agreed by the research team (Jünger et al., 
2017). For this to be achieved, 75% expert panel agreement that a component met the 
criteria of “very important” or “extremely important” and “very feasible” or “extremely 
feasible” was required at round three.   
4.6 Results 
Panel members who were invited to participate were volunteer experienced nurses 
(n=75) who, at the time of the e-Delphi, worked with older people in primary and 
community healthcare settings. Thirty-three of the panel members responded to the 
first round survey and one respondent withdrew from future rounds. Response rate to 
the round two survey was 72% (23 out of 32) and the round three survey achieved a 
91% response rate (21 out of 23).   
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4.6.1 e-Delphi round one 
Content analysis generated an initial 35 components suggested by the expert panel. 
These were aggregated into 30 components and grouped into six domains and ranked 
by number of responses. The domains were; (1) frameworks/care structures; (2) 
home/family/safety assessment; (3) personalised care and support planning; (4) long-
term condition management; (5) physical health assessment; (6) mental health 
assessment.  
Six additional components were incorporated from the literature review (Table 4.1). 
These were a system for information gathering, a shared care record, listening to the 
patient’s story as part of personalised care and support planning, assessment of pain, 
assessment of vision, hearing and dentition and assessment of bladder and bowel 
function. The combination of these components and those from the expert panel 




Table 4.1: Components identified in round one 
 Components Number of 
Responses 
 Frameworks/care structures 
1 Multi-disciplinary team discussion/review 8 
2 Coordinated multidimensional assessment and care with an identified lead 
clinician/case manager 
5 
3 A competent, well trained workforce who can deliver an assessment and 
care planning intervention 
3 
4 A timely response to crises  1 
5 A system for data/information gathering e.g. past medical history, social 
circumstances, family history 
* 
6 A shared care record * 
 Home/family/safety assessments 
7 Environmental assessment including housing and equipment aimed at 
maximising independence 
11 
8 Assessment of social support including financial concerns, benefits 
entitlement, social isolation 
8 
9 Assessment of functional ability and activities of daily living including 
reablement potential 
5 
10 Assessment of falls risk 3 
11 Assessment of carer’s needs 3 
12 Determining spiritual needs and support systems 1 
13 Exploring opportunities for employment/education/hobbies 1 
 Personalised Care and Support Planning 
14 Agreeing and formulating a plan together based on shared decision making 
and the preferences of the individual: working the partnership 
10 
15 Safeguarding this contract by documenting it in a co-created care or support 
plan: personalised care and support planning 
10 
16 Monitoring response to the care and support plan 10 
17 Review and revising of the care and support plan 10 
18 Empowerment and self-management and enabling behavioural change 6 
19 Determining advance care preferences 4 
20 Establishing the patient’s personal goals and where support is needed 
(person centred care) 
4 
21 Assessment of resilience and coping mechanisms – an asset based 
approach 
3 
22 Escalation/contingency planning: actions for when the patient’s condition 
deteriorates 
2 
23 Assessment of patient’s ability to actively participate in care and planning 2 
24 Establishing an individual’s narrative by active listening/appreciative enquiry * 
 Long Term Condition Management 
25 Medication review including ability to self-administer, concordance and de-
prescribing 
10 
25 Advanced clinical assessment skills – physical examination and ordering 
investigations 
6 
27 Problem/deficit identification 3 
28 Optimising management of long term conditions/multimorbidity 1 
 Physical Health Assessments 
29 Assessment for the presence and severity of frailty 2 
30 Assessment of nutritional status including hydration 1 
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 Components Number of 
Responses 
31 Sexual health assessment 1 
32 Assessment of pain * 
33 Assessment of vision, hearing and dentition * 
34 Assessment of bladder and bowel function * 
 Mental Health Assessments   
35 Assessment of cognition 6 
36 Assessment of mood and psychological well-being 6 
* Component taken from literature review 
 
4.6.2 e-Delphi round two 
In round two, the 36 components were presented to the panel members for ranking on 
importance and feasibility. Full results with frequencies, percentages, mean scores and 
standard deviations for all components in rounds two are presented in Supplementary 
Information 1 (Appendix 2). When analysed in the six domains, mean scores for 
importance were high across all components and lower for feasibility with the exception 
of the frameworks/care structures domain which were high for both importance (mean 
4.8; SD 0.06) and feasibility (mean 4.8; SD 0.06). All other domains had mean scores 
ranging from 4.4 (SD 0.50) to 4.59 (SD 0.11) for importance and between 3.47 (SD 
0.25) and 4.59 (SD 0.33) for feasibility. No additional components were suggested by 
panel members.  
4.6.3 e-Delphi Round three 
Results with frequencies, percentages, mean scores and standard deviations for all 
components in round three are presented in Supplementary Information 2 (Appendix 
3). Domain mean scores for both rounds are visualised in Figures 4.2a and 4.2b to 
demonstrate increasing mean scores and convergence of opinion across the rounds.  
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Generally, mean scores for importance remained high across all domains, with lower 
scores for feasibility. Scores relating to the domain of frameworks/care structures were 
higher in round three (mean 4.88; SD 0.13) than in round two (mean 4.80; SD 0.06) 
for importance, but with a larger standard deviation in round three, indicating more 
variability in scoring. However, feasibility scores reduced and had larger standard 
deviations from round two (mean 4.8; SD 0.06) to round three (mean 3.0; SD 1.5) 
indicating less consensus on feasibility of these components. The component relating 
to the need for a shared care record within this domain strongly influenced the overall 
mean score (mean 2.83; SD 0.75). Mean scores relating to the other four domains all 
increased from round two to round three with variable standard deviations; 
personalised care and support planning (importance: 4.55; SD 0.12 to 4.74; SD 0.12, 
feasibility: 3.47; SD 0.25 to 3.7; SD 0.44), long term condition management 
(importance: 4.53; SD 0.19 to 4.79; SD 0.18, feasibility: 3.59; SD 0.19 to 3.78; SD 
0.31), physical health assessments (importance: 4.47; SD 0.36 to 4.72; SD 0.00, 
feasibility: 3.85; SD 0.32 to 4.10; SD 0.35)  and mental health assessments 
(importance: 4.59; SD 0.11 to 4.82; SD 0.07, feasibility: 3.57; SD 0.23 to 3.9; SD 0.03). 
This may indicate overall convergence of opinion across rounds but with small 
numbers of outlying opinions which affected standard deviation.  
4.6.4 Panel consensus 
Following round three, all 36 components met consensus on importance, but only 11 
out of the 36 components reached consensus on feasibility at the pre-defined level of 
75% panel agreement (Table 4.2).  
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Table 4.2: Final percentages for each component (importance and feasibility) 
Components  Importance Feasibility 
Frameworks/care structures  
Multi-disciplinary team discussion/review 
100% 81.0% 
Coordinated multidimensional assessment and care with an identified lead clinician 
100% 76.2% 
A competent, well trained workforce who can deliver the intervention 
95.3% 47.6% 
A timely response to crises  
90.5% 19.1% 
A system for data/information gathering e.g. past medical history, social circumstances 
100% 47.6% 
A shared care record 
95.2% 57.8% 
Home/family/safety assessments  
Environmental assessment aimed at maximising independence 
95.2% 52.4% 
Assessment of social support including financial concerns, social isolation 95.2% 47.6% 
Assessment of functional ability and activities of daily living including reablement potential 
95.2% 85.7% 
Assessment of falls risk 
100% 81.0% 
Assessment of carer’s needs 
100% 66.7% 
Determining spiritual needs and support systems 
95.2% 57.1% 
Exploring opportunities for employment/education/hobbies 
81.0% 38.1% 
Personalised Care and Support Planning  
Agreeing and formulating a plan together based on shared decision making  
90.5% 57.1% 
Safeguarding this contract by documenting it in a co-created care or support plan 
85.7% 33.3% 
Monitoring response to the care and support plan 
85.7% 42.9% 
Review and revising of the care and support plan 
95.2% 61.9% 
Empowerment and self-management and enabling behavioural change 
95.2% 33.3% 
Determining advance care preferences 
100% 71.4% 
Establishing the patient’s personal goals and support needed (person centred care) 
95.2% 81.0% 
Assessment of resilience and coping mechanisms – an asset based approach 
95.2% 33.3% 
Escalation/contingency planning: actions for when the patient’s condition deteriorates 
100% 61.9% 
Assessment of patient’s ability to actively participate in care and planning 
85.7% 76.2% 
Establishing an individual’s narrative by active listening/appreciative enquiry 
90.5% 52.4% 
Long Term Condition Management  
Medication review including ability to self-administer, concordance and de-prescribing 
100% 81.0% 




Optimising management of long term conditions/multimorbidity 
100% 71.4% 
Physical Health Assessments  
Assessment for the presence and severity of frailty 
90.5% 81.0% 
Assessment of nutritional status including hydration 
100% 85.7% 
Sexual health assessment 
81.0% 28.6% 
Assessment of pain 
100% 95.2% 
Assessment of vision, hearing and dentition 
100% 66.7% 
Assessment of bladder and bowel function 
100% 81.0% 
Mental Health Assessments    
Assessment of cognition 
100% 71.4% 




In the frameworks/care structures domain all components met the consensus threshold 
for importance (range 90.5 -100%), but four out of the six did not reach consensus on 
feasibility; a competent, well trained workforce (47.6%), a system for data/information 
gathering (47.6%), a shared care record (57.8%) and a timely response to crisis 
(19.0%).  
In the home/family/safety assessments domain all components met the consensus 
threshold for importance (range 81.0 -100%), but five out of the seven did not reach 
consensus on feasibility; environmental assessment (52.4%), assessment of social 
support (47.6%), assessment of carer need (66.7%), determining spiritual needs 
(57.1%) and exploring opportunities for employment/education/hobbies (38.1%).  
In the domain of personalised care and support planning all components met the 
consensus threshold for importance (range 85.7 -100%), but nine out of the eleven did 
not reach consensus on feasibility; formulating a personalised care and support plan 
(PCSP) (57.1%), documenting in a co-created PCSP (33.3%), monitoring response 
(42.9%), review of the PCSP (61.9%), empowerment and self-management (33.3%), 
determining advanced care preferences (71.4%), assessment of resilience and coping 
mechanisms (33.3%), escalation/contingency planning (61.9%) and establishing the 
narrative (52.4%).  
All four components in the long-term condition management domain met the threshold 
for consensus on importance (range 90.5 -100%) while three of these did not achieve 
consensus on feasibility; advanced clinical assessment skills (51.2%) and 




In the domain of physical health assessments, all components met the consensus 
threshold for importance (range 80.1% -100%), and two out of the six did not reach 
consensus on feasibility; assessment of vision, hearing and dentition (66.7%) and 
sexual health assessment (28.6%). Finally, in the domain of mental health 
assessments, both components of assessment of cognition and assessment of mood 
met the consensus threshold for importance (range 66.7 -100%), but not for feasibility 
scoring 71.4% and 66.7% respectively.  
4.7 Discussion 
The purpose of this e-Delphi study was to establish consensus on important and 
feasible components of a person-centred, nurse-led assessment and care model for 
frail older people in primary care. Following three rounds of surveys, the expert panel 
identified what they considered to be both important and feasible components of the 
care model and consensus at the required level for importance was reached for all 
suggested components. The important components are similar to those contained in 
the BGS CGA toolkit (Turner et al., 2019), however, the panel did not think the majority 
of the components were feasible to deliver in current UK primary care. What is less 
clear is the reason for these beliefs. It may be that primary care nurses have concerns 
about the time and infrastructure available to complete a CGA or that there may be a 
lack of specialist skills.  
There was clear concern demonstrated in the low feasibility scores for the existence of 
a shared care record to enable information gathering and sharing across organisations 
and the components that relate to personalised care and support planning. In 2013, 
the National Collaboration for Integrated Care and Support published its report 
“Integrated Care and Support: Our Shared Commitment” (National Collaboration for 
Integrated Care and Support, 2013) which stated the government’s pledge to end 
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institutional divisions and provide seamless health and social care for older people. 
The panel members’ responses highlighted the importance of a competent, well trained 
workforce and demonstrated concerns about the feasibility of working across 
organisational boundaries in partnership to develop personalised plans of care. 
Studies have demonstrated the value of multi-professional involvement and a shared 
care record (Garrard et al., 2020; Phelan et al., 2007). It would seem that the reality in 
primary care is still far from the strategic vision of integrated care for older people. 
Other components that were thought not feasible relate to the possession of specific 
skills by primary care nurses. It was interesting that the panel thought nurses would 
not be able to conduct an assessment of carer’s needs, environmental assessments 
and determining preferred place of care. They also doubted the feasibility of nurses 
with advanced assessment skills. Some studies have reported a lack of specialist older 
people knowledge and skills amongst primary care nurses (Hertogh & Bastiaans, 2016; 
Hoogendijk, 2016) and it would appear that the expert panel in this study may share 
this view.  
Notwithstanding the concerns already discussed, it was encouraging to see that 
specific components from other domains were thought to be important and feasible 
within a nurse-led approach. These were; establishing the diagnosis and severity of 
frailty and assessment of functional ability including re-ablement, falls risk, pain 
assessment, medication adherence and optimisation, nutritional status (including 
hydration) and bladder and bowel function. This is important information in the design 
of a nurse-led CGA-based approach as, to date, studies of primary care based CGA 
have demonstrated some benefits relating to clinical outcomes and acceptance by 
patients (Fenton et al., 2006; Hermush et al., 2009; Phelan et al., 2007), however, they 
have not specifically detailed the content of the intervention under study. Transparency 
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about specific content would enable further evaluation or assessment in clinical 
practice. 
The panel members had reservations about whether completion of CGA in current 
primary healthcare practice is possible and this reflects global  concerns about 
shortage of primary healthcare professionals (World Health Organization, 2013) and 
the debate about how capacity and clinical quality can be increased by new models of 
care provided closer to home (Elkan et al., 2001). They also echo results of other 
studies that highlight the perceived challenges to the delivery of primary care-based 
CGA (Craig et al., 2015; Monteserin et al., 2010; Stijnen et al., 2014a). This may be an 
opportunity to examine who is the most appropriate clinician to provide care and 
support to frail older people with a view to increasing capacity within the primary care 
team and a more cost-effective and convenient approach for patients who would 
struggle to attend secondary care. Traditionally, in the UK, this is likely to involve a 
time-limited appointment with a GP (primary care doctor). A new model may include 
the substitution of nurses where care and treatment has previously been provided by 
doctors.  
Ensuring the most appropriate clinician delivers care and support is an ongoing debate, 
with increasing acceptance that care for older people with complex needs can be led 
by nurses. Three systematic reviews have reported that care provided by nurses is of 
equal quality to care provided by primary care doctors (Horrocks, Anderson & 
Salisbury, 2002; Laurant et al., 2005; Martínez-González et al., 2014). Recently, the 
BGS affirmed that nurses are best placed to lead CGA-based approaches in primary 
care  as they are “are well placed to manage the complexity of assessment in an 
efficient way drawing together the different strands to coordinate a personalised 
treatment plan” (Turner et al., 2019, p.4). Turner et al also emphasise that nurses have 
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a duty to act as patient advocate set out within their codes of conduct and are expert 
in enabling shared decision making. Given that CGA is a multi-dimensional 
assessment and care planning process, it has been advocated that multiple clinicians 
should be involved and that nurses are best placed to coordinate and lead the process 
ensuring best use of scarce resources and targeting of this approach at those who will 
most benefit (Schadewaldt et al., 2013).  
4.8  Study Limitations 
Older people and their carers were not included in the expert panel and this was a 
limitation of the study in that the panel may not reflect views on what is important them. 
In order to address this deficit, the Delphi findings were later shared with a research 
stakeholder group made up of older people, carers and clinicians to consult with them 
on the results of this study and final intervention content and delivery methods. 
Stakeholders agreed with the results of the e-Delphi survey but suggested some 
modification of components to improve personalisation and ensure the older person 
was able to express their views and concerns. Based on this, a conversation guide 
was added to the assessment pack (Supplementary Information 3 (Appendix 4)) which 
would be completed on first visit and guide the ongoing assessment and care planning 
process. This consisted of prompts to enable the older person to consider their own 
situation and engage in a conversation, which would lead to goal setting and care 
planning. It meant the approach would be uniquely person-centred and could address 
feasibility, as not all components of the assessment would be relevant to all people. 
This also has the potential to shorten and refine the assessment and care planning 




This e-Delphi study developed consensus on important and feasible components of a 
nurse-led, CGA-based approach in primary care. The study indicates which 
components of traditional CGA could be effectively delivered in primary care and which 
may not be as feasible in practice. It would seem that nurses may be the most 
appropriate clinician to lead this care in partnership with frail older people if there is a 
supportive infrastructure and sufficient numbers of skilled nurses available to meet the 
needs of the growing older population. There is now a need for development, further 
refinement and then feasibility testing of this new approach to ensure it is 
comprehensive and fit for purpose.  
4.10 Implications for Practice 
 The study indicates which components of traditional, hospital-based CGA may 
be effectively delivered in primary care and which components may not be 
feasible in practice. 
 There is potential to develop a new care model that will be clinically effective, 
person-centred and can be delivered by nurses in primary care settings. 
 This new approach has the potential to improve health outcomes, maximise 




4.11 Research Stakeholder Involvement 
The remaining sections of this chapter are not part of the journal manuscript but provide 
more detail of the research stakeholder engagement that followed the e-Delphi survey.  
The consensus components were drafted into an assessment pack to guide the 
assessment and care planning process. The final pack contained 33 assessment 
instruments which were evidence based tools relating to the components (Appendix 
6). Given the low scores on feasibility there was concern that components that were 
important to frail older people and their carers could be omitted from the final 
intervention. A limitation of this study was that older people and their carers were not 
included in the expert panel. In order to address this, the results were shared with a 
research stakeholder group to consult with them on the final intervention, its content 
and delivery methods. Notes of the group meeting are included as Appendix 5. 
The group consisted of two local clinical leads for older people’s care, the researcher 
and one academic supervisor. The meeting was held at a local events centre. In 
addition, a local general practitioner, an older person and their carer were invited to 
attend, but could not, so, the researcher consulted with these stakeholders outside of 
the meeting. Information from the e-Delphi survey was sent to the general practitioner 
and a telephone meeting arranged at a convenient time to gain feedback. The 
researcher went to the home of the older person and their carer, sharing information 
with them and recorded their views on content of the final intervention. This additional 
stakeholder involvement was designed to ensure the intervention to be tested in the 
fRCT was fit for purpose. The stakeholders were asked to discuss the components 
from the e-Delphi survey and to prioritise and decide what should be included in the 
intervention with a focus on what could work in clinical practice and would meet frail 
older peoples’ and carers’ needs.  
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4.11.1 Results of the research stakeholder group 
The group reviewed each component of the e-Delphi results and discussed and agreed 
whether it should be included or not within the HAPPI assessment pack and how it 
should be presented to ensure ease of use and feasibility in the trial. 
Care Structures/Processes 
These components included access to a shared system for information gathering 
(clinical record), multi-disciplinary team discussion/review, a timely response to crises 
and a competent, well-trained workforce to deliver the intervention. It was agreed that 
these components formed important feasibility outcomes for the trial, but were not 
elements of the assessment process. It was agreed that these elements would not be 
part of the assessment pack. 
Nursing/Advanced Clinical Practice 
It was agreed that tools to assess the presence or severity of frailty, falls risk, pain, 
medication review, nutrition/hydration/dentition, vision/hearing, bladder and bowel 
function, optimising long-term condition management and assessment of functional 
capacity should all be included in the assessment pack. Further discussion concluded 
that the conversation guide should also include prompts for problem/deficit 
identification, advance care planning and escalation/contingency planning. A 
personalised care plan template was under development in the county and it was 
agreed to use this template in the trial.  
Mental Health 
Stakeholders suggested that prompts to investigate mood and psychological wellbeing 
including anxiety and depression should be part of the conversation guide with more 
detailed assessments available in the assessment pack. 
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Social and Environmental Circumstances 
Stakeholders suggested that this part of the assessment pack should be re-titled as 
“Home and Safety” and be included within prompts in the conversation guide such as 
“do you feel safe at home”, “is there anything regarding your home that concerns you?” 
An exploration of loneliness and social isolation was included within the mood and 
psychological well-being section. It was agreed that exploration of spiritual needs and 
support systems would be included in advance care planning discussions. Although 
assessment of carers needs did not reach consensus for feasibility in the e-Delphi 
survey, it was strongly felt by stakeholders that this was an essential element of the 
intervention and would be included in the conversation guide as a prompt. 
Personalised Care and Support Planning 
It was agreed to combine and include the components in this section as essential pillars 
of personalised care and support planning. Assessment of resilience and ability to 
participate in care planning were felt to be an important element of the intervention and 
so it was agreed to include them in the conversation guide prompts.  
Intervention Delivery 
The stakeholders fed back that the HAPPI intervention should encompass the following 
key principles that make the intervention unique and different to current care for this 
population: 
a) The person will not be referred in crisis (as in current community matron 
practice) but will be approached proactively following identification. 
b) The community matron who delivers the intervention will visit without first 
gaining any past medical history or other information about the person’s health 
from the general practice record and initiate an “unbiased, open dialogue” with 
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the person. Any issues/problems/deficits will be generated from this dialogue 
and the assessment and care-planning intervention will develop from this point. 
c) There will be an ongoing development and review of a support plan in 
partnership with the person and carer (if appropriate). 
d) Outcome measures will focus on responsiveness to change/completeness of 
the intervention and discharge plans; what is different after the intervention is 
complete. 
e) The intervention will be based on a “conversation guide” rather than a 
prescriptive assessment template. Assessment tools will be available to be used 
if they are appropriate for that person’s needs/problems. 
4.12 Chapter conclusions 
In conclusion, the output from the Delphi survey combined with the research 
stakeholder consultation enabled the development of the HAPPI conversation guide, 
care plan templates and assessment pack, which formed the intervention for the fRCT 
(Appendix 6). The following chapter details the methods of the fRCT with embedded 




Chapter 5: Evaluating feasibility of the Intervention 
5.1 Chapter introduction 
In this chapter, the methods of the fRCT are presented as a paper which was published 
in the Journal of Advanced Nursing 2019;00:1–10. DOI: 10.1111/jan.14106 (Lyndon et 
al., 2019). The full trial protocol can be found in Appendix 7. An estimated contribution 
(%) of each author are as follows: Lyndon, H. (90%), Latour, J.M. (2%), Marsden, J. 
(2%), Campbell, S. (2%), Stevens, K. (2%), Kent, B. (2%).  
HL generated the initial idea, wrote the study protocol and coordinated contributions 
from the other authors. HL, BK, JML, SC and KS made substantial contributions to 
conception and design. HL, BK, JML, SC and KS were involved in drafting the 
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During an initial phase of this research, an e-Delphi survey was conducted to gain 
consensus among stakeholders on the components of a nurse-led assessment and 
care planning intervention for older people who live with frailty in primary care. This 
feasibility randomised controlled trial (fRCT) will test the proposed intervention and its 
implementation and determine methods for the design of a conclusive randomised 
controlled trial. 
Methods 
The fRCT, with embedded qualitative study, aims to recruit 60 participants. Moderately 
and severely frail older people will be identified using the electronic frailty index (eFI) 
and the intervention will be delivered by senior community nurses. The control 
participants will receive usual primary care for frailty. The study is funded by the 
National Institute of Health Research (NIHR) (funding granted in May 2016, ref: ICA-
CDRF-2016-02-018) and received NHS and University Ethical approval in 2018. 
Discussion  
There is evidence that the delivery of complex interventions for community-dwelling 
older people can reduce care home and hospital admissions and falls, there is less 
evidence for the benefit of any specific type or intensity of intervention or the additional 
benefits of targeting the frail population. This trial will determine feasibility of the 






This study aims to address the limitations of current research by using a systematic 
method of frailty diagnosis and participant identification, trialling implementation of a 
person-centred intervention and testing of feasibility parameters. 
Trial registration number: ISRCTN: 74345449 
Key Words 





Frailty is a multifactorial clinical syndrome associated with ageing. It is caused by 
incremental damage to body cells and systems as individuals’ age (Cesari, Vellas & 
Gambassi, 2013; Rockwood & Mitnitski, 2007). Although its specific pathophysiology 
is not fully understood, it is known to follow similar mechanisms to sarcopenia (muscle 
weakness), malnutrition and is underpinned by de-regulation of inflammatory 
processes (Cesari et al., 2014b; Jeejeebhoy, 2012; Li, Manwani & Leng, 2011). 
Although associated with older age, frailty can be distinguished from the effects of 
natural ageing. Frailty manifests when multiple body systems fail, the more systems 
that fail, the more likely it is that the person will become frail (Clegg et al., 2013; Morley 
et al., 2013). As people age, there is a loss of physiological reserve in all body systems, 
however, there is an intrinsic reserve buffer which enables homeostasis to be 
maintained and good function preserved. Once this threshold is breached then frailty 
will result with repair mechanisms no longer able to maintain homeostasis (Lang, 
Michel & Zekry, 2009). Other independent risk factors for frailty development include 
loneliness (Gale, Westbury & Cooper, 2018), deprivation (Hoogendijk et al., 2014), 
depression (Vaughan, Corbin & Goveas, 2015), low physical activity and 
polypharmacy (Heuberger, 2011). 
Given the multifactorial nature of frailty, an effective intervention should address 
relevant risk factors using a holistic, multi-dimensional approach. This approach is the 
founding principle of a comprehensive geriatric assessment (CGA) which is described 
as the management and treatment for prevention of deterioration in frailty (Gladman, 
2016).  The British Geriatrics Society describe CGA as  
“a multidimensional, interdisciplinary diagnostic process to determine the medical, 
psychological and functional capabilities of a frail older person in order to develop a 
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coordinated and integrated individualised care plan for treatment and long-term follow 
up in partnership with the patient and carers” 
 (British Geriatrics Society, 2014, p.10).  
This approach is part of routine care and well evidenced in the acute hospital setting 
within the speciality of geriatric medicine, but not well established in other healthcare 
settings such as primary care.  To meet the challenges of the increasingly frail and 
older population and to provide proactive, holistic care close to home, there is a need 
for a standardised intervention that can be implemented in primary care, which 
provides value for money, is not time consuming and has a high level of specificity to 
enable primary care resource to be targeted at patients who will most benefit from the 
intervention. If a primary care led standardised intervention is to become a reality, the 
burden of completion and effect on patient outcomes require further research as to the 
feasibility, acceptability, effectiveness and scalability. Informed by the existing 
literature and patient and public engagement (PPI), a primary care intervention that 
contains cost and clinically effective components of the acute CGA framework was 
developed.  
An e-Delphi survey was conducted to gain consensus among stakeholders on the 
components of the intervention. After mapping the components, a new intervention 
was developed including a conversation guide and assessment pack to structure the 
intervention to be tested in a feasibility randomised controlled trial (fRCT). This paper 
presents the study protocol of the fRCT. 
5.4 Background 
There is increasing evidence that, using a person-centred approach, frailty can be 
managed as a long-term condition with early identification, diagnosis and effective 
management in order to improve outcomes, prevent or delay deterioration and reduce 
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health and social care costs (De Lepeleire et al., 2009; Lee, Heckman & Molnar, 2015). 
Although they advocate the management of frailty in primary care settings De Lepeleire 
et al acknowledge that the identification of frailty and its application to clinical practice 
in this area are under-developed. Given its high prevalence, frailty management is 
likely to become the remit of primary care in the future. However, there may be 
insufficient capacity and lack of appropriate skills and knowledge in primary care 
settings to adequately manage numbers of frail patients. If an achievable, proactive 
model of care is developed, primary care is the ideal setting to implement a more 
person-centred approach because of the integrated nature of primary and community 
care and the opportunities to interact with patients in their home environment (Beswick 
et al., 2008). 
In 2014 the British Geriatrics Society (BGS) suggested that a primary care led ‘holistic 
review’ by a GP or specialist nurse may enable more frail older people to access 
services out of hospital. However, as previously discussed, it is not clear whether the 
acute hospital CGA framework is immediately transferable. The BGS have suggested 
other considerations that are missing from the traditional CGA framework, such as 
treatment escalation and advanced care planning (British Geriatrics Society, 2014). 
These considerations would appear to be highly relevant as part of a CGA intervention 
delivered in a primary care setting where the clinician has a more long-term and 
person-centred relationship with the patient. A recent review of person-centred care 
concluded that while there is no universal definition of the concept, there are well 
recognised behaviours displayed by nurses that promote person-centeredness, such 
as engaging with the patient as a partner and shared decision making (Sharma, 
Bamford & Dodman, 2016). These behaviours and their foundation in nurses’ 
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approaches to care would appear to make nurses appropriate clinicians to carry out 
CGA/holistic review in a primary care setting. 
5.5 Aim and Objectives 
The aim of this fRCT with an embedded qualitative study is to determine the feasibility 
of delivering the Holistic Assessment and care Planning Intervention (HAPPI) in 
primary care to older people with frailty and determine methods for the design of a 
conclusive randomised controlled trial (RCT). Detailed objectives of the trial are 




Table 5.1: Trial objectives 
 
Objectives a-h will be met within the feasibility randomised controlled trial: 
a. To assess compliance with the HAPPI intervention. 
b. To verify that proposed outcome measurement and follow-up schedules are feasible 
to collect.  
c. To determine achievable targets for recruitment and follow-up rates. 
d. To evaluate method of recruitment using the electronic frailty index (eFI). 
e. To evaluate characteristics and feasibility of the proposed outcome measures and to 
determine suitable outcome measures for the definitive trial. Outcome measures to be 
evaluated have been taken from the ICHOM Older Persons Reference Guide (Akpan 
et al., 2018).  
f. To calculate standard deviation of the outcome measures to estimate sample size for 
the definitive trial. 
g. To assess availability of clinical data and time needed to collect and analyse data 
required for numeric outcome measures. 
h. To explore factors that will enable future economic evaluation alongside the main trial. 
 
 
Objectives i-l will be met within the embedded qualitative study: 
i. To explore the acceptability of the intervention to patients, carers and clinicians in 
primary care. 
j. To identify barriers to delivery of the HAPPI intervention e.g. any operational 
difficulties. 
k. To evaluate clinicians’ willingness to identify, recruit and randomise eligible patients, 
and willingness of patients to be recruited and randomised. 







The trial will be a cluster randomised, controlled feasibility trial with an embedded 
qualitative study aiming to recruit 60 participants from six general practices. Cluster 
randomisation with the general practice as the unit of randomisation has been 
proposed to reduce contamination between control and intervention groups which may 
lead to biased estimates of effect size in the main trial. Three general practices will be 
allocated to the intervention and three to the control arm of the study, so that patients 
of individual general practices will either receive the intervention or usual primary care. 
As the HAPPI is an intervention that aims to impact on staff expertise, awareness and 
clinical practice, it is important to ensure separation of the control and intervention 
groups in this way. Fig 5.1 shows the flow diagram of the study design. 
97 
 




5.6.1 Study Setting and General Practice Eligibility 
Six general practices will be recruited to the study. The following factors will be used 
to determine suitability of practices to participate in this study: 
a. The practice use the electronic frailty index (eFI) to identify their moderately and 
severely frail population 
b. The practice are willing to fulfil the requirements of the study relating to 
screening, recruitment and provision of outcome data 
c. There is at least one senior community nurse attached to the practice who is 
willing to deliver the HAPPI intervention 
General practices registering an interest in the trial will be invited to complete a 
feasibility questionnaire to assess their suitability which will be checked by the Chief 
Investigator. Reasons for non-selection of practices will be fully documented to inform 
feasibility objectives. 
5.6.2 Recruitment 
Under the terms of the NHS England General Practice Contract (NHS England, 2017), 
practices are required to identify moderately or severely frail patients aged 65 years 
and over in their practice population. Practices use an appropriate evidenced based 
tool such as the electronic frailty index (eFI) (Clegg et al., 2016). The eFI is a 
computerised algorithm that is integrated into the majority of general practice electronic 
clinical records and is used to identify and grade severity of frailty using a cumulative 
deficit model based on a number of variables that including clinical indicators, long-
term conditions, disabilities and abnormal test results (Clegg et al., 2016).  
In order to generate a list of the moderately and severely frail patients, a practice 
administrator will run the eFI as a database search and this will classify the entire 
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practice population into fit, mildly frail, moderately frail and severely frail people. The 
output from the eFI, combined with the application of the trial inclusion/exclusion 
criteria, will identify initial potential participants for the trial.   
Potential participants will be eligible for the study provided they are: 
a. Aged 65 years and over 
b. Moderately frail: Electronic Frailty Index (eFI) >0.24 to 0.36 or severely frail (eFI 
> 0.36) 
c. Frailty confirmed by PRISMA7 instrument 
d. Able to give informed consent  
e. Living in own home/supported living accommodation 
 
Patients in receipt of palliative care with limited life expectancy, those who lack mental 
capacity to give informed consent or if they are already on the caseload of a senior 
community nurse will be excluded from the study. 
Ninety potential participants will be randomly sampled from the eFI list, 45 in the 
moderate and 45 in the severely frail categories. If there are less than 45 in either 
category then sampling will not occur and all patients go forward for eligibility checking. 
The eFI is a population risk stratification tool and cannot confer clinical diagnosis, 
therefore, a further step is required to make a diagnosis of frailty and confirm eligibility. 
Frailty diagnosis will be confirmed by the completion of the PRISMA7 questionnaire 
(Raiche, Hebert & Dubois, 2008).  An invitation to participate in the trial and PRISMA7 
will be sent to the 90 people. Names of interested patients who meet PRISMA7 criteria 
will be passed to the research team who will make contact. An appointment will be 
made for a visit at home or in the general practice to provide choice and minimise 
participant burden. During this consultation, the participant will be given the opportunity 
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to ask further questions about the study before consent is obtained and baseline 
assessments carried out.  
5.6.3 The intervention 
Participants in the intervention group (n=30) will receive the HAPPI intervention 
delivered by a senior community nurse who has received training in its delivery. Senior 
community nurses are experienced nurses with advanced assessment and prescribing 
skills, the required skills set to deliver the assessment and care planning intervention. 
They are attached to individual general practices and employed by the community 
services NHS Trust.  In order to ensure a standardised approach, training will be given 
prior to delivering the intervention using a training package delivered by face-to-face 
training by the Chief Investigator. 
A conversation guide, assessment pack and personalised support plan template have 
been developed to support delivery of the intervention and ensure treatment fidelity by 
detailing the content of the intervention and how it should be delivered. The intervention 
will be delivered at home and it is expected that it will consist of one assessment visit 
and up to six care planning visits conducted over a maximum of 12 weeks. For the 
purpose of the trial, the minimum “dose” of the intervention will be defined as one 
assessment visit and at least two care planning visits. Documentation of the 
intervention, including assessment, support plan and evidence of any referrals, will be 
recorded using a standardised template, which will be stored in the clinical record. 
5.6.4 Control 
Participants in the control group (n=30) will receive usual care. This cannot be 
standardised as approaches to care of older people with frailty varies in general 
practice (British Geriatrics Society, 2014). This may include the management of long-
term conditions, referrals to other services, prescribing of medications and routine 
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vaccinations. As part of the feasibility trial, components of usual care will be captured 
in order to standardise for the future definitive RCT.  
5.6.5 Outcomes 
The primary outcomes relate to feasibility of the intervention, feasibility of conducting 
the trial and assessing different potential primary and secondary outcomes of the future 
trial and are summarized in Table 5.1. All potential clinician and participant-reported 
primary and secondary outcome measures will be collected at baseline (following 





Table 5.1: Trial outcome measures 
Feasibility of the Intervention 
a. Numbers of completed HAPPI intervention conversation guides and personalised care plan 
templates 
b. Assess degree of contamination by number of staff moving between intervention and control 
practices 
Feasibility of Conducting the Trial 
c. Number of GP practices expressing an interest in participating 
d. Number of GP practices screened for selection and reasons for non-selection 
e. Number of GP practices withdrawing from the study, timing and reason for withdrawal 
f. Number of GP practices failing to progress through implementation milestones and reasons 
for failure 
g. Number of GP practices withdrawing during the implementation and delivery phases 
h. Numbers of participants screened as eligible, recruited, consented and followed up 
i. Numbers of participants identified using the electronic frailty index (eFI)  
j. Number of and timing of participant withdrawals from follow-up data collection, reasons for 
withdrawal, number of and timing of losses to follow-up 
Potential Primary and Secondary Outcomes 
k. Numbers of potential primary and secondary outcome measures completed at baseline and 
follow-up intervals  
l. Numbers of missing items for each potential primary and secondary outcome at each time-
point 
m. Estimation of the feasibility of collecting data to estimate cost-effectiveness; EQ-5D-5L; add-
on for economic evaluation (Janssen et al., 2013). 
n. Assessment of the following outcome measure instruments: 
 Review of usual care practice, using a clinical note review of control participants 
 Level of care at home received measured by participant self-reporting 




 Levels of loneliness and isolation measured by UCLA 3-Item Loneliness Scale (Velarde-
Mayol, Fragua-Gil & García-de-Cecilia, 2016) 
 Physical health and mobility, level of pain, mood and emotional health and health-related 
quality of life measured by the Medical Outcomes Study 36-Item Short Form Survey 
Instrument Version 1 (SF-36) (Ware & Sherbourne, 1992) 
 Confidence in own ability to manage health and in role as participants in care measured 
by the Health Foundation LTC6 questionnaire (Akpan et al., 2018) 
 Mortality; date and cause of death obtained from the clinical record 
 Number of hospital admissions, readmissions and total number of days spent in hospital 
obtained from the clinical record 
 
The Medical Research Council guidance (Craig et al., 2008) highlights the need to 
explain causative mechanisms and describe contextual factors associated with 
variation in outcomes. Process evaluation will form part of feasibility assessment. This 
highlights the importance of capturing fidelity, which includes assessing whether the 
intervention was delivered in the correct dose/quantity and to the expected number of 
participants. 
Fidelity will be measured in a variety of ways; nurses delivering the intervention will 
receive standardised training and use a conversation guide, assessment pack and 
personalised support plan template as a framework for the intervention.  They will 
record the completed components of the intervention and any adverse events related 
to the intervention. 
5.6.6 Data collection and storage  
Data will be collected through the competition of case report forms consisting of three 
sections relating to intervention delivery, participant outcome measures and data from 
the clinical record. In addition a screening log will be completed by the general practice, 
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detailing numbers of participants screened, those eligible, responses to recruitment 
letters and those who progress to consent or decline to participate. 
A customised database will be used for data entry and double entered data compared 
for discrepancies. Anonymised data will be securely stored for ten years after the 
completion of the trial in accordance with University policy. The Sponsor will be 
responsible for archiving all trial data following submission of the end of study report. 
In data gained from interviews all participants will be anonymised and pseudonyms 
used to demonstrate different participants’ experiences.  
5.6.7 Data analysis 
As a feasibility study, a formal sample size calculation based on considerations of 
power is not appropriate (Thabane et al., 2010). This study is not powered to detect 
clinically meaningful between-group differences in a primary outcome. One of the aims 
of the study is to provide accurate approximations of recruitment and follow-up rates, 
as well as provide estimates of the variability of the proposed primary and secondary 
outcomes to inform sample size calculations for the planned definitive trial. There is no 
consensus on the recommended number of participants required for a feasibility study, 
with suggested numbers ranging from 20 to 70 or more participants when the planned 
primary outcome is of a continuous nature. (Whitehead et al., 2016). Therefore, this 
feasibility study aims to recruit 60 participants in total. 
Participants will be recruited from a minimum of six general practices, with a total 
practice population of 491,000.  The planned recruitment period is six months and over 
this period, across the practices, it is anticipated that following initial screening (eFI), 
approximately 9000 (1500 per practice) potential participants will be identified and from 
these 540 (90 per practice) sampled for second screening (PRISMA7) and eligibility. 
105 
 
Following second screening, it is estimated that around 30% of eligible participants will 
consent to participate. The follow-up rate is estimated to be 70%, which would provide 
follow-up outcome data on a minimum of 42 participants across both allocated groups 
and three sites. 
As a feasibility study it would be inappropriate to test treatment effects, therefore the 
statistical analyses will be descriptive in design (Thabane et al., 2010). The statistical 
analysis plan will conform to guidance related to statistical analysis plans (Gamble et 
al., 2017) and take into consideration the CONSORT updated guidelines for reporting 
feasibility and pilot trials (Eldridge et al., 2016) and also give consideration to the 
CONSORT Patient-Reported Outcome (PRO) extension: Health and Quality of Life 
Outcomes (Calvert et al., 2013) and CONSORT Statement for Randomised Trials of 
Non-pharmacologic Treatments (Boutron et al., 2017). All analyses and data 
summaries will be conducted on the intention-to-treat (ITT) population which is defined 
as all participants randomised regardless of non-compliance with the protocol or 
withdrawal from the study. Participants will be analysed according to the intervention 
they received.  
The aim of the analysis is to assess the feasibility of the intervention, the feasibility of 
a full definitive trial and summarise potential primary and secondary outcome 





Table 5.2: Statistical Analysis Methods 
Measuring feasibility of the trial will include: 
 CONSORT diagram 
 timing of follow-up assessments (i.e. where they within a reasonable time frame) 
 time taken to recruit sites/participants 
 balance of baseline characteristics by allocation group 
 number of research assessors who became unblinded 
 movement between practices (although potentially this may not be representative of the 
country) 
 
Feasibility of the intervention will include: 
 numbers who complied 
 how much participants complied with intervention (i.e. one assessment and at least two care 
planning visits) 
 
Potential primary/secondary outcomes assessment will include: 
 summary statistics difference between baseline and follow-up visits 
 completeness of data (missing completely and missing items) 
 
 
5.6.8 Embedded Qualitative Study 
This component of the trial explores the experiences of the study participants, their 
carers, clinicians who will deliver the intervention and general practice staff who 
facilitate recruitment and eligibility screening. The aim is to generate 
recommendations and address unknowns including experiences of recruitment, 
retention, practical implementation and further refinement of the intervention and 




The research team will conduct in-depth semi-structured interviews to gain insight 
into their experiences in participating in the study from participants, carers, 
community nurses and practice administrators. 
5.6.8.2 Sampling 
A sample of participants will be invited for interview based on severity of frailty (equal 
numbers across moderate and severe). Half the sample of participants and carers 
will be interviewed at three months post-randomisation and half at six months to gain 
insight at each stage of the trial. Senior community nurses who delivered the 
intervention will be approached for interview and practice administrators who 
conducted screening and recruitment procedures. Maximum sample numbers are 
described below but if saturation is reached prior to these numbers, no further 
interviews will be conducted. The following purposive sample size is anticipated: 
 A maximum of six study participants (four from the intervention arm, two from 
the control arm of the RCT). 
 Four carers of study participants (two intervention arm, two control arm of the 
RCT). 
 Two people who declined to participate at the outset, and two people who 
withdrew from the study before completion.  
 A maximum of six senior community nurses who delivered the intervention. 
 Four general practice administrators who implemented recruitment and 
eligibility screening procedures 
It is understood that it might be ethically challenging to recruit to the qualitative study 
once a participant has declined the feasibility RCT. However, the importance of 
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including these people is to explore their reasons for declining participation or 
withdrawal in order to use these data to inform the larger study protocol and maximise 
recruitment and retention. 
5.6.8.3 Qualitative data collection 
In-depth semi-structured interviews will be undertaken using an interview protocol 
and topic guide which comprises of open questions relating to structure, process and 
outcome of the trial.  For clinicians, topics will include situations they found 
interesting with regard to implementation of the HAPPI intervention and any 
challenges with regard to its delivery.  Interviews with practice administrators will 
explore their experiences of the identification, screening and recruitment procedures. 
For patients and carers topics will include their experiences of the HAPPI 
intervention, participating in the trial and completing outcome measures 
questionnaires.  All interviews will be audio recorded and transcribed verbatim.  
Interviews with patients and carers will be conducted at the patient’s own home 
following an informal format, to assist in helping participants to share their 
experiences and allay any concerns that they are being too critical. Interviews with 
community nurses and practice administrators will be conducted at their local work 
base.  It will be re-iterated that all data will be anonymised and that interviewers are 
interested in all participants’ views and opinions and will not make judgements.  
5.6.8.4 Decliner and withdrawal interviews 
Up to two people who declined to participate at the outset will be interviewed and 
another two people will be interviewed if there are participants who withdraw once 
consented into the trial. At the time they decline to participate in the study, or 
withdraw, they will be asked once only if they would be willing to share their reasons 
why they declined in a brief interview. They will be informed that the researchers 
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would find any reasons they had for declining useful for developing this and future 
research. They will be clearly informed that this is entirely optional and they do not 
have to share their reasons. If they consent, they will be given an option to be 
interviewed alone or with their significant other. The aim is to explore their feelings 
about this feasibility study and reasons for declining or withdrawing in order to inform 
and optimise recruitment/retention for the remainder of the trial and subsequent main 
study. Data collection will occur within three days of declining or withdrawal.  
5.6.8.5  Qualitative data analysis 
Qualitative study results will be reported using the COREQ checklist for interviews 
and focus groups (Tong, Sainsbury & Craig, 2007). Thematic analysis will be used to 
analyse the data. This method includes a strategy for identifying themes and 
subthemes (Braun & Clarke, 2006). The interview transcripts will be uploaded to the 
qualitative analysis program NVivo. The first analysis step will involve two 
researchers becoming familiar with the narratives by reading the transcripts 
independently. In the next step, two researchers will independently code the text by 
allocating the text fragments to codes. The codes will be formulated from the text 
fragments and will possibly be revised during the process of reading the transcripts. 
Two researchers will then discuss the results of the individual codes and try to reach 
consensus. After this, the codes will be reviewed and themes will be formulated.  
5.6.8.6 Qualitative data presentation 
Demographic data items will be presented using descriptive statistics. Meaningful 
text fragments will be determined, as will codes (sub-themes) and themes related to 
the trial objectives. Data extracts will be accompanied by extracts from the transcripts 
to elaborate why the extract is interesting as part of analysis.  
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5.6.9 Ethical Considerations 
This study protocol was approved on 16th October 2018 by the National Health Service 
Research Ethics Committee (REC reference: 18/LO/1354; IRAS project ID: 229210) 
and the University Research Ethics Committee on 14th November 2018 (Reference 
Number: 18/19-1027).  
Protection of participants and researchers from harm is paramount. The trial will be 
conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki, 1996; the principles of Good Clinical Practice, and the UK 
Policy Framework for Health and Social Care Research. 
5.6.10 Consent, confidentiality and data protection 
All eligible people who have agreed to be approached by completion of the recruitment 
invitation letter will be given verbal and written information about the study. Information 
will be provided in an appropriate form, for example a supported conversation around 
written material (a patient information sheet) to maximise understanding of what is 
being asked of them and to support them to make decisions.  The patient information 
sheet is available in large print if required. People will be informed that their care will 
not be affected in any way by their decision to take part or not. 
People willing to take part in the trial will be invited to provide confirmation of 
informed consent to undergo baseline and follow-up assessments and data 
collection, and permission to access to patient’s medical and social care records will 
be sought. If the person has capacity to consent but cannot sign the consent form, 
this will be indicated on the consent form by the assessor.   
Data will be collected and stored in accordance with the Data Protection Act 
1998/General Data Protection Regulation 2018 (Data Protection Act, 2018). All paper 
111 
 
documents will be stored immediately after use securely in the Site File at each site 
separate from study data. All computerised data will be stored on a password protected 
device. After completion of the trial these will be accessible for the purposes of 
monitoring and auditing via the Sponsor who will be storing the anonymised data for 
ten years. All identifiable data will be destroyed as soon as the trial has ended and 
participants have been sent a summary of the results. 
5.7 Discussion 
Research into the management of frailty as a long-term condition and specifically in 
primary care is high priority for policy makers nationally and internationally. This 
study aims to test the feasibility of a uniquely person-centred approach to 
assessment and care planning led by nurses in partnership with patients and their 
carers. Testing feasibility is one of the key principles of developing a complex 
intervention (Moore et al., 2015) in order to assess acceptability and develop 
important parameters for a definitive trial. Research suggests that this preparatory 
work is often not undertaken fully leading to errors in design of full trials (Eldridge et 
al., 2004) and that interventions that would have made a difference fail due to 
challenges of delivery, implementation and compliance (Bower, Wilson & Mathers, 
2007; Prescott et al., 1999).  
There is some evidence that the delivery of complex interventions for older people at 
home can reduce care home and hospital admissions and falls, however, less is known 
about the benefit of any specific type or intensity of intervention (Beswick et al., 2008). 
In addition, Beswick’s systematic review notes that there was a lack of identification 
and recruitment of frail older people to studies and, therefore, we do not yet understand 
the additional benefits of targeting the frail population.  
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The nursing contribution to the management of frailty is poorly developed with few well-
designed studies assessing nurse-led interventions showing mixed results, again with 
very few focussing on targeting the frail population. Few studies have specified the 
content of the intervention and the competencies required by clinicians delivering the 
intervention (Gardner et al., 2017; Jovicic et al., 2015). One study has shown that 
nurses may be the most appropriate clinician to deliver a primary care-led intervention, 
but highlighted the issue of lack of treatment fidelity and identification of the most frail 
(Godwin et al., 2016). 
5.8 Conclusion 
This study aims to increase the evidence and to address the limitations of current 
research. This will be achieved by the use of a systematic method of frailty diagnosis 
and participant identification, implementation and testing of the acceptability of a 
uniquely person-centred intervention which is not prescribed or regimented but 
developed iteratively based on the needs and aspirations of the frail older person. It 
will enable testing of feasibility parameters to maximise success of a future definitive 





Chapter 6: Feasibility Randomised Controlled Trial Results 
6.1 Chapter Introduction 
This chapter presents the results from the feasibility RCT.  As this is a feasibility trial, 
descriptive statistics are presented relating to the feasibility objectives concerning 
eligibility (sites and participant), consent, recruitment, randomisation, experience and 
content of the intervention, safety, summary of missing data and baseline and 
demographics of the participants. The aim was to test trial procedures and determine 
acceptability to participants and clinicians. Progression to a full trial is considered 
viable if pre-specified criteria are met or if clear strategies are identified that could 
support the delivery of the full trial following successful identification of a suitable 
primary outcome. 
6.2 Eligibility 
6.2.1 Site Eligibility and retention 
The trial aimed to recruit six sites (general practices) located in Cornwall, UK. General 
practices registering an interest in the trial were invited to complete an eligibility 
questionnaire (Appendix 8) and those who fulfilled the required criteria were invited to 
take part in the study as sites. Out of the 14 general practices approached, eight met 
eligibility criteria and six progressed as sites; these were the first six who confirmed 
participation (Table 6.1).  Reasons for non-selection of practices included lack of a 









Number of general practice sites approached to participate in the study 
 
14 
Number (%) of general practice sites who were initially approached 
progressed to participating in the study 
 
6 (42.8) 




Number (%) of general practice sites who withdrew from the study 
prior to completion 
 
0 (0.0) 




Number (%) of sites completing screening/eligibility processes  within 
prescribed timescale (6 months from site initiation) 
5 (83.3) 
 
No sites withdrew from the study prior to completion, however, one site needed 
significant support from the research team including help to generate the eFI list and 
apply eligibility criteria. This site would have withdrawn without that support. All sites 
eventually completed all screening and eligibility processes in line with the protocol, 
however, there were some protocol deviations which are discussed in section 6.7. Five 
sites completed screening procedures within the prescribed timescale. The one 
practice that did not complete within the timescale had to repeat some procedures due 
to protocol deviations and difficulty in contacting the lead person at the site for a 
prolonged period of time led to delays. 
6.2.2 Sampling 
A total of 3292 moderately frail and 796 severely frail people were identified using the 
eFI across the six sites. To reduce the numbers of this initial cohort, a random sampling 
approach was used to create the initial enrolment sample. The clinical trials unit 
provided a list of 90 random numbers that was applied to the eFI list at each site. This 
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meant that no patient identifiable information left the site until consent was obtained. A 
total sample of 414 potential participants were identified at this stage of screening. 
While it was planned to identify 90 at each site (540 in total), three sites identified less 
severely frail people than anticipated. 
6.2.3 Participant enrolment, screening and eligibility 
Out of the 414 sampled, n=87 people (21.0%) were not eligible. Number and reasons 
for ineligibility are presented in Table 6.2, and the CONSORT flow chart (Figure 6.1). 
All data related to participant screening, enrolment, randomisation and follow up of 
individual participants are reported in the CONSORT flow chart (Eldridge et al., 2016) 
(Figure 6.1). As a cluster randomised controlled trial, there are specific features which 
require additional reporting in accordance with the CONSORT statement for the 
reporting of cluster randomised trials (Campbell, Elbourne & Altman, 2004) including 
the flow of both clusters through the trial, from assignment to analysis. In this study, 
there were six clusters (three assigned to intervention and three to control). No clusters 
withdrew or were lost to follow-up and data was analysed from all six. The mean cluster 
size in the intervention allocation was 10 participants, 8.67 participants in the control 









Table 6.2: Reasons for ineligibility 
Reason not eligible Number of 
participants % (n) 
 
Resident in care home 43.7 (38) 
 
In receipt of palliative care 9.2 (8) 
 
Lacks mental capacity to consent 11.5 (10) 
 
Already on community matron caseload 16.1 (14) 
 
Other 19.5 (17) 
 
 
Following eligibility screening, invitation letters (Appendix 10) were sent to 293 people. 
There were 136 (46.4%) people who did not respond to the letter and 81 phone calls 
were made by administrators to pursue a response. In total, 157 (53.6%) replies were 
received to the invitation letter expressing interest in participating in the trial. Of these, 
54 (34.4%) respondents were found to be ineligible on PRISMA7 questionnaire. The 
remaining (n=103) were contacted by phone by the research team to give more 
information about the trial and discuss participation further. After this contact, 89 
(86.4%) remained interested in participating and were registered onto the trial 
database. Exclusions at registration totalled n=14 (15.7%) and reasons for exclusion 
included, not meeting eligibility criteria or that the numbers required for the trial were 
already met. For the latter, the Chief Investigator (CI) contacted them and thanked 
them for their interest in participating and explained why they would not be included at 
this point. Baseline and consent visits were completed with 69 people, and of these, 
three did not consent and ten were excluded at baseline visit on final eligibility check. 
A participant information sheet (PIS) (Appendix 11) was provided and after the 
opportunity to ask questions, if the person was still willing to participate then consent 
was recorded on the informed consent form (Appendix 12). 
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6.3 Recruitment  
A total of 56 participants were recruited to the trial and randomised within the 
anticipated timeframe (Figure 6.1).   Numbers of participants screened and randomised 
plus withdrawals by site are summarised in Table 6.3. 
Table 6.3 Number of participants screened and randomised by site 
 Intervention sites 
 
Control sites 
Variable Site 01 Site 02 Site 05 Site 03 Site 04 Site 06 
Numbers n (%) screened 
Total  61 (14.7) 
 
90 (21.7) 90 (21.7) 50 (12.1) 33 (7.8) 90 (21.7) 
Reasons for non-participation (n) 
Did not meet inclusion 
criteria 
10 26 6 11 3 32 
Invited to participate 51 64 60 30 30 58 
Ineligible on PRISMA-7 5 10 14 12 0 13 
Declined to participate or 
did not respond to invitation 
34 40 26 7 18 26 
Did not consent 1 2 0 1 1 1 
Registered to trial database 11 12 20 11 12 19 
Number n (%) randomised* 
Total 10 (17.8) 
 
10 (17.8) 10 (17.8) 9 (16.1) 7 (12.5) 10 (17.8) 
Number n (%) discontinuation/withdrawal 
Total 1 (1.7) 
 
1 (1.7) 2 (3.6) 2 (3.6) 0 (0.0) 1 (1.8) 
Number n (%) of participants data fully analysed 
Total 9 (90.0) 
 
9 (90.0) 8 (80.0) 7 (77.8) 7 (100.0) 9 (90.0) 
*10 participants from each site contacted to arrange consent visit from those registered to the trial 
database, some then excluded at final eligibility check at consent visit 
As a feasibility study this trial was not powered to give an indication of sample size for 
a definitive trial, however, the trial has given the opportunity to consider the numbers 
of participants that can be recruited to detect a given effect size of the intervention with 
5% significance and 90% power. This is discussed in section 8.3.5. 
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6.3.1 Recruitment rate 
The target recruitment rate was 60 participants in ten months. There was an initial 
delay in receiving HRA approval so sites opening was delayed by one month. 
Recruitment began in December 2018 with staged opening of sites to allow for capacity 
within the research team to undertake consent visits. Following the first site, which 
opened in December 2018, the others followed in pairs (one intervention and one 
control) leaving one month between openings of sites. Although it had been anticipated 
that initial identification and screening for each site would take one month to complete, 
in reality, this process took longer; between one and six months to complete dependent 
on the site. 
The first participant was recruited on 27th February 2019 and, although the trial started 
later than planned, higher than anticipated recruitment rates were noted across all 
sites, with an average of 9.3 participants per month achieved (6 participants/month 
were predicted). Total number of participants recruited per month is shown in Figure 






Figure 6.2a: Participants recruited per month (all sites) 
 
 
Figure 6.2b: Participants recruited each month (per site) 
 
6.4 Randomisation 
Randomisation of clusters was conducted according to the randomisation specification 



















































Month participants were consented
Site 01 Site 02 Site 03 Site 04 Site 05 Site 06
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three sites (clusters) allocated to the intervention arm of the study and three sites 
(clusters) to control (usual care). 
6.5 Demographic and baseline data 




Table 6.4:  Baseline demographic data 
 Intervention  Control  All  









Gender n (%) 
Male 15 (50.0) 10 (31.5) 25 (44.6) 
Female 15 (50.0) 16 (68.5) 31 (55.4) 
Relationship Status n (%) 
Single 
 
1 (3.3) 2 (7.7) 3 (5.4) 
Married/civil partnership 19 (63.3) 15 (57.7) 34 (60.6) 
Divorced/civil partnership dissolved 2 (6.7) 1 (3.8) 3 (5.4) 
Widowed/surviving civil partner 8 (26.7) 8 (30.8) 16 (28.6) 
Living arrangements n (%) 
Alone 10 (33.3) 11 (42.4) 21 (37.5)  
Spouse/Partner 19 (63.4) 14 (53.8) 33 (59.0) 
Parent/s 0 (0.0) 0 (0.0) 0 (0.0) 
With children under 18 0 (0.0) 0 (0.0) 0 (0.0) 
With children over 18 0 (0.0) 1 (3.8) 1 (1.75) 
Other family 1 (3.3) 0 (0.0) 1 (1.75) 
Non-family 0 (0.0) 0 (0.0) 0 (0.00) 
Frailty Severity n (%) 
Moderately frail 18 (60.0) 18 (69.3) 36 (64.2) 
Severely frail 12 (40.0) 7 (26.9) 19 (34.0) 
Missing 0 (0.0) 1 (3.8) 1 (1.78) 
The mean age of participants was 82.4 years (range 67-100 years). Mean age in the 
control group (85.1 years; range 67-100 years) was 5.1 years older than in the 
intervention group (80.0 years; range; 67-95 years). There were more female 
participants (55.4%) in the trial than male (44.6%). There were equal numbers of male 
and female in the intervention group with 50% male (n= 15) and more female than 
male in the control group; 31.5% male (n= 10).The majority of participants lived with a 
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partner or spouse n=33 (59.0%), however, there was variation between the 
intervention and control groups (n=19 (63.4%) intervention, n=14 (53.8%) control). 
Similar proportions of people in the intervention and control groups were moderately 
frail (n=18 (69.3%) intervention and n=18 (60.0%) control). Overall, there were smaller 
numbers of severely frail participants recruited (total n=19 (34.0%)), with n=12 (40.0%) 
in the intervention group and n=7 (26.9%) in the control group. 
6.6 Retention and adherence 
Participant retention and adherence to the minimum dose of the intervention (defined 
as one assessment visit and a minimum of two care planning visits) by site are 
presented in Table 6.5. Retention across all sites was high with n=53 (94.6%) of 
participants completing three-month follow-up and n=49 (87.5%) completing six-month 
follow-up. Retention was similar in both groups with 96.7% of intervention participants 
completing three-month follow-up and 86.7% completing six-month follow-up 




Table 6.5: Participant retention and adherence 
 
Failure to complete three and six-month follow-up was, in all seven cases, due to 
withdrawal from the trial. All withdrawals were initiated by the individual participant 
themselves. In four cases, their health had deteriorated and they did not feel able to 
continue with the commitment of the trial, one participant had too many health-related 
appointments and did not have time to participate. One participant stated that the 
community matron did not attend on the agreed date and, consequently, they decided 
to withdraw and the remaining participant did not give a reason for withdrawal. 
6.7 Adherence to the trial protocol 
There were three instances of non-compliance with the trial protocol that related to 
participants. Two of these disclosed to the research team assessors that they were in 





Variable Site 01 Site 02 Site 05 Site 03 Site 04 Site 06 
 
Number (%) [ratio] of 
randomised participants who 




















Number (%) (ratio) of 
randomised participants who 















Number of randomised 
participants adhering to 
intervention minimum dose 
 
9 9 8 N/A N/A N/A 
Number of operational 
protocol deviations 
 
0 2 1 1 3 0 
Number of participant related 
protocol deviations 
1 1 1 0 0 0 
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allocation of all participants from that site. The other participant-related protocol 
deviation occurred when there was a delay in carrying out three-month outcome 
measures assessment; the delay was at the request of the participant.  
There were seven operational protocol deviations, which occurred either at a site or 
within the Clinical Trials Unit. In all cases these were related to procedures within the 
protocol, including incorrect application of trial eligibility criteria (identification of 
participants outside of the age range) and not sending stamped addressed envelopes 
with the invitation letter. A technical problem with the trial database was identified 
where reminders to sites to submit three and six month outcomes data were not sent 
out. This was rectified by the Clinical Trials Unit and the data obtained. None of the 
operational protocol deviations caused significant delay but did require some 
processes to be completed twice.  
Adherence to the intervention was good with n=4 (15.4%) participants receiving less 
than the minimum intervention dose. Reasons given for not completing the minimum 
dose included two instances of admission to hospital, one participant away on holiday 
and, in one case, difficulties contacting the participant. 
6.8 Refinement of intervention content  
One of the aims of this feasibility study was to further refine and finalise the content of 
the intervention and to capture which other health and care services are involved as 
part of the care planning process, to inform a full trial. The frequency of use of each 
type of assessment in the intervention pack were evaluated (Table 6.6) plus the 




Table 6.6: Frequency of intervention assessment documents used at intervention visit 
 Number (n) of assessment tools 
used at each visit (V) 
(all participants) 
 
HAPPI Intervention Assessment Tools V1 V2 V3 V4 V5 V6 Total 
Medication review summary 19 15 13 13 13 9 82 
Conversation Guide 22 14 9 10 6 7 68 
Clinical Frailty Scale 22 11 7 5 8 8 61 
Personalised support plan (1): my medical plan 0 7 9 11 11 12 50 
Personalised support plan (2): my wellbeing plan 0 6 8 8 11 11 44 
Numeric pain scale 6 7 7 4 6 3 33 
Barthel Index 12 5 3 2 4 5 31 
Caregiver strain index 6 8 4 4 3 3 28 
Pain assessment record 3 6 4 3 4 0 20 
Abbey Pain Scale  0 1 1 1 0 0 20 
Mental capacity assessment  6 9 3 1 0 0 19 
Comprehensive geriatric assessment  5 5 2 0 0 1 13 
Malnutrition universal screening tool   4 6 1 0 1 0 12 
Treatment escalation plan  1 4 1 2 2 2 12 
3-Item loneliness scale 0 6 3 1 2 0 12 
Hospital anxiety and depression scale  0 4 1 3 1 2 11 
Bowel assessment form 2 4 2 0 1 1 10 
Geriatric Depression Score  1 1 3 3 1 1 10 
Malnutrition universal screening tool Flowchart  3 3 1 0 1 0 8 
Clinical checklist lower urinary tract symptoms 0 2 3 1 1 0 7 
Falls Multifactorial risk assessment tool  2 3 1 0 0 0 6 
Malnutrition universal screening tool  1 3 1 0 1 0 6 
Checklist faecal incontinence 1 2 1 0 1 0 5 
Gait Speed Test  0 4 0 0 0 0 4 
STOPP-START medication review 1 2 0 0 0 0 3 
Self-assessment lower urinary tract symptoms 0 2 1 0 0 0 3 
GP assessment of cognition test 0 0 1 1 1 0 3 
Bladder diary 0 1 1 0 0 0 2 
Fracture risk assessment tool  0 1 0 0 0 0 1 
Royal College Physicians bedside vision test 0 1 0 0 0 0 1 
Whispered voice test 0 1 0 0 0 0 1 
Delirium screening tool 1 0 0 0 0 0 1 
 
A total of 32 assessment tools were included in the intervention pack (Appendix 6) and 
all of these were used in the course of the intervention but not with all participants 
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(Table 6.6). The most frequently used assessment tool was the medication review 
summary (used 82 times). Other most frequently used tools included the conversation 
guide used (68 times), the clinical frailty scale (used 61 times), and the personalised 
care plan templates one and two (used 50 and 44 times respectively). All participants 
completed the intervention with a personalised care and support plan in place that 
could be used beyond the life of the study to enhance self-management and as an 
information source for other clinicians involved in the participant’s care in future. 
Other assessment tools frequently used (used more than 20 times) were those relating 
to assessment of pain, function and caregiver strain. Assessment tools that were more 
specific in focus and related to particular health problems or syndromes were used 
less frequently (less than 20 times). This evaluation of the type and quantity of 
assessment tools used will be employed to inform the content of the assessment pack 
for a full trial and is discussed further in section 8.4.3. 
All referrals to health and care services across all intervention time points are 
summarised in Table 6.7. The highest number of referrals (n=31) was to general 
practitioners, with lesser numbers of referrals to physiotherapy and voluntary services 
(n=7), dementia services (n=6) and district nurses (n=4). Overall, referrals to other 
services was lower than anticipated. It was expected that a multidisciplinary approach 
would be required for the majority of participants, but this did not appear to be the case. 




Table 6.7: Frequency of type of referrals made at intervention time points 
 
 
Number (n) of referrals made at each visit (V) 
(all participants) 
 
Service referred to V1 V2 V3 V4 V5 V6 Total 
General Practitioner 5 8 7 4 1 6 31 
Physiotherapy 1 4 0 0 1 1 7 
Voluntary Sector 2 1 1 1 2 0 7 
Dementia Services 1 2 1 0 1 1 6 
District Nurses 1 1 0 1 1 0 4 
Adult Social Care 0 1 0 1 1 0 3 
Practice nurse 0 0 1 1 0 1 3 
Podiatry 1 1 0 0 0 0 2 
Social Prescribing 0 1 0 1 0 0 2 
Occupational Therapy 0 0 0 0 1 0 1 
Benefits Agency 1 0 0 0 0 0 1 
Community Matron 1 0 0 0 0 0 1 
Epilepsy Specialist Nurse 1 0 0 0 0 0 1 
Community equipment services 0 1 0 0 0 0 1 
Respiratory specialist nurse 0 1 0 0 0 0 1 
X-ray 1 0 0 0 0 0 1 
Surgical appliances 0 0 1 0 0 0 1 
Pendant Alarm 0 0 0 1 0 0 1 
 
6.9 Adverse events and serious adverse events 
Safety was assessed by comparing the number and nature of serious adverse events 
(SAEs) and adverse events (AEs) in both the intervention and control group. There 
were no reported deaths, AEs or SAEs in either the intervention or the control groups 
throughout the follow-up period. This was an unexpected finding and possible reasons 
for this are discussed in section 8.2.8. 
6.10 Assessment of sample size for the definitive RCT 
As stated in the Statistical Analysis Plan (Appendix 13) the calculation of a sample size 
for the definitive trial must take into account the effects of clustering. In order to assess 
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the effect of cluster randomisation, the intracluster correlation coefficient (ICC) can be 
calculated as a measure of relatedness of clustered data, in human studies values are 
normally between 0.01 and 0.02 (and ICC of 1 indicating all responses are identical). 
In this trial, ICC was cautiously estimated to be 0.05. In the statistical analysis plan it 
was agreed that the future definitive trial will aim to test the intervention with 5% 
significance and 90% power. Assuming an intra-cluster correlation coefficient (ICC) of 
0.05 and cluster size of 10 in a future trial (as in this trial), this yields a design effect 
1.45. The numbers required to detect a given effect size are summarised in Table 6.8. 
Table 6.8: Estimation of numbers required to detect a given effect size 
Effect size Minimum n 
Sample size 
inflated for 
cluster sizes of 
10 patients per 
practice 
0.1 857 1243 
0.2 215 312 
0.3 96 140 
0.4 54 79 
0.5 35 51 
 
Based on recruitment data from this fRCT it would seem feasible for a future trial to 
recruit 200-300 participants in this population and a modest effect size of 0.2 could be 
detected at 5% significance with 90% power from centres with an ICC of 0.05. 
6.11  Assessment of participant-reported outcome measures 
Outcome measures within the study were either participant-reported (SF-36; LTC-6; 
UCLA-3; Barthel Index; EQ-5D-5L) or data supplied by the general practice from the 
clinical record (date of death; cause of death; number of hospital admissions and 
readmissions; total number of days spent in hospital; number of prescribed 
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medications). All participant-reported outcome measures were collected at baseline, 
three-month and six-month study visits. Data was recorded using case report forms 
Appendix 14) and an outcome measure questionnaire (Appendix 15).  Feasibility of 
proposed outcome measures was evaluated with the aim of informing the selection of 
a primary outcome measure or, potentially, multiple outcomes requiring multivariate 
analysis within a definitive trial. This feasibility trial gave the opportunity to ascertain, 
which outcome measures are acceptable to the participants, which can be 
administered in primary care, and which are sensitive to change at the different time 
points. This was assessed by reporting of the mean, standard deviation, range, median 
and interquartile range for each measure at each time point (Table 6.9). In addition, 
levels of missing data for each outcome measure over time were reported and these 
are discussed in section 6.11.8. In order to give some indication of sensitivity of 
outcome measures to change over time, these data are reported with 95% confidence 
intervals.  Each outcome measure was assessed individually and compared against 
the others for feasibility in terms of completeness, ease of administration and 
acceptability. This will be considered further in the section 8.3.4. 
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Table 6.9: Participant-reported outcome measure data 
Variable  Intervention Group Control Group 
 
Time point  Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
SF-36 
Physical functioning:  
Items 3a, 3b, 3c, 
3d,3e,3f,3g,3h,3i,3j 















































Bodily pain:  
Items 7,8 
 






















General Health:  
Items 1,11a,11b,11c,11d 
















































Social functioning:  
Items 6,10 
 

















































  Intervention Group Control Group 
 
Time point  Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
Mental health:  
Items 9b,9c,9d,9f,9h 
 






















Reported health transition:  
Item 2 















































































































































6.11.1 Assessment of SF-36 
Mean scores for all eight health domains of the SF-36 were low across all participants 
and ranges were wide (Figures 6.3-6.11). Mean scores in the physical functioning 
domain reduced across the three time points in both groups (Figure 6.3).  
 
Figure 6.3: Change scores for physical functioning domain (SF-36) for participants who 
completed assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
In the social functioning domain, mean scores increased in both groups at 13 weeks 

































Figure 6.4: Change scores for social functioning domain (SF-36) for participants who 
completed assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
In the general health domain, scores initially increased at 13 weeks but dropped again 
to almost baseline levels at 26 weeks in the intervention group. In the control group 
scores reduced at 13 weeks and although they increased somewhat at 26 weeks, they 





Figure 6.5: Change scores for general health domain (SF-36) for participants who completed 
assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
Vitality domain scores were higher in the control group than in the intervention across 
all three time points and they increased at 13 and 26 weeks. Intervention group scores 
decreased at 13 weeks and 26 weeks (Figure 6.6).  
 
Figure 6.6: Change scores for vitality domain (SF-36) for participants who completed 




In the role-emotional domain, scores increased in both groups with a larger increase 
at 26 weeks in the intervention group (Figure 6.7).  
 
Figure 6.7 Change scores for role-emotional domain (SF-36) for participants who completed 
assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
Mental health domain scores were initially higher in the control group than in the 
intervention, however, at 26 weeks, control group scores had decreased, whereas 
intervention scores were stable at 13 weeks but increased above control group at 26 




Figure 6.8 Change scores for mental health domain (SF-36) for participants who completed 
assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
Role-physical domain scores were higher in the control group than in the intervention 
at baseline, both group scores decreased at 13 weeks and rose again at 26 weeks 
with the intervention group increasing more. (Figure 6.9). 
 
 
Figure 6.9: Change scores for role-physical domain (SF-36) for participants who completed 




Bodily pain domain scores were higher in the control than in the intervention group, 
with the control group scores remaining stable across the three time points. 
Intervention group scores were also stable at 13 weeks but increased at 26 weeks 
(Figure 6.10). 
 
Figure 6.10: Change scores for bodily pain domain (SF-36) for participants who completed 
assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
In the final item of the SF-36 (Reported Health Transition), participants gave their 
opinion on whether or not they expected their health to deteriorate. Scores on this 
domain decreased at 13 weeks in the intervention group but rose above baseline levels 
at 26 weeks. In the control group, scores rose at 13 weeks but reduced again at 26 





Figure 6.11: Change scores for reported health transition (SF-36) for participants who 
completed assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
6.11.2 Assessment of LTC-6 
A higher score in the LTC-6 questionnaire indicates higher levels of confidence in the 
participant’s own ability to self-manage their long term condition and participate in 
shared decision making. Ranges were wide across all groups at each time point (Table 
6.9). Overall scores were lower in the intervention group than in control. Scores rose 
from baseline at 13 and 26 weeks in the intervention group and did show an increase 
from baseline at 26 weeks. In the control group scores reduced compared to baseline 




Figure 6.12: Change scores for LTC-6 for participants who completed assessments at all time-
points in intervention (n=24) and control (n=21) groups 
 
6.11.3 Assessment of UCLA-3 
This three-item questionnaire measures the impact of loneliness for older people, with 
scores of 2-5 indicating “not lonely”, 6-9 indicating “lonely”. Mean scores remained 
stable across all time points in the intervention group. Scores in the control group were 
also relatively stable (Figure 6.13). Overall, across all time points, mean scores were 
higher in the intervention group than in the control group. The range of scores was 
































Figure 6.13: Change scores for UCLA-3 for participants who completed assessments at all 
time-points in intervention (n=24) and control (n=21) groups 
 
6.11.4 Assessment of Barthel Index 
The Barthel Index is a ten item questionnaire rating a person’s degree of independence 
in performing functional self-care and mobility activities with lower scores indicating 
increased disability. Mean scores rose in both groups at 13 weeks then remained 
stable at 26 weeks in the intervention group. Scores decreased at 26 weeks in the 



































Figure 6.14: Change scores for Barthel Index for participants who completed assessments at 
all time-points in intervention (n=24) and control (n=21) groups 
 
6.11.5 Assessment of EQ-5D-5L 
The EQ-5D-5L is a 25 item descriptive system measuring health status across five 
health dimensions. In this study, mean scores for index values (Figure 6.15) and VAS 
(Figure 6.16) as well as frequencies for each level in the five health dimensions (Table 
6.10) were generated. EQ-5D-5L descriptive system data were obtained with missing 
data relating to withdrawals rather than non-completion of questionnaires. In assessing 
the descriptive system using the five health domains (Table 6.10), the majority of 
participants recorded high scores in the domains of self-care, mobility, anxiety and 
depression and usual activity, indicating they experienced either no or slight problems. 
More participants recorded middle or lower scores in the pain domain, indicating 



































Table 6.10 EQ-5D-5L descriptive system frequencies across all time points 
EQ-5D Dimension n (%) Intervention Group Control Group 
 
Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
Baseline 13 (+/- 1) 
weeks 




1 no problems  
2 slight problems  
3 moderate problems 
4 severe problems  
5 extreme problems 
Level 1 6 (20.0) 
 
5 (16.7) 6 (20.0) 4 (15.4) 5 (19.2) 5 (19.2) 
Level 2 5 (16.6) 5 (16.7) 1 (3.3) 4 (15.4) 7 (26.9) 4 (15.4) 
Level 3 12 (40.0) 10 (33.3) 10 (33.3) 14 (53.8) 6 (23.1) 8 (30.8) 
Level 4 5 (16.7) 5 (16.7) 8 (26.7) 4 (15.4) 6 (23.1) 5 (19.2) 
Level 5 2 (6.7) 1 (3.3) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Missing data 0 (0.0) 1 (3.3) 4 (13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
Self-care 
Levels:  
1 no problems  
2 slight problems  
3 moderate problems 
4 severe problems  
5 extreme problems 
Level 1 14 (46.7) 20 (66.7) 10 (33.3) 19 (73.1) 17 (65.4) 12 (46.2) 
Level 2 10 (33.3) 2 (6.7) 10 (33.3) 3 (11.5) 4 (15.4) 6 (23.1) 
Level 3 3 (10.0) 3 (10.0) 5 (16.7) 2 (7.7) 1 (3.8) 4 (15.4) 
Level 4 3 (10.0) 1 (3.3) 0 (0.0) 2 (7.7) 2 (7.7) 1 (3.8) 
Level 5 0 (0.0) 0 (0.0) 1 (3.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Missing data 0 (0.0) 3 (7.7) 4 (13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
Usual activity 
Levels:  
1 no problems  
2 slight problems  
3 moderate problems 
4 severe problems  
5 extreme problems 
Level 1 7 (23.3) 5 (16.7) 9 (30.0) 6 (23.1) 11 (42.3) 7 (26.9) 
Level 2 9 (30.0) 11 (36.7) 5 (16.7) 9 (34.6) 6 (23.1) 6 (23.1) 
Level 3 9 (30.0) 6 (20.0) 6 (20.0) 6 (23.1) 3 (11.5) 4 (15.4) 
Level 4 2 (6.7) 3 (10.0) 3 (10.0) 0 (0.0) 3 (11.5) 4 (15.4) 
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Intervention Group Control Group 
 
Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
Level 5 3 (10.0) 1 (3.3) 3 (10.0) 5 (19.2) 1 (3.8) 2 (7.7) 
Missing data 0 (0.0) 3 (10.0) 4 13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
Pain 
Levels:  
1 no problems  
2 slight problems  
3 moderate problems 
4 severe problems  
5 extreme problems 
Level 1 3 (10.0) 3 (10.0) 8 (26.7) 7 (26.9) 7 (26.9) 7 (26.9) 
Level 2 8 (26.7) 4 (13.3) 2 (6.7) 10 (38.5) 7 (26.9) 4 (15.4) 
Level 3 7 (23.3) 13 (43.3) 9 (30.0) 4 (15.4) 5 (19.2) 11 (42.) 
Level 4 11 (36.7) 5 (16.7) 7 (23.3) 3 (11.5) 3 (11.5) 1 (3.8) 
Level 5 1 (3.3) 1 (3.3) 0 (0.0) 2 (7.7) 2 (7.7) 0 (0.0) 
Missing data 0 (0.0) 3 (10.0) 4 (13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
Anxiety/depression 
Levels:  
1 no problems  
2 slight problems  
3 moderate problems 
4 severe problems  
5 extreme problems 
Level 1 15 (50.0) 16 (53.3) 17 (56.7) 14 (53.8) 16 (61.5) 16 (61.5) 
Level 2 8 (26.7) 5 (16.7) 6 (20.0) 8 (30.8) 4 (15.4) 6 (23.1) 
Level 3 5 (16.7) 5 (16.7) 3 (10.0) 3 (11.5) 3 (11.5) 1 (3.8) 
Level 4 2 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.8) 0 (0.0) 
Level 5 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.8) 0 (0.0) 0 (0.0) 






Index value scores were lower in the intervention than the control group and both 
groups scores increased over time (Figure 6.15).  
 
Figure 6.15: Change scores for EQ-5D-5L (Index Values) for participants who completed 
assessments at all time-points in intervention (n=24) and control (n=21) groups 
 
VAS scores were higher at baseline in the intervention group, however, the control 
group increased above the intervention group at 13 weeks. At 26 weeks, control group 

































Figure 6.16: Change scores for EQ-5D-5L (VAS) for participants who completed assessments at 
all time-points in intervention (n=24) and control (n=21) groups 
 
6.11.6 Assessment of site-reported outcome data  
Remaining outcome data were obtained from the general practices (sites) and taken 
from the participant’s electronic clinical record (date of death; cause of death; number 
of hospital admissions and readmissions; total number of days spent in hospital; 
number of prescribed medications). Mean, standard deviation, range, median and 































Table 6.11: Site-reported outcome measures 
Variable  Intervention Group Control Group 
 
Time point  Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 
Baseline 13 (+/- 1) 
weeks 
26 (+/- 1) 
weeks 






















Number of hospital 
admissions 






















Number of hospital 
readmissions 





















Total number of days 
spent in hospital 






















Number of prescribed 
medications  
Mean (SD)  
[range]  
Median (IQR) 





















There were no reported deaths over the time of the study. Numbers of hospital 
admissions were lower in the intervention than the control group with one participant 
in the intervention group admitted at 13 weeks and one at 26 weeks. In the control 
group there were two admissions at 13 weeks and three at 26 weeks. Readmissions 
were low in both groups with one readmission in each group at 26 weeks. Days spent 
in hospital were lower in the intervention than the control group, however, these data 
should be viewed with caution as one participant experienced a long stay in hospital 
(28 days). As numbers were low for admissions and readmissions and mean scores 
were skewed by one participant’s data, means were not compared across study time 
points. 
Numbers of prescribed medications were comparable at baseline in intervention and 
control groups. Numbers increased at 13 weeks in the control group but fell at 26 
weeks back to baseline. In the intervention group numbers of medications prescribed 
decreased at 13 weeks and again at 26 weeks (Figure 6.17). 
 
Figure 6.17: Change scores for numbers of prescribed medications at all time-points in 































6.11.7 Timing of outcome measures assessment 
Full details of missing outcome measures are given in the CONSORT diagram (Figure 
6.1). All (100%) site-reported CRFs were completed within the trial time scales from all 
six sites, although in some sites there was a delay in returning the data caused by a 
database error. Timing of participant reported outcome measures assessments is 
reported in Table 6.12. 
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Table 6.12: Timing of outcome measures assessment by group and time point 




13 (+/- 1) weeks 
(n=29) 




13 (+/- 1) weeks 
(n=24) 
 
26 (+/- 1) weeks 
(n=23) 
Completion status including 
withdrawals 
Completed within protocol 
window (+/- seven days from 
due date) 
30 (100.0) 16 (53.3) 15 (50.0) 26 (100) 10 (38.5) 11 (42.4) 
Completed outside of protocol 
window 
 
0 (0.0) 12 (40.0) 11 (36.7) 0 (0.0) 14 (53.8) 12 (46.1) 
Not completed 0 (0.0) 2 (6.7) 
[n=1 withdrawn] 
[n= 1 incomplete] 
4 (13.3) 
[n=4 withdrawn] 




Completion status excluding 
withdrawals 
Completed within protocol 
window (+/- seven days from 
due date) 
30(100.0) 16 (55.2) 15 (57.7) 26(100) 10 (41.7) 11 (47.8) 
Completed outside of protocol 
window 
0 (0.0) 12 (41.4) 11 (42.3) 0 (0.0) 14 (58.3) 12 (52.2) 
Not completed 0 (0.0) 1 (3.4) 
[n= 1 incomplete] 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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At baseline, n=30 (100%) of outcome measures questionnaires were completed in the 
intervention group and n=26 (100%) completed in the control group. At 13 weeks, one 
participant had withdrawn from the intervention group and n=16 (53.3%) 
questionnaires were completed within the protocol window, at 26 weeks there were 
three further withdrawals and n=15 (50.0%) were completed within the protocol window 
out of a possible 30. In the control group, there were two withdrawals at 13 weeks and 
n=10 (38.5%) were completed within the protocol window, at 26 weeks there had been 
no further withdrawals and n=11 (42.4%) were completed within the protocol window 
out of a possible 26.  
6.11.8 Assessment of missing outcome data 
Completeness of the data is an important feasibility parameter for all outcome 
measures as it can be used to inform the likely pattern of missing data in a full-scale 
trial. If a considerable amount of outcome data is missing, this may suggest a need to 
reconsider the choice of outcome measures and will provide an insight into how 
missing data can be avoided in the subsequent full trial. The proportion of participants 
data missing at each outcome are summarised for each allocated group and at each 




Table 6.13: Missing outcome measures by group  
Outcome measure Intervention Group (n=) (%) Control Group (n=) (%) 
Time point Baseline 
 
13 (+/- 1) 
weeks 
 





13 (+/- 1) 
weeks 
 
26 (+/- 1) 
weeks 
SF-36 














Role-physical 0 (0.0) 4 (13.3) 4 (13.3) 0 (0.0) 2 (7.7) 2 (7.7) 
Bodily pain  
 
0 (0.0) 3 (10.0) 4 (13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
General Health 
 
0 (0.0) 4 (13.3) 5 (16.7) 0 (0.0) 3 (11.5) 4 (15.4) 
Vitality 
 
1 (3.3) 3 (10.0) 5 (16.7) 0 (0.0) 2 (7.7) 3 (11.5) 
Social functioning 
 
0 (0.0) 3 (10.0) 4 (13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
Role-emotional 
 
0 (0.0) 3 (10.0) 4 (13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
Mental health 
 
0 (0.0) 3 (10.0) 6 (20.0) 1 (3.8) 2 (7.7) 3 (11.5) 
Reported health 
transition 
0 (0.0) 3 (10.0) 4 (13.3) 0 (0.0) 2 (7.7) 3 (11.5) 
LTC-6 
 
0 (0.0) 3 (10.0) 6 (20.0) 0 (0.0) 2 (7.7) 3 (11.5) 
UCLA-3 
 
0 (0.0) 4 (13.3) 4 (13.3) 0 (0.0) 3 (11.5) 3 (11.5) 
Barthel Index 
 


















0.0 (0.0) 4 (13.3) 4 (13.3) 0.0 (0.0) 2 (7.7) 3 (11.5) 
Usual activities  0.0 (0.0) 4 (13.3) 4 (13.3) 0.0 (0.0) 2 (7.7) 3 (11.5) 
Pain/discomfort  0.0 (0.0) 4 (13.3) 4 (13.3) 0.0 (0.0) 2 (7.7) 3 (11.5) 
Anxiety/depression  0.0 (0.0) 4 (13.3) 4 (13.3) 0.0 (0.0) 2 (7.7) 3 (11.5) 
EQ-5D-5L VAS 
 
0.0 (0.0) 4 (13.3) 4 (13.3) 0.0 (0.0) 3 (11.5) 3 (11.5) 
Number of hospital 
admissions 
0.0 (0.0) 3 (10.0) 4 (13.3) 1 (3.8) 3 (11.5) 3 (11.5) 
Number of hospital 
readmissions 
0.0 (0.0) 3 (10.0) 4 (13.3) 1 (3.8) 3 (11.5) 3 (11.5) 
Total number of 
days spent in 
hospital 








Withdrawals were the main reason for non-completion of participant-reported and site-
reported outcome measures at 13 and 24 weeks. The LTC-6 was not fully completed 
by two participants in addition to those who had withdrawn at 24 weeks. The blinded 
assessors and administrators were not formally asked to record reasons for non-
completion, so these were not captured.  
6.11.9 Assessment of responsiveness of proposed outcome measures 
Findings presented here relating to responsiveness over time should be interpreted 
with caution because this feasibility trial was not powered for this purpose. 
In order to ascertain which statistical methods should be used to assess change over 
time, outcome measures data were tested for normality. A visual inspection of 
histograms and box plots was completed, skewness, kurtosis and z-values calculated 
for data obtained from all outcome measures. These data are presented in Tables 1-6 
in Appendix 16. Mean scores and mean difference are reported with 95% confidence 
intervals (Table 6.13) for all outcome measures for the intervention and control groups 
at 26 weeks. Based on these findings and findings from the qualitative study, 




Table 6.14: Mean difference with 95% confidence intervals for intervention and control 
groups at week 26 





Control Mean difference 
(95% CI) 
Physical functioning  
 
26; 271.15 (235.45) 23;  278.26 (263.21) -7.11 (-150.4, 136.2) 
Role-physical 
 
26; 216.35 (133.22) 23; 206.52 (142.47) 9.82 (-69.4, 89.1) 
Bodily pain 
 
26; 100.96 (60.18) 23; 115.43 (62.70) -14.47 (-49.8, 20.9) 
General Health 25; 187.20 (112.14) 22; 211.14 (96.30) -23.93 (-85.8, 37.9) 
 












24; 432.25 (204.04) 23; 393.48 (74.70) 38.77 (-52.2, 129.8) 
 
Reported health transition 
 
26; 38.65 (27.88) 23; 38.91 (24.68) -.259 (-15.5, 15.0) 
 








25; 17.72 (2.72) 22; 17.32 (3.83) .40 (-1.53, 2.34) 
 
EQ-5D-5L Index Values 
 




26; 60.15 (22.93) 23; 63.04 (19.52) -2.89 (-15.22, 9.44) 
 
Number of hospital 
admissions 
26; .15 (.37) 23; .39 (.78) -.23 (-.58, .11) 
 
 
Number of hospital 
readmissions 
26; .04 (.196) 23; .09 (.29) -.05 (-.19, .09) 
 
 
Total number of days 
spent in hospital 
26; .65 (1.72) 23; 3.00 (7.37) -2.35 (-5.59, .89) 
 
 
Number of prescribed 
medications  







6.12 Feasibility objectives 
The feasibility objectives have been evaluated and results relating to each objective 
are reported in Table 6.15. A number of these objectives were judged by the Trial 
Management Group and Trial Steering Committee as essential to the success of the 
study and would be used as criteria to evaluate progression to a full trial or not. These 
are specifically reported on in section 6.13. 
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Table 6.15: Feasibility Objectives 
Objective 
summary 
Outcome Measures  Study results Feasible 
(Y/N)  




Number of consented participants 
randomised to the intervention 
group who do not withdraw or die 
within the intervention period 
engaging with the minimum 
“dose” of the intervention. 
86.6% of consented participants 
randomised to the intervention group 
completed the minimum “dose” of the 
intervention. 
Y  
Assessment of number of 
community matrons moving 
between intervention and control 
sites 
 
100% (n=5) of community matrons 











Number of general practices 
expressing an interest in 




14 general practices were 
approached, 57.1% (n=8) met 
eligibility criteria. 
Y In a larger trial, a more systematic way of 
approaching general practices and publicising 
the study would be employed using Clinical 
Research and Primary Care Networks. 
Number of general practices 
approached that participated. 
42.8% (n=6) progressed to 
participation in the trial. 
 
Y 
Number of general practices 
screened for selection and 
reasons for non-selection. 
57.1% (n=8) general practices met 
eligibility criteria. Reasons for non-
selection of practices included no 
community matron in post or did not 
have the eFI integrated into the 
electronic clinical notes system. 
 
Y 
Number of general practices 
withdrawing from the study, timing 
and reason for withdrawal. 
0% (n=0) general practices withdrew 




Outcome Measures  Study results Feasible 
(Y/N)  
Suggested Modification  
Number of general practices 
failing to progress through 
implementation milestones and 
reasons for failure. 
16.7% (n=1) general practice did not 
complete screening/eligibility 
processes within prescribed 
timescale (6 months from site 
initiation). Others needed significant 
support to achieve milestones. 
Y Consider how support can be provided to sites 
in completing study processes in a timely 
manner through Clinical Research Network 
staff or dedicated research assistants. 
Number of general practices 
withdrawing during the 
implementation and delivery 
phases. 
 
0% (n=0) of general practices 
withdrew during the implementation 
and delivery phases. 
 
Y  
Numbers of participants identified 
using the electronic frailty index 
(eFI) as a denominator for 
number of those identified that are 
eligible. 
414 participants identified using the 
eFI. 
21.49% (89) participants were eligible 
on screening. 
N Review the use of eFI as the sole method of 
identifying potential participants. Consider 
how many patients would have to be identified 
in order to achieve final number of participants 
in a larger trial. 
Numbers of participants screened 
as eligible, recruited, consented 
and followed up 
21.49% (n=89) participants eligible on 
screening, further 8.9% (n=10) found 
to be ineligible at consent visit. 
n=56 participants consented. 
92.86% (n=52) completed three 
month follow up. 
87.5% (n=49) completed six month 
follow up. 
Y  
Follow-up rate was predicted to 
be 70%, with full outcome data on 
a minimum of 42 participants. 
Follow up rate was 87.5% with full 




Number of and timing of 
participant withdrawals from 
follow-up data collection, reasons 
for withdrawal, number of and 
timing of losses to follow-up. 
Intervention group: n=1 withdrawal 
following baseline, n=3 withdrawals at 
6 months. 
Control: n=2 withdrawals following 
baseline, n=1 withdrawal at 6 months. 




 Outcome Measures  Study results Feasible 
(Y/N)  







the future trial 
Numbers of potential primary and 
secondary outcome measures 
completed at baseline and follow-
up intervals. 
 
As above, all outcome measures 
completed unless participant 
withdrew. 
Y  
Numbers of missing items for 
each potential primary and 
secondary outcome at each time-
point. 
Overall, outcome measures showed 
high levels of completeness with the 
exception of LTC-6 which was not 
fully completed by two participants in 
addition to those who had withdrawn. 
Y  
Assessment of the feasibility of 
collecting data to estimate cost-
effectiveness using the EQ-5D-5L 
EQ-5D-5L showed high levels of 
completeness in both groups. Data 
analysed for descriptive system, 
index values and VAS. This can be 
used to estimate cost effectiveness in 





6.13  Progression to a full trial 
Decision on progression to a full trial was based on quantitative data from this fRCT 
combined with data from the embedded qualitative study and this will be discussed 
further in Chapter Seven. In relation to quantitative data, criteria for progression was 
set out in the Statistical Analysis Plan (Appendix 13).  Progression to a full trial would 
be considered viable if certain pre-specified feasibility criteria were met or if clear 
strategies were identified that could support the delivery of the full trial in tandem with 
successfully identifying a suitable primary outcome. The success criteria are listed in 
Table 6.15 and denoted against the following traffic light criteria (Battle et al., 2019). 
 Green indicates the target was achieved 
 Amber indicates the target was not achieved but progression to full trial would 
be possible with minor protocol amendments 
 Red indicates the target was not achieved and progression to full trial is unlikely 
to be supported 
All feasibility criteria were achieved (green) (Table 6.16) relating to site and participant 
recruitment, completion of outcome measures and engagement with the intervention. 
Of the general practice sites who were initially approached, 74% progressed to 
participation in the study and the target number of sites (n=6) was achieved. Almost all 
the participant recruitment target was achieved (93%, 56 participants out of the 
predicted 60) within the 43 week recruitment window. Similar figures were noted for 
participants who completed three-month outcome measures (92.85%) and 87.5% 
completed six-month follow up. 85.5% of consented participants completed at least the 
minimum dose of the intervention. The results of these feasibility criteria were 
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combined with data on selection of a primary outcome in order to consider progression 
to a full trial and this will be discussed section 7.6 
Table 6.16: Feasibility success criteria results 
Feasibility success criteria Green Amber Red Trial 
Results 
% of general practice sites that were initially approached 
and progressed to participating in the study 
≥ 50% 41-49% ≤ 40% 75.0% 
% of recruitment target achieved (60 participants) in the 
timescale of 43 weeks (01/11/2018-31/08/2019) 
 
≥50% 41-49% ≤40%  93.3% 
% of participants completing 3 month follow up ≥80%  51-79%  ≤50%  92.85% 
% of participants completing 5 month follow up ≥70% 51-59% ≤50% 87.5% 
% of consented participants randomised to the 
intervention group who do not withdraw or die within 
the intervention period engaging with the minimum 
“dose” of the intervention 
≥75% 51-74%  ≤50%  85.5% 
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Chapter 7: Embedded qualitative study findings 
This section presents data gained from interviews with trial participants, carers, 
community matrons and general practice administrators to gain their views on 
feasibility of trial processes and acceptability of the intervention.  
7.1 Aim of qualitative component 
The aim of the qualitative study was to explore the experience of the HAPPI 
intervention and related trial processes from the perspectives of the participants, 
carers, community matrons who delivered the intervention and administrators who 
carried out participant identification, eligibility screening and provision of outcome data. 
Its purpose was to identify what went well and any barriers to trial implementation with 
the aim of resolving issues and making improvements to maximise success of a 
subsequent definitive trial. 
7.2 Data Collection  
A total of sixteen interviews were conducted guided by the interview topic guides 
(Appendix 17). These included six trial participants, four from the intervention arm and 
two from the control arm as per the study protocol. Two carers of participants in the 
intervention arm were interviewed. It was planned to interview two carers of 
participants in the control arm, but this proved impossible to achieve because the 
research team had no way of determining if control participants required carer support.  
All five community matrons who delivered the intervention were interviewed and three 
administrators. It had been planned to interview four administrators, but it proved 
difficult to access and agree times to interview them. In addition, interviews with two 
people who declined to participate at the outset, and two people who withdrew from 
the study were planned, however, the CI was unable to achieve this despite contacting 
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some decliners and those who withdrew. Individuals had declined or withdrawn due to 
deterioration in their health and, consequently, did not feel able to participate in an 
interview. All participant and carer interviews were conducted at their place of 
residence and community matrons and administrators interviewed at their places of 
work. 
7.3 Data analysis 
Data analysis began during transcription of interview data as the start of the 
interpretative process. The researcher conducted and transcribed all interviews and 
field notes were written for context, taking account of non-verbal communication, 
interruptions and the researcher’s reflections on the experience. Inductive analysis was 
used to understand the opinions and experiences of those involved in the study without 
the researcher’s personal views, or those of the literature, intruding. Glaser and 
Strauss note that the inductive approach limits researchers from inaccurately imposing 
a predetermined result as codes are initially literal and verbatim drawn directly from 
the data set (Glaser & Strauss, 1967). The aim was to prioritise the participant voice 
and so terms used by the participants themselves were presented verbatim in initial 
coding.  
This approach is based in “Grounded Theory” (Glaser & Strauss, 1967, p.233).  Whilst 
wishing to be open to the true meanings of the data collected, it is recognised that the 
research objectives will have influence and may form a priori categories into which to 
“fit” the data. Saldana proposes that qualitative coding happens through an analytic 
lens and that all researchers wear different filters on the lens, which in turn affects 
perception and interpretation of the data (Saldaña, 2016).The researcher’s perspective 
in this case was to be reflexive, recognise that there are preconceptions, but that these 
preconceptions will only translate into emerging themes if they are truly supported by 
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the data.  Themes were largely semantic in nature, that is to say, descriptive with an 
attempt to interpret and theorise significance (Braun & Clarke, 2006). 
Thematic analysis was used as a framework to analyse the data. (Braun & Clarke, 
2006). After transcription, the interviews were uploaded to the qualitative analysis 
program NVivo. There then followed thorough reading and familiarisation with the data, 
with an initial list of aspects that appeared interesting highlighting relevant text extracts. 
A first cycle coding process was completed to generate initial codes, these were then 
transferred to a mind map using the “One Sheet of Paper (OSOP)” method (Ziebland 
& McPherson, 2006). This enabled generation of second cycle codes and some 
candidate categories and these were checked back to ensure they were genuinely 
supported by the data. 
Throughout the process a code book was completed with a detailed description of the 
content of each code. At this stage the emerging codes and categories were discussed 
with a supervisor. A fellow PhD student then coded a sample of transcripts and 
reviewed the candidate codes and categories to provide verification and to identify any 
that had been missed. In order to guide this process a Code to Theory Model was 
developed (Saldaña, 2016) and further supervisor support sought to identify 
relationships between codes, categories and to recognise emerging themes. In 
addition, the results of the data analysis were presented to fellow PhD students and 
the Trial Management Group to check and verify themes. 
It was not part of the original qualitative study protocol to use case study methodology, 
however, during interviews with community matrons they gave interesting examples to 
illustrate the impact of the intervention. After discussion with supervisors, it was 
decided this presented the opportunity to recount one trial participant story as an in-
depth case study in order to explore the intervention and its implementation in real life 
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context. Case study research methods can be used to answer “how” and “why” 
questions (Yin, 2018, p.23), in this case “How can the intervention be implemented?” 
and “Why is this likely to be effective for this group of participants?”. The story, as told 
by the community matron was analysed using narrative analysis to make sense of the 
story and offer insight into the lived experience (Braun & Clarke, 2013). 
7.4 Participant Characteristics  
All interview participant names have been replaced with a participant identifier to 
ensure confidentiality is maintained. Places of work of the community matrons and 
administrators have not been included as this could lead to identification given the 
small number of participants and sites/clusters. 
Trial participants’ ages ranged from 75-87 years, they were all retired. None had 
communication difficulties, however, four participants displayed some cognitive 
impairment and had difficulties recalling some aspects of participation in the study.  
Five trial participants were moderately frail and one was severely frail. Table 7.1 
provides trial participants’ characteristics. It may be that those who were severely frail 
were less likely to consent to an interview and this led to an imbalance in numbers 




Table 7.1: Trial participant characteristics 
Participant 
identifier 





P1 Male 75 Severe (0.35) Intervention 
P2 Male 79 Moderate (0.28) Control 
P3 Female 87 Moderate (0.25) Control 
P4 Female 79 Moderate (0.33) Intervention 
P5 Male 78 Moderate (0.28) Intervention 
P5 Female 75 Moderate (0.33) Intervention 
 
There was one female and one male carer who were identified as C1 and C2. All 
community matrons were female and administrators were two female and one male. 
Community matrons were identified as CM1, CM2, CM3, CM4, and CM5. General 
practice administrators were identified as GPA1, GPA2 and GPA3. 
7.5 Themes 
Three main themes and twelve sub-themes were identified from the data; these do 
reflect the research objectives but are expressed here primarily in language that was 
captured directly from interview data: 
i. “How was HAPPI for you?”: Experiences of trial procedures 
ii. “Filling the gaps”: Impact of the intervention 
iii. “I’m a person, not a patient”: The challenges of shared decision making 
Figure 7.1 maps the themes and sub-themes and these will be discussed in detail in 
forthcoming sections of this chapter. 
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Figure 7.1: Diagrammatical representation of themes
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7.5.1 Theme 1: “How was HAPPI for you?”  
This theme captures the experiences of participants, carers, community matrons and 
general practice administrators in participating in and implementing trial procedures 
and is sub-divided into seven sub-themes.  
7.5.1.1 Sub-theme: Targeting the Intervention 
Existing research indicates that CGA-based interventions may be more effective when 
aimed at those who are moderately or severely frail (Stuck, 1997). In order to take a 
systematic approach to identifying moderately or severely frail people, this study used 
the electronic frailty index (eFI) with verification of diagnosis by PRISMA-7 
questionnaire. As one of the first studies to use this method of identification, it was 
important to understand if this was an achievable selection method in primary care and 
an effective way of identifying appropriate participants to inform selection for a 
definitive trial. Administrators reported that the eFI was easy to run as a computerised 
database search and patient-reporting of the PRISMA-7, as part of an invitation to 
participate, was not onerous to implement. 
“Em, I want to say it was extremely easy, I haven’t changed my mind about it. So, that 
point in particular was relatively easy for me to do, almost press the button and up 
popped the names, so that was good” (GPA1) 
“No, apart from until we actually started I didn’t know it even existed (Laughs), yeah so 
actually it’s helped us. It’s already populated to its just narrowing it down to the ones 
you actually want” (GPA3) 
There were, however, some concerns about validity of the results generated by the eFI 
with an expectation that additional people would be identified as moderately or 
severely frail and thus administrators did not always agree with the classification. 
“I am not sure I quite understand how some of the people end up on (eFI list) be they 
severe, or moderate or whatever, because I look at some of the names of some of the 
people I have known for a long time within the practice, and I think I’m not sure you 
really fit that, but obviously, the computer has been set to pick up the criteria and it has 
done that thing and we go with it” (GPA1) 
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“I think I was a little bit surprised by the lists to be honest, the severely frail, I thought I 
would know more of them and I didn’t and I don’t know why I’ve missed them or they 
haven’t come up, em, the moderately frail, I guess we don’t see them as much” (GPA2) 
Community matrons also had mixed views about the validity of results from eFI, since 
the eFI classification did not always match the clinical assessment of frailty severity, 
which would have categorised participants as less frail than eFI scores indicated, and 
as compared to their usual patients.  
“They probably would have been moderately and severely frail but they were the well, 
they were all much better than my usual patients” (CM3) 
“…and sometimes I think I’m trying to work out how they would have come up, you 
know, as moderate or severe, no I don’t feel that any of the three of them were 
moderate to severe” (CM4) 
“I think the classification was right but it took me a while to re-gear from severe to 
moderate” (CM1) 
Community matrons did highlight, nonetheless, that these patients had complex, 
multiple health problems but had well-developed compensatory mechanisms and so 
may have appeared to be less frail on first assessment than they actually were.  
“Yes and some of them were quite elderly, em, but they had taken quite a responsibility 
in their own health, they had engaged with, not with my services, but they had engaged 
with rehab, they were much fitter than patients I would usually see” (CM3) 
“She would have been on the higher side of frailty, with her condition she would have 
sat there, but actually physically, if she hadn’t lost weight I think she was compensating 
and managing really well” (CM5) 
eFI was judged to be an effective method of identifying people at the latter stages of 
the frailty trajectory but before they present in crisis, enabling a more preventative 
approach to be taken. When asked if they thought there might be a more effective way 
of identifying participants for the study, the community matrons suggested that a 
clinical assessment, or triage, by someone who knew the patient well might present a 
more accurate picture of frailty severity. 
“I think it’s about your perception of frailty still, I think there’s still an issue with that, a 
scoring system is still different from a visual isn’t it?” (CM2) 
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“No, it’s about knowledge really isn’t it and physically the GPs having to think, well I 
saw that patient and I’ve looked” (CM5) 
“We go out and triage them now because we can’t tell on paper if this is how they really 
are and we are trialling that at the minute so I don’t know, because you can’t do 
everybody, you couldn’t but you have to have a guide, so if that’s the guide it may be 
that you need to look at a higher score?” (CM5) 
It was acknowledged that clinical assessment or even triage might be problematic to 
achieve in practice in terms of resources but also in making an objective judgement. 
This is corroborated by Fougére et al who concluded from their cross-sectional study 
that clinical “impression” of frailty is not as effective in making a diagnosis as using an 
objective frailty screening tool (Fougère et al., 2017). 
7.5.1.2 Sub-theme: Selecting and inviting eligible participants 
This part of the recruitment process was primarily the responsibility of administrators 
who, following random sampling of eFI patient lists, sent invitation letters, collated 
responses and completed the trial screening log. If there were inadequate responses 
to the letter then the administrators made follow-up phone calls to ensure the patients 
had received the information and invite them again to participate. The process for 
sending, receiving and processing replies was reported as straightforward and related 
trial procedures were followed without difficulty. Numbers involved were relatively small 
so this was not perceived to be an onerous task. 
“I think I accepted that as being a necessary part of what we were doing, there was no 
other way around it other than to prepare the letters, you have to merge and send, sign 
them off and send them off, it wasn’t that difficult, em, just part of it” (GPA1) 
“That was simple, I kept a list of all the people that was sent the letters out to and as 
they came back I basically just used a highlighter with yellow for the nos and the yeses 
in green. Simple as that really and then I obviously kept the replies and lists of when 
we heard back from them” (GPA3) 
 Some mistakes had occurred within the initial identification and invitation process and 
this led to the need to repeat some actions.  
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“I think, what I normally do is make up set searches for each of the criteria and then I 
join all the searches together so that it brings them all together, but then I forgot one 
of the searches (laughs), that was my issue” (GPA3) 
“I tried to do it on Docman as we generally use Docman to send letters to patients, but 
I  forgot the second part of the letter, so I had to send it twice, so… only my own silly 
mistakes really” (GPA3)     
Instructions for completion of the screening log were thought to be ambiguous and this 
led to some errors, which were addressed in consultation with the CI. 
“I thought that meant I had done my bit and it was over, but that’s not what it meant… 
yeah, because once you explained it I got it, but I had translated it in a completely 
different way” (GPA2) 
Some administrators felt uncomfortable making the follow-up phone calls as they did 
not want to be seen to be persuading people to participate when they did not want to. 
Some aggression was experienced from a few people who did not wish to be involved 
and so did not respond to the letter. Consequently, they were not happy to be asked 
again in a phone call. This was a small minority of patients and most were pleased to 
be asked to participate, even if they chose not to. 
(Laughs) “…em, yes, but in the main it was people, basically, their failure to respond 
was that they didn’t want to be involved, so being asked again on a follow-up phone 
call, they weren’t very pleased about that either. This is something we find in a lot of 
other instances where you are trying to invite people, they won’t respond to say, thank 
you but no, their inner thought is, “I’m not responding, I don’t want to get involved so I 
won’t respond” (GPA1) 
 
Eligibility criteria relating to age and living at home were considered to be clear and 
unambiguous and could be applied using information taken from the clinical record. It 
was difficult, at times, to establish mental capacity from the clinical record as often this 
was not formally recorded. One administrator who had a clinical background found 
that, when contacting the patient by phone, if in doubt, she was able to conduct a 
capacity assessment and make a decision on eligibility based on that conversation.  
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“So, excluding the care home patients and doing the living at home, that was easy. 
The capacity one, I felt some of them were quite borderline capacity, some have some 
cognitive impairment and I felt they were probably ok” (GPA2) 
“Absolutely, I mean there was one where it was clearly inappropriate, but there were 
others, like they did have, like there was a couple that said cognitive impairment but 
they had no diagnosis and when I  spoke to them they fully understood what I was 
saying, they were able to reflect and demonstrated capacity regarding that phone call. 
So, I was more than happy to include them” (GPA2) 
Another administrator, who was also the practice information technology specialist, set 
up electronic searches on the clinical record, which applied eligibility criteria, and 
suggested this was something that could be used in a definitive trial. All administrators 
indicated that they enjoyed this aspect of the trial as it was interesting and different 
from their normal role.  
“Yeah, I’m so used to making searches that I automatically go into building searches 
rather than manually, everything is done that way…so if you can get access to the 
clinical system you can get the searches already made up and then you can just sent 
it to them to run them” 
 
Overall, trial participants were content with methods used to invite them to participate, 
with a letter being the most acceptable method of contact. There was reluctance to 
respond to a phone call or email as first point of contact, as both these methods could 
be scams and participants tended to ignore them. Three out of the six trial participants 
had call screening on their telephones and said they would not answer unless they 
knew the person calling.  It was suggested that an approach through a trusted source, 
such as a general practitioner, might be an alternative and effective method of inviting 
participation.  
“I read through it and I thought yeah, why not? You don’t lose anything by doing this 
and I was interested, again, because of my original background” (P3) 
“I think, not calling them, I think people get bothered too much by phone, I’ve got a…. 
a call guardian on my phone and that stops people bothering me if I wish not to be 
bothered. Through the doctor might work quite well because people have faith in their 
doctor and anything coming from him or her might be a good way, but I didn’t mind 
being approached by letter” (P3) 
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No, I don’t think I would respond to an email, I don’t think so, I have so many, I only 
bother with the things I am really interested in or involved with, the rest of it goes to 
trash I’m afraid (laughs) (P3) 
 
One important issue identified here was that five out of the six trial participants had 
difficulty recalling aspects of the trial including receiving study information and 
invitation letters. This had the potential to induce recall bias which may, in turn, lead to 
inaccurate results and was not anticipated in designing this aspect of the study. If this 
became apparent at interview, participants were provided with copies of the invitation 
letter and participant information sheet again as a stimulus to memory and this enabled 
some participants to comment and give feedback. 
“Can I stop you there because I don’t think I had anything from my doctor before, I 
think when you came and introduced yourself, I can’t think, I must have been expecting 
you, but I didn’t think it was anything to do with my doctor” (P4) 
“Did I respond to that? (Asks wife about invitation letter). The nurse comes to take my 
blood pressure. It’s nice to think that so much is going on” (P2) 
 
7.5.1.3 Sub-theme: Randomisation 
Randomisation at cluster level was conducted by the Clinical Trials Unit. Once 
consented into the trial, the participants were informed, by letter, of their allocation to 
the intervention or control arm. Trial participants understood why randomisation was 
required and did not mind which group they were allocated to. It was also noted that 
carers of the intervention participants reported that they were glad their loved-ones had 
received the intervention. 
“Well, that’s the way it was, that’s the way it was, em, that’s what I agreed to so, yes I 
had no problem with that” (P1) 
“I didn’t mind, I just took it for granted that I was in this control group, that was it, I think 
having been a medical secretary I used to see these sorts of things happening all the 
time and I’ve never thought about whether I would want to be in one group or another, 
just accept where you are, without argument (laughs)” (P3) 
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“Yes, and that’s what, I don’t know why, but I expected to be in that strand, I did and 
when I was getting these conversations, I thought, well, I think I’m in the other one” 
(P4) 
“I think it’s nicer to be part of the study and to be the one the nurse comes to then you 
feel more involved than not” (C1) 
 
7.5.1.4 Sub-theme: Collection of Outcome Measures 
Outcome measures data were collected at baseline, three months and six months 
post-randomisation. These data came from three sources: (1) Clinical data from the 
general practice record entered by administrators onto the trial database; (2) Outcome 
measures questionnaires completed with trial participants by research nurses; (3) Data 
relating to completion of the intervention by community matrons. Administrators did not 
find it burdensome to return the information particularly as this was completed via a 
paperless database, something general practices are familiar with using. They 
appreciated the email reminders to complete the data submission and the direct link to 
the database was considered to be time-saving and convenient.  
“It wasn’t too onerous, I did think will I be sitting for days looking at this, but it wasn’t 
that, em, so no, it was quite interesting to be involved and yes, it was good” (GPA1) 
 “Well it was nice to see that it was mainly paperless which is obviously something that 
as general practices we are going that way, so I liked the fact that you sent links and 
we could add the patient data onto that, em and also the fact that it didn’t take much 
time, it was easy to do” (GPA3) 
 
Outcome measures questionnaires employed in the trial were extensive and took 
approximately one hour to complete. There were concerns that this would be an 
unacceptable burden for trial participants who may suffer high levels of fatigue due to 
frailty. On the whole, the questionnaires were well received with only one trial 
participant commenting that the questionnaires were long and repetitive, but she was 
still quite happy to complete them. All other trial participants stated that they did not 
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find the process of completion tiring, the questions were relevant and that they could 
complete them truthfully.  
“I found it perfectly easy and I enjoyed the company actually, very easy, not at all 
stressful and quite relaxing” (P5) 
“No, not at all, bearing in mind I had agreed to do this, so you do what is asked of you, 
it’s no good agreeing to something and then saying oh and getting bolshie over it” (P1) 
“The questions they asked were all sensible to which I think I answered all of them as 
much as I could…I found them easy, I could fill them in genuinely, what I felt, what I 
did” (P1) 
“In fact I was quite impressed, em, you get the idea that, you know, your information is 
going to be taken notice of” (P2) 
An aspect of the study that was highly valued and enjoyed was the visits from the 
research nurses to administer the questionnaires. Trial participants enjoyed the social 
interaction these visits afforded, including the company of the nurses. The research 
nurses put trial participants at their ease, took time to carefully explain the purpose of 
the questions and made it an interesting and pleasant experience.  
“They were helpful with me, they were helpful with what they were doing, they took the 
time to explain a few things that I asked, so that was good. I think they’ve been 
thorough, em, where I had a little problem filling in they helped or changed things, oh 
they didn’t change things, they spoke about it em and they were nice girls, I must say 
they were super to come in and talk and that’s it” (P1) 
“In fact there is no question that the nurse was, I don’t know, I suppose it’s their job, 
em, to make it interesting, and, em, and strange as it may seem the actual questions 
and the way it was all done, to me was very professional” (P2) 
“I’ve really enjoyed it, I don’t get the chance to speak to people much since I’ve not 
been able to go out over the past four years, so being able to talk to people and to find 
they wanted to talk about me was really quite enjoyable, no trouble at all…I had a 
whale of a time with one of them, yes, she said to me before she left “You’re a dynamic 
woman”. I said “what me?” oh, she really did me good (laughs)” (P4) 
There was, however, some concern expressed that some of the questions did seem 
impersonal and ambiguous. 
“I just filled in forms and answered questions and ticked boxes really, that’s what the 
whole process has been like, answer questions, tick boxes and sign, em, in that way I 
suppose it’s been quite impersonal” (P5) 
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“Some of them were… I didn’t know quite how to answer, and even the person asking 
the questions was like she didn’t know quite why that question was there, I can’t think 
of any examples at the moment but I felt with some of the questions they were a bit 
ambiguous, you could give two meanings” (P3) 
 
Belief in contributing to public interest is reported to be an important motivation for 
older people in contributing to research (Baczynska et al., 2017) and this is confirmed 
by this trial cohort. Trial participants appreciated a positive focus on the needs of older 
people and, while they understood that the research could confer no direct benefit to 
them, they expressed personal benefits and that the time commitment was worthwhile. 
Whether in the control or intervention group, trial participants and carers confirmed that 
they had learnt something useful in relation to their health and enjoyed the experience. 
It was reassuring to see that far from being burdensome, the experience was, 
generally, a positive one. 
“I think we were just looking at it helping people in the future rather than helping (trial 
participant’s name) because it really hasn’t done anything to help him, so really we are 
just looking to the future for people that need help” (C1) 
“I think the major thing is, I thought it was going to do something that was good for all, 
that was the main thing and that’s what they put over, that you are trying to learn about 
people like me and everybody else but put it all together” (P5) 
“I am pleased that I might be in any small way offering some help, em, I suppose I 
should be pleased, I am pleased that in any small way I might be offering some help” 
(P2) 
“No I didn’t think it would gain me any awards or any merit at all (laughs), it’s just being 
helpful to someone else” (P3) 
 
7.5.1.5 Sub-theme: Clarity of study aims and purpose 
One of the major challenges identified by trial participants and community matrons was 
lack of clarity about the aims of the study. Trial participants did not understand fully the 




“I didn’t really understand the purpose of the em, em, the study…it was just this not 
quite understanding the whole purpose of it…but it’s just the fact that I didn’t quite 
understand the reason for it, or the outcome of it, or the possible outcome of it” (P5) 
“I think the only thing that would help or for me that I would like is if you were explaining 
what you were aiming at, what the final aim was, em, because we didn’t really get that, 
I don’t think the nurses knew so much, they gave a lot of information but where’s it 
going is a different question” (P1) 
Only one trial participant had understood and could articulate the study aims fully. 
“I think the idea of the study was to find out how people who are living with some sort 
of disability or frailty are managing and what was stressed was, it’s not just enough to 
be trying to get good results for people’s health but also for their happiness, and I go 
along with that very strongly” (P5) 
 
Community matrons also remarked that the participants did not always understand the 
purpose of the trial and expressed difficulty themselves in articulating the study aims, 
at least initially.  
“And the patient didn’t really understand what the HAPPI study was about, I found it 
quite hard to explain it actually. I think I’ve got better as time has gone on, but initially 
I think I felt nervous, I was trying to explain what the study was, they didn’t really seem 
to understand themselves” (CM4) 
“It was just when you said to them “I’m here because of the HAPPI” and they 
remembered it, but they couldn’t always remember what it was for, and trying to explain 
the purpose of the study I found a little bit hard to start with and I think I was trying to 
use the words, a more academic approach which is not my natural, but I found it difficult 
to explain to them the purpose of the trial”(CM1) 
“I think that the patients obviously get so much information that they don’t obviously 
retain it or understand it and so that first visit felt like the blind leading the blind a little 
bit, I don’t mean that rudely, but then on subsequent visits and with other patients, 
that’s improved” (CM4) 
 
The lack of clarity appeared to be related to the concept of feasibility, and it proved 
difficult to explain to participants that the study did not aim to prove effect of the 
intervention but tested procedures relating to the trial and intervention. This was 
compounded by the fact that the intervention was not prescribed or standardised, but 
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completely person-centred and, therefore, different for each person. This meant that 
neither the research team nor the community matrons were able to tell the patients 
what they were likely to experience apart from the basics of a nurse visiting them at 
home, potential number of visits and other broad details.  
“I felt a bit clumsy on the first couple and then after that I thought what is HAPPI, what 
do I understand by it, then I tried to explain to them just like you said, we are looking 
at it in a different way, you know, in healthcare we are quite reactive, you know, but we 
are trying to be proactive, we are trying to know from your point of view what would 
help, we are trying to guide how you could be, I tried to unpick it a little” (CM1) 
“And I think it was even harder because it was feasibility” (CM4) 
“I think people can’t understand that, I think you are right, if it’s a or b they understand 
that, but I think, em, I don’t want to use the word woolly in a rude way, but I think it’s a 
bit more fluid then, that’s nice and woolly (laughs), it’s a bit more fluid, I don’t think 
people can always understand that, because I think you’re right, they hear a study and 
they think a or b, they don’t think it’s going to be an intervention that is kind of led by 
them and I don’t think they could get it really” (CM4) 
 
The non-standardised nature of the intervention made it more difficult to manage 
patient expectations related to the study and what to expect after the intervention 
ended. It was suggested that an agreed script could be used initially to explain the aim 
and what could be expected, however, the community matrons did acknowledge that 
their ability to articulate the purpose did improve over time as they became more 
practised in this approach.  
“I said we are just trying to see, can we actually do this, can we engage people, do 
they stick the course, do they stick with the six visits, do they feel they have contributed 
and that we haven’t wasted their time” (CM2) 
“I would have liked a bit of a script that I could use on the introductions to all of them 
so they all started in the same vein and just for them to be a bit clearer, cos I struggled 
with the fact that they don’t, they don’t seem to understand it or know what it’s about” 
(CM4) 
“I did feel like I did need something like a statement that was reflective of the research 




In discussing why the trial participants did not seem to be able to grasp the aim, one 
of the community matrons observed that these were “well” patients, often with busy 
lives and the study was not high priority for them. In addition, there was often a number 
of weeks between participant consent and first intervention visit, which led to 
participants having difficulty recalling conversations and written information about the 
study purpose.  
“Yes, yes, and these patients are living a life aren’t they, that lady had been cruising 
and doing all those other things, so they will have forgotten, or it won’t be high on her 
list of priorities” (CM4) 
“And I think a lot of people, I don’t mean to be rude, but they weren’t really readers, 
they sort of scan it, and the other thing they said was the duration, the time from when 
they were consented to actually having a knock on the door was actually quite a long 
time, and although they remembered HAPPI they didn’t really kind of know why I was 
there” (CM4) 
 
7.5.1.6 Sub-theme: The HAPPI Intervention 
The HAPPI intervention was designed to be entirely person-centred and its 
individualisation and unique content for each participant were key principles of the trial. 
Community matrons were provided with an assessment and care planning toolkit 
containing evidence-based tools constructed from the components of the intervention 
developed in the first phase of the study. As part of the evaluation, community matrons 
were asked to comment on the usefulness of the assessment pack/process and its 
relevance in clinical practice and all found it a useful resource which was 
comprehensive and supported a holistic assessment.  
“But the assessment pack is definitely invaluable, I’m sure if the service, or whatever 
happens next evolves then it will evolve but fundamentally, it’s brilliant” (CM1) 
“I think it (assessment and care planning toolkit) was absolutely brilliant and having 
that now is giving us permission, its updating what we already do, but having it in paper 




“I thought it was very holistic as it was meant to be, I think it made us, or me feel I do 
an holistic assessment on my patients, and I think we do things holistically and don’t 
realise we are doing it…so it kind of reaffirmed our role in being experts in holistic 
assessment I think” (CM3)  
The whole suite of tools was never used in entirety with any trial participant, but rather 
the most appropriate resource was selected to explore or objectively assess issues in 
more detail and to help participants to understand their condition more fully. All 
community matrons found the conversation guide to be the most helpful and frequently 
used tool as it prompted discussions and guided the content of the ongoing intervention 
and care planning process.  
“I think the conversation guide was the first one that we used and then you were about 
to dip in and out of the other tools” (CM2) 
“Every first visit I used the conversation guide. On the first few visits I just used it as a 
guide, as a verbal prompt and a visual prompt, so actually, just completing that 
conversational guide you can find out so much, if you just do an holistic assessment 
with no, em, medical model, it is the conversational guide isn’t it?” (CM1) 
Some tools were found to be useful in guiding practice when the community matron 
felt they needed to add to existing skills and knowledge, in particular the assessment 
of depression, anxiety and loneliness.  
“Then I did dip into some of the assessments. I did use HADS (Hospital Anxiety and 
Depression Scale) and the loneliness one quite a lot because that was hugely 
important, and that led to discussions about total symptom management, you know 
about how mood affects health, health affects mood, that kind of thing” (CM1) 
“We did all the basic things like activities of daily living, and we did MUST (Malnutrition 
Universal Screening Tool) scores, and we did medication reviews at every visit. We 
looked at capacity a few times before you are convinced that they are ok, and we used 
MFRAT (Multifactorial Falls Risk Assessment Tool), you know, I used quite a few of 
the things, I tried the loneliness one" (CM2) 
 
When asked if there were any missing components of the assessment process or tools, 
community matrons highlighted the need for a mapping of local voluntary and 
community support services, information on state benefits and some additional health 
assessment tools including a food chart, safeguarding flowchart and a particular 
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cognitive assessment (the Six-item Cognitive Impairment Test) which was in common 
use in the area. Paper copies of the tools and a toolkit folder were preferred over digital 
versions. A new clinical computer system had recently been introduced and there were 
concerns that the use of digital tools would be more time-consuming at this point in 
time.  
The HAPPI intervention was designed to be completed in a maximum of six visits to 
the patient and the number could be tailored according to patient need.  Community 
matrons agreed that six visits was the absolute maximum required, with the majority of 
patients requiring less. Having a limit to number of visits was perceived to be useful in 
that it enabled clarity, in terms of trial participants’ expectations, and avoided fostering 
dependence on the community matron service. Contact details were shared with 
participants and they were encouraged to contact community matrons beyond 
completion of the intervention should problems arise or their condition deteriorated.  
“I think six is good because once I realised I didn’t have to do six, I got into a better 
“right we’ve done this, we’ve done that we are gonna do this”, fine, I don’t think I would 
have needed more than six” (CM1) 
“So I think more than six visits would not be good, to have that limit is good” (CM1) 
“It was enough, it was enough, I don’t think… I started introducing the PCP 
(Personalised Care Plan) at about visit three or four and then going back so that we 
could clarify things as they started looking at things in more depth so, I wouldn’t think 
that you needed more than six to be honest” (CM2) 
 “I was hoping to wind him up today and not do visit 5 but no, he wants me to go back 
again in a fortnight, so yes, you’ve got to be careful about not fostering the 
dependency” (CM2) 
These observations on toolkit content and number of visits will help to refine the design 
and inform the content of the intervention toolkit for a definitive trial.  
7.5.1.7 Sub-theme: Training and Development 
Community matrons described benefits for them, personally and professionally, arising 
from working as part of the study team, despite the demands of completing the study 
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tasks alongside managing their busy patient caseloads. Perceived benefits included 
having the opportunity to provide high-quality, evidence-based nursing care whilst 
updating on research methods and implementation.  
“Well, I thought it was quite interesting, doing something that was slightly different, eh, 
contributing to the knowledge base really which is how nursing has evolved” (CM2) 
“I think you’ve just got to look at what you were getting out of it and I just feel that I 
have had a bit of revision with the research process and it has been useful, it has 
reminded me about different aspects so that’s good” (CM2) 
“So it was lovely to be able to go in and have that time, it was quality nursing, like old 
school nursing” (CM1) 
In preparation for their role in the study, community matrons were required to attend a 
two hour face-to-face training session provided by the CI and to complete the online 
NIHR Good Clinical Practice (GCP) training package. The community matrons enjoyed 
the face-to-face training and reported that it was relevant and supported their role in 
the study. They appreciated the training pack provided, which reinforced the session, 
seeing this as a good resource and reminder once they were back in clinical practice.  
“I liked the training session because it was face to face and you had the opportunity to 
interact and ask questions, what I really loved about the training was that it came with 
two files so the assessment pack came with me to every single visit and I loved having 
that” (CM1) 
“Yes, that was fine, it gave us a good brief on what we would be doing, having the pack 
you could familiarise yourself with some of the tools if there was anything new in there, 
most of it we had come across before anyway” (CM2) 
“I found that really good, I was quite excited by the pack, I know that sounds really sad, 
there were definitely tools in there, where I thought “oh this is really useful”” (CM3) 
The intervention itself contained familiar components and so, in the main, community 
matrons were comfortable to deliver it supported by the assessment pack, although 
one community matron observed that it was helpful to have some additional support 
and mentorship.  
“No, well we all learn in different ways, I learn when I am doing something on the job, 
but I did appreciate having someone who had done it before just to make sure I am 
taking in everything” (CM3) 
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“But I made sure that I was able to touch base with (names a community matron) and 
say “am I doing this right and do I photocopy this?”, so it was good to have somebody 
that was a little bit ahead of me” (CM3) 
 
The online GCP training was less well received. Community matrons had difficulty 
accessing the site and found the training time-consuming and not entirely relevant to 
their role in the study. However, the training was recognised as necessary for all staff 
involved in trials and a useful opportunity for professional development that supported 
revalidation requirements.  
“The training was long (laughs), long and I don’t think I could remember all of it.  Yes 
and it makes you think “gosh this is very thorough” but I can’t really…oh I remember 
bits and pieces of it, but it’s a lot to remember.” (CM3) 
“The online training was horrible (laughs) horrific and took a lot longer than I 
anticipated. But I think maybe it took me about five hours in total which, and I’m not 
sure I remember much of it if I’m honest, so your training and the pack brilliant, the 
online not brilliant” (CM4) 
“We did the online training, the research training, which was quite in-depth, took quite 
a time…accessing that online e-learning, because it was an external provider, you 
know, it took a little bit of working out … but you give a big hooray when you get your 
certificate and you put it towards your re-validation (laughs)”  (CM2) 
 
Whilst they were enthusiastic about working more proactively with patients earlier in 
the frailty trajectory, the community matrons acknowledged that this was a different 
way of working from their normal practice. This felt uncomfortable for them,  at least 
initially, and they commented that they were not entirely equipped to work in this way. 
“I wonder though, if I carried on seeing HAPPI patients for the next six months say, I 
wonder if my dialogue would develop better, do you know what I mean and whether I 
would be able to elicit, because in the past I’ve done courses on motivational stuff. I 
certainly enjoyed it more as it went on and I became much more confident, and I left 
those silences like I would in real life when I know my subject, and I’d give them 
homework which they all were a bit… but, so I wonder if I did it for another six months 
I’d be better at pulling a goal” (CM1) 
“The first patient I felt like, I came away feeling a little bit upset like “oh my gosh I’m not 
doing this right” because it wasn’t terribly, it didn’t work out very well if I’m honest and 
I think some of that was learning about how to tackle this. I felt a little bit like I was 
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seeing them too early, so they felt they didn’t need or didn’t want to engage with what 
I offered and I suppose, I don’t know, I’m not really used to people saying “No I don’t 
need that” or “No I don’t want that” so personally, I think the first patient really knocked 
my confidence and I really struggled” (CM4) 
 
In addition, as part of the study procedures, community matrons were asked not to find 
out any past medical history or other information about the participants before the first 
visit. This was meant to ensure the assessment and care planning process flowed from 
the initial conversation without any pre-conceived ideas from the clinician. This request 
was a change for them as in their day-to-day practice, they would receive information 
from the referrer and gain past medical history, and medication lists from the general 
practitioner prior to seeing the person. Therefore, this change created unfamiliar 
territory for the community matrons and, whilst some reported that this was 
challenging, others enjoyed the opportunity to get to know the person without any 
prescribed agenda from their perspective. As the study progressed, all became more 
practiced and comfortable with this approach.  
“Frightening, I found it frightening which is why I think my first one was all just a bit, 
because I felt a bit unsure…I’m going in blind without any information about the patient 
as well, which is alien to us, so I kind of went in very blind and the patient didn’t really 
understand what the HAPPI study was about, I found it quite hard to explain it actually. 
I think I’ve got better as time has gone on, but initially I think I felt nervous” (CM4) 
“I found it quite challenging because I am always leading the conversation and directing 
the conversation to get what I want because I want specific things so, em, it took longer, 
you know, so it was interesting (laughs)”(CM3) 
“So, each first visit I knew nothing, I made sure that I was completely blind, obviously 
I knew their names and where they were, but that was it and that was brilliant and I 
really felt that I was able to get to know them a little bit before we went straight into 
what are the challenges etc., etc., em and the assessment forms, the guides” (CM5) 
 
7.5.2 Theme Two: Filling the gaps in primary care 
This theme presents views of trial participants and community matrons on the added 
value of the intervention and its potential to fill the gaps experienced by older people 
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in UK primary care. It is divided into two sub-themes and contains a participant case 
study, which indicated that, combined with delivery by skilled clinicians, this 
intervention may have wide ranging and multi-faceted impact. 
7.5.2.1 Sub-theme: Meeting the needs of older people and carers 
Trial participants gave compelling and often emotive accounts of their experiences of 
primary care services and were accepting of poor service and dismissive attitudes of 
clinicians. They recounted difficulty in obtaining appointments with general 
practitioners and lack of time allocated to them to discuss their multiple health issues.  
“Well, I feel that it’s been very helpful, there has been times when, it has been very 
good because certain aspects of the way (CM4) handled things were very good 
because they were aspects that I was concerned about in general about the way the 
doctors work, em, and she sort of filled in the gaps, it was very good” (P5) 
 “No, it’s like you go into the doctors and you’ve got two or three little niggles, one major 
one and you don’t know as a layman, what could be related to what you know. In fact, 
I had that situation and I was asked, whether it was a humorous comment at the time, 
but it was commented “what is this buy one get one free day?” which didn’t, when you 
are not feeling well and you are not sure of that particular person, I wasn’t sure whether 
they were joking or not, it’s very detrimental” (P5). 
 “Yeah (CM1) was very helpful and was prepared to talk to me if I had a bit of a “what 
do you think is happening here?” and she said, she told me, you know, she was very 
good, very good, so I don’t mind her coming back (laughs). Cos I personally think the 
whole, all of the doctors and nurses thing is falling apart and we just don’t get looked 
after, especially as you get older, so it’s nice to have somebody come in and talk to 
you, it’s good” (P1) 
 “It’s difficult to make appointments to see your doctor unless you make them on the 
day and I always feel that if you make them on the day then it should be something 
urgent, but we find if you make an appointment and you can’t get one for about three 
weeks, when the three weeks are up you can be in quite a different situation” (P4) 
Community matrons also alluded to these issues and acknowledged that it has almost 
become the norm for clinicians to convey their hectic workloads to the patient at every 
consultation as a justification for keeping the consultation short. 
“Yeah, and I think they wait for a crisis now patients I think, oh you are very busy, oh 
the doctor is very busy and I almost feel embarrassed now that we keep saying that, I 
think we need to stop saying that because when patients are reciting it back to you, I 
think you are saying it too much” (CM1) 
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“Yes, you hear it and it’s not ok, if you want a lazy job you don’t work in healthcare, 
you are busy, but you don’t say it to the patients, the patients should not be able to 
pick up on that, they need to be able to feel that they have our attention when we are 
with them and I think we are losing that” (CM1) 
“I think the patients really appreciated the time we took, I think that was said repeatedly, 
you know, so grateful for the time and they have never been able to speak to someone 
for such a long time and tell them about everything and they felt they were being 
listened to which in think is quite important” (CM3) 
 
Trial participants highly valued the visits from community matrons and saw them as 
knowledgeable clinicians whose specific role was to discuss the challenges of their 
multiple health problems and who had time to listen to them.  They described how the 
community matrons were interested in the detail of their health and social care issues, 
how they actively problem-solved and sign-posted them to sources of support. This 
was seen as providing what was currently missing in their interactions with primary 
care clinicians, particularly general practitioners.  
“Oh yes, particularly if like me you are on your own and you’ve got some silly little 
niggle and if you can talk it over with someone, even if only for a couple of minutes, 
“oh, ok that’s fine, I can forget that, I can just go along with it”, whereas if no one talks 
to you about it, it’s still rattling round in your head and you don’t know whether it’s 
something that is important or of no problem at all” (P5) 
“It was very useful, em, in general, that is what is missing in GP care generally, while I 
say they do as much as they can, because of the pressure they are under, em, you’ve 
got the feeling of being listened to with (CM2), quite frankly although my doctor is very, 
very good, she is rushed the same as every other doctor is, so I found that, the fact 
that (CM2) was actually listening to me was something I miss in general, I felt, I found 
that very, very good, yes” (P1) 
 
Only two carers were interviewed, thus, there was limited feedback on the intervention 
from their perspectives. One carer did state that she would have preferred a more 
private assessment as she did not always feel she could be honest about her concerns 
and personal health issues with her partner present. 
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“Yeah, I think asking you as a carer in front of the person wasn’t good cos I didn’t 
answer honestly and you are not going to say a stress level of ten when it is sometimes” 
(C1) 
More in-depth information regarding views of study processes could potentially have 
been gathered from additional interviees, however, there were no negative comments 
relating to this aspect and both carers believed their loved-ones had gained benefit 
from the intervention and being part of the trial.  
“Nothing bad, I think it’s done (P4) some good, but, you know I can’t put my finger on 
anything but I mean, she has looked forward to you people coming so she must have 
been thinking she is getting something good out of it” (C2) 
 
7.5.2.2 Sub-theme: Reversing or managing frailty 
Community matrons are advanced practitioners who provide care and support to the 
most unwell, complex, community-dwelling, multi-morbid patients. Such patients 
usually present to them when referred in crisis. The HAPPI study was viewed by the 
community matrons as an exciting opportunity to try a more proactive model of working 
in partnership with older people at an earlier stage of frailty progression, when there is 
a higher probability of avoiding or delaying adverse effects. They recognised that trial 
participants seemed far less unwell than their usual caseload and were enthusiastic 
about the opportunity to intervene earlier. They viewed trial participants as their 
potential usual patients in years to come and saw the intervention as a chance to delay 
that progression or prevent adverse outcomes such as loss of independence.   
“But we now have people who are on practice nurses lists, we’ve got a lady having a 
hip replacement and having surgery, we’ve done falls work, I mean there is stuff that 
will prevent them hurling our way. I mean there is stuff we’ve genuinely done as well 
as the more holistic, difficult to quantify stuff, you know there are patients that have 
had interventions, that I decreased medications, postural drops picked up, real stuff” 
(CM1) 
“I think that is advantageous and when I spoke to them about we are trying to be 
proactive rather than reactive and trying to look at where you are now and keep you 
well, make sure you understand your conditions and what to look out for and see that 
you can manage your own health, I think they got that and it was useful” (CM1) 
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“Because I feel that these patients are essentially my patients in ten years’ time, they 
are almost like an early version of our patients, so that’s why I think because we are 
used to working at a certain level, sometimes it was quite hard because I think we, I 
don’t want to use the word task, but we often are unpicking things, looking for problems 
and sorting them or addressing them and stuff and actually there wasn’t the level of 
difficulties that there are with our patients. So, I chose to do it that way to try and 
educate them, so I didn’t, I didn’t take control of things maybe like I do with my CM 
patients” (CM4) 
 
There were occasions when the community matrons diagnosed serious health 
concerns in trial participants which, if treatment had been delayed, would have led to 
crisis. There was a strong belief that these patients may have slipped through the net 
of usual services as they were not yet sick enough or had not yet experienced a health 
crisis to bring them to a clinician’s attention, yet still required significant support to self-
manage and preserve independence.   
“Like one of the ladies we have ended up having to fast track into hospital for 
investigation, she had been waiting six weeks, she hadn’t contacted the GP, she’d 
been losing weight for six weeks and was waiting for me to go in and I said “have you 
made an appointment to see your GP? “oh no” and she did it then and there and went 
to see him that day, it was really good” (CM5) 
“They would have been, they would have presented with a crisis because they weren’t 
being monitored, yeah, and that’s important, that’s two patients that are now being 
reviewed annually that weren’t before” (CM1) 
Community matrons highlighted challenges in articulating frailty in their discussions 
with trial participants and remarked on the correlation between physical and mental 
health and well-being in the study population.  
“From my perspective as a nurse, I understand about frailty and I am passionate about 
it like many people, I think I’ve been talking about it even before it became, but using 
different words like performance status, functional ability and I’ve been talking about 
resilience to patients and speed to recover and all those things, I think you can see the 
value of this piece of work and I think if you are going to talk about frailty” (CM1) 
 “I mean she had become housebound from her anxiety, she had disengaged from her 
anxiety, she had disengaged from medicine, medical support, just from primary care, 
so if that festered and carried on she would have aged before her years wouldn’t she, 




“And it was just really obvious that if we can sort out her pain and sort out her long term 
depression and anxiety that we can then look at social prescribing” (CM4) 
 
A key finding in their intervention assessment, which was reported by all community 
matrons, was the high prevalence of loneliness and its impact on frailty progression. 
Community matrons noted that the existence of loneliness was present in the majority 
of trial participants and were aware of its significant link to mental and physical health 
issues. However, they felt ill-equipped to address this issue. While it was important to 
identify loneliness, it was hard to talk about, and they had little to offer in addressing 
the problem.  
“The loneliness was phenomenally apparent, I was quite shocked… but these patients 
were capable of leaving the house and yet they had an overwhelming loneliness and 
one patient actually said to me “You are asking me all these questions but all it is is 
that I’m lonely” and I just felt that was a bit of a goose bump moment for me. I think 
that the patients that we see are perhaps more lonely than I have credited, but I have 
accredited it to a different word like isolation, and I think people actually can get out, 
they are able to talk, they have got the breath and yet they are lonely and the effect of 
that, and how they could even pinpoint themselves how this affects their mood and 
their ability to look after themselves and it was, you know, and it was hard to talk about, 
because saying to someone, yes I understand that you are isolated if you are unwell, 
or you are dying and people find it difficult to visit you, I can talk about that until the 
cows come home, but someone saying they are lonely, that’s a very personal thing, 
very emotional” (CM1) 
“The loneliness one was interesting, its only three questions but it is a theme which 
crops up all the time with the type of patients we see, loneliness” (CM2) 
“A lot of loneliness actually, because our CM patients, due to their complexities they 
often have people coming in like health care providers or care packages, carers, so 
they do have a certain turnover of people because they are often quite dependent, 
whereas, these are somewhere in between, so they are not still working, they maybe 
aren’t quite well enough to be collecting the grandchildren, that kind of thing, in terms 
of this particular person, but they are not at the point where they need care packages 
so actually she was in a really lonely bracket” (CM4) 
“It really is and also you didn’t want to patronise and also if you take a conversation 
further, I have an expectation on myself as a practitioner that I will make a suggestion, 




They noted a lack of awareness of community and voluntary sector support to address 
social isolation and the challenges of supporting trial participants to engage with these 
services, highlighting transport issues in a rural area as a major prohibitive factor. 
Some general practices had recently appointed a Social Prescriber and community 
matrons anticipated that these roles would provide better knowledge of and access to 
support services for this population. 
“Because I did speak about socialisation and trying to get out, there is some stuff, but 
there is only one thing in this area where I can guarantee transport, two other things 
that provide some transport are fully booked and are at Eden and people are 
apprehensive about the hills and it also, I don’t mean this disrespectfully, but Cornish 
people see miles in a long way so even Eden seems a long way to them” (CM1) 
“Yes, I mean I have referred to them PCDPs (Primary Care Dementia Practitioners), I 
have referred to Social Prescriber and Volunteer Cornwall and that’s what’s required, 
that social support” (CM5) 
 
7.5.2.3 Case Study 
It was not part of the original design of the qualitative study to capture participants’ 
stories, however, the opportunity to illustrate the potential impact of the intervention on 
participants manifested as part of the interview process with community matrons who 
wanted to tell their patient’s stories. Analysed using narrative enquiry, the following 
case study demonstrates the impact the intervention had on a trial participant as told 
through the lens of the clinician who delivered the intervention. Both the trial participant 
and the community matron have been given pseudonyms to preserve their anonymity. 
Ruth, the trial participant is a white female in her early-seventies who lives with her 
husband, David, in a large village. David described himself as Ruth’s carer. Ruth was 
classified as moderately frail according to eFI and had not left her house for over a 
year due to anxiety and depression. Ruth withdrew from the HAPPI research study 
follow-up visits shortly after consenting, but opted to continue with the intervention. 
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Anna, the community matron told Ruth’s story as part of her study interview as she 
believed implementing the HAPPI intervention had a profound effect on Ruth’s health 
and well-being. Anna first met Ruth when she visited her at home to begin the HAPPI 
intervention.  At the initial visit, Anna was very concerned about Ruth’s level of mental 
distress along with multiple physical health issues. 
“She was just so distressed, and it wasn’t just like a discreet tear, she was sobbing, 
she had become very isolated, she didn’t want to go out, she didn’t want to talk to 
people, physically she hadn’t been reviewed, her medications hadn’t been reviewed, 
she was in low mood clearly, she wasn’t sleeping, she had pain in her foot, there were 
lots of physical issues but her emotional health or well-being seemed to prevent her 
going out of the house and engaging in addressing any of that” (Anna) 
In addition, Ruth told Anna about her worries regarding her estranged daughter who 
was subject to domestic violence. Anna also noted the emotional impact this was 
having on David and his feelings of helplessness in witnessing Anna’s distress. 
“…and there was some really distressing family dynamics which she couldn’t seem to 
get through… she has a situation with her daughter who was in an abusive relationship 
and they had broken contact which was her ultimate distress” (Anna) 
“It was always a joint visit with her husband and he was always very supportive, but he 
also seemed a little bit adrift as to where to go with the tears” (Anna) 
Anna listened and allowed Ruth to tell her story, conscious that she needed to develop 
and maintain a trusting relationship. Over several consultations and using tools from 
the HAPPI assessment pack, Anna began to try to unravel the root causes for Ruth’s 
distress and social isolation.   
“So, I listened and I just agreed, got her to agree to let me back that was all I could 
achieve that visit. And, I went back, I took all the HAPPI stuff with me, I went back and 
we talked again, all tears, throughout the whole visit. ” (Anna) 
 
Ruth and David talked through their concerns and, despite Ruth’s low mood and levels 
of anxiety, in partnership with Anna, they agreed manageable goals and a plan of care 
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to achieve them. Initially the clinician needed to take the lead due to the level of Ruth’s 
distress and managing the distress was agreed as the first priority. 
“I did a medication review, we started her on her medication, she definitely felt better 
even within two weeks, but definitely come six weeks that medication was helpful and 
she didn’t want to stop it, and bearing in mind that she seemed to have an aversion to 
medication she actually must have felt something. But also her husband was a really 
good co-therapist, so he was able to see a difference in her, so that was good. And we 
talked about expectations and that it wasn’t going to turn the key for her, that is was 
just going to give her hopefully the ability to move a little bit forward herself with some 
non-pharmacological actions” (Anna) 
Anna talked about how, despite her low mood, it was important for Ruth to take control 
and manage her condition with her support. 
“So then, once she had settled a little bit, we worked on some goals, but the thing is, 
she came up with the things she wanted to do…and interestingly of all the people I 
saw she was in the most desperate distress, and yet she actually moved herself quite 
a long way with just some gentle, gently cathartic interventions because I didn’t do it 
all for her, I didn’t wrap her up” (Anna) 
Ruth was able, with support and honest conversation, to recognise how some of her 
behaviours were adding to her distress and make some plans to leave the house and 
engage in some activity.  
“Then we looked at setting some goals about how she was going to manage her health 
better, but also I spoke to her quite honestly about that I was concerned that she was 
so housebound when she was physically completely self-caring… and so, I said to her 
about how the housebound aspect worried me and she took all that on board and so 
she started having, she goes to the supermarket the same time every week, so now 
they meet a friend there every week and they have a meal, so socialisation, and she 
could understand the value of that and they never miss it now and she even plans what 
she is having on the menu, she really looks forward to it, so that’s cool isn’t it?”(Anna) 
 
In order to continue this progress towards a more active and less isolated lifestyle, 
Anna looked to next assess Ruth’s physical health. Anna identified that Ruth had 
several long-term conditions, which were not being regularly monitored as she felt 
unable to leave the house and attend the general practice for her regular appointments.  
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Whilst Anna could have carried out the reviews as part of her visits in the home, she 
felt it was important for Ruth to regain responsibility for managing her conditions. 
“I kept saying to her, you need to be proactive about your health, you need to manage 
your own health, so you need to book your blood tests, you need to keep on top of 
things, if you know they are needing doing, don’t be cross that the surgery haven’t sent 
you a letter, phone them up and tell them you need them doing, it’s your health, take 
control” (Anna) 
In order to support Ruth, Anna facilitated the process by taking steps to ensure Anna 
would attend an appointment and that the general practitioner was aware of some of 
her concerns.  
“I know it sounds a little bit extreme, but then, I had to turn the key somehow, so I found 
out who her favourite GP was, I went and spoke to them, I gave them a handover of 
the level of distress, I got her an appointment at a time of the day that she felt able to 
attend it” (Anna) 
Ruth had some blood tests while she was at the surgery and the results were within 
acceptable limits which provided some reassurance. Having facilitated a successful 
encounter with a clinician, Anna next addressed Ruth’s foot pain by referring her to a 
podiatrist who Ruth also saw at the general practice. This resulted in resolution of the 
pain and so enabled her to consider more activity outside of the house. Following 
discussions about the links between mental and physical health and maintaining well-
being, Anna reflected to Ruth that during their conversations, she could be distracted 
from her distressing thoughts and so asked her to consider if there was an activity that 
she would consider to provide distraction and promote well-being. Anna and David had 
previously enjoyed walking and were enthusiastic about trying to build short walks into 
their daily routine.  
“She says that she ruminates, she constantly ruminates but even when she was at her 
most tearful, by the end of an hour I could get her laughing, so she does respond to 
that type of distraction. So we talked about that and so they now go for a walk three 
times a week together as husband and wife from the house, and when I went to the 
last couple of visits especially the last one, it’s just so lovely because she was able to 




Anna described how she felt out of her depth in hearing Ruth’s concerns about her 
daughter’s situation and how she lacked training in supporting relatives of those who 
experience domestic violence. She was not prepared to leave this issue unaddressed 
and so, with Ruth’s permission, reached out to other clinicians within the 
multidisciplinary team for support. 
“Well, how do you help someone with that, I can’t say that’s not distressing can I? But, 
I also felt a little bit out of my depth on that, so platitudes were not cool, so I spoke to 
the CPN (Community Psychiatric Nurse) in MDT with her permission just to ask for 
some advice, as to how do you support a family of people that are going through 
domestic violence, because I don’t know” (Anna) 
The CPN provided information on sources of support for Ruth and Anna shared this 
with her. Ruth was grateful for the information but did not want to access support at 
that time. Interestingly, on the final HAPPI intervention visit, Anna raised the issue 
again to ensure that Ruth was still aware of the support and could access it if needed. 
Anna admitted she felt scared to do this as she feared opening old wounds and causing 
more distress, however, it became clear that having someone listen to her worries and 
provide sources of support had enabled Ruth to change her thinking and reduce her 
level of anxiety about the issue. 
“I was a little bit nervous about bringing up the domestic abuse again because I didn’t 
feel skilled, do you know what I mean? That is a massive subject isn’t it? And she said 
to me and I said, “how do you feel about your children?” thinking “oh gosh, I’m going 
to make her cry” but she actually said to me “I can’t change it but I definitely feel like I 
can get help if I need to” which was a massive step. I don’t know how that key was 
turned and I don’t know whether it’s just because we saw that she was distressed and 
didn’t leave her distressed and actually just stuck with it a little bit” (Anna) 
 
When telling Ruth’s story, Anna commented on the stoicism of frail patients and linked 
this to Ruth’s age group who do not want to be a burden or ask for help from a doctor 
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unless they perceive their situation to be very serious. She also reflected that Ruth and 
David were aware that things were going wrong but did not know who to ask for help. 
“…especially that generation where a GP is a GP, I think that unless they need a doctor 
they don’t know where to go and it snowballs doesn’t it, but I don’t think people know 
who to call and I think that we have distilled unwittingly this culture of you know “don’t 
come to A&E unless, don’t come to Minor Injuries unless, we are really busy, there’s 
no appointments, I’m sorry but the doctor can’t call you back”, we cultivate this “we’re 
busy” and I think that generation they don’t want to be a burden, they don’t want to 
bother us, their leg’s not falling off” (Anna) 
“I believe that she needed help, she knew she needed help, but she didn’t know how 
and I kind of feel that it was a fortuitous letter, that somehow, they needed something 
but didn’t know where to go kind of thing” (Anna) 
 
Anna strongly believed that had the study and the offer of the HAPPI intervention not 
come along at that point, Ruth would have deteriorated further and suffered significant 
mental and physical health decline. She was excited by the opportunity to intervene at 
an earlier stage when it was possible to make significant changes to prevent further 
deterioration and ultimately a health crisis. 
“I mean she had become housebound from her anxiety, she had disengaged with her 
anxiety, and she had disengaged from medicine medical support, from primary care, 
so if that festered and carried on she would have aged before her years wouldn’t she? 
I think and she could have had quite significant mental health issues if it’s not 
addressed” (Anna) 
“I just do think the HAPPI study, it’s almost, it is exciting, but it’s almost a bit of sweet 
excitement because I just think if we could do a little bit more at this moderate stage, 
you know catching them before they enter into this downward spiral it would just be 
phenomenal” (Anna) 
 
Anna was keen to emphasise that, while Ruth had been able to re-gain control of her 
health and take responsibility for it in the future, this was through her support and she 
made sure that Ruth had a safety net if things deteriorated. This included reinforcing 
the need to continue her re-engagement with primary care and giving permission for 
her to make contact if needed. 
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“I said to them, you know, just keep my number and if you feel like things are just 
getting difficult you should be phoning the GP and making an appointment, and if you 
phone me I’ll be getting you to the GP surgery, but if you feel like you are slipping 
backwards then just call me, don’t get that distressed” (Anna) 
Anna reported that in just six consultations, there were significant changes to Ruth’s 
mental and physical health and well-being and this had impacted positively on both her 
own, and her husband’s happiness.  
“So it did take a little bit of work but that lady now has had a complete review, a 
complete medication review, she has had medication changes that have made a 
difference, she’s had not only pain management, but pain resolved, she’s now 
physically exercising three times a week, she’s socialising with a meal once a week 
and she can do a whole visit with a community matron and not cry! (laughs). It’s 
amazing. And her husband was just so grateful, massive, you could see. And the last 
visit was just full of laughter… I was so happy on that last visit, I was like “Wow!” There 
were hugs and kisses galore.” (Anna) 
 
In conclusion, this case study has demonstrated the positive impact of a holistic 
assessment and care planning intervention for a frail, older person with complex 
physical and mental health needs. Using the HAPPI intervention framework and toolkit, 
the community matron was able to attend to and make sense of the person’s health 
needs and plan care accordingly. However, whilst the framework and toolkit provided 
structure, the high level of skill and knowledge demonstrated by the community matron 
cannot be underestimated. Anna, as an experienced nurse qualified to a high level, 
showed enhanced clinical assessment, facilitation and counselling skills enveloped in 
outstanding compassion and empathy. In addition, Anna was able to recognise 
limitations in her skills and seek support from other team members, providing holistic 
management to her patient. This enabled Ruth and her husband to move from a 
position of extreme distress and powerlessness to re-engaging with social support, 
health services and re-gaining enjoyment in their lives. This was achieved through 
partnership working with the community matron who provided that support to self-care 
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and independence. Delivery of the HAPPI intervention provided the opportunity to be 
proactive in addressing problems which would have led to crisis in the future. Whilst it 
would appear that the intervention could be used successfully within a definitive trial 
where all participants are unlikely to need such intensive support, adequate clinician 
training to ensure appropriate skills level will be essential.  
7.5.3 Theme Three: “I’m a person not a patient”:  
A key objective of this study was to determine whether the HAPPI approach can 
support moderately or severely frail older people to play an active role in making 
decisions about their health and social care and in the prevention and management of 
their long-term conditions. This theme reports on the successes and barriers to this 
approach from the perspective of the community matrons and trial participants. There 
two sub-themes. 
7.5.3.1 Sub-theme: Setting health goals 
Trial participants did not recognise their role in shared decision making and goal 
setting; instead they looked to the clinicians to lead this process. Irrespective of their 
level of frailty, trial participants did not view themselves as patients in need of care and 
support from a nurse.  A home visit by a nurse was viewed as indicating a much more 
serious health need than their own and because their condition/s were stable they did 
not recognise the need to be proactive in preventing deterioration and crisis in the 
future 
“See, I hadn’t really understood (CM2)’s role, I hadn’t realised she was going to be a 
nurse who would actually come and visit, because I still don’t treat myself or think of 
myself as a patient, you know…so, the thought of a nurse coming round to see me 
when I haven’t asked for a nurse, I don’t feel, I’ve never had a home visit before, it just 
hadn’t occurred to me that that was what her role was going to be” (P5) 
“I’ve never thought about a nurse coming round and seeing you in your home, if I want 
medical treatment, I call up the doctor and lo and behold a month later he comes and 




Community matrons remarked on the passivity of participants in managing their 
conditions and expectations that clinicians will lead decision-making in relation to 
health goals. Community matrons acknowledged, however, that they were used to 
directing the consultation when patients are very unwell and in need of crisis support. 
Trial participants appeared less sick but still displayed passivity in the person-clinician 
relationship, expecting the community matron to have the answers and set the goals. 
“And then you look at goal setting, well that fascinated me because I love personalised 
care planning, I always have, advanced ceilings, I love all that, but these people could 
not formulate a goal but they wanted to me to, and that shocked me because after all 
that spiel about what should happen and I would say “What do you want to get out of 
this, what would you like to set as a goal?” and drawing a goal out of them was 
incredibly difficult” (CM1) 
“I think when you reflect that back and say “what do you think you could do?” there is 
almost a frown of puzzlement because there isn’t that expectation that they have to do 
anything, they’ve come to me for the answer… I thought that would be a bit different 
because I was anticipating that they would be slightly younger and more mobile, I mean 
mobile in a really functional way, that they might have been a little more proactive and 
have more of an opinion, but no. I found that quite fascinating, the goals as really 
difficult, really difficult. If I suggested something they were really happy, excuse the 
pun (laughs) but they did seem to want that paternalism that I was trying to avoid, if 
that makes sense?” (CM1) 
“I mean, in terms of goal setting I can’t think of one that wanted to set goals… and it 
was motivation, it is motivation to set a goal and is the goal relevant to them at the 
time, and I think for a lot of patients in this instance it’s not just a possibility. And they 
have already set their own goals and their goals are not our goals it’s their goals” (CM5) 
“So more or less all of them have now got a PCP (Personalised Care Plan), I’ve left 
them with PCPs so they have short profiles in, so they are quite astounded by that 
because they have never seen all that before, but they find it very interesting and very 
reassuring that all these things are being dealt with and documented… I think the goal 
setting is the hardest bit isn’t it, in that  patients are not used to that, in when we are 
doing preventative work” (CM2) 
 
Working in partnership to set personal health goals proved to be the most challenging 
aspect of the intervention. Trial participants did not appear to be motivated or 
acknowledge they had a role to play in making changes to their health and well-being. 
This was underpinned by lack of knowledge about their health conditions and impacted 
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by family and relationship dynamics, which fed into the need to remain passive in 
relation to their health and care.   
“I think as usual, you never cease to be amazed at about how little they understand 
about their own conditions , do they really, they can be very vague.” (CM2)  
“The people that we see have had this condition for at least a decade or more and I’ve 
always been quite surprised how inert they are in the management of their long term 
condition, and sometimes that’s because they’ve never been told or never been shown, 
I doubt that’s completely the case, I think that’s human nature when you are working 
and you are told you have a bit of hypertension or a bit of COPD you don’t correlate 
that with 10 or 15 years’ time, I think that’s just human, but I think they expected me to 
fix it” (CM1)  
“There were lots of physical issues but her emotional health or well-being seemed to 
prevent her going out of the house and engaging in addressing any of that, and there 
was some really distressing family dynamics which she couldn’t seem to get through” 
(CM1) 
“So one of her goals was actually to have some time to herself and yet at the moment 
that is an impossible goal because the effect it has on him (partner) then impacts on 
her, and then so trying to set that goal he felt he was being marginalised, you know 
and that wasn’t good for him. And so there are a lot of dynamics” (CM5) 
 
Community matrons addressed these challenges with a range of strategies to 
encourage more active participation and partnership and this proved successful in 
improving participants’ health and well-being. These included changes of terminology 
to be more person-friendly, providing praise and encouragement for all goal-setting 
attempts, however small, signposting to sources of support rather than actively 
providing the support needed and ensuring goals were small, achievable and 
measurable, so that progress was apparent. 
“I did wonder if it was my phraseology and if it was new terminology to them, so I did 
use phrases like “What do you think this can do for you” “What can we do together”? I 
did try to soften it. I did wonder if they had anticipated that I wouldn’t have anything to 
answer” (CM1) 
“The importance of personalised care plans, the importance of communication with 
patients because even though they knew their conditions, they, I think personalised 
care planning was another step that maybe they had forgotten about or just needed 
reminding of why they were doing what for their particular condition, sort of 
reinforcement…. Yes, I think I felt more at ease to actually give them a bit more 
responsibility and encourage that responsibility for their own health…yes you are doing 
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the right thing and actually you could take it a bit further, take it a little more forward, 
maybe go and see the GP about that problem, almost giving them permission” (CM3). 
 “They were a bit alienated with that, but from the first visit, we just set objectives for 
the next one. So, for the first visit, I just let them talk, they spent the whole hour talking 
about themselves and their perceptions and then that was when I was able to say, we 
are able to make some measurements which will give us baselines, so that when I 
come back next time, what I want to do is …” (CM2) 
 “So it’s just about encouraging them and saying this is about your own self-care and 
self-management and “well done” type of thing. That’s me, that’s the way I’ve always 
worked. It isn’t about “give it to me to do”, it’s about “you can do this, you are going to 
be absolutely fine”, you know and in my view that’s the role” (CM2) 
 “I became very focussed on what they understood about their health, what they 
thought their health needed, what they thought would help  and I enjoyed finding out 
what they knew and what they did to help” (CM1) 
 
Community matrons’ strategies appeared to be successful in most cases and trial 
participants and carers were able to describe how the community matron had worked 
in partnership with them. This included making health and care improvements such as 
developing a plan of care and support, which persisted beyond the life of the 
intervention. They particularly appreciated the focus on contingency planning, 
developing a health information plan to share in an emergency and having the 
opportunity to discuss and agree a treatment escalation plan.  
“Very helpful, she introduced things that we, my husband and I didn’t know about like 
the information that is collected and I can keep here so that if anything happens to me, 
paramedics or whoever can come in and refer to that straight away. I think that’s an 
excellent idea” (P4)  
“Fine, she was very easy to talk to, I got the feeling that she knew what she was talking 
about and was very knowledgeable in all areas of the subject and I was happy to listen 
to her advice and take it, as far as that went, yes” (P4) 
 “We talked about bladder control and that was useful, I’m sure there were other things 
that I can’t recollect just like that. She told us about, at the end we heard about is it 
called NICE? Where if my husband were taken ill he puts something in his telephone 
a number so if he were taken ill say if he were out shopping and he was rushed off in 
an ambulance they could find out that there is somebody at home who it totally 
dependent on him and expecting him back” (P4) 
C1:“I think the bit they are doing at the end, filling in information sheets for him to keep 
here, in case there is nobody here, I think that is a brilliant idea” 
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Interviewer: So you mean the care plan that they leave, that is done with you and is 
left in the house? 
C1: Yes, I think that’s a really good idea because if I’m not in and something happens 
and they come, he’s got that sheet and we only have to find somewhere to keep it 
where they will find it” (C1) 
“Yes planning early is a good thing because then the NHS should understand the 
patient more than when they go there and they don’t know them from Adam” (C1) 
7.5.3.2 Sub-theme: Implementing new models of care and support 
Community matrons articulated the tension they felt in trying to fully commit to the 
proactive HAPPI approach alongside their normal role and how this may have 
impacted on their ability to be more thorough in supporting goal-setting and shared 
decision making. They described how their own caseload of patients in acute need 
would always take priority as they were deemed to be more in need of immediate 
attention. Consequently, work with trial participants was sometimes delayed. 
Community matrons were disciplined with time-management but still needed to be 
flexible to meet the needs of participants and their own patients.  
“Ok, its more work than I thought it would be and if I’m honest I have found that quite 
tough because I work part time. My community matron caseload is quite taxing so I 
have found it challenging” (CM4) 
“I didn’t realise how much the community matron role has changed and this is, I keep 
saying, it’s like going back to how it used to be, which isn’t a bad thing, it’s just that our 
ability to see and get to know patients like this has diminished” (CM5) 
 
Community matrons who worked part time, or who were participating in the study 
outside of their normal geographical area faced additional challenges of making time 
for study work and lack of usual support networks. Furthermore, at the time of the 
study, the NHS Trust was implementing a new digital clinical records systems and this, 
alongside the paper recording for HAPPI, was challenging for some. Generally, 
completing study activity was difficult in the time scales even with small numbers of 
participants for each community matron.  
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“The only thing was I would, I put my own work before the HAPPI because we were 
into escalation and some of my patients were quite poorly, the RIO project has come 
up which has taken quite a lot of my time so it’s unfortunate, so there is one chap that 
I’ve still got and I should have seen, so it’s kind of delayed, I had two visits booked up 
which were put off because kind of things went a bit awry in my own job” (CM3). 
“But that was part of the challenge because I’ve only got one day a week, I’ve managed 
to swap around so when one patient was poorly and I saw them on the Friday, I did 
not want to wait to the next Friday so I saw them on the Tuesday and just swapped 
days around” (CM5) 
“I would feel a little bit stressed if we got a bigger study and we had to do this as well 
because then I would feel I would be letting you down because I hadn’t done it in the 
appropriate time frame” (CM3) 
 
Community matrons discussed whether it would be easier to manage if there were 
designated nurses for the study, who only saw HAPPI participants. This may have 
enabled more focus on the study and less feelings of being spread too thinly across 
the HAPPI study and their usual caseloads. Other suggestions included that aspects 
of the intervention could be delivered by others, particularly the parts relating to social 
isolation and loneliness, which may be better addressed by voluntary and local 
community groups. However, there was a general acknowledgement that these 
services are not widely available. 
“I would have enjoyed it more and found it, if I was the HAPPI Chick…as opposed to a 
HAPPI Juggler (laughs). You can use that as a quote!” (CM4) 
“No, I don’t think in terms of those, if we talk about clinical goals a lot of those clinical 
goals would be my goals not theirs and the goals they wanted to achieve then yes, I 
can facilitate them to a degree, but they don’t need a community matron to do that, but 
they need some support, yeah definitely and that is lacking and there isn’t that support” 
(CM5). 
 
To summarise this theme, the challenges of goal-setting, shared decision making and 
promoting self-care were strongly articulated by community matrons. In addition, taking 
responsibility for their own health did not feature as a strong concept in interviews with 
trial participants. This may be because they did not view themselves as unwell and, 
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therefore, despite having multiple long term conditions and significant frailty, did not 
see themselves as having a role in its management. This demonstrated the inherent 
complexity of living a life with frailty and multiple health needs and how, even with these 
challenges, the HAPPI intervention may impact positively on health and well-being. 
7.6 Qualitative results summary 
Themes identified in the qualitative component of this trial present challenges and 
opportunities that may be critical to the success of a future definitive trial. They include 
factors relating to trial procedures and implementation of the intervention itself. In the 
following discussion chapter, this information will be used in combination with data from 
the quantitative component to enable a more comprehensive and multi-layered 




Chapter 8: Feasibility randomised controlled discussion 
8.1 Chapter introduction 
The fRCT with its embedded qualitative study aimed to determine the feasibility of 
delivering the novel HAPPI intervention in primary care to frail older people and to test 
potential trial methods to inform the design of a definitive RCT. Its objectives were 
related to the feasibility of trial processes and the intervention and evaluation of 
outcome measures. In this chapter, recommendations for the design of a definitive 
RCT are made based on discussion of the findings. As a mixed-methods study, the 
principles of complementarity have been adopted using the quantitative and qualitative 
study findings to ensure all objectives were met including whether it is feasible to 
conduct a RCT and to understand participants and clinicians experiences of 
participating in the trial (Plano Clark & Ivankova, 2016).  Results have been interpreted 
to demonstrate where the aim and objectives have been achieved, and discussed in 
relation to the existing evidence base.  
8.2 Trial Processes 
This fRCT has identified important factors related to processes including evaluation of 
participant identification using the electronic frailty index (eFI); determining achievable 
recruitment and follow-up rates; evaluation of the sites’ willingness to identify and 
recruit eligible patients; and the willingness of patients to be recruited. These factors 
will be discussed next in sections 8.2.1 to 8.2.8 and will inform future work related to 
the design of a definitive trial. 
8.2.1 Site recruitment and retention 
Evaluation of the ability to recruit and retain general practices as sites within the RCT 
was an important feasibility parameter. Previous research has found that recruiting and 
204 
 
retaining general practices in clinical trials is challenging (Wilson et al., 2000; Yallop et 
al., 2006). Bower et al. (2014) identified a lack of evidence about factors associated 
with the recruitment of general practices to research studies, thus, it was important to 
understand how to maximise engagement or overcome any barriers. Some authors 
have noted that interest in the research topic, invitation method, and general interest 
in research are important in recruiting general practices into studies (Dormandy et al., 
2008). These aspects were demonstrated as important in engaging general practices 
in this study. General practice contracts were amended in 2017 to include the 
mandatory identification of severely frail patients (NHS England, 2017). Consequently, 
many of the general practices were interested in frailty but had little knowledge about 
effective management strategies. Participation in the study gave them an opportunity 
to learn more about the topic, use a systematic tool to identify their frail patients and to 
test a new clinical management model.  
Initial access to general practices proved difficult. The CI initially wrote to all general 
practices, explaining their anticipated roles in the study, commitment required and 
funding provided, with no response. Primary Care Research Network (PC-CRN) 
nurses then identified 13 research-active general practices and two who had not yet 
participated in research, but were keen to be involved. It was useful to identify the 
research-active practices and to be able to approach them through a known and 
trusted source i.e. PC-CRN nurses. However, the two research-naïve practices who 
participated proved to be efficient and enthusiastic in their approach to screening and 
data collection and met the study milestones just as effectively as the more 
experienced practices. The CI conducted individual meetings with representatives of 
these general practices. There was a good response, with eight practices meeting 
eligibility criteria and six agreeing to participate as sites. Whilst it was encouraging that 
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site recruitment targets were met, it proved labour intensive with the CI committing to 
multiple meetings with the associated time and travel.  This was accounted for in the 
study grant timeline and costings, however, when estimating funding for a full scale 
trial across disparate sites, other methods of communication should be considered, 
such as virtual meetings and the involvement of local research champions.  
Once recruitment targets were met, it was important to consider retention of the general 
practice sites to avoid potential withdrawal of a cluster, which would have threatened 
integrity of the trial. Certain actions have been demonstrated to improve retention of 
general practices in clinical trials (Dormandy et al., 2008). These include effective 
communication, easy data-collection methods, and payment upon meeting pre-agreed 
targets. All of these factors were implemented in this trial. The CI maintained regular 
contact with the practices by email and in person. Some of the practices did struggle 
to meet study milestones due to capacity and the CI provided support in the form of 
advice, information and practical help with tasks involved. With a small number of sites 
it was possible to provide reminders of time scales and physical presence in the 
surgeries when needed. However, in the definitive trial, with larger numbers of sites 
and participants, it may be more cost and time-effective to allocate funded hours to a 
research assistant to carry out some of the tasks relating to screening, enrolment and 
recruitment to ensure timescales are met. 
As part of determining the study design, there was discussion about the easiest 
methods of general practice data collection. Most UK general practices have adopted 
a “paperless” approach in clinical record keeping and practice administration (National 
Information Board, 2015) and were familiar with electronic recording of clinical 
information. In this trial, data collection was designed to be paperless and achieved by 
uploading the information onto the trial database in response to timed e-mail 
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reminders. Finally, at the outset, sites were made aware that payment for research 
costs was available and all sites claimed the funding. In summary, there were important 
factors identified that facilitated full recruitment and retention of general practices as 
study sites. In the definitive study, consideration of these factors will need to be built 
into planning and funding. 
8.2.2 Participant recruitment 
If a clinical trial is unable to recruit and retain the target sample size then statistical 
strength, as well as internal and external validity cannot be guaranteed (Bower et al., 
2009; Tyson et al., 2015). Slow recruitment may delay the completion of the trial, which 
can ultimately reduce the impact of findings on clinical practice (Kadam et al., 2016). 
The recruitment and retention targets in this fRCT were achieved, however, there were 
challenges in various aspects of the recruitment process, and their resolution provided 
important learning for the definitive trial.  
Rate of recruitment was significantly influenced by having capacity at the sites to 
complete the initial identification, invitation and screening procedures. At one site, 
support was provided by the CI who applied eligibility criteria and compiled a list of 
people to be invited to participate. This accelerated the process and demonstrated that, 
with targeted support, initial procedures could be completed within the specified time 
frame. There is evidence of under-recruitment of older people to research studies, 
particularly RCTs (Clegg et al., 2015). Studies have reported high participant exclusion 
and refusal rates especially in trials recruiting older people with frailty (Azad, Molnar & 
Byszewski, 2008). These issues did not appear to affect recruitment to the HAPPI trial 
since, despite some delays, recruitment was completed as anticipated within ten 
months, however, the process was sporadic and did not follow the planned study 
timetable. In a definitive trial, with larger numbers of participants, it is likely that 
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significant support may need to be provided to sites to complete the recruitment 
processes. The support given by the CI and its influence on timely recruitment 
demonstrated the importance of dedicated research support capacity and this needs 
be adequately funded so should be built into a grant application for the definitive trial. 
8.2.3 Identification of frail cohort  
The trial sample of 414 frail patients was created by random sampling of the eFI patient 
list at each site. Each site had varying numbers of moderately and severely frail 
patients and, overall, there were less severely frail patients identified than was 
anticipated. Based on available evidence (Seymour, 2018), it was predicted that, for 
an average-sized general practice (14,000 practice population), the eFI would identify 
approximately 1000 moderately and 500 severely frail people. After random sampling 
and application of eligibility criteria, it was predicted that this would have resulted in the 
target of 60 participants. In fact 56 participants were recruited across the six sites (36 
moderately and 19 severely frail).   
The reason for the lack of severely frail patients is not clear but may be due to the 
following factors. Firstly, two of the sites had a smaller than average practice population 
and so did not generate the expected numbers of severely frail patients. Secondly, one 
of the largest sites had no care homes within their geographical area. There are a 
higher number of severely frail patients residing in care homes so this may have led to 
less availability of severely frail patients for recruitment, however, care home residents 
were later screened out through application of eligibility criteria. Finally, the eFI is a 
computerised algorithm that relies on effective clinical coding of symptoms, signs, 
diseases, disabilities and abnormal laboratory values to populate and give scores 
(Clegg et al., 2016). Whilst all sites said their clinical coding was completed effectively, 
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coding practices are known to be variable with limitations to the coding systems in the 
UK (de Lusignan, 2005).  
The number of severely frail patients then reduced further at later stages of the 
screening process when letters were sent inviting them to participate. Physical and 
cognitive limitations accompany severe frailty and this may have inhibited response to 
the letters and follow-up phone calls (Harris & Dyson, 2001). To the author’s 
knowledge, with the exception of one pilot study (Lansbury et al., 2017), this fRCT is 
one of the first studies to use the eFI as a research participant identification method. 
This method had advantages, since the use of an automated algorithm means that 
selection of potential participants is rapid and straightforward. Multiple frailty screening 
tools are available (Section 1.4.4) and many have been evaluated, but there is no 
consensus on a definitive screening method for use in research (Walston, Buta & Xue, 
2018). Whilst its ease of administration was positive, there were some concerns 
expressed about the use of the eFI to identify frail people. Community matrons, for 
example, reported that their assessment of the severity of a participant’s frailty did not 
always correlate with their eFI score It is known that there may be a risk of over-
identification of the frail population because counting the number of eFI-comprising 
deficits results in overestimation among those registered with the general practice for 
longer periods of time (Alharbi et al., 2020). In addition, as previously mentioned, the 
algorithm requires effective coding (Reeves et al., 2018).  
NHS England has recommended that, following screening using eFI, a clinical 
assessment is conducted to confirm degree of frailty (NHS England, 2017). This may 
not be feasible in community-based clinical practice and there is a lack of evidence 
that clinician’s judgement is more effective than screening tools to diagnose frailty. A 
recent study by van Walree et al (2020) found that sole reliance on clinical judgment 
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to identify frailty could result in missing patients with relevant impairment. In order to 
design a feasible method, a second step of self-completion of the PRISMA-7 
questionnaire was added into this study to confirm the diagnosis of frailty. This did lead 
to the screening out of significant numbers of participants at that stage (34%), which 
may account for the false positives generated by the eFI. This does support the 
requirement to identify large numbers of frail people at the outset to provide an 
adequate sample size following eligibility screening. 
To summarise, an accurate method of differentiating degree of frailty is essential 
because CGA-based interventions are most effective for those who are moderately 
and severely frail, rather than non-frail or mildly frail older people (Hoogendijk et al., 
2019). Evaluation of the eFI as a participant identification and screening tool in this 
feasibility study has provided valuable information for a definitive trial. The eFI is easy 
to administer and can rapidly screen for moderately and severely frail patients in a 
practice population (accepting the risk of false positives). However, it did not identify 
sufficient numbers of severely frail patients. The addition of PRISMA-7 reduced 
numbers further but was a necessary step to ensure more accurate diagnosis of frailty 
and, therefore, ascertain appropriateness of participants for the study. In order to make 
enrolment processes manageable for the sites, eFI patient lists were randomly 
sampled to produce 90 people to be invited to participate. For the definitive trial it is 
recommended that larger numbers of moderately and severely frail patients are 
sampled so that there is a larger “pool” of potential participants to be invited, or an 
alternative frailty identification method is used. This is discussed further in section 8.7.   
8.2.4 Participant eligibility  
As a feasibility trial, eligibility criteria were as broad as possible to facilitate full 
recruitment. In order to reduce workload for primary care clinicians, the trial evaluated 
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application of eligibility criteria by practice administrators who had no clinical 
background.  Eligibility criteria were designed to be easy to check using the clinical 
record (aged 65 years and over, living at home, not known to the community matron 
service and having mental capacity to consent).  Practice administrators reported that 
it was not onerous to find the information to complete eligibility checks and, in the main, 
completed the screening log fully. It would appear that a clinician is not needed to apply 
eligibility criteria as long as they are unambiguous and there are clear instructions to 
follow. 
The eligibility criterion of possessing mental capacity to consent was not in the original 
research proposal and was added by the NHS Research Ethics Committee (REC). The 
original proposal recommended inclusion of those who lacked mental capacity where 
assent could be provided by a consultee. This was to ensure that large numbers of frail 
people with cognitive impairment were not excluded from the study. The application of 
this criterion reduced the numbers of potential participants further with 20 participants 
excluded at either at eligibility screening or at consent visit. In addition, mental capacity, 
or lack of, was often not formally recorded on the clinical record. Consequently, this 
was not identified until the consent visit. If in doubt, the research nurses, following 
training, conducted a mental capacity assessment as part of the visit.  
The REC referred to approval criteria set out in Section 31 of the Mental Capacity Act  
that the research must be connected with an 
 “…impairing condition affecting the participant or its treatment and research of equal 
effectiveness could not be carried out if confined to participants with capacity”. 
 (Mental Capacity Act, 2005, p.25)  
They concluded that, as a feasibility trial, these two criteria could not be met. It is likely 
that in a definitive trial, these criteria could be satisfied and it would be possible to 
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include those who lack mental capacity and have a consultee who is willing to give 
assent. This will ensure an important group of the population are not excluded from 
participation and is likely to enhance recruitment by providing adequate participant 
numbers for the definitive trial. If those who lack capacity to consent are included, it 
will be important to consider the additional support to enable participation. This may 
include acceptable and inclusive methods of inviting participation and the use of 
appropriate outcome measures instruments. These issues are discussed further in 
section 8.3.4.  
8.2.5 Participant Enrolment  
Methods of inviting eligible people to participate in the trial were assessed. Previous 
studies have demonstrated that the number needed to be screened to recruit one older 
person is approximately 3:1 (McMurdo et al., 2011), and so maximising engagement 
was an important feasibility parameter. The plan was to screen 540 people for 
eligibility, which, it was estimated, would have led to 180 people to invite to participate.  
As previously discussed, only 414 people were available for screening, so it was 
imperative to maximise recruitment by using effective and appropriate enrolment 
methods. A recent review of studies recruiting older people found that recruitment 
methods using referral by recognised agencies reported higher rates of eligibility and 
enrolment (Ige et al., 2019). However, there is mixed evidence in relation to enrolment 
through primary care. Some studies have demonstrated that approaching potential 
participants through primary care is an efficient method of gaining access to a large 
number of older people with the condition under study (Barnes et al., 2005), 
nevertheless, it is important to be aware of over-restrictive gatekeeping by clinicians, 
who may exclude people for reasons other than specified eligibility criteria (Lee, 2005).  
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In this trial, enrolment procedures were designed to avoid clinical gatekeeping by using 
the automated eFI and then practice administrators to apply eligibility criteria and invite 
participation. Overall, trial participants were content with methods used to invite them 
to participate, with a letter from a trusted source named as the most acceptable method 
of contact. In summary, the learning for the definitive trial is that a letter from the 
general practice is the preferred approach and that the use of non-clinicians in 
administering and following up invitations to participate is feasible. 
8.2.6 Clarity of study aims and purpose  
Study aims and purpose were stated in the PIS (Appendix 11) and a verbal explanation 
was given at consent visit. Community matrons remarked that the participants did not 
always understand the purpose of the trial and expressed their own difficulty in 
articulating the study aims. It appeared that the aims of a feasibility trial were more 
difficult to articulate and for participants to understand. In addition, the non-prescriptive, 
personalised nature of the intervention meant that it was more difficult to explain 
exactly what participants would receive if they were randomised to the intervention arm 
of the study. In her paper on feasibility studies, Tickle-Degnen (2013) acknowledges 
this issue and highlights that this poses more challenges to researchers whose 
interventions are complex. In the HAPPI study, the intervention is individualised, made 
up of a number of blended components that act together to affect outcomes, which in 
themselves are not standardised.  These features can make it difficult to meaningfully 
describe aims and the study “offer” to participants.  
However, other factors may also be influential, such as regulatory requirements, which 
mean that PISs contain compulsory text that has little meaning to participants and 
consequently may be difficult to understand. The primary aim of the PIS should be to 
provide information to help the potential participant in making a decision as to whether 
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to take part in research or not (Innes et al., 2018).  A systematic review by Kirkby et al 
(2012) found little correlation between the regulatory items included in Health 
Research Authority guidance  and the topics participants rate as important in informing 
their decision to take part in research or not. In fact, Armstrong et al (2012) suggest 
that PISs are written to comply with regulatory procedures as opposed to supporting 
potential participants’ decision making. The PIS in this study was co-produced with PPI 
representatives, but these were research aware and, therefore, wording and content 
relating to the study purpose may not have been as easy to understand as it could 
have been for potential participants. In addition, as a novice CI working with research-
naïve clinicians, it may be that the team lacked the skills to clearly verbalise this 
information to the patients.  
These aspects will need to be carefully considered for the definitive trial, with more 
user-friendly information and the production of shorter, more meaningful “scripts” that 
can be used by the research team with participants to initially articulate and then 
reinforce study aims. During qualitative interviews, participants said they had not read 
the PIS fully and that it did not aid their understanding. One solution to this issue was 
suggested by the community matrons, who would have appreciated an aide-mémoire; 
a very short, written explanation of the study aims, which they could have used to 
explain the study to participants. This could also be incorporated into the PIS, invitation 
letters and used at consent visits to provide a consistent, coherent description at all 
stages of recruitment. An aide-mémoire will be developed in consultation with PPI 
representatives in preparation for use in the definitive trial. 
8.2.7 Participant retention 
McMurdo at al (2011) report dropout rates of between 5% and 37% in their review of 
studies that recruited older people.  Certain strategies can improve retention in clinical 
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trials, such as the provision of monetary incentives and the use of short outcome 
measures and questionnaires (Brueton et al., 2014). This study did not have the 
finances, or ethical approval, to provide incentives and the outcome measures 
questionnaires were lengthy and numerous due to the need to test feasibility of multiple 
outcome measures. An interesting finding from the qualitative study concerned 
participants’ motivations for taking part. Trial participants appreciated a positive focus 
on the needs of older people and, while they understood that the research could confer 
no direct benefit to them, they enjoyed participating and felt that the time commitment 
was worthwhile irrespective of their allocation to the intervention or the control groups.  
It was reassuring to see that, far from being burdensome, the experience of 
participating was, generally, a positive one. This is borne out by the literature where 
studies have found that clinicians judge older people as vulnerable and needing 
protection from research (McMurdo et al., 2011), yet, older people themselves display 
as much or more willingness to participate as any other sector of the population 
(Peterson et al., 2002). Therefore, the research team aimed to enhance the experience 
of participants. The research nurses were warm and friendly in their approach and all 
outcome measures were completed at one visit at each time point to reduce burden. 
This personal approach, whilst more time consuming than administering postal 
questionnaires, contributed to excellent retention rates and is recommended for 
adoption in the definitive trial. 
8.2.8 Safety  
The risks associated with taking part in this trial were assessed as low (Lyndon et al., 
2019) but assessment of safety was an important aspect of feasibility.  Acute illness 
resulting in hospitalisation, new medical problems and deterioration of existing medical 
problems were to be expected in this population of moderately and severely frail 
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patients (Hoogendijk et al., 2016a). It was anticipated that participants would 
experience frailty syndromes, such as admission to hospital for falls, immobility, 
delirium, incontinence and iatrogenic side effects of medication regardless of 
participation in the trial (Turner & Clegg, 2014). Therefore, the Trial Management 
Group recommended that only AEs and SAEs related to the trial would be reported by 
the research team and then screened by the CI for relatedness and expectedness 
according to the safety reporting flow chart (Appendix 18). There were no reports of 
AEs or SAEs during the intervention or follow-up period. This may have been because, 
although falls, hospital admissions and suchlike did occur, they were judged to be 
unrelated to the trial.  
Whilst it is encouraging, it is unusual not to have any reported AEs and it is known that 
the collection, reporting and analysis of AE data in clinical trials are inconsistent 
(Phillips et al., 2019). For a definitive trial, a clearer definition of what AEs should be 
reported and when is recommended. As an assessment and care planning 
intervention, it is unlikely that the majority of the HAPPI intervention components could 
cause an AE, however, some components such as medication review/de-prescribing 
may have the potential to lead to harm. For example, de-prescribing of a drug may 
cause an increase in symptoms or event such as a fall. It is recommended that AEs 
relevant to other de-prescribing studies (Potter et al., 2016) are reported in the 
definitive trial. These include falls, fractures, GP consultations and admissions to 
hospital. Then the same relatedness and expectedness assessment is completed by 
PIs before reporting to the Trial Management Group and Trial Steering 
Committee/REC as appropriate. 
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8.3 Evaluation of outcome measures  
A two-fold assessment of the feasibility of trial outcome measures was conducted; (1) 
to verify proposed outcome measurement and follow-up schedules and (2) to evaluate 
proposed outcome measures to determine a primary outcome measure or potential 
multiple outcome measures for a definitive trial. Evaluation included acceptability of 
outcome measures to participants, ease of administration and sensitivity to change at 
trial time points. To date, studies evaluating the care of older people with complex 
needs have sought to measure a variety of outcomes using a plethora of outcome 
measures. In their systematic review of chronic care programmes for older people, 
Drouin et al (2015) included 14 studies measuring a broad range of impacts. These 
included health and social care system utilisation, such as emergency department 
visits, hospitalisations and re-hospitalisations, hospital bed days, care home admission 
and numbers of prescribed medications; quality of care; and individual impacts such 
as health related quality of life and function. In relation to quality of life, at least six 
instruments were used and seven different instruments used to measure function. The 
review authors concluded that this lack of uniformity in outcome measures is a common 
issue in evaluation of interventions targeting older people and this limits comparison of 
results across studies. In addition, it can be difficult to ascertain whether negative study 
results are due to an ineffective intervention or insufficient/inappropriate measurement.  
In order to alleviate these concerns, in 2018 a standard set of outcome measures for 
older persons was published (Akpan et al., 2018), which established a minimum set of 
outcomes for evaluating healthcare for older people. The outcome measures in this 
fRCT were drawn from this document. Data from a combination of participant-reported 
outcome measures of physical and mental health (SF-36),  confidence in own ability to 
manage health and in role as participants in care (LTC-6), loneliness and isolation 
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(UCLA-3), function (Barthel Index), health-related quality of life (EQ-5D-5L) and site-
reported outcome measures (death; cause of death; number of hospital admissions 
and readmissions; total number of days spent in hospital; number of prescribed 
medications) were collected. The outcomes of health, self-efficacy, loneliness, function 
and quality of life are key features of the development of frailty and concepts often 
used by older people themselves to describe what frailty means to them (Britain Thinks, 
2015). However, as a feasibility study, it was not known which outcomes could be 
impacted by the HAPPI intervention, so it was important to determine feasibility of a 
range of outcome measures to inform a definitive trial. 
8.3.1 Ease of administration and completeness  
Data for all outcome measures proved feasible to collect with high levels of 
completeness. All participant-reported outcome measures were collated into one 
questionnaire booklet (Appendix 15) and completed at one visit by the blinded 
assessor, consequently, there was very little difference in completeness rates between 
outcome measures. There are known disadvantages to face-to-face assessment in 
that it can lead to bias (Sackett, 1979) and a blinded assessor in a cluster trial has the 
potential to be unblinded if the participant reveals allocation during the interview (Bello, 
Moustgaard & Hróbjartsson, 2014). However, in research with older participants who 
may have physical or cognitive impairments, McMurdo et al (2011) advocate a more 
pragmatic approach enabling involvement by having a researcher to read the question 
to support those with visual or hearing impairment. This approach does not conform to 
accepted rules of standardised interviewing when administering questionnaires and it 
can be argued that interviewers' contributions may increase bias and influence 
responses (Schaeffer & Maynard, 2002). DeVries et al (2014) recommend a 
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collaborative approach where the interviewer can interact with the participant to ensure 
understanding and encourage positive interaction.  
In conclusion, in assessing feasibility for a definitive trial, it appeared that completing 
outcome measures questionnaires in a face-to face visit enabled excellent completion 
rates and improved participants’ experiences, which have enhanced retention. Such 
an approach needs to be balanced with a standardised administration of the 
questionnaires to reduce potential for bias. An information sheet for use by blinded 
assessors will be developed with standardised prompts and instructions on how the 
questions should be read and/or repeated to ensure consistency with all participants. 
8.3.2 Timing of outcome measures  
The study protocol stated that participant-reported outcome measures should be 
completed up to seven days before or after their due date (calculated from date of 
consent). In reality, it proved problematic to meet this target, with up to half of all visits 
completed outside of the protocol window (after the due date). Whilst the research 
team were diligent in booking visits within the window, often visits were cancelled by 
the participant. Reasons given for cancellation were either related to ill health, 
hospitalisation of the participant or other commitments such as health-related 
appointments. It appears that +/- seven days around the due date is an overly 
ambitious target and it is recommended that this is extended for the definitive trial. A 
range of seven days before and 14 days after the due date may be more achievable, 
but it should be recognised there may need to be flexibility in timing of outcome 
measures collection.  
Outcome measures were assessed at three-months and six-months after consent in 
this fRCT. As a feasibility study, the purpose was not to assess efficacy of the 
intervention but to test if it was possible to collect the data. It may be that a longer 
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follow-up period is required in the definitive trial as, by their nature, interventions that 
address symptoms of frailty may take some time to show effect. There is no agreed 
follow-up period advocated in the literature. A recent systematic review of studies 
assessing single frailty interventions reported follow-up times of between three-months 
and one year (Kidd et al., 2019). When evaluating complex interventions, it is 
recommended that follow-up should be as long-term as is possible, within the 
constraints of the trial, to determine whether short-term changes persist, and whether 
additional benefits or hazards may manifest at a later time (Craig et al., 2008).   
In the definitive study it will be important to assess change in outcome measures during 
the life of the intervention (three-months), following completion of the intervention, and 
to assess sustainability of any effect in the longer term. It is, therefore, recommended 
that follow-up time points for the definitive trial are at three-months, six-months and 
one year. This recommendation needs to be balanced with the potential disadvantages 
of longer follow-up, which may include increased adverse events and reduction in 
retention with more participants choosing to withdraw from the trial (Kearney et al., 
2018). However, in analysing results of five large RCTs, Akl et al (2012) did not find 
significant associations between the extent of loss to follow-up and the scale of 
treatment effect, therefore, these factors may not be influential on the outcome of the 
definitive trial. 
8.3.3 Sensitivity to change of outcome measures  
Although the aim of this feasibility study was to test the procedures for the 
administration of outcome measures, it also enabled examination of their sensitivity to 
change in people with moderate and severe frailty. Responsiveness of the instrument 
to detect change refers to the ability to perceive improvement/deterioration, an 
important attribute for determining the efficacy of the intervention (Singh & Aithal, 
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2018). Analyses from this fRCT must be viewed with caution as the study was not 
adequately powered to detect change, so evidence was sought from the literature, 
which showed variable information on sensitivity to change in the outcome measures 
under study. The SF-36 and EQ-5D-5L (used with older people) appear to be similar 
in their ability to measure change over time with some evidence of greater sensitivity 
to lower levels of morbidity in the SF-36 (Brazier et al., 1996). The UCLA-3 has been 
shown to be sensitive to small changes in loneliness over time (Velarde-Mayol, 
Fragua-Gil & García-de-Cecilia, 2016). There is no published evidence on sensitivity 
to change relating to the LTC-6 scale. Finally, an integrative review found no evidence 
related to the ability to detect change over time for the Barthel Index in older people 
(Liebzeit, King & Bratzke, 2018). 
In this fRCT, all outcome measures appeared able to detect change over the time. In 
all domains of the SF-36, mean scores were low and ranges were wide, which may 
indicate the participants were heterogeneous in health status. It is of note that scores 
in physical function and general health domains decreased in the intervention and 
control groups over time. This change may be expected in participants who live with 
moderate and severe frailty and concurs with evidence that function deteriorates as 
frailty increases in severity (Chen et al., 2018; Milte & Crotty, 2014). It may be that, in 
a definitive trial, a stabilisation of scores could be seen as positive rather than an 
expectation of improvement. This highlights the importance of the randomised control 
design in long-term conditions such as frailty, where natural progression is likely to be 
deterioration. The design allows comparison between intervention and control groups 
and can be used to detect any differences in health-related quality of life that may be 
related to the intervention.  
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As in the SF-36, data from the LTC-6 questionnaire revealed wide ranges of response 
and large standard deviations, with overall scores lower in the intervention than the 
control group. Mean scores rose in the intervention group at both study time points, 
whereas, in the control group they fell at 13 weeks but rose above baseline at 26 
weeks. Data from the UCLA-3 remained stable across all trial time points in both 
groups and did not appear sensitive to change. This does not concur with the work of 
Velarde-Mayol et al (2016), who investigated the validity of this instrument. It may be 
that this tool is less likely to detect change over a relatively short period of time. In 
addition, it may be that the contact provided as part of the trial improved participants’ 
self-perception of their loneliness. This is borne out in the qualitative data, which 
revealed that community matrons recognised how lonely many of the participants 
were, and by participants themselves, who reported how much they enjoyed the social 
interaction of the study visits. This provision of social contact could be mitigated by 
asking participants to complete postal or online questionnaires, but this needs to be 
balanced against the excellent completeness rates achieved by study visits. Other 
loneliness/social isolation tools could be considered for the definitive trial. In its 
evaluation of measurement of loneliness in adults, the Office for National Statistics 
recommended the use of the UCLA-3 combined with a single question “How often do 
you feel lonely?” as this enables capture of different features of loneliness and supports 
with more direct language (Office for National Statistics, 2018a). 
Mean scores for the Barthel Index rose at 13 weeks and remained higher than baseline 
at 26 weeks in both groups. As the trial was not powered to detect change, this is likely 
to be coincidental and was not in alignment with SF-36 data on function and mobility. 
Whilst the Barthel Index is widely used in older people and rehabilitation trials, studies 
have found that its ability to detect change in highly functional individuals is limited, 
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with a ceiling effect (Quinn, Langhorne & Stott, 2011). This may be important to note 
for a definitive trial. Many of the moderately frail participants were highly functioning 
and so this may not be the most sensitive outcome measure. Data from the EQ-5D-5L 
index values appear to confirm these high levels of function. Across the five health 
domains, participants reported high scores for self-care, mobility, anxiety and 
depression and usual activity, indicating that they experienced little or no problems.  
On analysing data from all participant-reported outcome measures, it may be that the 
control group were less functionally impaired than the intervention group. It is not 
known why this would be, due to random allocation of clusters to intervention or control, 
however, there may have been demographic differences in the practice populations. 
To inform a definitive trial, it may be necessary to closely examine the eFI and 
PRISMA-7 scores of the individual participants, to see if there is any difference in level 
of frailty severity within the clusters and, if so, adjust accordingly to ensure equivalent 
levels of frailty within intervention and control groups. In a definitive trial, with larger 
participant numbers, it would also seem appropriate to analyse data for the moderately 
and severely frail participants separately, which may lead to less heterogeneity of 
scores. This is recognised as a methodological limitation of the study and will be 
discussed further in Chapter Nine. 
In assessing site-reported outcome measures, as previously discussed in relation to 
safety reporting, it is notable that there were no deaths over the time of the study. This 
was an unexpected finding. Studies investigating frailty as a predictor of death have 
found that frailty was an independent predictor of three-year mortality (Hao et al., 2019; 
Yang et al., 2018). However, there are important differences in these studies’ 
populations and methods compared to the HAPPI fRCT. Hao et al’s research was 
carried out on a population who had been admitted to hospital and Yang et al’s work 
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was with older people in a nursing home setting, whereas the HAPPI study focussed 
on a community dwelling-population. In addition, both former studies examine three-
year mortality rates, whereas follow-up in the HAPPI study was limited to six-months. 
A systematic review of the impact of frailty on mortality in community-dwelling older 
people reported that it was associated with poor survival with a dose-responsive 
reduction in survival related to increasing number of frailty criteria (Shamliyan et al., 
2013). Recruitment for the study was conducted predominantly in the spring and 
summer months when there may be less excess winter-related deaths (Hajat & 
Gasparrini, 2016). If recruitment had been conducted over the winter period, it is 
possible that mortality may have been higher as those who are frail are more 
susceptible to winter illnesses, such as influenza, leading to hospital admissions and 
deaths. CGA-based interventions are known to have an effect on mortality in 
hospitalised patients (Stuck & Iliffe, 2011), however, it is less clear whether such an 
effect can be replicated in primary care, therefore, this will be an important outcome 
for the definitive trial. It may be necessary to have a longer follow-up period to ensure 
this effect is captured. 
Data on numbers of admissions and readmissions and days spent in hospital were 
collected with low numbers in both allocation groups. Once more, as the trial was not 
powered to detect difference between groups, results should be treated with caution. 
Numbers of days spent in hospital were lower in the intervention group, but this was 
influenced by the small number of participants, and one participant in the control group 
who experienced an extended hospital stay. The final site-reported outcome measure 
concerned numbers of prescribed medications. Numbers were similar in the 
intervention and control groups at baseline. Interestingly, numbers of medications rose 
in the control group at 13 weeks and fell again to baseline at 26 weeks. However, in 
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the intervention group, fewer medications were prescribed at 13 weeks and with a 
further reduction again at 26 weeks. It is known from assessment of intervention tools 
used that medication review was one of the most frequently used tools. Review of 
medication is a key aspect of CGA as certain medications are known to have significant 
adverse effects in frail older people (Hilmer & Gnjidic, 2017). A randomised controlled 
trial showed that de-prescribing reduced the number of regular medicines consumed 
by frail older with no significant adverse effects on survival or other clinical outcomes 
(Potter et al., 2016). It would appear that the community matrons in the HAPPI study, 
reviewed medication regularly as part of the intervention and consequently may have 
reduced numbers of medications prescribed. Therefore, numbers of prescribed 
medication would appear to be a clinically important outcome measure for a definitive 
trial.  
8.3.4 Selection of a primary outcome measure 
As stated in the Statistical Analysis Plan (Appendix 13), the choice of primary outcome 
measure/s for a definitive trial was guided by a number of factors: the number of 
outcome measures completed at the study time points; those most acceptable to 
participants; ease of administration in primary care; and those which are sensitive to 
change at the different time points. As discussed in the previous sections, all outcome 
measures appeared to broadly meet these criteria in that there was little missing data, 
they could be administered easily at one study visit and appeared able to detect 
change over time and difference between the allocated groups. HAPPI participants 
indicated that they did not find any of them burdensome to complete.  
Whilst it is encouraging to see the outcome measures met feasibility criteria, an 
additional factor needs to be considered in selecting a primary outcome/s measure for 
a definitive trial. As previously discussed, people who lacked mental capacity to 
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consent were excluded from this trial on the instructions of the NHS REC (Appendix 
19). It is recommended that the eligibility criteria for the definitive trial do not exclude 
those who lack mental capacity if they have a consultee who can provide assent and 
can complete outcome measures as the participant’s proxy. Recent research has 
demonstrated the coexistence of physical and cognitive impairments and that cognitive 
frailty can enhance the impact of physical frailty leading to negative health outcomes 
(Majnarić et al., 2020), so for this reason, it is important that the definitive trial is 
representative of the whole population group.  In addition, in the HAPPI trial, none of 
the participants had communication difficulties that prevented participation in collection 
of outcome measures, but this does need to be considered. 
Using participant-reported outcome measures assumes the person can understand 
the question and express a response. Proxy responses are a reasonable alternative 
when patients have cognitive and/or communication difficulties, which prevent them 
from answering outcome measures questions (Graham, 2016). There may, however, 
be the potential for measurement error or bias if there is disagreement between the 
proxy and participant responses (Neumann, Araki & Gutterman, 2000).  The literature 
on each outcome measure has been reviewed to assess for effectiveness of 
completion by a proxy.  
The SF-36 has shown only poor to moderate agreement between participant and proxy 
(Pierre et al., 1998). The Barthel index has been shown to have wide limits of 
agreement between participant and proxy but it is, nevertheless, recommended for use 
as a proxy instrument (Chen et al., 2007). There is no available evidence for the use 
of the LTC-6 as a proxy tool and it is recommended that the UCLA-3 is not administered 
using a proxy (Office for National Statistics, 2018a). The EQ-5D-5L is validated for 
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proxy completion and there is a proxy version for use where people are not capable of 
reporting on their health-related quality of life (EuroQuol, 2019).  
An alternative may be to consider outcome measures that are designed for use by 
those with cognitive or communication difficulties. A review by Ready et al (2003) 
demonstrated that there are multiple scales designed to assess quality of life in people 
who live with dementia. These differ in their assessment methods and suit different 
research situations, for example if a carer is present, or the extent to which the 
participant can contribute. The authors caution that there is a lack of evidence as to 
which tool is superior in demonstrating change over time. Given this uncertainty, it may 
be appropriate to consult with relevant stakeholders to determine an inclusive primary 
outcome measure for a definitive trial. These stakeholders should include those with 
cognitive impairment, carers and relevant representative organisations such as 
Dementia UK. 
To summarise this discussion of the selection of a primary outcome measure for a 
definitive trial, the advantages and disadvantages of each participant-reported 
outcome measures have been fully evaluated. It is recommended that the EQ-5D-5L 
instrument is adopted to measure health status and health related quality of life in a 
definitive trial. This tool was well completed, easy to administer and has the advantage 
of a proxy version, which can be used with consultees in a full trial. It is not known 
whether responsiveness to change is maintained when completed by a proxy and this 
does not yet appear to have been assessed in the literature. However, one study aims 
to assess responsiveness to change of the proxy-completed EQ-5D-5L in older 
patients with substantial multimorbidity and polypharmacy and results are expected in 
a future paper (Bhadhuri et al., 2020).  In addition, the EQ-5D-5L-VAS can be used for 
a future economic evaluation as a validated tool for calculating quality adjusted life 
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years (QALYS) (Whitehead & Ali, 2010). In addition to measuring health status and 
quality of life, the six dimensions of the EQ-5D-5L give a wider picture of functional 
status, independence, pain and mental health status. Use of this outcome measure will 
provide a broad assessment of the characteristics of frailty, which can be impacted on 
by a CGA-based intervention.  
It is recommended that prior to commencement of a definitive trial, a project team of 
stakeholders including older people, carers and organisations representing conditions 
that affect cognition is formed to agree a primary outcome measure. It may be possible 
to include an outcome that is important to those with cognitive deficits, and the use of 
an appropriate outcome measure that is inclusive and meaningful to that population. 
8.4 Estimation of sample size for a definitive trial 
As a cluster RCT, participants were randomised at site (cluster) level, however, data 
were analysed at individual level and it is planned to adopt this method in a definitive 
trial. Over-estimation of effect size can occur as similarities between individuals in 
clusters can reduce variability of response compared to individual randomisation (Killip, 
Mahfoud & Pearce, 2004). It may be possible to increase the cluster size by recruiting 
more participants at each site, however, a high number of clusters and with a lower 
number of participants in each will result in the smallest design effect and so is 
statistically preferable. In terms of feasibility, this approach would also reduce burden 
on individual community matrons, with less participants per clinician. This fRCT has 
demonstrated that initial engagement of general practices can be challenging, 
therefore, in reality, and dependent on resources available, large numbers of clusters 
may not be recruited to a definitive trial. Therefore, it will be important to consider the 
design effect if similar numbers of clusters but with larger numbers of participants are 
recruited and statistical advice will be sought prior to commencement of the trial.  
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8.5 Refinement of the HAPPI Intervention  
The HAPPI intervention was designed through an e-Delphi survey and research 
stakeholder consultation (Chapter Four). One objective of this fRCT with embedded 
qualitative study was to assess its acceptability to participants, carers and clinicians, 
further refine the intervention content and assess any barriers to its delivery. 
8.5.1 Acceptability of the HAPPI intervention to participants 
Studies of nurse-led assessment and care planning interventions in primary care 
(although not specifically including older people with frailty) have demonstrated high 
levels of acceptability to patients. A systematic review of studies of case management 
of patients with complex health needs by nurses in primary care (Stokes et al., 2015) 
found the intervention had a significant effect in improvement in health status and 
quality of life. In this fRCT, it appeared that the person-centred assessment and care 
planning approach delivered through the HAPPI intervention led to high levels of 
satisfaction among participants.  
Trial participants talked about how HAPPI filled gaps in their current primary health 
care service, by providing time, conversation and problem-solving with a skilled 
clinician. A recent study by Kelly et al (2019) reported that older people display low 
levels of satisfaction with primary care services and express strongly-held perceptions 
that their health needs are overlooked (Kelly, Mrengqwa & Geffen, 2019). The 
researchers report that these perceptions relate to lack of prioritisation of older people, 
negative and unhelpful attitudes of healthcare staff and clinician shortages leading to 
rushed consultations. For older people who live with frailty, continuity of care is 
important to manage the complexity of their multiple health and social care needs 
(Saultz, 2003), yet experience of continuity of care is reportedly low (Gjevjon et al., 
2014). The results of these studies resonate strongly with findings of the HAPPI 
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qualitative study and it is encouraging to note that the HAPPI intervention appeared to 
provide many of the features of continuity of care that appear to be missing from 
mainstream primary care for frail older people. These include the allocation of a clinical 
care manager who acts as a conduit for information and communication and who has 
dedicated time to form a trusting relationship with service users and carers (MacInnes, 
Baldwin & Billings, 2020). 
8.5.2 Feasibility of the HAPPI intervention to clinicians 
Regular patient discharge in primary care services helps to manage capacity and can 
ensure that patients with the greatest need are able to access support in a timely way 
(Roland et al., 2005). The trial allowed evaluation of whether it was possible to conduct 
a time-limited, CGA-based assessment in primary care where the lead clinician is a 
nurse rather than a doctor.  
To support the movement of CGA from secondary to primary care, the BGS recently 
published a Comprehensive Geriatric Assessment Toolkit for Primary Care 
Practitioners (Turner et al., 2019). This toolkit is 48 pages in length and takes a 
minimum of two hours to complete. The BGS themselves acknowledge that completion 
by general practitioners may not be possible due to short appointment times and lack 
of capacity in current UK primary care. Additionally, its full completion may not ensure 
a person-centred approach as not all components may be appropriate for all frail older 
people.  
The HAPPI intervention toolkit promoted an alternative flexible, person-centred 
approach. The initial assessment was based on a two-page conversation guide and 
one-page CGA summary, which community matrons reported as being quick and easy 
to complete. These guided the development of the personalised care and support plan 
and the use of the additional standardised assessment tools if they were appropriate 
230 
 
for that person and their assessed needs. The clinicians found this approach to be 
feasible in terms of time to complete, with the pack of additional assessment tools used 
for support if they did not have specific knowledge regarding a certain health condition. 
The community matrons welcomed the opportunity to test a more proactive model of 
working with frail people earlier in their frailty trajectory. They perceived that there was 
more opportunity to make improvement or prevent further deterioration before a crisis 
occurred. There is systematic review evidence to support early intervention by 
proactive management of mild to moderate frailty (Puts et al., 2017; Travers et al., 
2019) and the community matrons strongly believed this could be an effective 
approach in their clinical practice.  
In particular, the community matrons highlighted the negative effects of social isolation 
and recognised this as a risk factor for frailty development in the participants. 
Loneliness has shown to be detrimental to health in multiple studies. A meta-analysis 
in 2015 concluded that social isolation resulted in a fifty percent increase in premature 
death and is an equivalent risk factor for early death to smoking and a sedentary 
lifestyle (Holt-Lunstad et al., 2015). There were limited resources available to address 
this issue in local communities in the study, however, the new role of social prescriber 
had been implemented recently at some of the sites, and was highlighted as a potential 
solution. Social prescribing is a way of linking patients in primary care with sources of 
support within the community to help improve their health and well-being, usually 
through a link worker (Bickerdike et al., 2017). The community matrons were hopeful 
that these new workers could signpost the participants to groups and other community 
resources that could address their loneliness and social isolation. As loneliness is an 
independent risk factor for frailty and given its high prevalence, it would be important 
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for the definitive trial to ensure that similar resources are available and able to be 
accessed by the clinicians delivering the intervention. 
8.5.3 Refinement of the HAPPI intervention content 
One of the aims of the study was to further refine and finalise the content of the HAPPI 
intervention. The intervention pack contained two documents that were to be used with 
each participant (the conversation guide, and personalised care and support plan) and 
an additional suite of 29 assessment tools to be used selectively based on the 
participants’ assessed needs and health conditions. All assessment tools were used 
during the course of the trial, but not with all participants. The most frequently used 
tool was the medication review summary and this was often used repeatedly over 
several visits. This may suggest that review of medication was an important component 
that needed to be considered with the majority of participants. As previously discussed, 
suboptimal prescribing and polypharmacy can lead to poor health outcomes for frail 
older people such as adverse drug reactions, hospital admissions and subsequent 
healthcare costs (Lund et al., 2010; Passarelli, Jacob-Filho & Figueras, 2005), so 
regular review is important. Other frequently used tools were those relating to 
assessment of severity of frailty, pain, functional independence and caregiver strain. 
Although the HAPPI intervention was aimed at participants, an assessment tool for 
caregiver strain was included advocated by the PPI consultants and as increased 
caregiver burden is known to be associated with the physical frailty of the care recipient 
(Ringer et al., 2017).  
A recent realist review of most effective approach to CGA in care homes noted that 
engagement of a multidisciplinary team (MDT) was required (Chadborn et al., 2019). 
In the HAPPI fRCT, referrals to and the involvement of other health and social care 
services were evaluated and there were few referrals made to other services across 
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all participants. It is not clear why the number of referrals was so small. It may be that 
there was little need to involve other services, or that referral was not wanted by the 
participants. Integrated care by a MDT is an effective way to improve outcomes for 
people living with complex long-term conditions, however few multidisciplinary 
programmes have been specifically designed to manage frailty (Hendry et al., 2018). 
Further research is required to evaluate the specific added value of integrated care for 
frailty, but for the definitive trial it seems that MDTs would need to be available for the 
lead clinician to involve or refer to as required according to the needs of participants. 
In summary, the ethos of the HAPPI intervention is that it is a unique package entirely 
based on the needs of the individual participant. However, given the frequency of their 
usage of certain assessment tools in this fRCT and the likely outcome measures for 
the definitive trial, it may be appropriate to standardise the assessment package to 
include mandatory assessment of severity of frailty, medication, pain, 
function/independence and carer strain with the remaining assessments used as 
appropriate and as time allows. Research has been evolving whilst the HAPPI trial has 
been conducted. A recent meta-analysis recommended that resistance exercise 
coupled with optimising nutrition improved physical performance in frail older people 
(Macdonald et al., 2020). Based on this new evidence, the intervention for the definitive 
trial should include assessment of ability to participate in resistance exercise (as part 
of the mandatory functional assessment) and mandatory assessment of nutritional 
status.  
8.6 Barriers to implementation of the HAPPI intervention 
In their paper on the Medical Research Council’s revised guidance on evaluating 
complex interventions, Moore et al (2015) note that an intervention may have limited 
effects because weaknesses in implementation may lead to inaccurate results relating 
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to efficacy. They recommend incorporating qualitative methods to understand any 
unknown barriers to implementation when testing feasibility of an intervention. The 
qualitative arm, in particular, of the HAPPI study has enabled exploration of challenges 
to implementation and revealed some unexpected barriers. This is an advantage of 
feasibility studies, as they can establish how an intervention might be optimally 
designed, prior to conducting a definitive trial (Public Health England, 2018). The 
identified challenges in implementing the HAPPI intervention will be discussed and 
potential solutions offered next. 
8.6.1 Sharing decision-making and setting health goals 
There has been major international and national policy moves towards shared decision 
making and personalisation of healthcare in recent decades in an attempt to promote 
self-determination. This is based on evidence that self-care can improve clinical 
outcomes and quality of life (Stacey et al., 2017). In the UK, this has led to the 
publication of clinical guidance to support shared decision making by the National 
Institute for Health and Care Excellence (2019b). One of the key expectations of the 
HAPPI intervention was its person-centred ethos with the clinician working in 
partnership with the participant to understand their health status and set personal 
goals. It was recognised that this approach, though favoured by the older people, 
carers and clinicians who designed the HAPPI intervention, might be difficult to achieve 
in practice. There is less evidence for shared decision-making in older people with 
complex health needs when additional challenges are faced including diminishing 
capacity to self-manage. With increasing frailty, the nature of decisions are more likely 
to be affected by resource availability, concordance and absence of support networks 
(Bunn et al., 2018). Preference for active participation declines with increasing 
numbers of long term conditions among older adults (Wolff & Boyd, 2015) and there is 
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evidence that the majority of older people do not associate ageing with the 
development of long-term conditions. Consequently, they do not recognise their role in 
self-managing to remain healthy and such challenges make self-care and goal setting 
more problematic (Netuveli & Blane, 2008). 
In the HAPPI study, participants did not appear to acknowledge they had a role in 
shared decision-making and goal setting, but looked to the clinicians to lead this 
process. This appeared to be, in part, because they did not see themselves as patients 
in need of treatment and assistance from a nurse, regardless of their level of frailty. 
Community matrons expressed surprise and some frustration at participants' passivity 
and assumptions that they, as clinicians, would lead the decision-making process. 
Participants’ had a lack of knowledge about their health conditions and complications 
of family and relationship dynamics also fed into the need to remain passive in relation 
to their health and care.  This confirms the difficulties experienced by frail older people 
in actively participating in care planning and concurs with the findings of studies 
previously mentioned (Netuveli & Blane, 2008; Wolff & Boyd, 2015). 
Van Hooft et al (2017) found that the intrinsic motivation of people with long-term 
conditions to participate is an important factor in self-management programmes and 
this motivation can be lacking in frail older people with poorer health and multimorbidity 
(Bleijenberg et al., 2017b). Reporting on their recent qualitative study, La Grouw et al 
(2020) highlight how the diverse viewpoints of frail older people and clinicians may 
impact on the efficacy of shared decision making and care planning. They describe the 
key elements of this approach as needing clarity on both the “factual” and “normative” 
dimensions (La Grouw, Bannink & van Hout, 2020, p.2). The factual dimension 
comprises the facts about the person’s problems and the normative dimension details 
the behaviour/action that can be taken to address the problem.  
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Frailty management is distinguished by a wide variety of factual and normative 
understandings. Clinicians may interpret frailty as a biomedical problem and propose 
a solution such as a new medication, whilst the older person may view frailty as a 
consequence of their social or environmental circumstances, such as loss of 
independence, and may propose a social solution, such as joining an exercise group. 
Neither solutions are wrong, but they do come from differing underpinning beliefs and 
norms, which may be difficult to reconcile. This fundamental difference in normative 
understanding can threaten the clinician/patient relationship and ultimately the success 
of the intervention. Le Grouw and colleagues recommend that partnership working can 
be enriched by participating in a dialogue in which both perspectives are acknowledged 
as meaningful and valuable (La Grouw, Bannink & van Hout, 2020). This accords with 
the HAPPI intervention which was based on a conversation guide, where the 
participant’s concerns are explored and listened to and then the participant and the 
community matron worked together to agree and move towards goals which were 
meaningful to them both. Demonstrable changes included developing a plan of care 
and support, which persisted beyond the life of the intervention, focussing on 
contingency planning, developing a health information plan to share in an emergency 
and an agreed treatment escalation plan. 
Whilst they were enthusiastic about working more proactively with patients earlier in 
the frailty trajectory, community matrons acknowledged that this was a different way of 
working from their normal practice. They acknowledged that working in a collaborative 
partnership with the participants was challenging and suggested that additional training 
was needed in motivational interviewing, a recognised technique for enabling patients 
to assess for themselves what is important and how change may be achieved (Miller 
& Rollnick, 2002). Daniels et al (2011) suggest that motivational interviewing 
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techniques may address difficulties older people have in engaging in self-management 
and goal-setting. The techniques, which include reflective listening, the use of open 
questions, reflecting, gentle probing and summarising, can be built into the assessment 
process to support clinicians in working in a more collaborative way. Thus, it is 
recommended that motivational interviewing training is provided for all clinicians who 
implement the intervention in a definitive trial. In addition, the intervention package will 
be structured, using the principles of motivational interviewing to enable clinicians to 
become more confident in their practice. 
In summary, there were some unexpected and expected barriers to the implementation 
of the HAPPI intervention in real-life clinical practice. Conducting the feasibility trial 
gave the opportunity to understand the challenges in detail and to hear potential 
solutions from those who worked in primary care and experienced them first hand. 
This, combined with the evolving literature, has provided rich information for the design 
and planning of the definitive trial, which will be discussed further in section 8.7.  
8.7 Achievement of feasibility criteria and progression to a definitive trial 
It was gratifying to see that all criteria for progression to a definitive trial, as defined in 
the statistical analysis plan, were met (Table 6.16). Targets for site and participant 
recruitment, retention and adherence to the intervention were achieved, in addition, a 
primary outcome measure has been recommended for a definitive trial. However, this 
discussion chapter has also highlighted how the use of mixed-methods has proved 
helpful in identifying issues, which can be modified to enhance the chance of success 




Table 8.1: Lessons learned, challenges identified and recommendations for a definitive randomised controlled trial 
Study activity Lessons learned/challenges identified Recommendations for a definitive trial 
Trial Procedures 
Recruitment and retention of general 
practices as study sites. 
Initial difficulties in generating interest in 
the trial and concern over lack of capacity 
in general practice to participate. 
1. Use local CRN and Primary Care Lead General Practitioner 
to publicise the trial and gain interest. 
2. Fully estimate costs to the site of participation and ensure 
prompt payment or allocate funding for research assistant 
time to work with sites to complete study tasks. 
3. Ensure automated site-reported data collection wherever 
possible. 
 
Participant recruitment Recruitment rates at individual sites was 
influenced by capacity and protocol 
deviations. 
1. Targeted research assistant support as above. 
2. Additional training at site visit to ensure familiarisation with 
the trial protocol. 
 
Lack of severely frail participants 
recruited.  
eFI did not identify sufficient numbers of 
severely frail participants and more were 
likely to be screened out. 
1. Sample larger numbers of severely frail from the initial eFI 
list. 
2. Include those who lack capacity to consent (but have a 
consultee). This would need to be approved by the NHS 
REC. 
 
Communication of study aims. Study participants reported lack of clarity 
about study aims and clinicians 
experienced difficulty in articulating aims. 
1. Development of an aide-memoire, a short plain English 
written explanation of study aims to be used by assessors 
and clinicians. 
2. Wording to be incorporated into PIS so there is consistency 
of explanation across verbal and written processes. 
 
Participant retention. Participants valued the face-to face 
contact with the assessors which 
enhanced their experience of 
participation and may have led to 
enhanced retention. 
1. Participant-reported outcome measures are completed in a 
visit from the assessor, rather than by post or telephone 
interview. 
2. Ensure all outcome measures assessment is completed in 
one visit at each study time point to reduce participant time 




Study activity Lessons learned/challenges identified Recommendations for a definitive trial 
Collection of safety data No adverse SAEs or AEs were reported 
during the trial period. 
1. Develop guidance for assessors and clinicians in reporting 
AEs relating to components of the intervention which may 
cause harm, to ensure full reporting of AEs. 
 
Trial Design 
Implementation of the intervention Community matrons’ clinical caseloads 
took priority over HAPPI intervention 
delivery. This led to delays.  
 
1. Take a flexible approach to implementation at sites based 
on organisational challenges or opportunities. It may be 
appropriate for existing clinicians to deliver the intervention, 
or it may be more feasible to identify or employ “HAPPI” 
nurses who work exclusively on the study. 
2. Consider using clinicians other than nurses to implement 
the intervention including a MDT approach. 
 
Cluster randomisation Cluster randomisation avoided 
contamination of the control group but 
unblinding of one assessor led to 
unblinding of allocation for the whole 
cluster. 
1. Continue with written and verbal instructions to participants 
at consent and on randomisation. 
2. Assessors to remind participants at the start of all study 
visits not to reveal allocation. 
 
Follow-up period Due to time constraints of this feasibility 
trial, follow-up was limited to three 
months and six months.  
1. It is likely that a longer follow-up period is required to 
assess efficacy of the intervention. 
2. Add an additional follow-up time point so that outcome 
measures are assessed at three-months, six-months and 
one year after consent. 
Intervention 
Protocolisation of the intervention HAPPI is a flexible, person-centred 
intervention, but there is a need to 
standardise for effective comparison 
between intervention and control groups. 
1. Mandate the use of the conversation guide, personalised 
care and support plan and assessment tools for frailty 
severity, pain, functional independence, nutritional status 
and carer strain. 
2. Ensure CRFs for the definitive trial allow capture data on 
other tools used in the intervention. 
3. Localise “usual care”. The fRCT has detailed the content of 
usual care based on the national primary care frailty 
contract. There may be local development of additional 




Study activity Lessons learned/challenges identified Recommendations for a definitive trial 
Facilitating shared decision-making and 
goal setting as part of the intervention. 
It was difficult for participants to 
participate in a collaborative approach. 
Community matrons could be directive 
and struggled to share decision-making. 
Certain aspects of the care planning 
process were valued by participants.  
1. Provide training in motivational interviewing for clinicians 
implementing the intervention. 
2. Provide a written guide to be used at intervention visits to 
support the principles of a collaborative approach to guide 
clinicians in their practice. 
3. Ensure personalised care and support planning includes 
contingency and treatment escalation plans with a written 
copy that can be retained by the participant after the life 
of the trial. 
 
Outcome measures 
Completion of outcome measures. Completion of all outcome measures in 
one visit by assessor enabled high levels 
of completeness, but had the potential to 
introduce bias. 
1. Ensure face-to-face data collection in the participants’ 
home. 
2. Develop a written, protocol for asking the questions with 
standardised prompts to reduce potential bias. 
 
Timing of outcome measures. 50% of outcome measures were 
completed outside of the protocol window 
of +/- 7 days of the due date. 
1. Lengthen protocol window to a range of 7 days before and 
14 days after the due date.   
Sensitivity to change of outcome 
measures. 
All outcome measures appeared 
sensitive to change in the trial (with more 
limited evidence in the literature). There 
is likely to be less change improvement 
noted in severely frail due to existing 
morbidity/disability.  
1. Analyse data for moderately and severely frail participants 
separately to reduce heterogeneity of scores. 
2. Conduct a detailed literature review to determine how much 
improvement in primary outcome can be expected in 
moderately and severely frail. Maybe that stabilisation of 





8.8 Towards a definitive RCT  
The frailty literature has evolved during the time of this feasibility study and fellowship 
(2017-2020) primarily driven by international policy relating to frailty management in 
primary care (World Health Organization, 2017). Whilst the HAPPI study has allowed 
testing of study methods and intervention refinement, it is important to consider the 
findings of other studies that have been conducted concurrently. These findings have 
been incorporated into sections of this discussion to ensure transparency and that 
evidence is as current as possible.  
Relevant specifically to the design of the definitive trial, three systematic reviews 
(Garrard et al., 2020; Travers et al., 2019; Van der Elst et al., 2018) and one narrative 
synthesis (Frost et al., 2020) have provided guidance on efficacy and content of CGA-
based and other interventions to manage older people with complex conditions in 
primary care. In addition, the helpful findings of two studies have provided further 
information on methods of identification of frail people (Bleijenberg et al., 2017b; Lee 
et al., 2020). Garrad et al’s systematic review (2020) demonstrates the scarcity of good 
quality studies into primary care CGA with only four studies included from 97 full texts 
screened, only one of which was nurse-led. The review concluded that primary care 
based CGA was acceptable but provided variable outcome benefit and, like other 
reviews (Beswick et al., 2008), highlighted the difficulty of identifying appropriate frail 
patients. The other two systematic reviews (Travers et al., 2019; Van der Elst et al., 
2018) included a variety of heterogeneous interventions, including CGA. These 
reviews were useful in that the majority of interventions did not appear to have a 
positive impact on outcomes, with the exception of a combination of muscle strength 




frailty and the easiest to implement in primary care. Finally, the narrative review (Frost 
et al., 2020) demonstrated the positive impact of interventions that included self-
management, assessment and care planning procedures and structured care 
pathways led by more experienced and qualified nurses. The findings from Frost’s et 
al’s work concur with the HAPPI study and the findings from Travers et al regarding 
assessment for function/physical activity and nutritional supplementation will be 
included in the mandatory element of the intervention for the definitive trial. The HAPPI 
study community matrons were very experienced nurses with advanced clinical 
assessment skills. It will be important to ensure delivery of the intervention by similarly 
skilled clinicians in the definitive trial.   
In this feasibility trial, the eFI was used to identify moderately and severely frail people 
to participate. As discussed, this method did not identify sufficient numbers of severely 
frail participants and there were some concerns about accuracy and number of false 
positives. This is a crucial factor for the success of the trial and thus it would seem 
appropriate to consider an additional participant identification method for the definitive 
trial, which will require many more participants. However, there is no definitive, feasible 
primary care frailty screening method as discussed in section 1.4.4. Bleijenberg et al 
(2017b) reviewed the results from two RCTs and found that a nurse-led intervention 
had a positive impact on daily functioning in the oldest old population i.e. aged 80 years 
and over. It would seem appropriate to target this age group as frailty prevalence and 
severity increases with age (Gale, Westbury & Cooper, 2018). In addition, a very recent 
study from Canada has tested a novel approach to screening for frailty, which aims to 
identify those at highest risk to poor outcomes (Lee et al., 2020). This dual trait 
approach based on gait speed and grip strength as a proxy for the Fried frailty 




primary care practice. In addition, they recommend only screening those aged 85 and 
over, plus those aged 75 years and over who have had two or more falls in the past 
six months. An advantage of this is that less people would need to be screened initially 
to obtain the study sample. It is, therefore, recommended that the definitive trial uses 
two methods of participant identification; eFI plus PRISMA-7 and the dual trait method 
(subject to the permission of the authors) and the age of participants is raised to 80 
years. Consideration could then be given to analysis of the data from the two arms as 
comparison groups within the study. 
Based on these changes from the original HAPPI study design, a model for the design 
of the definitive RCT has been developed (Figure 8.1). This builds on the findings of 
this study and informed by the new evidence from the very recent literature regarding 









8.9 Chapter summary 
This fRCT with embedded qualitative component has demonstrated the feasibility of 
conducting an RCT of a nurse-led assessment and care planning intervention in 
primary care. In addition, it has provided valuable information to plan the design of the 
definitive trial. The next and final chapter will conclude this thesis with a summary of 
the research aims and their achievement, discussion of the overall contribution to 
knowledge, the limitations of the studies, provide recommendations for future research 






Chapter 9: Conclusions 
9.1 Achievement of research aims 
The HAPPI study aimed to develop, implement and test a nurse-led holistic 
assessment and care planning intervention and to determine important parameters for 
the design of a definitive RCT. The study was co-produced and designed in partnership 
with frail older people and carers through a PPI consultation. Consensus on the content 
and delivery of the intervention was achieved through an e-Delphi survey and further 
refined with the output from a research stakeholder group. Then an fRCT with 
embedded qualitative study determined the feasibility of the intervention and 
conducting the trial including its acceptability to patients, carers and clinicians. All 
research aims were achieved and both the feasibility of the intervention and conducting 
of a RCT were established. 
In this final chapter, methodological limitations are discussed, and the implications of 
the findings are considered in relation to existing research and clinical practice. 
Specific contributions to new knowledge are reported and recommendations made for 
practical implementation and future research. The author’s personal research journey 
is discussed with plans for the future. 
9.2 Study limitations 
There were limitations to both the e-Delphi study and the feasibility RCT. In the e-
Delphi study, consensus levels for feasibility and importance were set at 75% based 
on discussion between the author and her supervisors in the absence of definitive 
guidance on setting consensus levels in Delphi studies. If consensus levels for 
feasibility had been set at 70%, rather than 75%, then an additional four components 




had been set at 70% agreement that a component was “feasible”, in addition to “very 
feasible” or “extremely feasible”, then all components would have met the criteria for 
feasibility. This decision on consensus led to the exclusion of important intervention 
components and required additional stakeholder consultation to resolve. Due to the 
explorative nature of this study, it may have been more appropriate to look to define 
and establish the preferred consensus level during the course of the survey rounds, 
rather than prior to commencement of the study. 
Insufficient recruitment of severely frail participants was the main limitation of the 
feasibility RCT. This meant the study sample was not fully representative of the two 
levels of frailty the intervention can support and there was heterogeneity of responses 
with large ranges around the mean scores in all outcome measures as both levels were 
analysed as one group. These two issues must be addressed in the definitive trial by 
sampling more severely frail participants from the initial eFI lists, so that once eligibility 
criteria are applied there are still sufficient numbers to invite to participate. An 
alternative would be to consider an alternative frailty screening method, as discussed 
in section 8.7. It will be important to ensure clusters have similar proportions of 
moderately and severely frail participants so that comparisons can be made between 
the intervention and control group. This would allow data from the moderate and the 
frail groups to be analysed separately, however, there will need to be consideration of 
the larger sample size that will be required to achieve statistical power. If this is not 
deemed achievable in the definitive trial, there could be a secondary analysis 
undertaken of the moderately and severely frail participants’ data.  
The small sample size of 60 participants is also acknowledged as a limitation in the 




participants were recruited in ten months, thus, the actual monthly recruitment rate 
exceeded the target recruitment rate. 
An additional limitation concerned the cluster design. Unblinding of one assessor by a 
participant revealing allocation, led to unblinding for the whole cluster. Further 
reinforcement of the need for participants to conceal allocation will be required in the 
definitive trial, as this is a known complication of the cluster design (Magill et al., 2019). 
There is a trade-off here between the prevention of contamination, i.e. the receipt of 
the intervention amongst participants in the control arm, and the risk of unblinding of 
assessors inherent in cluster design. The cluster design prevented clinicians who were 
treating intervention participants from treating control participants, which is essential 
where the intervention is a new model of care involving elements that can be 
incorporated into usual practice.  Therefore, despite this limitation, the cluster design 
is still recommended for a definitive trial. 
The final limitation concerned the embedded qualitative study. It was planned to 
interview carers of participants in both the intervention and the control groups. 
However, it was not established at the consent visit whether or not participants had 
carers and, consequently, there was no way of identifying carers of the control group 
participants to invite for interview. This may not be relevant in the definitive trial as it is 
yet to be determined if there will be a qualitative component, but it did mean that the 
views of control group carers were not included and thus some important feedback on 




9.3 Contributions to knowledge and clinical practice 
9.3.1 Knowledge 
The study has determined that it is feasible to conduct a clinical trial of a nurse-led 
assessment and care planning intervention for frail older people. It has established the 
content of the intervention and how to support effective implementation. Primary and 
secondary outcome measures have been evaluated and recommendations made for 
a definitive trial. This study is unique in its use of the eFI as a tool for identifying the 
target population and this has shown that it is a practical way to select moderately and 
severely frail participants. Limitations of the eFI have been explored and alternative 
frailty screening methods considered. 
The author has been unable to source any other feasibility studies in this area in order 
to make comparisons with existing literature, however, as discussed in the evidence 
review of this thesis, randomised controlled trials of nurse-led CGA-based 
interventions have produced mixed results and recommended further research due to 
the heterogeneity of both the interventions and research methods. These studies have 
failed to evaluate the impact of a nurse-led, person-centred intervention for older 
people who live with frailty. While this feasibility trial was not designed to test the 
efficacy of the HAPPI intervention, it was able to test methods to address 
methodological deficiencies identified in the current literature with the aim of improving 
the chances of success of a definitive trial.  
9.3.2 Clinical practice 
The study has ascertained which components of the CGA can be delivered in primary 
care by nurses without specialist geriatrician involvement, in real life practice with the 




include lack of training in promoting shared decision making and capacity to undertake 
proactive care alongside acute caseloads, have been identified and potential solutions 
recommended. The importance of a person-centred, flexible approach has been 
highlighted, but the trial has also identified the evidence-based mandatory content that 
has enabled protocolisation of the intervention for a future trial. It has also 
demonstrated that, by adopting a person centred approach, a holistic assessment can 
be offered to older people who live with frailty within the time constraints of primary 
care practice. It was exciting to see that this study has proved it is feasible to conduct 
a RCT, using an intervention that was well received by older people, carers and 
clinicians. 
9.4 Final conclusions 
This thesis charts my four-year research journey of personal development from a 
novice to a more proficient independent researcher able to plan, design and conduct 
research using a range of methodologies. It is important at this stage to reflect on my 
personal and professional growth. This has been an incredibly steep learning curve, 
however, the award of the NIHR Clinical Doctoral Fellowship meant that I was in the 
fortunate position of being able to design my own training and development 
programme and then put these skills into practice in my role as CI in the different 
phases of the study. With the unwavering support of with my supervisors and some 
lively, productive academic debate, I was able to advance my skills and develop 
expertise, which will progress my clinical academic career in future. At times, 
conducting three research studies across multiple sites using different methodologies 
seemed like I may have over-stretched my abilities. However, I viewed this as a unique 




learn how to truly mix methods, using complementarity to draw findings from the 
studies and unite them to answer the research questions. Practically, I learnt so much 
about research funding, regulations and procedures that will prepare me personally for 
future research design and planning. I gained important skills related to how to conduct 
research in demanding clinical settings, where real life constantly intrudes and where 
your study is not a priority to busy clinicians. Most importantly, I was able to explore 
how, by using mixed-methods, it is possible to provide a more enriched and profound 
evaluation of the implementation of a complex healthcare intervention in an under-
researched population. 
As a specialist nurse, I have witnessed the challenges faced by older people who live 
with frailty and the uncertainty that exists among clinicians concerning optimum 
support and management for this vulnerable group. These dilemmas are often 
compounded by the current climate of reducing budgets with limited time and capacity 
to care. This research, and its associated thesis, have attempted to address some of 
these concerns and complete initial, important steps to developing a new model of 
care, which may be clinically effective and feasible for the future. The practical issues 
of undertaking research in primary care have been examined and the qualitative work 
with older people, carers and nurses truly emphasised the different perspectives of the 
reality and complexity of partnership working between them.     
Despite the challenges, a person-centred assessment and care planning intervention 
has been developed and the trial results make a unique contribution to the existing 
evidence base by showing that it is indeed feasible to conduct a RCT of the intervention 
in primary care, with nurses as the lead clinician. The next steps will be to explore the 




clinical academic career pathway. Further research is now needed to determine the 
impact of the intervention on clinical outcomes and quality of life. I plan to apply for 
funding to conduct the definitive RCT, answering these questions and, ultimately, 
advancing nursing practice and improving patient outcomes. 
People are living longer, but extra years of life are not always spent in good health. As 
the renowned actor Bette Davis once said: “Old age ain't no place for sissies” 
(Chandler, 2008, p.294) and there is no doubt that, as the decades pass, challenges 
to health and wellbeing increase. As a nurse, I witness courage, resilience and good 
humour every day among older people who live with frailty. I believe we owe our older 
citizens the best possible care and support, close to home, to remain independent and 
fulfilled as frailty develops. As one of the wonderful HAPPI participants said: 
 “It’s not just enough to be trying to get good results for people’s health but also for 





Appendix 1: Evidence review search strategy 
Database: PubMed. 
Search date: 6/6/2019. 
Platform: OVID via University of Plymouth. 
 
Search Query Items found 
#40 Search (#8 AND #11 AND #24 AND #30 AND #39) 103 
#39 Search (#31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR 
#38) 
519699 
#38 Search "Office Nursing"[Mesh] 343 
#37 Search "General Practice"[Mesh] 73263 
#36 Search general practice[Title/Abstract] 36599 
#35 Search (((("Community Health Services"[Mesh:NoExp]) OR 
"Community Health Nursing"[Mesh] 
55356 
#34 Search family medicine[Title/Abstract] 9951 
#33 Search (primary care OR primary health care) 402727 
#32 Search community health care[Title/Abstract] 1037 
#31 Search community care[Title/Abstract] 4401 
#30 Search (#27 OR #28 OR #29) 369170 
#29 Search social function*[Title/Abstract] 13418 
#28 Search ((wellbeing[Title/Abstract] OR well-being[Title/Abstract] OR well 
being[Title/Abstract])) 
80386 
#27 Search (#25 OR #26) 300459 
#26 Search "Quality of Life"[Mesh] 176937 
#25 Search quality of life[Title/Abstract] 244465 
#24 Search (#14 OR #17 OR #18 OR #23) 117279 
#23 Search (#21 AND #22) 6634 
#22 Search nurs*[Title/Abstract] 438620 
#21 Search (#18 OR #20) 9671 
#20 Search geriatric assessment[Title/Abstract] 3557 
#19 Search "Geriatric Assessment"[Mesh] 25427 
#18 Search nursing intervention*[Title/Abstract] 6117 
#17 Search (#15 OR #16) 41006 
#16 Search "Patient Care Planning"[Mesh:NoExp] 37724 
#15 Search "care plan*"[Title/Abstract] 4162 
#14 Search (#12 OR #13) 75828 
#13 Search "Nursing Assessment"[Mesh] 32177 
#12 Search nurs* assessment[Title/Abstract] 51445 
#11 Search (#9 OR #10) 3493252 
#10 Search ((elder*[Title/Abstract] OR aged[Title/Abstract] OR "older 
people"[Title/Abstract] OR "older person"[Title/Abstract] OR 
geriatric[Title/Abstract] OR senior[Title/Abstract] OR 





Search Query Items found 
#9 Search (("Aged"[Mesh]) OR "Aged, 80 and over"[Mesh]) 2951024 
#8 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7) 192870 
#7 Search "Sarcopenia"[Mesh] 3256 
#6 Search (("Frailty"[Mesh]) OR "Frail Elderly"[Mesh]) 10950 
#5 Search "complex needs"[Title/Abstract] 1334 
#4 Search vulnerab* 125911 
#3 Search fragil*[Title/Abstract] 39452 
#2 Search sarcopenia[Title/Abstract] 6633 
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% n % n % n % n % n n Mean SD
A system for data/information gathering e.g. past medical history, social circumstances, family history.0% 0 0.0% 0 40.0% 8 40.0% 8 20.0% 4 20 4.8 0.6
Multi-disciplinary team discussion/review. 0% 0 15.0% 3 30.0% 6 35.0% 7 20.0% 4 20 4.8 0.6
Coordinated multidimensional assessment and care with an identified lead clinician/case manager0% 0 15.0% 3 50.0% 10 20.0% 4 15.0% 3 20 4.7 0.7
A shared care record 10% 2 40.0% 8 15.0% 3 30.0% 6 5.0% 1 20 4.7 0.5
A timely response to crises 0% 0 10.5% 2 47.4% 9 31.6% 6 10.5% 2 19 4.9 0.3
A competent, well trained workforce who can deliver an assessment and care planning intervention0% 0 15.0% 3 20.0% 4 50.0% 10 15.0% 3 20 4.8 0.5
Assessment for the presence and severity of frailty 0% 0 9.1% 2 27.3% 6 27.3% 6 36.4% 8 22 3.9 1.0
Assessment of functional ability and activities of daily living including reablement potential0% 0 4.8% 1 23.8% 5 38.1% 8 33.3% 7 21 4.0 0.9
Assessment of falls risk 0% 0 4.6% 1 31.8% 7 13.6% 3 50.0% 11 22 4.1 1.0
Assessment of cognition including identification of delirium and capacity assessment 0% 0 13.6% 3 27.3% 6 31.8% 7 27.3% 6 22 3.7 1.0
Assessment of mood and psychological well-being 0% 0 22.7% 5 31.8% 7 27.3% 6 18.2% 4 22 3.4 1.0
Assessment of pain 0% 0 4.6% 1 13.6% 3 27.3% 6 54.6% 12 22 4.3 0.9
Medication review including ability to self-administer, concordance and de-prescribing 0% 0 4.6% 1 45.5% 10 40.9% 9 9.1% 2 22 3.6 0.7
Assessment of nutritional status including hydration 0% 0 4.6% 1 36.4% 8 27.3% 6 31.8% 7 22 3.9 0.9
Assessment of social support including financial concerns, benefits entitlement, social isolation0% 0 13.6% 3 50.0% 11 27.3% 6 9.1% 2 22 3.3 0.8
Assessment of vision, hearing and dentition 0% 0 19.1% 4 38.1% 8 23.8% 5 19.1% 4 21 3.4 1.0
Assessment of bladder and bowel function 0% 0 13.6% 3 27.3% 6 31.8% 7 27.3% 6 22 3.7 1.0
Environmental assessment including housing and equipment aimed at maximising independence0% 0 4.6% 1 63.6% 14 18.2% 4 13.6% 3 22 3.4 0.8
Determining spiritual needs and support systems 5% 1 13.6% 3 31.8% 7 27.3% 6 22.7% 5 22 3.5 1.1
Sexual health assessment 5% 1 18.2% 4 63.6% 14 4.6% 1 9.1% 2 22 3.0 0.9
Exploring opportunities for employment/education/hobbies 5% 1 14.3% 3 47.6% 10 19.1% 4 14.3% 3 21 3.2 1.0
Optimising management of long term conditions/multimorbidity 0% 0 9.1% 2 36.4% 8 50.0% 11 4.6% 1 22 3.5 0.7
Advanced clinical assessment skills – physical examination and ordering investigations 0% 0 18.2% 4 45.5% 10 13.6% 3 22.7% 5 22 3.4 1.0
Problem/deficit identification 0% 0 9.5% 2 28.6% 6 23.8% 5 38.1% 8 21 3.9 1.0
Determining advance care preferences 0% 0 13.6% 3 50.0% 11 22.7% 5 13.6% 3 22 3.4 0.9
Escalation/contingency planning: actions for when the patient’s condition deteriorates 0% 0 9.1% 2 36.4% 8 45.5% 10 9.1% 2 22 3.6 0.8
Establishing the patient’s personal goals and where support is needed (person centred care)0% 0 9.1% 2 31.8% 7 22.7% 5 36.4% 8 22 3.9 1.0
Empowerment and self-management and enabling behavioural change 0% 0 22.7% 5 54.6% 12 18.2% 4 4.6% 1 22 3.1 0.8
Assessment of patient’s ability to actively participate in care and planning 0% 0 4.6% 1 36.4% 8 40.9% 9 18.2% 4 22 3.7 0.8
Assessment of resilience and coping mechanisms – an asset based approach 9% 2 18.2% 4 40.9% 9 13.6% 3 18.2% 4 22 3.1 1.2
Assessment of carer’s needs 5% 1 4.6% 1 40.9% 9 22.7% 5 27.3% 6 22 3.6 1.1
Establishing an individual’s narrative by active listening/appreciative enquiry 0% 0 9.1% 2 54.6% 12 18.2% 4 18.2% 4 22 3.5 0.9
Agreeing and formulating a plan together based on shared decision making and the preferences of the individual: working the partnership5% 1 4.6% 1 36.4% 8 31.8% 7 22.7% 5 22 3.6 1.0
Safeguarding this contract by documenting it in a co-created care or support plan: personalised care and support planning0% 0 18.2% 4 40.9% 9 31.8% 7 9.1% 2 22 3.3 0.9
Monitoring response to the care and support plan 0% 0 18.2% 4 40.9% 9 22.7% 5 18.2% 4 22 3.4 1.0
Review and revising of the care and support plan 0% 0 4.6% 1 50.0% 11 22.7% 5 22.7% 5 22 3.6 0.9




Appendix 3: Supplementary Information 2, Delphi Paper Chapter 4 
Figure Legend:  Percentages, frequencies, mean scores and standard deviations for all components in round three 
 
Component Total
% n % n % n % n % n n Mean SD
A system for data/information gathering e.g. past medical history, social circumstances, family history0.0% 0 0.0% 0 0.0% 0 0.0% 0 100.0% 24 24 5.0 0.0
Multi-disciplinary team discussion/review 0.0% 0 0.0% 0 0.0% 0 8.3% 2 91.7% 22 24 4.9 0.3
Coordinated multidimensional assessment and care with an identified lead clinician/case manager0.0% 0 0.0% 0 4.2% 1 12.5% 3 83.3% 20 24 4.8 0.6
A shared care record 0.0% 0 0.0% 0 8.3% 2 16.7% 4 75.0% 18 24 4.7 0.6
A timely response to crises 0.0% 0 0.0% 0 0.0% 0 0.0% 0 100.0% 24 24 5.0 0.0
A competent, well trained workforce who can deliver an assessment and care planning intervention0.0% 0 0.0% 0 4.2% 1 0.0% 0 95.8% 23 24 4.9 0.4
Assessment for the presence and severity of frailty 0.0% 0 0.0% 0 12.5% 3 12.5% 3 75.0% 18 24 4.6 0.7
Assessment of functional ability and activities of daily living including re-ablement potential0.0% 0 0.0% 0 4.2% 1 16.7% 4 79.2% 19 24 4.8 0.6
Assessment of falls risk 0.0% 0 4.2% 1 0.0% 0 20.8% 5 75.0% 18 24 4.6 0.7
Assessment of cognition including identification of delirium and capacity assessment0.0% 0 0.0% 0 0.0% 0 25.0% 6 75.0% 18 24 4.8 0.4
Assessment of mood and psychological well-being 0.0% 0 0.0% 0 0.0% 0 12.5% 3 87.5% 21 24 4.9 0.3
Assessment of pain 0.0% 0 0.0% 0 0.0% 0 4.2% 1 95.8% 23 24 5.0 0.2
Medication review including ability to self-administer, concordance and de-prescribing0.0% 0 0.0% 0 0.0% 0 4.2% 1 95.8% 23 24 5.0 0.2
Assessment of nutritional status including hydration 0.0% 0 0.0% 0 4.2% 1 12.5% 3 83.3% 20 24 4.8 0.5
Assessment of social support including financial concerns, benefits entitlement, social isolation0.0% 0 0.0% 0 4.2% 1 4.2% 1 91.7% 22 24 4.9 0.4
Assessment of vision, hearing and dentition 0.0% 0 0.0% 0 0.0% 0 12.5% 3 87.5% 21 24 4.9 0.3
Assessment of bladder and bowel function 0.0% 0 0.0% 0 0.0% 0 20.8% 5 79.2% 19 24 4.8 0.7
Environmental assessment including housing and equipment aimed at maximising independence0.0% 0 0.0% 0 4.2% 1 8.3% 2 87.5% 21 24 4.8 0.5
Determining spiritual needs and support systems 0.0% 0 0.0% 0 4.2% 1 29.2% 7 66.7% 16 24 4.6 0.6
Sexual health assessment 0.0% 0 4.2% 1 12.5% 3 33.3% 8 50.0% 12 24 4.3 0.8
Exploring opportunities for employment/education/hobbies 0.0% 0 4.2% 1 12.5% 3 50.0% 12 33.3% 8 24 4.1 0.8
Optimising management of long term conditions/multimorbidity 0.0% 0 0.0% 0 0.0% 0 8.7% 2 91.3% 21 23 4.9 0.3
Advanced clinical assessment skills - physical examination and ordering investigations0.0% 0 4.2% 1 8.3% 2 20.8% 5 66.7% 16 24 4.6 0.8
Problem/deficit identification 0.0% 0 0.0% 0 8.3% 2 16.7% 4 75.0% 18 24 4.7 0.6
Determining advance care/end of life preferences 0.0% 0 0.0% 0 0.0% 0 8.3% 2 91.7% 22 24 4.9 0.3
Escalation/contingency planning: actions for when the patient's condition deteriorates0.0% 0 0.0% 0 0.0% 0 16.7% 4 83.3% 20 24 4.8 0.4
Establishing the patient's personal goals and where support is needed (person centred care)0.0% 0 0.0% 0 4.2% 1 8.3% 2 87.5% 21 24 4.8 0.5
Empowerment and self-management and enabling behavioural change 0.0% 0 0.0% 0 4.2% 1 20.8% 5 75.0% 18 24 4.7 0.5
Assessment of patient's ability to actively participate in care and planning 0.0% 0 0.0% 0 12.5% 3 4.2% 1 83.3% 20 24 4.7 0.7
Assessment of resilience and coping mechanisms - an asset based approach 0.0% 0 0.0% 0 4.2% 1 25.0% 6 70.8% 17 24 4.7 0.6
Assessment of carers needs 0.0% 0 0.0% 0 0.0% 0 12.5% 3 87.5% 21 24 4.9 0.3
Establishing an individual's narrative by active listening/appreciative enquiry 0.0% 0 4.2% 1 4.2% 1 12.5% 3 79.2% 19 24 4.7 0.8
Agreeing and formulating a plan together based on shared decision making and the preferences of the individual: working the partnership0.0% 0 0.0% 0 8.3% 2 12.5% 3 79.2% 19 24 4.7 0.6
Safeguarding this contract by documenting it in a co-created care or support plan: personalised care and support planning0.0% 0 0.0% 0 12.5% 3 12.5% 3 75.0% 18 24 4.6 0.7
Monitoring response to the care and support plan 0.0% 0 0.0% 0 16.7% 4 0.0% 0 83.3% 20 24 4.7 0.8
Review and revising of the care and support plan 0.0% 0 0.0% 0 8.3% 2 8.3% 2 83.3% 20 24 4.8 0.6





% n % n % n % n % n n Mean SD
A system for data/information gathering e.g. past medical history, social circumstances, family history0.0% 0 0.0% 0 19.1% 4 28.6% 6 52.4% 11 21 4.3 0.7
Multi-disciplinary team discussion/review 0.0% 0 0.0% 0 23.8% 5 57.1% 12 19.1% 4 21 3.9 0.6
Coordinated multidimensional assessment and care with an identified lead clinician/case manager0.0% 0 9.5% 2 42.9% 9 42.9% 9 4.8% 1 21 3.4 0.7
A shared care record 0.0% 0 38.1% 8 42.9% 9 19.1% 4 0.0% 0 21 2.8 0.8
A timely response to crises 0.0% 0 4.8% 1 47.6% 10 28.6% 6 19.1% 4 21 3.5 0.8
A competent, well trained workforce who can deliver an assessment and care planning intervention0.0% 0 4.8% 1 42.9% 9 42.9% 9 9.5% 2 21 0.1 0.8
Assessment for the presence and severity of frailty 0.0% 0 4.8% 1 14.3% 3 42.9% 9 38.1% 8 21 4.0 0.9
Assessment of functional ability and activities of daily living including re-ablement potential0.0% 0 0.0% 0 14.3% 3 52.4% 11 33.3% 7 21 4.1 0.7
Assessment of falls risk 0.0% 0 0.0% 0 19.1% 4 23.8% 5 57.1% 12 21 4.4 0.8
Assessment of cognition including identification of delirium and capacity assessment0.0% 0 4.8% 1 23.8% 5 42.9% 9 28.6% 6 21 3.9 0.8
Assessment of mood and psychological well-being 0.0% 0 4.8% 1 28.6% 6 38.1% 8 28.6% 6 21 3.9 0.8
Assessment of pain 0.0% 0 0.0% 0 4.8% 1 33.3% 7 61.9% 13 21 4.5 0.7
Medication review including ability to self-administer, concordance and de-prescribing0.0% 0 0.0% 0 19.1% 4 57.1% 12 23.8% 5 21 4.0 0.7
Assessment of nutritional status including hydration 0.0% 0 0.0% 0 14.3% 3 38.1% 8 47.6% 10 21 4.3 0.8
Assessment of social support including financial concerns, benefits entitlement, social isolation0.0% 0 4.8% 1 47.6% 10 38.1% 8 9.5% 2 21 3.4 0.8
Assessment of vision, hearing and dentition 0.0% 0 0.0% 0 33.3% 7 66.7% 14 0.0% 0 21 3.6 0.5
Assessment of bladder and bowel function 0.0% 0 0.0% 0 19.1% 4 61.9% 13 19.1% 4 21 4.0 0.6
Environmental assessment including housing and equipment aimed at maximising independence0.0% 0 4.8% 1 42.9% 9 38.1% 8 14.3% 3 21 3.6 0.8
Determining spiritual needs and support systems 0.0% 0 4.8% 1 38.1% 8 33.3% 7 23.8% 5 21 3.7 0.9
Sexual health assessment 0.0% 0 23.8% 5 47.6% 10 19.1% 4 9.5% 2 21 3.1 0.9
Exploring opportunities for employment/education/hobbies 0.0% 0 9.5% 2 52.4% 11 23.8% 5 14.3% 3 21 3.4 0.9
Optimising management of long term conditions/multimorbidity 0.0% 0 0.0% 0 28.6% 6 66.7% 14 4.8% 1 21 3.8 0.6
Advanced clinical assessment skills - physical examination and ordering investigations0.0% 0 9.5% 2 33.3% 7 38.1% 8 19.1% 4 21 3.5 0.9
Problem/deficit identification 0.0% 0 4.8% 1 23.8% 5 42.9% 9 28.6% 6 21 3.9 0.9
Determining advance care/end of life preferences 0.0% 0 9.5% 2 19.1% 4 42.9% 9 28.6% 6 21 3.8 0.9
Escalation/contingency planning: actions for when the patient's condition deteriorates0.0% 0 0.0% 0 38.1% 8 42.9% 9 19.1% 4 21 3.9 0.8
Establishing the patient's personal goals and where support is needed (person centred care)0.0% 0 0.0% 0 19.1% 4 47.6% 10 33.3% 7 21 4.8 0.5
Empowerment and self-management and enabling behavioural change 0.0% 0 9.5% 2 57.1% 12 19.1% 4 14.3% 3 21 3.3 0.8
Assessment of patient's ability to actively participate in care and planning 0.0% 0 0.0% 0 23.8% 5 61.9% 13 14.3% 3 21 3.8 0.7
Assessment of resilience and coping mechanisms - an asset based approach 0.0% 0 9.5% 2 57.1% 12 33.3% 7 0.0% 0 21 3.2 0.6
Assessment of carers needs 0.0% 0 9.5% 2 23.8% 5 42.9% 9 23.8% 5 21 3.9 0.9
Establishing an individual's narrative by active listening/appreciative enquiry 0.0% 0 9.5% 2 38.1% 8 33.3% 7 19.1% 4 21 3.6 0.9
Agreeing and formulating a plan together based on shared decision making and the preferences of the individual: working the partnership0.0% 0 0.0% 0 42.9% 9 23.8% 5 33.3% 7 21 3.9 0.9
Safeguarding this contract by documenting it in a co-created care or support plan: personalised care and support planning4.8% 1 0.0% 0 61.9% 13 23.8% 5 9.5% 2 21 3.4 0.9
Monitoring response to the care and support plan 0.0% 0 4.8% 1 52.4% 11 33.3% 7 9.5% 2 21 3.5 0.7
Review and revising of the care and support plan 4.8% 1 0.0% 0 33.3% 7 38.1% 8 23.8% 5 21 3.8 1.0
Not at all feasible Slightly feasible Feasible Fairly feasible Very feasible
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Appendix 5: Notes of research stakeholder meeting 
The HAPPI Study: Research Stakeholder Meeting 
St Austell Printworks, Boardroom 31/01/2018, 09.30-11.30. 
In Attendance: Marie Prior, Frailty and Non-Medical Prescribing Lead, Cornwall 
Foundation NHS Trust (MP) 
 Kerry Crowther, Falls Lead, Cornwall Foundation NHS Trust KC) 
 Jos Latour, Professor in Clinical Nursing, Associate Head of School – 
Research, School of Nursing and Midwifery, Plymouth University (JL) 
 Helen Lyndon, NIHR Clinical Doctoral Research Fellow, Plymouth 
University, Nurse Consultant Older People Cornwall Foundation NHS 
Trust (HL) 
Apologies: Tracy Hind, Workforce Transformation Lead, Cornwall Foundation NHS 
Trust 
  Professor Sir Roger Boyle, PPI Group Chair, Roseland Surgery 
  Mrs Hazel Boyle, PPI Representative 
  Dr Julie Tomlinson, St Austell Group Practice 
Notes of the Meeting 
No. Item 
1 Introductions 
Everyone introduced themselves and HL updated on apologies and 
arrangements to meet with other stakeholder group members who could 
not attend today outside of the meeting. 
 
2 Introduction to the overall HAPPI Study 
HL gave a brief overview of the study, progress to date and explained the 
purpose of the stakeholder group, which is to review the results of the e-
Delphi survey and refine and agree the final components and design of 
the HAPPI intervention. HL stressed that this intervention needs to be 
feasible to deliver in clinical practice in primary care, but also likely to 
improve outcomes for frail older people. 
 
3 Review and refinement of the HAPPI intervention 
HL shared the results of the e-Delphi survey (Appendix 1) and indicated 
which components had reached consensus and which had not. The 
group reviewed each component in detail and debated which should be 
included and which should not.  
 
It was agreed that the principles of the intervention would be based in 
person-centred care and the following are key principles that make the 
intervention unique and different to current care for this population: 
 
a) The person will not be referred (as in current community matron 
(CM) practice) but will be approached proactively following 




identification using the electronic frailty index and PRISMA7 
screening tool. The CM will visit without first gaining any past 
medical history or other information about the person’s health from 
the general practice record and initiate an “unbiased, open 
dialogue” with the person. Any issues/problems/deficits will be 
generated from this dialogue and the assessment and care-
planning intervention will develop from this point. 
b) There will be an ongoing development and review of a support 
plan in partnership with the person and carer (if appropriate). 
c) Outcome measures will focus on responsiveness to 
change/completeness of the intervention and discharge plans; 
what is different after the intervention is complete? 
d) The intervention will be based on a “conversation guide” rather 
than a prescriptive template. Assessments reflecting the results of 
the e-Delphi will be available to be used if they are appropriate for 
that person’s needs/problems. 
 
The group reviewed each component of the e-Delphi results and 
discussed and  agreed whether it should be included or not within the 
conversation guide or assessment pack and how it should be presented 
to ensure ease of use and feasibility: 
 
Care Structures/Processes 
These components included access to a shared system for information 
gathering (clinical record), multi-disciplinary team discussion/review, a 
timely response to crises and a competent, well-trained workforce to 
deliver the intervention. It was agreed that these components formed 
important feasibility outcomes for the trial, but were not elements of the 
assessment process. HL agreed to include these as feasibility outcome 
measures. 
 
Nursing/Advanced Clinical Practice 
It was agreed that tools to assess presence/severity of frailty, falls risk, 
pain, medication review, nutrition/hydration/dentition, vision/hearing, 
bladder and bowel function including sexual health assessment, 
optimising long-term condition management and assessment of 
functional capacity should all be included in the assessment pack. 
 
Further discussion concluded that the conversation guide should also 
include prompts for problem/deficit identification, advance care planning 
and escalation/contingency planning. There is a personalised care 
template under development in the county and MP agreed to share it with 
HL for use in the trial. 
 
It was agreed that the need for advanced assessment skills was to be 
included in the care structures/processes section as a feasibility outcome 
measure for the trial.  
 
Mental Health 
It was agreed that assessment of cognition should be included in 
assessment of falls risk to avoid duplication of assessment. Prompts to 




investigate mood and psychological wellbeing including anxiety and 
depression should be part of the conversation guide with more detailed 
assessments available in the assessment pack. 
 
Social and Environmental Circumstances 
It was agreed that this should be re-worded as “Home and Safety” and be 
included within prompts in the conversation guide such as “do you feel 
safe at home”, “is there anything regarding your home that concerns 
you?” An exploration of loneliness and social isolation will be added to 
the mood and psychological well-being section.  
 
It was agreed that exploration of spiritual needs and support systems 
would be included in advance care planning discussions. 
 
Although assessment of carers needs did not reach consensus for 
feasibility in the e-Delphi survey, it was strongly felt by stakeholders that 
this is an essential element of the intervention and would be included in 
the conversation guide as a prompt. 
 
Personalised Care and Support Planning 
It was agreed to combine and include the first, second, sixth and seventh 
components in this section as essential pillars of personalised care and 
support planning. Assessment of resilience and ability to participate in 
care planning was felt to be an important element of the intervention and 
so it was agreed to include it in the conversation guide prompts.  
 
The final three components of the development of a plan, monitoring 
response and reviewing the plan were agreed as important outcome 
measures for the trial. 
 
4 Final decisions and wrap-up 
HL thanked all those for their invaluable input. The following actions were 
agreed: 
 
a) HL to develop a draft of the conversation guide and assessment 
pack and circulate to group members for final comment. 
b) HL to circulate the next draft of the trial protocol for comments. 
c) MP and KC kindly agreed to sit on the Trial Steering Committee. 
HL to send a doodle poll of dates for the first meeting in April 2018. 
d) MP to share the personalised care and support planning template 
with HL for use in the trial. 
 
  




Appendix 6: HAPPI Assessment Pack Contents 
Full copies of all assessments can be found on the HAPPI study website: 
https://www.plymouth.ac.uk/research/the-holistic-assessment-and-care-planning-in-
partnership-intervention-study-happi 
Domain Page no 
Physical Health Assessments 
Assessment for the presence and severity of frailty 
1. Gait Speed Test 





Assessment of falls risk and bone health 






Assessment of pain 
1. Numeric pain scale 
2. Pain assessment record 






Medication review  
1. Medication review summary 





Assessment of nutritional status including hydration 
1. MUST 5 Step Guidance 
2. MUST Flowchart 






Assessment of vision, hearing and dentition 
1. RCP Bedside Vision Check 





Assessment of bladder and bowel function 
1. Clinical Checklist for Lower Urinary Tract Symptoms 
2. ICIQ Bladder Diary 
3. Self-Assessment of Your Urinary Problems 
4. Bowel Assessment Form 








Optimising management of long term conditions/multimorbidity and 
Problem/deficit identification 










Domain Page no 
Determining advance care/end of life preferences 
1. CFT Treatment Escalation Plan Policy 





Home, family and Safety 
Assessment of functional ability and activities of daily living including re-
ablement 









Assessment of carers needs 




Mental Health Assessments 
Assessment of cognition including identification of delirium and capacity 
assessment 
1. CFT Capacity Assessment Policy 







Assessment of mood and psychological well-being 
1. Geriatric Depression Score 





Personalised Care and Support Planning 
1. HAPPI Conversation Guide 
2. CFT Personalised Support Plan Template: Part 1 My Medical Plan 















A cluster randomised, controlled feasibility study of a nurse-led, 
holistic assessment and care planning intervention for older people 
living with frailty in primary care. 
 
 
The Holistic Assessment and care Planning 
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4. STUDY SUMMARY 
 
Study Title The Holistic Assessment and care Planning  in Partnership Intervention Study 
[HAPPI]: 
A cluster randomised, controlled feasibility study of a nurse-led, holistic 
assessment and care planning intervention for older people living with frailty 
in primary care. 




People aged 65 years and over who are moderately or severely frail. 
Study Setting General Practice populations in Cornwall, UK. 
Intervention Delivery of the HAPPI intervention by trained community matrons in 
accordance with the conversation guide and assessment pack to ensure 
treatment fidelity. The intervention will be an individualised assessment and 
care planning process including development of person-centred goals 
supported by planning and relevant referrals. It will be carried out at the 
participant’s home. Documentation of the intervention including assessment, 
individualised care and support plan and evidence of any referrals will be 
recorded using a standardised document/computerised template. 
Control Participants in the control group will receive usual care. This cannot be 
standardised as approaches to care of older people with frailty varies in general 
practice. This may include the management of various long-term conditions, 
referrals to other services, prescribing of medications and routine vaccinations. 
As part of the feasibility trial, components of usual care will be captured using 
a standardised proforma in order to describe for the future definitive trial. 






The primary aim of this cluster randomised, controlled feasibility study of a 
nurse-led Holistic Assessment and care Planning in Partnership Intervention 
(HAPPI) is to determine the feasibility of delivering the intervention in primary 
care to older people with frailty and to test potential trial methods to inform 
the design of a definitive randomised controlled trial (RCT). 




a. To assess compliance with the HAPPI intervention. 
b. To verify that proposed outcome measurement and follow-up 
schedules are feasible to collect.  
c. To determine achievable targets recruitment and follow-up rates. 
d. To evaluate methods of recruitment using the electronic frailty index 
(eFI). 
e. To evaluate characteristics and feasibility of the proposed outcome 
measures and to determine suitable outcome measures for the 
definitive trial. Outcome measures to be evaluated have been taken 
from the ICHOM Older Persons Reference Guide (1).  
f. To calculate standard deviation of the outcome measures to estimate 
sample size for the definitive trial. 
g. To assess availability of clinical data and time needed to collect and 
analyse data required for numeric outcome measures. 
h. To explore factors that will enable future economic evaluation 
alongside the main trial. 
 
Objectives h-j will be met within the embedded qualitative study: 
i. To determine acceptability of the intervention to patients, carers and 
clinicians in primary care. 
j. To assess barriers to delivery of the HAPPI intervention e.g. any 
operational difficulties within the community matron service. 
k. To evaluate clinicians’ willingness to identify, recruit and randomise 
eligible patients, and willingness of patients to be recruited and 
randomised. 
l. To determine acceptability of trial processes and collection of outcome 
measures to participants. 
Outcomes The outcomes relate to feasibility of the intervention, feasibility of conducting 
the trial and assessing different potential primary and secondary outcomes of 
the future trial.  
Feasibility of the intervention 
a. Numbers of completed HAPPI intervention conversation guides and 
personalised care plan templates 
b. Number of staff moving between intervention and control GP practices 
 
Feasibility of conducting the trial 




d. Number of GP practices screened for selection and reasons for non-
selection 
e. Number of GP practice withdrawing from the study, timing and reason 
for withdrawal 
f. Number of GP practices failing to progress through implementation 
milestones and reasons for failure 
g. Number of GP practices  withdrawing during the implementation and 
delivery phases 
h. Numbers of participants screened as eligible, recruited, consented and 
followed up 
i. Numbers of participants identified using the electronic frailty index (eFI)  
j. Number of and timing of participant withdrawals from follow-up data 




Assessing different potential primary and secondary outcomes of the future 
trial 
k. Numbers of potential primary and secondary outcome measures 
completed at baseline and follow-up intervals  
l. Numbers of missing items for each potential primary and secondary 
outcome at each time-point 
m. Estimation of the feasibility of collecting data to estimate cost-
effectiveness; EQ-5D-5L; add-on for economic evaluation. 
n. Assessment of the following outcome measure instruments: 
 Review of usual care practice, using a clinical note review of control 
participants 
 Level of care at home received measured by participant self-
reporting 
 Polypharmacy – number of medications prescribed and participant 
perception of adverse effects 
 Number of falls measured by participant self-reporting 
 Levels of loneliness and isolation measured by UCLA 3-Item 
Loneliness Scale 
 Physical health and mobility, level of pain, mood and emotional 
health and health-related quality of life measured by the Medical 





 Confidence in own ability to manage health and in role as 
participants in care measured by the Health Foundation LTC6 
questionnaire 
 Mortality; date and cause of death obtained from the clinical record 
 Number of hospital admissions, readmissions and total number of 
days spent in hospital obtained from the clinical record 
All outcome measures will be conducted at baseline (following randomisation), 
three months (post intervention) and six months. 
Inclusion 
criteria 
Potential participants will be eligible for the study provided they are: 
f. Aged 65 years and over 
g. Moderately frail: Electronic Frailty Index (eFI) >0.24 to 0.36 or severely 
frail (eFI > 0.36) 
h. Frailty confirmed by PRISMA7 instrument 
i. Able to give informed consent  




Potential participants meeting any of the following criteria will be excluded 
from study participation: 
a. Fit or mildly frail (eFI 0.13 – 0.24) 
b. Lives in a care home 
c. Patients in receipt of palliative care, on gold standards framework 
register or where clinician feels they have limited life expectancy 
d. Lacks mental capacity to give informed consent 
e. Patients already on the caseload of a Community Matron. 
 
Key Milestones May 2018: Set up phase and recruit GP practices  
November 2018: Participant identification and eligibility check  
January 2019: Consent and baseline measures  
March 2019: Intervention 
June 2019: 3-month follow-up data collection 










5. TRIAL FLOW DIAGRAMS 
Figure 1: Flow diagram of the trial design 
 
*Qualitative interviews will be conducted with selected a maximum of six participants, four 














6. BACKGROUND AND RATIONALE FOR THE PROPOSED STUDY 
6.1 Understanding Frailty 
Healthcare support needs to change radically to better meet the needs of the ageing 
population. In the UK, the number of people aged 65+ is projected to rise by over 41% in the 
next 17 years to over 16 million. By 2040, nearly one in four people in the UK (24%) will be 
aged 65 or over (2). In older people, limiting disability is often preceded by a state 
characterised by reduced capacity to respond to stressors, caused by a decline in functional 
reserves (3,4). This condition is called frailty. There are multiple definitions of frailty in the 
literature but the most common characteristics are summarised by Roriguez-Manas and Fried 
as being: 
 “an age associated, biological syndrome characterised by decreased biological reserves, 
due to dysregulation of several physiological systems, which puts an individual at risk 
when facing minor stressors, and is associated with poor outcomes (i.e. disability, death, 
and hospitalisation)” (5)  
As frailty progresses, individuals become more susceptible to developing conditions known 
as frailty syndromes, which include multiple falls, acute confusion/delirium, sudden loss of 
mobility and incontinence (6). These events often result in admission to hospital, following 
which frail older people experience increased lengths of stay and are more prone to 
complications such as developing hospital acquired infections, pressure sores, delirium and 
loss of independence (7). 




Some authors have advocated a move towards the early identification, diagnosis and 
management of frailty in order to improve outcomes, prevent or delay deterioration and 
reduce health and social care costs (8,9). Frailty is rarely formally diagnosed in any speciality 
other than geriatric medicine and is not yet recognised as a long-term condition (LTC) in 
primary care, despite the introduction in 2014 of diagnostic read codes by the Health and 
Social Care Information Centre. De Lepeleire et al (8) advocate the management of frailty in 
primary care settings. However, they acknowledge that the identification of frailty and 
application to clinical practice in this area are under-developed. Given its high prevalence, 
most of the on-going frailty management will, in all likelihood, fall into the remit of primary 
care in the future. Further research is therefore urgently needed to explore feasibility and 
resource issues as it is unlikely that there is sufficient capacity or appropriate skills and 
knowledge in primary care settings to adequately manage the numbers of frail patients. 
However, if an achievable preventive model of care is developed, primary care is the ideal 
setting to implement a more person-centred approach because of the integrated nature of 
primary and community care and the opportunities to interact with patients in their home 
environment (10). 
6.3 The Management of Frailty 
One evidence-based approach to the management of moderate and severe frailty is the 
Comprehensive Geriatric Assessment (CGA). CGA is a multidimensional, interdisciplinary 
diagnostic process to determine the medical, psychological and functional capabilities of a 
frail older person in order to develop a coordinated and integrated individualised care plan 
for treatment and long-term follow up in partnership with the patient and the carers (11). 




speciality of geriatric medicine but not well established in other healthcare settings such as 
primary care.   
6.4 Frailty Interventions in Primary Care 
In 2014 the British Geriatrics Society (BGS) (11) suggested that a primary care led ‘holistic 
review’ by a GP or specialist nurse may enable more frail older people to access services out 
of hospital, however, as previously discussed, it is not clear whether the acute hospital CGA 
framework is immediately transferable. In 2014, Stijen (12) evaluated practice nurse-led CGA 
and found prohibitive issues for the primary care team including lack of skills, time constraints 
and ineffective targeting of the frail population. A study evaluating nurse-led CGA in primary 
care reported significant barriers including lack of skills, time constraints and ineffective 
targeting of the frail population (13). A recent review noted a lack of an agreed 
implementation model and concerns of workforce capacity in the current UK primary care 
model (14). 
The BGS have suggested other considerations that are missing from the traditional CGA 
framework, such as treatment escalation and advanced care planning (11). These 
considerations would appear to be highly relevant as part of a CGA intervention delivered in 
a primary care setting where the clinician has a more long-term and person-centred 
relationship with the patient. A recent review of person-centred care concluded that while 
there is no universal definition of the concept, there are well recognised behaviours displayed 
by nurses that promote person-centeredness, such as engaging with the patient as a partner 
and shared decision making (15). These behaviours and their foundation in nurses’ 
approaches to care would appear to make nurses the ideal clinician to carry out CGA/holistic 




6.5 Beyond Best Practice and This Study 
To meet the challenges of the increasingly frail and older population and to provide proactive, 
holistic care close to home, there is a need for a standardised intervention that can be 
implemented in primary care, which provides value for money, is not time consuming and has 
a high level of sensitivity to enable primary care resource to be targeted at patients who will 
most benefit from the intervention. If a primary care led ‘holistic review’  is to become a 
reality, the burden of completion and frail patient outcomes require further research as to 
the feasibility, acceptability, effectiveness and scalability. Informed by the existing literature 
and PPI engagement, the proposed study seeks to develop a primary care intervention that 
contains cost and clinically effective components of the acute CGA framework and determines 
if this intervention is suitable for nurse-led delivery.  
During an initial phase of this research, an e-Delphi survey was conducted to gain consensus 
among stakeholders on the components of the intervention and any existing skills and 
knowledge deficits. Using these data, a component map was formulated whereby the 
components were mapped to patient need using the best available evidence to ascertain 
those which may be feasible in terms of clinical and cost effectiveness.  After mapping the 
outcomes, a conversation guide and assessment pack to structure the intervention were 
developed to be used in this feasibility randomised controlled trial (RCT).  
 
7. AIMS AND OBJECTIVES 
7.1 Aims 
The primary aim of this cluster randomised, controlled feasibility study of a nurse-led Holistic 




feasibility of delivering the intervention in primary care to older people with frailty and to test 
potential trial methods to inform the design of a definitive randomised controlled trial (RCT). 
7.2 Objectives 
Objectives a-h will be met within the feasibility randomised controlled trial: 
a) To assess compliance with the HAPPI intervention. 
b) To verify that proposed outcome measurement and follow-up schedules are feasible 
to collect.  
c) To determine achievable targets for recruitment and follow-up rates. 
d) To evaluate method of recruitment using the electronic frailty index (eFI). 
e) To evaluate characteristics and feasibility of the proposed outcome measures and to 
determine suitable outcome measures for the definitive trial. Outcome measures to 
be evaluated have been taken from the ICHOM Older Persons Reference Guide (1).  
f) To calculate standard deviation of the outcome measures to estimate sample size for 
the definitive trial. 
g) To assess availability of clinical data and time needed to collect and analyse data 
required for numeric outcome measures. 
h) To explore factors that will enable future economic evaluation alongside the main 
trial. 
Objectives i-l will be met within the embedded qualitative study: 
i) To determine acceptability of the intervention to patients, carers and clinicians in 
primary care. 
j) To assess barriers to delivery of the HAPPI intervention e.g. any operational difficulties 
within the community matron service. 
k) To evaluate clinicians’ willingness to identify, recruit and randomise eligible patients, 
and willingness of patients to be recruited and randomised. 
l) To determine acceptability of trial processes and collection of outcome measures to 
participants. 
 
8. TRIAL DESIGN 
The trial is a pragmatic, cluster randomised, controlled feasibility trial with embedded 
qualitative study aiming to recruit 60 participants from general practices in Cornwall. Figure 
1 details the trial design.  Cluster randomisation by general practice has been chosen to test 




effect size in the main trial and so this feasibility trial aims to evaluate this randomisation 
method. Half of the general practices will be allocated to the intervention and half to the 
control arm of the study, so that patients of individual practices will either receive the 
intervention or usual primary care. By randomising at general practice level, it will avoid the 
potential for “intervention-creep” between the intervention and the control group. In the 
area under study, community matrons (CMs) are attached to specific general practices and so 
individual CMs would only visit participants in the control or the intervention group, never 
both. As the HAPPI is an intervention that aims to impact on staff skills, knowledge and clinical 
practice, it is important to ensure separation of the control and intervention groups in this 
way.  
CI/RAs will have no role in initial screening or approach, this will be carried out by the clinical 
care team at the General Practice (PIC). The CI/RAs will only have access to personal data with 
the participant’s permission from the invitation letter so they can contact them to carry out 
consent/baseline assessment. Patient screening, consent, recruitment and collection of 
outcome measures will be undertaken by the CI or RAs (Cornwall Foundation Trust Research 
Nurses or SWCRN Research Nurses) who have no role in the delivery of care or treatment. 
The RAs will remain blind to treatment allocation until completion of the six-month outcome 
measures and will be unblinded for the qualitative interviews. Contamination will be assessed 
by frequent monitoring of staff movement and recording clinical practices through regular 
contact with GP practices carried out by the CI. If staff movement between intervention and 






8.1 Study Setting and GP Practice Eligibility 
It is anticipated that there will be six GP practices involved in this study, located in Cornwall, 
UK. The following factors will be used to determine suitability of practices to participate in 
this study: 
d. The practice use the electronic frailty index (eFI) to identify their moderately and 
severely frail population 
e. The practice are willing to fulfil the requirements of the study relating to screening 
and recruitment with the support of the SWCRN 
f. There is at least one CM attached to the practice who is willing to deliver the HAPPI 
intervention 
 
GP practices registering an interest in the trial will be invited to complete a Participant 
Identification Centre Feasibility Questionnaire and will be offered a visit by the CI/SWCRN 
Nurse. Practices deemed suitable to implement and deliver HAPPI (demonstrated by fulfilling 
the above criteria) will be invited to take part in the study. Reasons for non-selection of 
practices will be fully documented. 
 
8.2 Recruitment 
8.2.1 Initial Screening and Enrolment Process 
The enrolment process is detailed in Figure 2, and represents the procedure conducted by GP 
practices and PenCTU to identify and recruit eligible participants. Under the terms of the NHS 
England General Practice Contract 2017/18 (16), practices are required to identify patients 
aged 65 years and over, who are living with moderate or severe frailty, among their practice 
population. Practices use an appropriate evidenced based tool such as the eFI (17). The eFI is 




records and is used to identify and grade severity of frailty based on a cumulative deficit 
model on the basis of a range of variables that include symptoms, signs, diseases, disabilities 
and abnormal laboratory values (17). A practice administrator will run the eFI as a database 
search and this will classify the entire practice population into fit, mildly frail, moderately frail 
and severely frail people. The output from the eFI, combined with the application of the trial 
inclusion/exclusion criteria, will identify initial potential participants for the trial.  Based on 
available evidence it is likely that, for an average-sized practice (14,000 practice population), 
the eFI will identify approximately 1000 moderately and 500 severely frail people. 
8.2.2 Sampling 
A flow diagram of the enrolment and sampling process can be seen in Figure 2. In order to 
create the initial enrolment sample, the practice administrator at each practice will create a 
list of potential eligible participants aged 65 years and over identified by running the eFI, 
indicating those who are moderately and those who are severely frail. Eligibility criteria of 
living at home and not in receipt of palliative care/limited life expectancy will be applied at 
the general practice and PenCTU will use stratified sampling to identify 90 potential 
participants from the eFI list, 45 in the moderate and 45 in the severely frail categories. The 
eFI is not a clinical diagnostic tool, rather it is a population risk stratification tool, therefore, a 
further step is required to make a diagnosis of frailty and confirm eligibility. In this trial, that 
diagnosis will be confirmed by the completion of the PRISMA7 questionnaire (18).  An 
invitation to participate in the trial and PRISMA7 will be sent to the 90 people. Interested 
patients will be invited to return the completed PRISMA7 and a completed portion of the 
invitation to participate in the stamped addressed envelope to the CI.  However, if this 




until 10 participants per practice are recruited. It is estimated that inviting approximately 90 
patients will enable 10 per practice to be recruited to the trial in the time allowed for 
recruitment.  
Names and contact details of people who have expressed an interest in participation, and 
where frailty has been confirmed by the PRISMA7, will be passed to the CI by the practice 
administrator by secure email (NHS mail). If people express an interest in participating but 
then are found not eligible, or maximum numbers for recruitment have been achieved, the CI 
will telephone the person to thank them for their interest in the study and explain why they 
have not been recruited. 
For those eligible and to be recruited, a period of 24 hours will be left between completion of 
PRISMA7 and receiving the reply before contacting to arrange to gain consent. This gives 
potential participants time to consider whether or not they wish to enter the trial. They will 
then be contacted by the CI/RA by telephone and an appointment made for a visit at home 
or in the surgery to provide choice and minimise participant burden. During this consultation, 
the participant will be given the opportunity to ask further questions about the study before 
consent is obtained and baseline assessments carried out. 
8.2.3 Demographic Detail 
The following demographic data will be collected. These will be in addition to the outcome 
measures described in Table 1 for all participants. The demographic data will be recorded on 
a CRF by the CI or RA. 
 Demographic data: date of birth, gender, marital status 






Once informed consent has been received, and confirmation of eligibility and baseline data 
have been collected, the CI/RA will then register the participant on the study database using 
a unique username and password log-in details, entering initials and gender and will assign a 
study number. In line with CONSORT guidelines for randomised pilot and feasibility studies 
(19), and in order to report the generalisability of the results, study- specific screening logs 
will be kept, with anonymised details of those potential participants who the research team 
approached to be considered for entry to the study, but who were not recruited or 
randomised.  The web-based screening log will be completed by the CI or another 
authorised delegate. 
Anonymised information on participants that have consented but are not recruited for 
CONSORT reporting will include: 
a. Age 
b. Gender 
c. Frailty status: eFI and PRISMA7 scores 
d. Reason not eligible for trial participation, or if they are eligible but declined. 
 
8.3 Baseline Assessments  
Once consent has been received, baseline assessment of outcome measures will be 
undertaken with the participants. All baseline assessments will be carried out in one session 
and at the same time as consent is obtained to minimise burden of multiple contacts for 
participants. They will be undertaken by the CI or authorised delegate (RAs). Consent and 
baseline outcome measures will be collected in the participant’s place of residence and it is 




duration. Support and additional time/visit will be offered to participants who may need 
suffer fatigue, cognitive impairment etc.  As a feasibility study, any difficulties will be noted 
and adjustment made to the design of the main trial.  
The assessor will record the results of the baseline assessments on the case report form (CRF) 
and enter the results into a secure password protected web-based system.  This will generate 
an email for the community matron who will be carrying out the intervention informing that 
he/she can contact the participant and arrange the first visit in accordance with the 






Table 1: Outcome Measures, Data Sources and Collection Measures 
Variable Objective Data Source Outcome Measure and 
Collection Method 
BASELINE CLINICAL FACTORS 
Function To investigate the use of the BI 
in this setting and for this 
population as a measure of 
function by collecting 
completion rates and 
expressed views on 
acceptability to participants. 
Participant 
reported 
Barthel Index of Activities of 
Daily Living (20) 
Participants will self-report 
based on their abilities on the 
day of assessment. 
Level of care 
received 
To investigate if it is possible to 
collect data on level of care 




Participants will self-report on 
current local authority 
provided home support. 
Polypharmacy To investigate if it is possible to 
collect data on number of 
medications and how best to 
report this. 
 
To investigate the use of 
participant self-reporting on 
adverse effects of medication 
by collecting completion rates 
and expressed views on 








Total number of medications 




Participants will self-report any 




To investigate participant self-
reporting as an accurate 
method of estimating number 
of falls experienced. 
Participant 
reported 
Participants will self-report 
number of falls in the past 12 
months including those that 
resulted in contact with health 
services and outcome. 




To investigate the use of the 
SF-36 in this setting and for this 
population as a measure of 
physical health and mobility by 
collecting completion rates and 
expressed views on 
acceptability to participants. 
Participant 
reported 
Questions 1-16 of Medical 
Outcomes Study 36-Item 
Short Form Survey Instrument 
Version 1 (SF-36) (21) 
Participants will self-report 
based on their activities on the 
day of assessment. 
Loneliness and 
social isolation 
To investigate the use of the 
UCLA 3-Item Loneliness Scale  
in this setting and for this 
Participant 
reported 





population as a measure of 
social isolation and loneliness 
by collecting completion rates 
and expressed views on 
acceptability to participants . 
Participants will self-report 
their experience on the day of 
assessment. 
Pain To investigate the use of the 
SF-36 in this setting and for this 
population as a measure of 
levels of pain by collecting 
completion rates and 
expressed views on 
acceptability to participants. 
Participant 
reported 
Questions 21 and 22 of 
Medical Outcomes Study 36-
Item Short Form Survey 
Instrument Version 1 (SF-36)  
Participants will self-report 





To investigate the use of the 
SF-36 in this setting and for this 
population as a measure of 
mood and emotional health by 
collecting completion rates and 
expressed views on 
acceptability to participants. 
Participant 
reported 
Questions 17-20 of Medical 
Outcomes Study 36-Item 
Short Form Survey Instrument 
Version 1 (SF-36) 
Participants will self-report 
their experience on the day of 
assessment. 
Health-related 
quality of life 
To investigate the use of the 
SF-36 in this setting and for this 
population as a measure of 
health-related quality of life by 
collecting completion rates and 
expressed views on 
acceptability to participants. 
Participant 
reported 
Questions 23-36 of Medical 
Outcomes Study 36-Item 
Short Form Survey Instrument 
Version 1 (SF-36)  
Participants will self-report 




own ability to 
manage own 
health and in 
role as a 
participant in 
care 
To investigate the use of the 
LTC6 in this setting and for this 
population as a measure of 
confidence by collecting 
completion rates and 
expressed views on 
acceptability to participants. 
Participant 
reported 
Health Foundation LTC6 
questionnaire (23) 
Participants will self-report 
their experience on the day of 
assessment. 
CLINICAL STATUS 
Mortality To investigate if it is possible to 
collect data on mortality and 
how best to report this. 
Clinical data Date and cause of death 







To investigate if it is possible to 
collect data on numbers of 
admissions, re-admissions and 
total time spent in hospital and 
how best to report this. 
Clinical data All obtained from the clinical 
record: 
How many times the 




and total time 
spent in 
hospital 
 to hospital as an emergency in 
the past 12 months. 
How many times has the 
participant been readmitted to 
hospital within 30 days of a 
previous admission. 
Total length of stay in hospital 
within the past 12 months. 
 
8.4 Intervention 
Participants in the intervention group (n=30) will receive the HAPPI intervention delivered by 
a CM who has received training in delivering the intervention. In Cornwall, CMs are 
experienced nurses with advanced assessment and prescribing skills and, therefore have the 
required skills set to deliver the assessment and care planning intervention. CMs are attached 
to individual general practices and employed by the community services NHS Trust (Cornwall 
Foundation NHS Trust).  In order to ensure a standardised approach, training will be given 
prior to delivering the intervention using a training package delivered by face-to-face training 
by the CI. 
The holistic assessment and care planning intervention (HAPPI) will encompass the following 
key principles that make the intervention unique and different to current care for this 
population: 
a. The person will not be referred in crisis (as in current CM practice) but will be 
approached proactively following identification using the eFI and PRISMA7 screening 
tool. 
b. The CM will visit without first gaining any past medical history or other information 
about the person’s health from the general practice record and initiate an “unbiased, 
open dialogue” with the person. Any issues/problems/deficits will be generated from 
this dialogue and the assessment and care-planning intervention will develop from 
this point. 
c. There will be an ongoing development and review of a support plan in partnership 




d. Outcome measures will focus on responsiveness to change/completeness of the 
intervention and discharge plans; what is different after the intervention is complete. 
e. The intervention will be based on a “conversation guide” rather than a prescriptive 
assessment template. Assessment tools will be available to be used if they are 
appropriate for that person’s needs/problems. 
 A conversation guide, assessment pack and personalised support plan template have been 
developed to support delivery of the intervention and ensure treatment fidelity by detailing 
the content of the intervention and how it should be delivered. The intervention will be 
carried out in the participant’s home and it is expected that it will consist of one assessment 
visit and up to six care planning visits conducted over a maximum of 12 weeks. For the 
purpose of the trial, the minimum “dose” of the intervention will be defined as one 
assessment visit and at least two care planning visits. Documentation of the intervention, 
including assessment, support plan and evidence of any referrals, will be recorded using a 
standardised document/computerised template, which will be stored at in the clinical record 
at the Community Matron’s base with a copy in the electronic general practice clinical record. 
8.5 Control 
Participants in the control group (n=30) will receive usual care. This cannot be standardised 
as approaches to care of older people with frailty varies in general practice (11). This may 
include the management of various long-term conditions, referrals to other services, 
prescribing of medications and routine vaccinations. As part of the feasibility trial, 
components of usual care will be captured in order to standardise for the future definitive 
RCT using a standardised template.  
8.6 Outcomes 
The primary outcomes relate to feasibility of the intervention, feasibility of conducting the 




8.6.1 Feasibility of the Intervention 
a) Numbers of completed HAPPI intervention conversation guides and personalised 
care plan templates 
b) Assess degree of contamination by number of staff moving between intervention 
and control practices 
 
8.6.2 Feasibility of Conducting the Trial 
a) Number of GP practices expressing an interest in participating 
b) Number of GP practices screened for selection and reasons for non-selection 
c) Number of GP practices withdrawing from the study, timing and reason for 
withdrawal 
d) Number of GP practices failing to progress through implementation milestones 
and reasons for failure 
e) Number of GP practices withdrawing during the implementation and delivery 
phases 
f) Numbers of participants screened as eligible, recruited, consented and followed 
up 
g) Numbers of participants identified using the electronic frailty index (eFI)  
h) Number of and timing of participant withdrawals from follow-up data collection, 
reasons for withdrawal, number of and timing of losses to follow-up 
 
8.6.3 Potential Primary and Secondary Outcomes 
a) Numbers of potential primary and secondary outcome measures completed at 
baseline and follow-up intervals  
b) Numbers of missing items for each potential primary and secondary outcome at each 
time-point 
c) Estimation of the feasibility of collecting data to estimate cost-effectiveness; EQ-5D-
5L; add-on for economic evaluation. 
d) Assessment of the following outcome measure instruments: 
 Review of usual care practice, using a clinical note review of control participants 
 Level of care at home received measured by participant self-reporting 
 Polypharmacy – number of medications prescribed and participant perception of 
adverse effects 
 Number of falls measured by participant self-reporting 
 Levels of loneliness and isolation measured by UCLA 3-Item Loneliness Scale 
 Physical health and mobility, level of pain, mood and emotional health and health-
related quality of life measured by the Medical Outcomes Study 36-Item Short 




 Confidence in own ability to manage health and in role as participants in care 
measured by the Health Foundation LTC6 questionnaire 
 Mortality; date and cause of death obtained from the clinical record 
 Number of hospital admissions, readmissions and total number of days spent in 
hospital obtained from the clinical record 
All potential clinician and self-reported primary and secondary outcome measures will be 
collected at baseline (following randomisation), three months (post intervention) and six 
months.  
As a feasibility trial, process evaluation is a key part of the intervention development process 
to enable conclusions to be drawn about the strengths and weaknesses of a trial.  The Medical 
Research Council guidance highlights the need to clarify causal mechanisms and identify 
contextual factors associated with variation in outcomes. It highlights the importance of 
capturing fidelity (whether the intervention was delivered as intended); dose (the quantity of 
intervention implemented) and reach (whether the intended audience comes into contact 
with the intervention, and how). 
Fidelity will be measured using several mechanisms: nurses delivering the intervention will 
receive standardised training and use a conversation guide, assessment pack and 
personalised support plan template as a framework for the intervention.  They will record the 
content of their intervention and any adverse events related to the intervention or any 
intercurrent illnesses in the CRF. 
 
9. TRIAL PARTICIPANT SELECTION 
9.1 Inclusion Criteria 




a. Aged 65 years and over 
b. Moderately frail: Electronic Frailty Index (eFI) >0.24 to 0.36 or severely frail (eFI > 0.36) 
c. Frailty confirmed by PRISMA7 instrument 
d. Able to give informed consent  
e. Lives in own home/supported living accommodation 
 
9.2 Exclusion Criteria 
Potential participants meeting any of the following criteria will be excluded from study 
participation: 
a. Fit or mildly frail (eFI 0.13 – 0.24) 
b. Lives in a care home 
c. Patients in receipt of palliative care, on gold standards framework register or where 
clinician feels they have limited life expectancy 
d. Lacks mental capacity to consent to participate 
e. Patients already on the caseload of a Community Matron. 
 
9.3 Consent 
During the consent/baseline visit potential participants will be given a further brief verbal 
explanation of the study. During this visit the participant will be given the opportunity to ask 
further questions about the study and decline the invitation to participate at this point, should 
they wish. If they agree to participate then the consent form will be completed at this time.  
Consent process for participants is below: 
The following procedure will be used to obtain informed consent agreement for participation: 
a. All eligible people who have agreed to be approached will be given verbal and written 
information about the study. Information will be provided in an appropriate form, for 
example a supported conversation around written material (e.g. patient information 
leaflets) to maximise understanding of what is being asked of them and to support 
them to make decisions.   
b. People will be informed that their care will not be affected in any way by their decision 




People with mental capacity willing to take part in the trial will be invited to provide 
confirmation of informed consent to undergo baseline and follow-up assessments and data 
collection, and permission to access to patient’s medical and social care records. If the 
person has capacity but cannot sign the consent form, this will be indicated on the consent 
form by the CI/RA completing the relevant box on the patients consent form and signing it.  
The original consent will be retained in the site file and checked by the CI. The CI/RA will 
confirm to PenCTU that written consent has been obtained and recorded on the CRF. 
9.4 Randomisation 
In order to avoid contamination of the control group, this study is designed as a feasibility 
pragmatic cluster RCT with randomisation at general practice level. It is anticipated that 50% 
of the general practices will be randomised to intervention and 50% will be randomised to 
control. Randomisation will take place once six PIC sites have been recruited to the trial and 
prior to consent and baseline outcome measures assessment. The exact details of the 
algorithm will be determined between the trial statistician and PenCTU programming team 
only. 
9.5 Withdrawal Criteria 
Each participant has the right to voluntarily withdraw from the study at any time, without 
recourse. Circumstances where this might occur, for instance, may be where he or she 
perceives an intolerable AE has occurred. In addition, the CI may discontinue a participant 
from the study at any time if the investigator considers it necessary due to: 
a. Ineligibility which may have been overlooked at screening 
b. An AE which requires discontinuation of the study intervention or results in inability 




The judgement as to whether an AE is of sufficient severity to require the participant’s 
intervention to be discontinued will be made by the CI in joint discussion with the participant, 
participant’s clinician (e.g. General Practitioner/Community Matron). The reason for 
withdrawal will be recorded on a withdrawal form. For this feasibility study all participant 
drop outs will be included in the CONSORT diagram for pilot and feasibility trials.  
Withdrawal of treatment from either the intervention or control group may occur due to 
intervention intolerance and reluctance/refusal of participating in the intervention. Number 
and reasons for withdrawals and any unanticipated/adverse events will be recorded and 
reported by the community matron or an RA using a withdrawal form. Participants who 
withdraw from treatment will be encouraged to remain in the trial for follow-up assessments. 
Wherever possible, study assessments will be undertaken at the appropriate sessions (three 





10. TRIAL SCHEDULE 
Table 2: Trial Schedule 
 
 
10.1 Trial Procedures by Visit 
Once consent has been received, baseline assessment of outcome measures will be 
undertaken with the participants. All baseline assessments will be carried out in one session 
and at the same time as consent is obtained, then at three months (post-intervention) and six 
months after randomisation. They will be undertaken by the blinded assessor. All outcome 
measures and their corresponding assessments are detailed in Table 1. 
10.2 Potential Primary and Secondary Outcome Measures 
Standardised, validated clinician-rated and patient self-reported clinical outcomes will be 
measured in both groups at baseline and follow-up (three and six months). The blinded 
assessor will conduct assessments at these time points in the participant’s home. All of the 




assessments prior to 
randomisation
3 months post 
randomisation





Collection of demographic information X X X
Barthel Index of Activities of Daily Living X X X
UCLA 3-Item Loneliness Scale X X X
SF-36 X X X
Health Foundation LTC6 questionnaire X X X
EQ-5D-5L X X X
Number of falls X X X
Number of medications X X X
Number of hospital admissions X X X
Number of readmissions X X X
Total number of days spent in hospital X X X
Interviews with participants X X
Interviews with carers X X
Interviews with clinicans X
Pre-intervention Post-intervention
   
   
   
   
   















There will be two methods of data collection; from the primary care clinical record held on 
the general practice computer system and using patient reported outcome measures. 
Patient-reported and clinical record outcome measures will be collected at baseline, three 
and six months to minimise burden of multiple visits on frail patients and their carers. Answers 
to the questionnaires will be elucidated by the blinded assessors and answers recorded on 
the CRFs. All questionnaires have been validated for self-completion and the assessors will 
offer minimal assistance i.e. read out the questions as they appear on the document and hold 
up any visual analogue scales for the participant to point at the chosen point on the scale. The 
assessments will take approximately 60 minutes. They will be undertaken in the same order 
(as laid out in Table 1) for all participants to minimise the impact of confounding variables 
such as fatigue. Outcome measures have been informed by the literature and chosen in 
discussion with PPI representatives as important and relevant. Data will be collected on the 
feasibility of undertaking the outcome measures and the percentage of full outcome sets 
completed.  As far as is possible, all outcome data will be collected for all participants, 
regardless as to whether or not they have adhered to the protocol. Reasons for non-
adherence will be ascertained as far as practicable for the future study. 
If a study visit to undertake assessments is missed, then the blinded assessor will book 
another appointment by telephone, as close as possible to the original scheduled date. The 
degree of compliance with the study schedule will be assessed. 
10.3 Expected Duration of Participation 
The expected duration of participation for all participants will be a maximum of seven months 
from consent.  The intervention will begin within one month of consent and will consist of 




by the community matron over a 12 week period. Baseline assessments will be carried out at 
consent visit and follow-up assessments of outcome measures will occur at three and six 
months for all participants in the intervention and control arms. 
10.4 End of Trial 
The end of trial is the date of the last follow-up of the last participant. The following criteria 
will be used by the sponsor or TSC to prematurely stop the research: 
 Unacceptable number of AEs  
 A decision made by the TSC and TMG on the grounds of an unacceptably slow 
recruitment rate which does not seem retrievable within the study timeline. 
 An evaluation via a fully powered RCT of a similar assessment and care planning 
intervention in moderately and severely frail people in primary care. Note that there 




11. INTERVENTION PERIOD 
11.1 Compliance 
Reasons for non-compliance with the protocol will be provided. Clinician interviews as part of 
the embedded qualitative element at the end of the trial will help to ascertain possible 
reasons for non-compliance. If the delivery of the intervention and usual care is affected by 
logistical reasons within the community matron service these will be addressed by working 
with clinicians and their managers. 
11.2 Unblinding 
Trial assessors will be blind to group allocation at baseline and follow-up. Success of blinding 
will be recorded at these stages by the assessors on the CRF. If accidental unblinding occurred 
during this period the assessor will record details of the circumstances leading to unblinding. 




blinded assessor which may lead to unblinding prior to the first post-intervention assessment. 
At the start of each encounter with participants and/or family members during the period of 
blinding, the assessor will kindly ask them not to discuss anything about their care and 
emphasise the importance of the assessor remaining blinded to group allocation. 
 
12. EMBEDDED QUALITATIVE COMPONENT 
This component of the trial explores the experiences of the study participants, their carers 
and the experiences of the clinicians who have delivered the intervention and GP practice 
staff who facilitated recruitment and eligibility screening. The aim is to generate 
recommendations and address unknowns including experiences of recruitment, retention, 
practical implementation and further refinement of the intervention and outcome measures 
for the design of the future RCT. This is to satisfy the trial objectives i-l (pp 16) In particular 
to: 
1. To determine acceptability of the intervention to patients, carers and clinicians in 
primary care. 
2. To assess barriers to delivery of the HAPPI intervention e.g. any operational difficulties 
within the community matron service. 
3. To evaluate willingness to identify, recruit and randomise eligible patients, and 
willingness of patients to be recruited and randomised. 





A sample of participants will be invited for interview based on their characteristics and levels 




interviewed at three months post-randomisation and half at six months. A maximum of six 
CMs who delivered the intervention will be approached for interview. As this is a feasibility 
study, this method allows identification of a targeted sample rapidly, and sampling for 
proportionality is not the main concern. Maximum sample numbers are described but if 
saturation is reached prior to these numbers, no further interviews will be conducted. The 
following purposive sample size is anticipated: 
 A maximum of six study participants (four from the intervention arm, two from the 
control arm of the RCT). 
 Four carers of study participants (two intervention arm, two control arm of the RCT). 
 Two people who declined to participate at the outset, and two people who withdrew 
from the study before completion.  
 A maximum of six community matrons who delivered the intervention. 
 Four general practice administrators who implemented recruitment and eligibility 
screening procedures 
It is understood that it might be ethically challenging to recruit to the qualitative study once 
a participant has declined the feasibility RCT. However, the importance of including these 
people is to explore their reasons for declining participation or withdrawal in order to use 
these data to inform the larger study protocol and maximise recruitment and retention. 
12.1.2 Inclusion Criteria 
Participants will be eligible for this part of the study provided they are: 
a. Able to use a range of communication methods including speech, gesture and/or 
writing. 
b. Able to recall involvement in the study or study processes with or without prompts 
or aids (e.g. study documentation) as required. 
c. Are able to provide written informed consent for a semi-structured interview 
related to their participation in the trial. 
Carers will be eligible for the study provided they are: 
a. Aged ≥16 years. 




c. Able to provide written informed consent for a semi-structured interview related to 
their family member/close friend’s participation in the trial. 
Clinicians will be eligible for the study provided they are: 
a. A CM who delivered the intervention 
b. Willing to provide written informed consent for a semi-structured interview related 
to the feasibility of implementing the intervention and associated study processes 
General Practice Administrators will be eligible for the study provided they: 
a. Willing to provide written informed consent for a semi-structured interview related 
to the feasibility of implementing the intervention and associated study processes 
 
12.1.3 Exclusion Criteria 
Participants will not be eligible for the study if any of the criteria below are met: 
a. Severely impaired communication and/or deficits in cognitive skills or hearing 
impacting on their ability to participate in an interview 
Carers will not be eligible for the study if any of the criteria below are met: 
a. Aged <16 years 
b. Not a family member/close friend of a participant in either the intervention or 
control group 
c. Refuse to provide written informed consent for a semi-structured interview related 
to their family member/close friend’s participation in the trial 
Clinicians will not be eligible for the study if any of the criteria below are met: 
a. Refuse to provide written informed consent for a semi-structured interview related 
to the feasibility of implementing the intervention and associated study processes. 
General Practice Administrators will not be eligible for the study if any of the criteria below 
are met: 
a. Refuse to provide written informed consent for a semi-structured interview related 
to the feasibility of implementing the intervention and associated study processes. 
 




In-depth semi-structured interviews will be undertaken by the CI, which will last 
approximately 40 minutes. An interview protocol and topic guide will comprise questions 
relating to structure, process and outcome of the trial. The topic guide will not be exhaustive, 
with flexibility to offer space and the opportunity for participants to raise other issues which 
they might consider pertinent. All interviews will be audio recorded for their entire duration 
and transcribed verbatim by the CI or delegated staff.  Interviews for patients and carers will 
be conducted at the patient’s own home following an informal format, which it is envisaged 
will assist in creating a situation in which experiences will be openly shared, without 
participants fearing they are being too critical. Interviews for the community matrons will be 
conducted at their local work base or other CFT premises.  All respondents will be assured of 
the anonymity of the data and that the interviews are intended to be non-judgemental.  
 
12.1.5 Interviews  
Community Matron Interviews 
In particular, the CMs will be asked to describe, discuss and elaborate on: 
 The situations they found interesting and challenging with regard to implementation 
of the HAPPI intervention with patients 
 The situations they found interesting and challenging with regard to delivery of the 
HAPPI intervention e.g. any operational difficulties within the community matron 
service. 
General Practice Administrator Interviews 
In particular, the GP administrators will be asked to describe, discuss and elaborate on: 
 The situations they found interesting and challenging with regard to the 





Trial participant interviews 
In particular, the participants will be asked to describe, discuss and elaborate on: 
 The situations that they found interesting and challenging with regard to receiving the 
HAPPI intervention or usual care 
 The situation that they found interesting and challenging with regard to the 
completion of each of the questionnaires  
 The experience of participating in the trial 
 
Decliner and Withdrawal Interviews 
Up to two people who declined to participate at the outset will be interviewed and another 
two people will be interviewed if we have study participants who withdraw from the study. 
At the time they decline to participate in the study, or withdraw, they will be asked once only 
if they would be willing to share their reasons why they declined in a brief interview. They will 
be informed that the researchers would find any reasons they had for declining useful for 
developing this and future research. They will be clearly informed that this is entirely optional 
and they do not have to share their reasons. If they consent, they will be given an option to 
be interviewed alone or with their significant other. The aim is to explore their feelings about 
this feasibility study and reasons for declining or withdrawing in order to inform and optimise 
recruitment/retention for the remainder of the trial and subsequent main study. Data 
collection will occur within three days of declining or withdrawal. For the home visit, which is 
required as part of the qualitative interviews, the CI will comply with the NHS Trust lone 





12.1.6 Data Analysis 
Qualitative study results will be reported using the COREQ checklist for interviews and focus 
groups (24). Thematic analysis will be used to analyse the data. This method includes a 
strategy for identifying themes and subthemes (25).The transcripts of the interviews will be 
uploaded to the qualitative analysis program NVivo. 
The first analysis step will involve familiarisation of the narratives and two researchers will 
independently read the transcripts. In the next step, two researchers will independently code 
the text by allocating the text fragments to codes. The codes will be formulated from the text 
fragments and will possibly be revised during the process of reading the transcripts. The two 
researchers will then discuss the results of the individual codes and try to reach consensus. 
After this, the codes will be reviewed and themes will be formulated.  
 
12.1.7 Qualitative data presentation 
Demographic data items will be presented using descriptive statistics. Meaningful text 
fragments will be determined, as will codes (sub-themes) and themes related to the trial 
objectives. Data extracts will be accompanied by narrative to elaborate why the extract is 
analytically interesting. All participants will be anonymised and pseudonyms used to 
demonstrate different participants’ experiences. If any information is disclosed during the 
trial that could pose a risk of harm to the participant or others, the CI where appropriate, will 





13. SAFETY REPORTING 
Adverse events (AEs) may be non-serious or serious (see definitions below).  Adverse events 
to be recorded in this study are:- 
 All non-serious AEs considered to be related to the intervention  
 All Serious Adverse Events (in all participants) 
 
13.1 Definitions 
An adverse event (AE) is defined as any unfavourable and unintended sign, symptom or 
disease that develops or worsens during the period of the trial, whether or not it is considered 
to be related to the trial intervention. Adverse events include unwanted side effects, injury 
or intercurrent illnesses. 
An adverse event is classified as a Serious Adverse Event (SAE) if it: 
 results in death 
 is life threatening 
 requires hospitalisation or prolongation of existing hospitalisation 
 results in persistent or significant disability or incapacity 
 consists of a congenital anomaly or birth defect (not relevant in this population) 
 or is considered by the investigator to be an important medical event 
In this patient population of moderately and severely frail patients, acute illness resulting in 
hospitalisation, new medical problems and deterioration of existing medical problems are 
expected. For participants in this study who are moderately or severely frail, this will include 
SAEs relating to frailty syndromes such as admission to hospital for abrupt onset of falls, 
immobility, delirium caused by infection/sepsis, incontinence and iatrogenic side effects of 
medication. 
Deaths and falls are expected in this patient population at a higher prevalence than those 




was 3.10 (95% CI 2.91–3.31) for moderate frailty and 4.52 (95% CI 4.16–4.91) for severe frailty. 
30% of people aged 65 and over will fall at least once a year and for those aged 80 and over 
it is 50% (27). Increasing frailty is associated with higher prevalence of falls.  In a recent 
systematic review frailty was significantly associated with higher risk of future falls (pooled 
HR = 1.24, 95% CI = 1.10–1.41, P < .001) (28). Numbers of deaths and falls are an outcome 
measure will be collected between the time of consent, three months and final follow up (six 
months).  
13.2 Reporting adverse events 





Figure 3: Flow chart of reporting AEs and SAEs 
 
 
Adverse Events related to the intervention will be recorded in the CRF at three month and six 
month follow up visits by the blinded assessors (RAs) for all participants. For those 
participants at GP practices that have been allocated the intervention, Adverse Events will 
also be recorded in the CRF by the Community Matrons who are delivering the intervention.  
 
13.3 Reporting Serious Adverse Events 
Any adverse event that happens to a participant in the study that may be considered ‘serious’ 




on the study to PenCTU using the SAE report form. Once complete, the form will be faxed to 
PenCTU within 24 hours of the research staff becoming aware of the event and the original 
filed in the site file. PenCTU will advise the CI that an SAE has been reported, giving basic 
details and asking the CI for their opinion on relatedness. If either the reporting person or the 
CI considers that the SAE is possibly, probably or definitely related to the study treatment, 
then the CI and/or the TMG will be asked to determine whether or not the event is expected, 
based on the information given in section 13.1. 
As described in section 13.1 high numbers of SAEs are expected within the study population. 
All SAEs will be reported annually to the Sponsor, Trial Steering Committee (TSC) Research 
Ethics Committee (REC) by way of routine annual progress reports in accordance with the trial 
monitoring plan. SAE listings will be reviewed at TMG meetings on an ongoing basis 
throughout the course of the data collection period. 
For all participants, SAEs will be reported from the time they give consent to take part in the 
study until their 6 month follow up visit (or until they otherwise withdraw from the study). All 
SAEs will be followed up until the event has resolved or a final outcome has been reached. 
 
13.4 Related and Unexpected SAEs – expedited reporting 
SAEs which are considered possibly, probably or definitely related to the trial intervention 
and are considered unexpected by the CI and/or the TMG will trigger an expedited reporting 
procedure (in addition to the routine reporting described in section 13.2.2). The CI will contact 
the TSC to ask them to review the event and to consider if any corrective action needs to be 




by the PenCTU to the Research Ethics Committee by email within 15 days of the local research 
team having become aware of the event.  
 
14. DATA MANAGEMENT 
14.1 Data Collection 
The CRF will be a printed paper document. Data captured in the CRF for the sole purpose of 
this study will be considered source data.  The CRF will consist of three sections: 
a. Intervention CRF: HAPPI intervention data: recorded by the community matron 
(intervention group only).  
b. Participant Baseline and Follow-up CRF:  Participant related baseline, 3 month follow 
up, 6 month follow up; recorded by the CI/blinded RA (all participants) 
c. GP Practice Records CRF: GP Practice records; recorded by CST (all participants) 
Completeness of outcome data will be maximised by the CI/RA, who will: 
a. Wherever possible, arrange another assessment session, should the pre-scheduled 
session be cancelled 
b. Ensure the participant will be referred to by their study participant number, not by 
name on all study-specific documents, other than (a) the signed consent and (b) the 
contact details form 
c. Ensure that a  record of all participating patients is kept on a participant log, filed in 
the site file along with the  originals of signed information consent forms 
d. The site files with the essential documentation will be stored at the Cornwall 
Foundation Trust Research nurse team and at the Kernow CCG CST office. 
e. Ensure each site retains a copy of each CRF that they send to PenCTU to ensure the CI 
can provide access to the source documents to a monitor, auditor, or regulatory 
agency. 
Data will be recorded on the CRFs by the CI/RA and CMs. CRFs will be posted using pre-printed 
freepost labels to PenCTU for double data entry onto a password-protected database.  
A customised database will be used for data entry. Data entry will be completed by a PenCTU 
Administrator.  Double entered data will be compared for discrepancies. Discrepant data will 




anonymity is maintained by ensuring each participant is allocated a study number which will 
be allocated during completion of the baseline CRF.  Participant numbers will consist of 4 
digits. The first two digits will relate to a number allocated to the GP practice from which the 
participant was identified and recruited. The next two numbers will be consecutively 
allocated by the CI as the baseline assessment visits are conducted. 
Anonymised data will be securely stored for ten years after the completion of the trial in 
accordance with Plymouth University policy. The Sponsor will be responsible for archiving all 
trial data following submission of the end of study report. 
 
14.2 Source Data 
Data generated as a result of this trial will be available for inspection on request by the 
participating research team, Plymouth University representatives, the REC, local R&D 
Departments and Sponsor. 
 
14.3 Data Confidentiality 
Source data will only be accessed by the CMs delivering the intervention, the CI and RAs. Data 
will be collected and stored in accordance with the Data Protection Act 1998/General Data 
Protection Regulation 2018. All paper forms (including all original signed informed consent 
forms and copies of the CRFs) will be stored immediately after use in the Site File at each site 
separate from study data. After completion of the trial these will be accessible for the 
purposes of monitoring, auditing via the Sponsor who will be storing the anonymised data for 




statisticians. All identifiable data will be destroyed as soon as the trial has ended and 
participants have been sent a summary of the results. 
 
15. STATISTICAL CONSIDERATIONS 
15.1 Sample Size 
As a feasibility study, a formal sample size calculation based on considerations of power is not 
appropriate (29); this study is not powered to detect clinically meaningful between-group 
differences in a primary outcome. One of the aims of this study is to provide robust estimates 
of the likely rates of recruitment and follow-up, as well as provide estimates of the variability 
of the proposed primary and secondary outcomes to inform sample size calculations for the 
planned definitive trial. There is no consensus on the recommended number of participants 
required for a feasibility study, with published “rules of thumb” ranging from 20 to 70 or more 
participants, when the planned primary outcome is of a continuous nature. A recent paper 
recommended a feasibility study sample size should recruit 25 participants per allocated 
group, if the planned definitive trial will have a two-arm parallel group design, with 90% 
power and two-sided 5% significance level, to detect a “small” standardised effect size (30). 
Therefore, this feasibility study aims to recruit 60 participants in total. 
Participants will be recruited from a minimum of six general practices in Cornwall, with a total 
practice population of 491,000.  The planned recruitment period is six months and over this 
period, across the practices, it is anticipated that following initial screening (eFI), 
approximately 9000 (1500 per practice) potential participants will be identified and from 
these 540 (90 per practice) sampled for second screening (PRISMA7) and eligibility. Following 




participate. Whilst the aim is to recruit 10 participants per cluster, once a cluster has between 
eight and 12 participants, the next cluster will be opened for recruitment. 
Given the nature of the study, with measures being collected at baseline, three and  six 
months, with time required for travelling between participant’s homes and qualitative 
interviews, logistically it is estimated that the maximal recruitment rate is five to six 
participants per month.  
A target sample size of 60 participants will allow the follow-up rate to be estimated to within 
±15%.  The follow-up rate is estimated to be 70%, which would provide follow-up outcome 
data on a minimum of 42 participants across both allocated groups and three sites. 
 
15.2 Statistical Analysis 
A statistical analysis plan will be drafted by the CI with support from the trial statisticians and 
approved and signed off by the TSC. It is inappropriate to use feasibility study data to formally 
test treatment effects, therefore the statistical analyses will be of a descriptive nature (29). 
The plan will conform to guidance related to statistical analysis plans (31) and take into 
consideration the CONSORT updated guidelines for reporting feasibility and pilot trials (32) 
and also give consideration to the CONSORT Patient-Reported Outcome (PRO) extension: 
Health and Quality of Life Outcomes (33) and CONSORT Statement for Randomised Trials of 





15.3 Analysis populations 
All analyses and data summaries will be conducted on the intention-to-treat (ITT) population 
which is defined as all participants randomised regardless of non-compliance with the 
protocol or withdrawal from the study. Participants will be analysed according to the 
intervention they received. 
15.4 Frequency of analysis 
There is no planned interim analysis. Statistical analysis will be undertaken after the last 
participant’s last visit and the database is locked. The statistical analysis plan will be 
developed and approved prior to database lock. 
15.5 Outcome analysis 
As a feasibility study, analysis will focus on descriptive statistics and confidence interval (CI) 
estimation rather than formal hypothesis testing (36). The aim of the analysis is to assess the 
feasibility of the intervention, the feasibility of a full definitive trial and summarise potential 
primary and secondary outcome measures.  
Feasibility of a trial will include: 
 CONSORT diagram 
 timing of follow-up assessments (i.e. where they within a reasonable time frame) 
 time it took to recruit sites/participants 
 balance of baseline characteristics by allocation group 
 number of researchers who became unblinded 
 movement between practices (although potentially this may not be representative of 
the country). 
Feasibility of the intervention will include: 
 numbers who complied 
 how much participants complied with intervention (i.e. one assessment and at least 




Potential primary/secondary outcomes assessment will include: 
 summary statistics difference between baseline and follow-up visits 
 completeness of data (missing completely and missing items). 
 
16. DATA MONITORING 
16.1 Data Monitoring Plan 
Data will be monitored for quality and completeness by the PenCTU, using established 
verification, validation and checking processes. Two attempts will be made to gain any missing 
data, confirmed as not available, or when the trial is at analysis. The PenCTU/Sponsor reserve 
the right intermittently to conduct source data verification on a sample of participants. Source 
data verification will involve direct access to patient notes at the participating sites, and other 
relevant investigation reports.  
16.2 Quality Assurance 
The study will be conducted in accordance with the principles of Good Clinical Practice (GCP) 
in clinical trials, as applicable under UK regulations, the UK Policy Framework for Health and 
Social Care Research and through adherence to PenCTU Standard Operating Procedures 
(SOPs). 
A Trial Monitoring plan will be developed and agreed by the Trial Management Group (TMG) 
and Trial Steering Committee (TSC). This will be informed by a Trial Risk Assessment which 
will consider the safety or physical or mental integrity of the trial participants and the 
scientific value of the research (including the potential risk associated with the 
implementation of the intervention and recruitment which can, if not monitored and 




study). This monitoring plan will detail the timing and content of reports to monitor trial 
conduct and implementation and adherence with the Consolidated Standards of Reporting 
Trials (CONSORT) (33). This monitoring plan may also include site monitoring.  
For a feasibility study of this nature and duration, a separate Data Monitoring Committee is 
not required. Rather, the TSC will adopt a safety monitoring role, with the constitution of a 
sub-committee to review safety issues where this becomes necessary. 
16.3 Trial Steering Committee (TSC) 
The TSC comprises a multi-disciplinary group of individuals who are independent to the TMG 
and include patient and public representatives. The TSC will meet once before the trial starts 
and at least six-monthly over the course of the trial. In addition, they will receive a quarterly 
update of the SAEs, and a telephone conference / additional face-to-face meeting will be 
instigated by the Chair or the CI should any issues need to be discussed. 
The role of the TSC is to provide overall supervision of the HAPPI study on behalf of the study 
Sponsor and funder. In particular, the TSC will monitor the scientific integrity of the study 
including trial progress, adherence to the protocol and the consideration of new information. 
The TSC will also be responsible for reviewing accumulating safety data in order to monitor 
participant safety. 
The TSC will provide advice through its independent Chairperson to the CI and the local trial 
management team on all aspects of the trial.  TSC members will be constructively critical of 
the ongoing trial, but also supportive of its aims and methods. Minutes of the TSC will be sent 




investigators. There will be at least 40% independent representation (independent chair, 
independent scientist and three lay members). 
The composition of the TSC for this trial is detailed in Table 3. 
Table 3: Trial Steering Committee 
Dr Iain Lang (Chair)* Senior Lecturer in Public Health  
Mr John Goddard* Patient & Public Involvement Representative 
Mrs Margaret Lappin* Patient & Public Involvement Representative 
Mrs Marie Prior* Frailty Lead/Registered Nurse 
Mrs Kerry Crowther* Falls Lead/Registered Nurse 
Dr Paul McEleney* General Practitioner 
Dr Frances Harrington* Geriatrician 
Helen Lyndon Chief Investigator 
Dr Chen Ji* Independent Statistician 
*Independent TSC Members 
17. DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS 
The CI and the Plymouth University will permit trial-related monitoring, audits, REC review 
and regulatory inspections by providing direct access to source data and other documents. 
 
18.        ETHICS APPROVALS 
The trial will not be initiated before the protocol, informed consent forms, Participation 




and interview topic guides) have received approval from an NHS REC, and HRA approval is in 
place. 
This trial protocol has been reviewed by the Trial Management Group, Trial Steering 
Committee and the Sponsor. Should a substantial protocol amendment be required, the 
changes in the protocol will not be instituted until the amendment and revised study 
documentation (if appropriate) have been reviewed and received approval from the REC and 
HRA. A protocol amendment intended to eliminate an apparent immediate hazard to 
participants may be implemented immediately providing that the REC are notified as soon as 
possible and an approval is requested. Non-substantial amendments for logistical or 
administrative changes will be submitted to the HRA for approval before implementation. 
The trial will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, 1996; the principles of Good Clinical Practice, and the UK Policy 
Framework for Health and Social Care Research. All correspondence with the REC will be 
retained in the Trial Master File and Investigator Site File. 
An annual progress report will be submitted by the CI to the REC within 30 days of the 
anniversary date on which the favourable opinion was given, and annually until the trial is 
declared ended. The CI will notify the REC of the end of the study. If the study is ended 
prematurely the CI will notify the REC, including the reasons for the premature termination. 
Within one year after the end of the study, the CI will submit a final report with the results, 
including any publications/abstracts, to the REC. 
 




Plymouth University indemnity scheme will meet the potential legal liability of the sponsor(s): 
• for harm to participants arising from the management of the research  
• for harm to participants arising from the design of the research  
• arising from harm to participants in the conduct of the research  
This is a Plymouth University research study. If an individual suffers negligent harm as a result 
of participating in the study, the Plymouth University indemnity scheme covers University 
employed. In the case of non-negligent harm, Plymouth University is unable to agree in 
advance to pay compensation, but the normal procedures for non-negligent harm will address 
this and an ex-gratia payment may be considered in the event of a claim. 
 
20. PUBLICATION POLICY 
The CONSORT Guidelines checklist will be reviewed prior to generating any publications for 
the trial to ensure they meet the standards required for submission to high quality peer 
reviewed journals etc.  On completion of the trial, the data will be analysed and tabulated and 
a Final Study Report for the NIHR prepared by the CI. The full study report will be able to be 
accessed on the study web-site page. The participating investigators will have rights to publish 
the trial data; this will be undertaken only after discussion and in collaboration with the CI 
and after publication of the trial’s main paper. There are no time limits or review 
requirements on the publications. The NIHR (the funding body) will be acknowledged within 
the publications. They do not have review and publication rights of the data from the trial. 
All participants, who consent to receiving notifications, will be notified in writing of the 




dissemination of information will include the progression of this research. For example, future 
funding applications to undertake a randomised controlled trial to investigate the 
effectiveness of the HAPPI intervention. 
The trial protocol will be submitted for publication in an Open Access Journal; it is anticipated 
that this will be available within one year of the recruitment start date for this trial. Findings 
based on the trial results will be published in peer-reviewed scientific journals, such as Age 
and Ageing, and in journals read by practicing clinicians in primary and community care, such 
as the British Medical Journal and the International Journal of Older Peoples Nursing. This will 
ensure dissemination to both academics and those responsible for service delivery in the NHS. 
Results will be presented at national and international conferences, such as the British 
Geriatrics Society Autumn and Spring Conferences and the Royal College of Nursing Older 
Peoples Conference. Additionally, older people will be informed through organisations such 
as AgeUK. If the trial is found to be feasible, the study-specific procedure guide and training 
materials will be implemented in the subsequent main trial. 
 
21. STUDY ORGANISATIONAL STRUCTURE 
Individuals and individual organisations: 
Chief Investigator 
As defined by the NHS Research Governance Framework, the Chief Investigator is responsible 
for the design, management and reporting of this study, the whole research programme and 





The Sponsor is responsible for trial initiation management and financing of the trial. These 
responsibilities are delegated to the PenCTU as detailed in the trial contract.  
Peninsula Clinical Trials Unit (PenCTU) 
The PenCTU will support set-up and monitoring of study conduct to PenCTU SOPs and MRC 
GCP standards including randomisation design and implementation, registration design and 
implementation, database development and provision, assisting the CI with protocol 
development, CRF design, study design, monitoring schedule and statistical analysis and 
reporting. The PenCTU will be responsible for the database administrative functions, data 
management, safety reporting, and supporting the CI with statistical analyses.  
South West Peninsula Clinical Research Network (SWCRN) (Primary Care Clinical 
Speciality) 
The SWCRN will support main REC and Research and Development submissions, and site set-
up and on-going management including non-clinical training, monitoring reports and 
promotion of the study. The SWCRN will be responsible for day-to-day management of the 
study, supporting the CI with R&D submissions, liaison with local collaborators, management 
and overall supervision of the performance and conduct of the research team, source data 
verification (where required) and promotion of the programme. 
Research Assistants (RAs)  
Study-specific RAs (specifically Cornwall Foundation Trust Research Nurses) will have 
responsibility for screening, consenting patients, conducting baseline and follow-up 
assessments. 




Site staff are responsible for conducting the study in accordance with the trial protocol, the 
HAPPI conversation guide, personalised support plan template and assessment pack.   
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Appendix 8: Site Eligibility Questionnaire 
General Practice Participant Identification Site Eligibility Form 
To participate in the HAPPI research study as a Participant Identification Site the 
Practice will need to agree to complete the following actions: 
1. Run the electronic frailty index (eFI) database search to identify all moderately 
and severely frail patients aged 65 years and above. 
2. Send an anonymised list of these patients to the Peninsula Clinical Trials Unit 
to enable sampling to be carried out. 
3. Apply additional eligibility criteria to patients sampled:  
 Confirm the patient is able to give informed consent or consent can be 
obtained from a consultee 
 Confirm the patient lives in own home/supported living accommodation 
 Confirm the patient is not in receipt of palliative care, on gold standards 
framework register or where clinician feels they have limited life expectancy 
4. Send a recruitment letter to a maximum of 90 potential participants (sampled 
by the CTU) and receive replies. If 90 is not reached in the initial invitation, 
CTU will repeat sampling until 90 is reached. 
5. Follow-up recruitment letter with one telephone call if reply not received within 
fourteen days 
6. Send details of 10 potential participants to the Chief Investigator(CI) 
7. Complete email proforma report on 3 and 6 month outcome measures from 
general practice records system 
A total of £ 193.76 will be paid to the practice in research and service support costs. 
Please confirm the following criteria: 
The practice uses the electronic frailty index (eFI) to identify their 
moderately and severely frail population 
 
☐ 
The practice are willing to fulfil the requirements of the study above 
relating to screening and recruitment  of participants 
 
☐ 
The practice has at least one Community Matron attached to the 
practice who is willing to deliver the HAPPI intervention** 
 
☐ 
** NB this will be confirmed by the CI with Cornwall Foundation NHS Trust (Community Matron employer) 
General Practice Name: ---------------------------------------------------------------------------- 
Signed By:   --------------------------------------------------------------------------- 
Signature:   ---------------------------------------------------------------------------- 
Role:    ---------------------------------------------------------------------------- 
Contact details:  Phone Number: ------------------------------------------------------ 











Appendix 10: HAPPI Invitation to Participate  
General Practice Headed Notepaper 
<<Date>> 
<<Name of potential participant>> 
<<Address>> 
<<Town/City, County, Postcode>> 
 
Re: The HAPPI Study, Lead Researcher: Helen Lyndon 
 
Dear <<insert name>>: 
 
I am writing to let you know about an opportunity to participate in a research study to 
test a new care plan for older people, to see if it is practical and achievable. This study 
is being conducted by myself, Helen Lyndon at the School of Nursing and Midwifery, 
University of Plymouth. Our research aims to explore how older people can be best 
supported at home and how community nurses could work to provide individualised 
support. We want to explore if we can measure improvements for older people 
enabling them to be as independent as possible, improve wellbeing, prevent falls and 
reduce the need for unplanned hospital care.  
 
You have been identified as being a suitable candidate to participate in this research 
study by your General Practitioner Dr <<insert Dr’s name>>. If you are interested in 
taking part in the study, please complete the questionnaire and the confirmation of 
participation sheet that is on the back of this letter and return it to the surgery in the 
stamped-addressed envelope provided. This will enable us to check if you are suitable 
to take part in the study. If you return the questionnaire and are suitable to join the 
study, a member of the research team will contact you by telephone to arrange to visit 
you at home to explain the study further and gain your written consent if you still wish 
to participate.  
 
If we do not hear from you within 14 days, someone from the surgery will contact you 
by telephone. If you do not want to be contacted, please let us know by calling the 
surgery on <<insert surgery number>> and requesting that we make no further contact 
regarding this research.  Agreement to be contacted or a request for more information 
does not mean that you will then have to participate in the study.  
 
If you would like additional information about this study, please call me, Helen Lyndon, 





Helen Lyndon (Mrs) 








Please tick any that apply to you currently: 
 
PRISMA-7 Questions Please 
tick 
Are you aged more than 85 years? 
 
 
Are you male? 
 
 
In general do you have any health problems that require you to limit 
your activities? 
 
Do you need someone to help you on a regular basis? 
 
 
In general do you have any health problems that require you to stay 
at home? 
 
In case of need can you count on someone close to you? 
 
 









I am interested in participating in this research study if I am eligible 
and would like a member of the research team to contact me. I am 
happy for my name and phone number to be shared with the 
research team. 
 
I am not interested in participating in this research study and want no 































































































Appendix 13: HAPPI Statistical Analysis Plan 
The Holistic Assessment and care Planning 
 in Partnership Intervention Study 
(HAPPI) 
 
A cluster randomised, controlled feasibility study of a 
nurse-led, holistic assessment and care planning 
intervention for older people living with frailty in primary 
care. 
 
STATISTICAL ANALYSIS PLAN 
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1.  Study Summary 
Study Title The Holistic Assessment and care Planning  in Partnership Intervention Study 
[HAPPI]: 
A cluster randomised, controlled feasibility study of a nurse-led, holistic 
assessment and care planning intervention for older people living with frailty in 
primary care. 
Study Design Feasibility, cluster randomised controlled trial with embedded qualitative study. 
Study 
Participants 
People aged 65 years and over who are moderately or severely frail. 
Study Setting General Practice populations in Cornwall, UK. 
Intervention Delivery of the HAPPI intervention by trained community matrons in accordance 
with the conversation guide and assessment pack to ensure treatment fidelity. 
The intervention will be an individualised assessment and care planning 
process including development of person-centred goals supported by planning 
and relevant referrals. It will be carried out at the participant’s home. 
Documentation of the intervention including assessment, individualised care 
and support plan and evidence of any referrals will be recorded using a 
standardised document/computerised template. 
Control Participants in the control group will receive usual care. This cannot be 
standardised as approaches to care of older people with frailty varies in general 
practice. This may include the management of various long-term conditions, 
referrals to other services, prescribing of medications and routine vaccinations. 
As part of the feasibility trial, components of usual care will be captured using 
a standardised proforma in order to describe this for the future definitive trial. 




Study Aims  The primary aim of this cluster randomised, controlled feasibility study of a 
nurse-led Holistic Assessment and care Planning in Partnership Intervention 
(HAPPI) is to determine the feasibility of delivering the intervention in primary 
care to older people with frailty and to test potential trial methods to inform the 






Potential participants will be eligible for the study provided they are: 
k. Aged 65 years and over 
l. Moderately frail: Electronic Frailty Index (eFI) >0.24 to 0.36 or severely 
frail (eFI > 0.36) 
m. Frailty confirmed by PRISMA7 instrument 
n. Able to give informed consent  




Potential participants meeting any of the following criteria will be excluded from 
study participation: 
f. Fit or mildly frail (eFI 0.13 – 0.24) 
g. Lives in a care home 
h. Patients in receipt of palliative care, on gold standards framework 
register or where clinician feels they have limited life expectancy 
i. Lacks mental capacity to give informed consent 




May 2018: Set up phase and recruit GP practices  
November 2018: Participant identification and eligibility check  
January 2019: Consent and baseline measures  
March 2019: Intervention 
June 2019: 3-month follow-up data collection 






2. Administrative Information 
Title of Trial The Holistic Assessment and care Planning in Partnership 
Intervention Study [HAPPI] 
 
A cluster randomised, controlled feasibility study of a nurse-led, 
holistic assessment and care planning intervention for older people 





Protocol Version  2.1 18/03/2019 
SAP Version 1.0 
SAP Revisions  
 
























File Note: 28/01/2019 
This final version of the SAP was discussed at the Trial Steering Committee 
(date 22/11/2019) and all comments were addressed. Due to unforeseen 









3. Abbreviations  
 
AE Adverse Event 
BGS British Geriatrics Society 
BI Barthel Index 
CGA Comprehensive Geriatric Assessment 
CRF Case Report Form 
EQ-5D-5L European Quality of Life-5 Dimensions 
fRCT Feasibility Randomised Controlled Trial 
HADS Hospital Anxiety and Depression Scale 
HAPPI Holistic Assessment and care Planning in Partnership 
Intervention trial 
LTC-6 Long Term Conditions 6-item Questionnaire 
LUTS  Lower Urinary Tract Symptoms 
MFRAT Multifactorial Falls Risk Assessment Tool 
PenCTU Peninsula Clinical Trials Unit 
PSP Personalised Support Plan 
RCT  Randomised Controlled Trial 
SAE  Serious Adverse Events 
SF-36 Medical Outcomes Study 36-Item Short Form Health Survey 
TEP Treatment Escalation Plan 
TMG  Trial Management Group 
TSC Trial Steering Committee 
UCLA-3 UCLA 3-item Loneliness Scale 







4.1 Background and rationale for the trial 
The full background and rationale for the trial can be found in the HAPPI study protocol V 
2.1. The primary aim of this cluster randomised, controlled feasibility study of a nurse-led 
holistic assessment and care planning intervention is to determine the feasibility of delivering 
the intervention in primary care to older people with frailty and to test potential trial methods 
to inform the design of a definitive randomised controlled trial (RCT). 
4.2 Purpose of statistical analysis plan 
The trial protocol includes an outline of the statistical methods to be employed in the analysis 
of the trial data. The purpose of the Statistical Analysis Plan is to provide full details of the 
planned statistical methods to be used in the primary report of the trial results. HAPPI is a 
feasibility trial, therefore formal statistical analysis and hypothesis testing is not appropriate 
and thus will not be undertaken. This plan is based on “Guidance for the Content of 
Statistical Analysis Plans in Clinical Trials” (Gamble et al., 2017). 
5. Trial objectives and outcome measures 
The objectives and outcome measures are taken from the study protocol version 2.1. 
5.1 Objectives 
m. To assess compliance with the HAPPI intervention. 
n. To verify that proposed outcome measurement and follow-up schedules are feasible 
to collect.  
o. To determine achievable targets for recruitment and follow-up rates. 
p. To evaluate the method of recruitment using the electronic frailty index (eFI). 
q. To evaluate characteristics and feasibility of the proposed outcome measures and to 
determine suitable outcome measures for the definitive trial.  
r. To calculate estimates from the distribution of the measure identified as the primary 
outcome that may be used to inform the number of participants needed to be recruited 
to a definitive trial. 
s. To assess availability of clinical data and time needed to collect and analyse data 




t. To explore factors that will enable future economic evaluation alongside the main trial.  
This will include an assessment of the feasibility of collecting EQ-5D-5L data which 
can be used to calculate quality-adjusted life years (QALYs).   
u. To determine acceptability of the intervention to participants, carers and clinicians in 
primary care. 
v. To assess barriers to delivery of the HAPPI intervention e.g. any operational difficulties 
within the community matron service. 
w. To evaluate clinicians’ willingness to identify, recruit and randomise eligible patients, 
and willingness of patients to be recruited and randomised. 
x. To determine acceptability of trial processes and data collection to participants, sites 
and clinicians. 
5.2 Outcome measures 
The feasibility randomised controlled trial (fRCT) compares the delivery of the HAPPI 
intervention with usual primary care for frail older people. The outcomes relate to feasibility of 
the intervention, feasibility of conducting the trial and assessing potential primary and 
secondary outcomes for the future trial. These are summarised in Table 2: 
Table 2: Summary of study objectives and outcome measures 
Objective summary Outcome measure (s) 
Feasibility of the 
intervention 
i. n/% of consented participants randomised to the 
intervention group who do not withdraw or die within the 
intervention period engaging with the minimum “dose” of the 
intervention 
ii. Number of staff moving between intervention and control 
GP practices 






i. Number of GP practices expressing an interest in 
participating 
ii. Percentage of GP practices who were initially approached 
that participated 
iii. Number of GP practices screened for selection and reasons 
for non-selection 
iv. Number of GP practice withdrawing from the study, timing 
and reason for withdrawal 
v. Number of GP practices failing to progress through 
implementation milestones and reasons for failure 
vi. Number of GP practices  withdrawing during the 
implementation and delivery phases 
vii. Numbers of participants identified using the electronic frailty 
index (eFI) as a denominator for number of those identified 




viii. Numbers of participants screened as eligible, recruited, 
consented and followed up 
ix. Number of and timing of participant withdrawals from follow-
up data collection, reasons for withdrawal, number of and 





outcomes of the 
future trial 
i. Numbers of potential primary and secondary outcome 
measures completed at baseline and follow-up intervals  
ii. Numbers of missing items for each potential primary and 
secondary outcome at each time-point 
iii. Assessment of the feasibility of collecting data to estimate 
cost-effectiveness using the EQ-5D-5L 
iv. Assessment of the suitability/feasibility of delivering the 
following outcome measure instruments: 
 Levels of loneliness and isolation measured by UCLA 3-
Item Loneliness Scale 
 Physical health and mobility, level of pain, mood and 
emotional health and health-related quality of life 
measured by the Medical Outcomes Study 36-Item 
Short Form Survey Instrument Version 1 (SF-36) 
 Confidence in own ability to manage health, as 
participants in care measured by the Health Foundation 
LTC6 questionnaire 
 Mortality; date and cause of death obtained from the 
clinical record 
 Number of hospital admissions, readmissions and total 
number of days spent in hospital obtained from the 
clinical record 
v. Polypharmacy – number of medications prescribed in total 
at study time points 
 
 
All clinical outcome measures will be conducted at baseline (T1), three months (T2) 
and six months (T3). 
 
6. Study Methods 
6.1 Trial design 
A feasibility, cluster randomised controlled trial with embedded qualitative study for 
older people who live with moderate or severe frailty in a primary health care setting. 




the electronic frailty index (eFI) as the initial identification method and random 
sampling. Randomisation occurred at general practice level with participants from 
three practices allocated to the control group and participants from three general 
practices allocated to intervention. Control participants receive care as usual, 
intervention participants receive the HAPPI intervention.  
6.2 Eligibility Criteria 
The trial population will be people who are: 
i. Aged 65 years and over 
ii. Moderately frail: Electronic Frailty Index (eFI) >0.24 to 0.36 or severely frail (eFI 
> 0.36) 
iii. Frailty confirmed by PRISMA7 instrument 
iv. Able to give informed consent  
v. Living in own home/supported living accommodation 
People meeting any of the following criteria are excluded from participating in 
the trial: 
i. Fit or mildly frail (eFI 0.13 – 0.24) 
ii. Lives in a care home 
iii. Patients in receipt of palliative care, on gold standards framework register 
or where clinician feels they have limited life expectancy 
iv. Lacks mental capacity to give informed consent 
v. Patients already on the caseload of a Community Matron. 
 
6.3 Randomisation and Allocation Concealment 
In order to avoid contamination of the control group, this study was designed as a 
feasibility pragmatic cluster RCT with randomisation at general practice level. 
Randomisation took place following recruitment of all six sites and prior to consent 
and baseline outcome measures assessment. Sites were randomised into allocated 
groups of equal size, so that the control and intervention groups each comprised 
three randomly allocated. This was performed by an independent statistician, 
external to the trial, to maintain blinding of the trial statistician. Allocation was 




eligibility. The full randomisation specification and the programming code used is 
included as Appendix 1. 
 
6.4 Blinding 
Due to the nature of the intervention, it was not possible to blind the trial participants 
or community matrons delivering the intervention. It is also not possible for the Chief 
Investigator to remain blinded as she was responsible for training the community 
matrons to deliver the intervention. However, assessors were blinded, and 
participants asked not to reveal their treatment allocation during assessments. 
6.5 Sample size 
It is not appropriate in a feasibility study to calculate sample size based on 
considerations of power (Thabane et al., 2010). This study is not powered to detect 
clinically meaningful between-group differences in a primary outcome. There is no 
consensus in the literature on the recommended number of participants required for 
a feasibility study, with suggested numbers ranging from 20 to 70 or more 
participants when the planned primary outcome is of a continuous nature (Whitehead 
et al., 2016). 
This feasibility study aimed to recruit 60 participants in total. Ten participants at 
each site were identified as a reasonable compromise between collecting 
information about the viability of conducting a larger trial and available resources 
for implementing this feasibility study. Participants were recruited from six general 
practices, with a total practice population of 491,000.  Recruitment took place over 
a six month period and it was anticipated that following initial screening using the 
electronic frailty index (eFI), approximately 9000 (1500 per practice) potential 
participants would be identified and from these 540 (90 per practice) sampled for 
second screening for eligibility according to the PRISMA7 instrument (Appendix 
11). A maximum recruitment rate was set at 10 participants per month across all 
sites. Numbers of participants screened and randomised by site will be reported as 
in Table 3. The follow-up rate is estimated to be 70%, which would provide full 




6.6 Sampling Methods 
The total number of patients within each eFI stratum was determined at each site. 
Each site, therefore, provided two lists (one for each stratum) with the date of their 
generation. Each patient was uniquely identified by a number ranging from one to 
the number of patients in each stratum at each site. The statistician generating the 
sampling sequence provided each practice with a list of random numbers based on 
the total number of patients in each stratum in the order they were to be approached 
for eligibility. If an insufficient number of patients consented to participate from any 
strata, then the sampling process was  repeated (without replacement) for that 
stratum, from the remaining list of unsampled patients either until five patients were 
recruited for each stratum or until no further patients were available. The full 
sampling specification is included as Appendix 2. 
6.7 Timing of final analysis 
Statistical analysis will be undertaken once final data collection has occurred and the 
database is locked. 
7. Statistical Methods. 
7.1 Statistical significance Levels 
As a feasibility trial, there will be no hypothesis testing undertaken. 
7.2 Adherence and protocol deviations 
Non–compliance with the trial protocol may occur in two ways. Firstly participants 
may not complete the minimum dose of the intervention according to the protocol. 
This may occur due to illness, admission to hospital, increasing frailty or if the 
participant makes the decision not to continue with the intervention. The number and 
proportions of participants categorised as non-compliant will be summarised as will 
all observed outcomes by allocated group. Secondly sites may not comply with 
protocol procedures relating to screening and recruitment. This is be recorded using 
the trial non-compliance form and numbers and types of instances of non-




7.3 Analysis populations 
Primary analysis (in the form of summary statistics, not formal analysis) will be 
undertaken based on intention to treat (ITT) descriptive analysis. There will be 
comparison of a per-protocol subset of intervention participants versus the ITT 
intervention group versus the control group. As a feasibility study the differences will 
not be tested for statistical significance i.e.: p-values will not be calculated and 
statistical inference will not be made from confidence intervals.  
If there are any cases of missing follow-up outcome data, the associated 
participant(s) will be removed from the analysis. This will enable exploration of what 
happens if varying number of questions are not answered or missing, and help to set 
a cut-off value.  
7.4 Data Sources and Data Quality 
The data from this trial will come from information entered onto Case Report Forms 
(CRFs) completed by community matrons delivering the intervention, blinded 
assessors at baseline and general practice staff from the clinical record. In addition 
outcome measure questionnaires are completed at baseline, three months and six 
months. 
7.5 Trial population 
Data from the screening process through to the completion of the trial will be 
recorded and presented following The Consolidated Standards of Reporting Trials 
(CONSORT) guidelines for pilot and feasibility trials (Eldridge et al., 2016) (Figure 1). 
7.6 Participants who discontinue, withdraw or are lost to follow-up 
It is possible that participants will withdraw consent partway through the trial, or their 
treatment may be discontinued due to medical reasons. Reasons for withdrawal or 
loss to follow up will be summarised, when reported, in the CONSORT diagram 
(Figure 1) and by site in Table 4. 
Participants who withdraw from the trial will not be replaced although their available 




the database. The extent of discontinuation, withdrawal and loss to follow up will be 
used to inform the design of the fully powered subsequent trial to ensure a 
sufficiently powered trial after drop-out. 
8. Statistical Analysis 
8.1 Statistical software 
The statistical analyses will be undertaken using Statistical Package for the Social 
Sciences (SPSS) version 24(IBM Corporation, Released 2016). 
8.2 Assessment of baseline variables 
The following baseline variables will be summarised by allocated group: 
i. Demographics (age, gender, relationship status, living arrangements). 
ii. Frailty severity 
For full details of included variables see Table 5. 
8.2 Assessment of recruitment, retention and adherence 
Numbers of participants screened, eligible, randomised, consented and withdrawn 
from the study will be reported by trial site and in total. Numbers will be reported for 
the intervention group and control group. The information will be summarised as a 
CONSORT flow diagram (Figure 1). Reasons for exclusion and for withdrawal will be 
summarised, where reported. 
Baseline demographic and clinical data will be summarised for the ITT population, 
for each of the two treatment groups and overall.  
Continuous variables will be summarised as mean (standard deviation) and median 
(interquartile range) whilst categorical variables will be summarised by the frequency 
of each level and their percentage of each group. There will be no statistical testing 
for any of the summary measures whilst comparing the variables between the 
treatment groups. Where appropriate, uncertainty around estimates of candidate 




8.3 Feasibility parameters 
Feasibility parameters will be reported that relate to the feasibility of trial procedures 
including site processes, recruitment, retention and ability to collect outcome 
measures data (Table 3, Table 4, Table 10). Other feasibility indicators relate to 
testing the intervention and include retention and adherence to the intervention 
(Table 4). 
8.4 Intervention delivery/refinement 
Treatment fidelity will be measured by the percentage of participants who receive the 
minimum “dose” of the intervention which is defined as one assessment visit and at 
least two care planning visits (Table 4). The content of the intervention will be refined 
for the definitive trial by evaluating the number of each type of assessment from the 
intervention pack that are completed (Table 7) and the number of referrals to other 
services made (Table 8). In addition, number of referrals per participant and average 
number of referrals will be calculated. 
8.5 Assessment of outcome measures 
The feasibility of the proposed outcome measures will be evaluated by the number of 
outcome measures completed at T1, T2 and T3. This criterion will help inform the 
choice of primary outcome measure or, potentially, multiple outcomes requiring 
multivariate analysis within a definitive trial. The feasibility trial gives the opportunity 
to ascertain, which outcome measures are acceptable to the participants; which can 
be administered in primary care; and which are sensitive to change at the different 
time points. Outcome measure data will be reported by group as in Table 10. 
Physical health and mobility, level of pain, mood and emotional health and 
health-related quality of life measured by the Medical Outcomes Study 36-Item 
Short Form Survey Instrument Version 1 (SF-36) (Ware & Sherbourne, 1992). 
There is evidence for reliability, validity and responsiveness of this measure and 
it is particularly recommended where a detailed and broad ranging assessment 
of health is required, particularly in community dwelling older people (Haywood, 
Garratt & Fitzpatrick, 2005). The SF-36 examines eight health concepts and 




1. Physical functioning: 10 items, range = 0 -1000.  
2. Role limitations due to physical health problems: 4 items, range = 0-400 
3. Bodily pain: 2 items, range = 0-200 
4. General health perceptions: 5 items, range = 0-1400 
5. Vitality: 4 items, range = 0-400 
6. Social functioning: 2 items, range = 0-200 
7. Role limitations due to emotional health problems: 3 items, range = 0-300 
8. Mental health: 5 items, range = 0-500 
Plus a single item on reported health transition: 1 item, range = (0-100).  
A global measure of health-related quality of life cannot be generated from the 
questionnaire (Lins & Carvalho, 2016). The lower the score on each concept, the 
higher the level of disability. 
Confidence in own ability to manage health and in role as participants in 
care measured by the Health Foundation LTC6 questionnaire. This measure 
asks patients with a long term condition about their experience and 
understanding of their healthcare over the last 12 months. It includes questions 
about involvement in decision- making and support for self-management (Health 
Foundation 2013). Range of values 0-18 with a higher score indicating higher 
levels of confidence. 
Levels of loneliness and isolation measured by UCLA 3-Item Loneliness 
Scale. This scale measures the impact of loneliness in later life (Gale, Westbury 
& Cooper, 2018). It has been found to be a reliable and valid measure of 
loneliness by comparing the results against a self-identifying statement and 
validated for self-completion and by completion by interview (Hughes et al., 
2004). Range of values 3-9, scores 2-5 indicate “not lonely”, 6-9 indicate “lonely”. 
Function measured by the Barthel Index (BI) (Mahoney & Barthel, 1965) The BI 
rates a person’s degree of independence performing functional self-care 
(feeding, grooming, bathing etc.) and mobility activities (transferring in/out of 





Feasibility of collecting data for future economic evaluation measured by 
the EQ-VAS (5L version) (Janssen et al., 2013).This visual analogue scale can 
also be used to measure quality of life, however, in this trial it is used only to test 
feasibility of obtaining data. For a future RCT this can then be used in the 
calculation of quality-adjusted life years within an overall economic evaluation. In 
addition to the VAS there is a 25- item descriptive system comprised of the 
following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension has 5 levels: no problems, slight problems, 
moderate problems, severe problems and extreme problems. Ticking a box 
results in a 1-digit number expressing the level selected for that dimension. The 
digits for 5 dimensions can be combined in a 5-digit number describing the 
respondent’s health state. It should be noted that the numerals 1-5 have no 
arithmetic properties and, therefore, a summary index number is not 
recommended:  
Level 1: indicating no problem 
Level 2: indicating slight problems 
Level 3: indicating moderate problems 
Level 4: indicating severe problems 
Level 5: indicating extreme problems 
Data from the descriptive system will be presented as percentage of intervention 
and control participants reporting levels 1 to 5. 
EQ VAS values will be presented by intervention and control groups; mean + 
standard deviation and median + interquartile range. In addition, numbers and 
proportions of participants reporting levels within the EQ-5D-5L dimensions will be 
reported by intervention and control (Table 11). 
8.6 Identification of the primary outcome 
Conditional on the completeness of the candidate outcomes at baseline and the 
follow-up visits, an initial indication of possible efficacy in a future definitive trial and 
the power to detect such an outcome will be in part determined by consideration of 
the possible detectable effect size in a future definitive trial. Detection of an effect 
depends on the size of the standard deviation (SD) relative to the difference between 




Differences in each outcome between baseline and three months, and baseline and 
six months shall be calculated. The difference (∆) between each arm in the mean 
change in the outcome divided by the pooled standard deviation from each arm 
yields the estimated effect size: 
𝐸𝑓𝑓𝑒𝑐𝑡 𝑠𝑖𝑧𝑒 =




The number needed for a future definitive trial testing the intervention with 5% 
significance and 90% power can be calculated from the formula: 





Assuming an intra-cluster correlation coefficient (ICC) of 0.05 and cluster size of 10 
in a future trial (as in this trial), this yields an design effect of 1 + 0.05*(10-1)=1.45. 
The numbers required to detect a given effect size are, therefore, derived as: 
Effect size Minimum n 
Sample size 
inflated for 
cluster sizes of 10 
patients per 
practice 
0.1 857 1243 
0.2 215 312 
0.3 96 140 
0.4 54 79 
0.5 35 51 
 
Given it would not be unfeasible for a future trial to recruit 312 participants in this 
population, a modest effect size of 0.2 could be detected at 5% significance with 
90% power from centres with an ICC of 0.05. On the scale of change since baseline 
in any one of the potential primary outcomes, the common standard deviation, SD, 
would therefore have to be no more than five times the difference, ∆, between the 




However, the population standard deviation (δ) is necessarily estimated with error by 
the sample SD. For a unit SD (i.e. SD=1), the limits for the 95% confidence intervals  
associated with sample size, n, can be seen to stabilise after a sample size of 30 
(Figure 4). 
 
Figure 4: Plot of 95% confidence intervals for the sample standard deviation 
expressed as a factor (SDfactor) of SD=1 against sample size, n. 
From an initial target of 60 participants to be recruited, over half could be reasonably 
expected to provide data on the outcomes of interest. Furthermore, since the upper 
confidence limit (CL) would be critical in determining the sample size, then a one-
sided CL is estimated at the 5% significance level. Therefore, from a sample size of 











Therefore adjusting the size of the standard deviation relative to the difference 
between groups, the sample standard deviation needs to be less than 4 times (5/1.3 
≈4) the difference between allocated groups, i.e. SD < 4∆. 
8.7 Missing data 
Completeness of the data is an important feasibility parameter for all outcome 
measures. The proportion of participants missing each outcome will be summarised 
for each allocated group and at each time point, with reasons for missing outcomes 
documented wherever possible (Table 12). Data could be missing for a number of 
reasons: 
1. Participant opts out of trial before follow-up data collection 
2. Participant refuses to participate in collection of measures 
3. Participant is uncontactable  
4. Participant moves out of the trial geographical area before follow-up data 
collection 
5. Participant is medically unwell or receiving end of life care 
6. Participant dies and is withdrawn from the trial. 
Missing outcome data will be noted and used to inform the likely pattern of missing 
data in a full-scale trial. If a considerable amount of outcome data is missing, this 
may suggest a need to reconsider the choice of outcome measures. This may also 
provide an insight into how missing data can be avoided in the subsequent full-scale 
trial.  
8.8 Safety 
Safety of the intervention will be measured by the number of adverse events and 
serious adverse events relating to the intervention that occur during the intervention 
period. Community matrons will be responsible for reporting any AEs that are related 
to the intervention or SAEs. Safety during data collection will be assessed by the 
number of adverse events or serious adverse events that occurred during the follow-
up period. The blinded assessors are responsible for recording any adverse events 




The adverse event (AE) risks of taking part in this trial have been assessed to be 
low. This is an assessment and care planning intervention which is unlikely to cause 
any harm to participants. In this patient population of moderately and severely frail 
patients, acute illness resulting in hospitalisation, new medical problems and 
deterioration of existing medical problems are expected. For participants in this study 
who are moderately or severely frail, this will include SAEs relating to frailty 
syndromes such as admission to hospital for abrupt onset of falls, immobility, 
delirium caused by infection/sepsis, incontinence and iatrogenic side effects of 
medication. Therefore, only AEs which relate to the intervention will be recorded and 
assessed for severity and causality. 
Serious adverse events are classified as: 
 results in death 
 is life threatening 
 requires hospitalisation or prolongation of existing hospitalisation 
 results in persistent or significant disability or incapacity 
 consists of a congenital anomaly or birth defect 
 or is considered by the investigator to be an important medical event 
 
All adverse and serious adverse events will be reported for the intervention group 
only and assessed for clinical relevance to inform the design and conduct of a full 
trial (Tables 13 and 14). 
8.9 Criteria for progression to full trial 
Progression to a full trial will be considered viable if the pre-specified criteria are met 
or if clear strategies are identified that could support the delivery of the definitive trial 
in tandem with successfully identifying a suitable primary outcome. The success 
criteria are listed  in Table 2 and denoted against a traffic light criteria (Battle et al., 
2019): 




 Amber indicates the target was not achieved but progression to full trial would 
be possible with minor protocol amendments 
 Red indicates the target was not achieved and progression to full trial is 
unlikely to be supported 
 
Table 2: Criteria for progression to full trial 
Feasibility success criteria Green Amber Red 
% of general practice sites that were 
initially approached and progressed to 
participating in the study 
≥ 50% 41-49% ≤ 40% 
% of recruitment target achieved (60 
participants) in the timescale of 43 weeks 
(01/11/2018-31/08/2019) 
 
≥50% 41-49% ≤40%  
% of participants completing 3 month 
follow up 
≥80%  51-79%  ≤50%  
% of participants completing 6 month 
follow up 
≥70% 51-69% ≤50% 
% of consented participants 
randomised to the intervention group 
who do not withdraw or die within the 
intervention period engaging with the 
minimum “dose” of the intervention 
which is defined as one assessment 
visit and at least two care planning 
visits 
≥75% 51-74%  ≤50%  
 
9. Qualitative Analysis 
This component of the trial explores the experiences of the study participants, their 
carers and the experiences of the clinicians who have delivered the intervention and 
GP practice staff who facilitated recruitment and eligibility screening. The aim is to 
generate recommendations and address unknowns including experiences of 
recruitment, retention, practical implementation and further refinement of the 
intervention and outcome measures for the design of the future RCT. Qualitative 
study results will be reported using the COREQ checklist for interviews and focus 
groups (Tong, Sainsbury & Craig, 2007). Thematic analysis will be used to analyse 




(Braun & Clarke, 2006).The transcripts of the interviews will be uploaded to the 
qualitative analysis program NVivo. 
The first analysis step will involve familiarisation of the narratives and two 
researchers will independently read the transcripts. In the next step, two researchers 
will independently code the text by allocating the text fragments to codes. The codes 
will be formulated from the text fragments and will possibly be revised during the 
process of reading the transcripts. The two researchers will then discuss the results 
of the individual codes and try to reach consensus. After this, the codes will be 
reviewed and themes will be formulated.  
9.1 Qualitative data presentation 
Demographic data items will be presented using descriptive statistics. Meaningful 
text fragments will be determined, as will codes (sub-themes) and themes related to 
the trial objectives. Data extracts will be accompanied by narrative to elaborate why 
the extract is analytically interesting. All participants will be anonymised and 
pseudonyms used to demonstrate different participants’ experiences. If any 
information is disclosed during the trial that could pose a risk of harm to the 





10.  References 
Battle, C., Hutchings, H. A., Driscoll, T., O’Neill, C., Groves, S., Watkins, A., Lecky, F. E., 
Jones, S., Gagg, J., Body, R., Abbott, Z. & Evans, P. A. (2019) 'A multicentre randomised 
feasibility STUdy evaluating the impact of a prognostic model for Management of BLunt 
chest wall trauma patients: STUMBL Trial'. BMJ Open, 9 (7), pp. e029187. 
 
Braun, V. & Clarke, V. (2006) 'Using thematic analysis in psychology'. Qualitative Research 
in Psychology, 3 (2), pp. 77-101. 
 
Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L. & 
Lancaster, G. A. (2016) 'CONSORT 2010 statement: extension to randomised pilot and 
feasibility trials'. BMJ, 355  
 
Gale, C. R., Westbury, L. & Cooper, C. (2018) 'Social isolation and loneliness as risk factors 
for the progression of frailty: the English Longitudinal Study of Ageing'. Age and Ageing, 47 
(3), pp. 392-397. 
 
Gamble, C., Krishan, A., Stocken, D., Lewis, S., Juszczak, E., Dore, C., Williamson, P. R., 
Altman, D. G., Montgomery, A., Lim, P., Berlin, J., Senn, S., Day, S., Barbachano, Y. & 
Loder, E. (2017) 'Guidelines for the Content of Statistical Analysis Plans in Clinical Trials'. 
Jama, 318 (23), pp. 2337-2343. 
 
Haywood, K. L., Garratt, A. M. & Fitzpatrick, R. (2005) 'Quality of Life in Older People: A 
Structured Review of Generic Self-Assessed Health Instruments'. Quality of Life Research, 
14 (7), pp. 1651-1668. 
 
Hughes, M. E., Waite, L. J., Hawkley, L. C. & Cacioppo, J. T. (2004) 'A Short Scale for 
Measuring Loneliness in Large Surveys: Results From Two Population-Based Studies'. Res 
Aging, 26 (6), pp. 655-672. 
 
IBM Corporation (Released 2016) SPSS Statistics for Windows. Version 24.0. Armonk, NY: 
IBM Corporation. Available. 
 
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., Swinburn, 
P. & Busschbach, J. (2013) 'Measurement properties of the EQ-5D-5L compared to the EQ-
5D-3L across eight patient groups: a multi-country study'. Qual Life Res, 22 (7), pp. 1717-
1727. 
Lins, L. & Carvalho, F. M. (2016) 'SF-36 total score as a single measure of health-related 
quality of life: Scoping review'. SAGE open medicine, 4 pp. 2050312116671725-
2050312116671725. 
 
Mahoney, F. I. & Barthel, D. W. (1965) 'FUNCTIONAL EVALUATION: THE BARTHEL 





Thabane, L., Ma, J., Chu, R., Cheng, J., Ismaila, A., Rios, L. P., Robson, R., Thabane, M., 
Giangregorio, L. & Goldsmith, C. H. (2010) 'A tutorial on pilot studies: the what, why and 
how'. BMC Medical Research Methodology, 10 (1), pp. 1. 
 
Tong, A., Sainsbury, P. & Craig, J. (2007) 'Consolidated criteria for reporting qualitative 
research (COREQ): a 32-item checklist for interviews and focus groups'. International 
Journal for Quality in Health Care, 19 (6), pp. 349-357. 
 
Ware, J. E. & Sherbourne, C. D. (1992) 'The MOS 36-Item Short-Form Health Survey (SF-
36): I. Conceptual Framework and Item Selection'. Medical Care, 30 (6), pp. 473-483. 
 
Whitehead, A. L., Julious, S. A., Cooper, C. L. & Campbell, M. J. (2016) 'Estimating the 
sample size for a pilot randomised trial to minimise the overall trial sample size for the 
external pilot and main trial for a continuous outcome variable'. Stat Methods Med Res, 25 








Appendix 1: Randomisation Specification 
CHIEF INVESTIGATOR TRIAL STATISTICIAN 
STATISTICIAN GENERATING 
ALLOCATION SEQUENCE 
   
Helen Lyndon 
Room S09, School of Nursing and 
Midwifery, Faculty of Health and 
Human Sciences, University of 
Plymouth, Knowledge Spa, Royal 
Cornwall Hospital, Treliske, Truro, 





N15, Medical Statistics, ITTC1 
Plymouth Science Park, 
Plymouth, PL6 8BX 
adam.streeter@plymouth.ac.uk 
Telephone: 01752 764203 
Joanne Hosking 
N15, Medical Statistics, ITTC1 
Plymouth Science Park, 
Plymouth, PL6 8BX 
joanne.hosking@plymouth.ac.uk 
Telephone: 01752 764203 
  
PROTOCOL VERSION: V 2.0 
SETTING: General Practice populations in Cornwall, UK 
PERSONNEL: CTU staff 
RECRUITMENT TARGET: 6 General Practices 
ALLOCATION RATIO: 1:1 
TREATMENT GROUPS: HAPPI, Control 
BLINDING STATUS: Research nurses / Trial assessors 
START DATE / END DATE: January 2019 / April 2020 
IMPLEMENTATION: Notification by data managers at CTU 




METHOD DETAILS: Static randomisation 
SEQUENCE GENERATION: R version 3.5.1 (2018-07-02) 
 
gplist <- c("The Clays Practice, Roche", "St Austell Health Group", 
"The Roseland Practice, Portscatho", 
        "The Alverton Practice, Penzance", "Carn to Coast Health 
Centres, Redruth, Pool and Illogan", 





gp1 <- as.data.frame(gplist) 




gp1$randnum <- runif(N) 
 
gp1 <- gp1[order(gp1$randnum),]  
 
gp1$allocation <-  c('I', 'I', 'I', 'C', 'C', 'C') 
 
FURTHER DETAILS: 
I = HAPPI intervention 
C = control 
 
Finalised specification agreed and approved by:    
      
Trial statistician   
      
Name: Adam Streeter Signature:  Date:  
      
      
CTU lead developer   
      
Name: Laura Cocking Signature:  Date:  
      
      
      
Independent statistician   
      
Name: Chen Ji Signature:  Date:  
      
 
For CTU office use only 
CONFIRMATION OF ALLOCATION SEQUENCE RECEIPT <enter N/A if not applicable> 
The following items have been received by the PenCTU lead developer and stored securely in a 
password-protected location:  
 Tick to confirm 
File of code used to generate the sequence (with version number and 
date) 
 
Allocation sequence generation seed number  
Allocation sequence output (with version number and date)  
NB: THE ABOVE ITEMS MUST NOT BE SHARED WITH THE TRIAL STATISTICIAN 
Confirmation: 
 





Appendix 2: Sampling Specification 
HAPPI STUDY 
SAMPLING SPECIFICATION FORM 
 
CHIEF INVESTIGATOR TRIAL STATISTICIAN 
STATISTICIAN GENERATING 
SAMPLING SEQUENCE 
   
Helen Lyndon 
Room S09, School of Nursing 
and Midwifery, Faculty of 
Health and Human Sciences, 
University of Plymouth, 
Knowledge Spa, Royal 
Cornwall Hospital, Treliske, 





N15, Medical Statistics, ITTC1 
Plymouth Science Park, 
Plymouth, PL6 8BX 
adam.streeter@plymouth.ac.uk 
Telephone: 01752 764203 
Joanne Hosking 
N15, Medical Statistics, ITTC1 
Plymouth Science Park, 
Plymouth, PL6 8BX 
joanne.hosking@plymouth.ac.uk 
Telephone: 01752 764203 
  
PROTOCOL VERSION: V 1.0 
SETTING: General Practice populations in Cornwall, UK 
PERSONNEL: CTU staff 
RECRUITMENT TARGET: 6 General Practices 
ALLOCATION RATIO: 1:1 
TREATMENT GROUPS: HAPPI, Control 
BLINDING STATUS: Research nurses / Trial assessors 
START DATE / END DATE: January 2019 / April 2020 
IMPLEMENTATION: Notification by data managers at CTU 
STRATIFICATION 
VARIABLES: 
Electronic frailty index: 
1. Moderately frail (0.24, 0.36] 
2. Severely frail (0.36, 1.00] 




The number of patients within each eFI stratum shall be determined at each site. Once the 





(one for each stratum) with the date of their generation. Each patient shall be uniquely 
identified by a number ranging from one to the number of patients in each stratum. , The 
statistician generating the sampling sequence shall send each practice a list of random 
numbers based on the total number of patients in each stratum in the order they are to be 
approached for eligibility. Therefore the steps shall be: 
 
1. Each General Practice (GP) collates two lists of patients, for whom eFIs are available, 
and whose eFIs are  greater than 0.24, but not more than 0.36 (moderately frail), or 
greater than 0.36 (severely frail). 
2. For the purpose of sampling, the patients will be identified by the number pertaining to 
the order they appear in the list. This number should be retained until the sampling 
procedure has been completed. 
3. The CI shall communicate to the statistician generating the sampling sequence 
(SGSS): 
a. the number of patients in each stratum at each GP 
b. the stratum label (moderate or severe) 
c. the GP site. 
4. The SGSS shall then draw a random sample (without replacement) of 45 patients from 
each stratum of each GP, based on a uniform distribution with a maximum pertaining 
to the number of available patients in each eFI stratum of each GP. Where this number 
is less than 45, then no random sampling list is required and all available patients within 
the stratum will be considered for the next stage of having their eligibility checked 
against the selection criteria. 
5. Once a randomised list for GP is passed back to the CI, the patients should be 
assessed for eligibility in the order stipulated on the randomised sample list. 
If an insufficient number of patients consent to participate from any strata, then the 
sampling process shall be repeated (without replacement) for that stratum, from 
the remaining list of unsampled patients until either five patients are recruited or no 





Finalised specification agreed and approved by:   




Trial statistician   
      
Name: Adam Streeter Signature:  Date:  
      
      
Chief Investigator   
      
Name: Helen Lyndon Signature:  Date:  






Appendix 3: Figures and Tables 






Table 3: Number of participants screened and randomised by site 
 Intervention sites Control sites 
Variable Site 01 Site 02 Site 05 Site 03 Site 04 Site 06 
Numbers n (%) screened       
Total  xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) 
Reasons for non-
participation (n) 
      
Did not meet inclusion 
criteria 
xx xx xx xx xx xx 
Declined to participate or did 
not respond to invitation 
xx xx xx xx xx xx 
Other reasons xx xx xx xx xx xx 
Number n (%) randomised       
Total xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) 
Number n (%) 
discontinuation/withdrawal 
      
Total xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) 
Number n (%) of 
participants data analysed 
      
Total xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) 
 
Table 4: Retention of participants 
 Intervention sites Control sites 
Variable Site 01 Site 02 Site 05 Site 03 Site 04 Site 06 
Number (%) (ratio) of 
randomised 
participants who 
completed three month 
follow up 
nn/xx nn/xx n/xx n/xx nn/xx nn/xx 
Total  xx(xx.x)  xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) 
Number (%) (ratio) of 
randomised 
participants who 
completed six month 
follow up 
nn/xx nn/xx n/xx n/xx nn/xx nn/xx 
Total xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) xx(xx.x) 
Number of randomised 
participants with no 
protocol deviations – 
adherence to 
intervention dose 
nn/xx nn/xx n/xx N/A N/A N/A 
Number of operational 
protocol deviations 




Number of patient 
related protocol 
deviations 
xx xx xx xx xx xx 
Table 5: Baseline variables by group 




Age (years)  Mean (SD) [range] 
 
xx (xx.x)[x-x] xx (xx.x)[x-x] 
 Median (IQR) 
 
xx(xx) xx(xx) 
Gender n (%) Male xx (xx.x) xx (xx.x) 
 Female xx (xx.x) xx (xx.x) 
Relationship Status n (%) 
 
Single xx (xx.x) xx (xx.x) 
 Married/civil 
partnership 




xx (xx.x) xx (xx.x) 
 Widowed/surviving 
civil partner 
xx (xx.x) xx (xx.x) 
Living arrangements n 
(%) 
Alone xx (xx.x) xx (xx.x) 
 Spouse/Partner xx (xx.x) xx (xx.x) 
 Parent/s xx (xx.x) xx (xx.x) 
 Children under 18 xx (xx.x) xx (xx.x) 
 Children over 18 xx (xx.x) xx (xx.x) 
 Other family xx (xx.x) xx (xx.x) 
 Non-family xx (xx.x) xx (xx.x) 
Frailty Severity n (%) Moderately frail xx (xx.x) xx (xx.x) 







Table 6: Site feasibility 
Variable  
Number (%) of general practice sites who were initially 
approached progressed to participating in the study 
xx(xx.x) 
Number (%) (ratio) of practices approached who met initial 
eligibility criteria 
 
Number (%) of general practice sites who withdrew from 
the study prior to completion 
xx(xx.x) 
Number (%) of sites completing screening/eligibility 
processes as per study protocol 
xx(xx.x) 
Number (%) of sites completing screening/eligibility 




Table 7: Frequency of intervention assessment documents used at specific 
intervention time points 
Number (n) of assessment 
















Conversation Guide xx xx xx xx xx xx xx 
Gait Speed Test  xx xx xx xx xx xx xx 
Clinical Frailty Scale xx xx xx xx xx xx xx 
MFRAT xx xx xx xx xx xx xx 
FRAX tool xx xx xx xx xx xx xx 
Numeric pain scale xx xx xx xx xx xx xx 
Pain assessment record xx xx xx xx xx xx xx 
Abbey Pain Scale  xx xx xx xx xx xx xx 
Medication review  xx xx xx xx xx xx xx 
STOPP-START  xx xx xx xx xx xx xx 
MUST 5 Step Guidance xx xx xx xx xx xx xx 
MUST Flowchart xx xx xx xx xx xx xx 




RCP Bedside Vision  xx xx xx xx xx xx xx 
Whispered Voice Test xx xx xx xx xx xx xx 
Clinical Checklist LUTS xx xx xx xx xx xx xx 
ICIQ Bladder Diary xx xx xx xx xx xx xx 
Self-assessment LUTS xx xx xx xx xx xx xx 
Bowel Assessment Form xx xx xx xx xx xx xx 
Checklist Faecal Incontinence xx xx xx xx xx xx xx 
BGS CGA and Problem List xx xx xx xx xx xx xx 
CFT TEP  xx xx xx xx xx xx xx 
Barthel Index xx xx xx xx xx xx xx 
UCLA 3-Item Loneliness Scale xx xx xx xx xx xx xx 
Caregiver Strain Index xx xx xx xx xx xx xx 
CFT Capacity Assessment  xx xx xx xx xx xx xx 
CAM Delirium Screening Tool xx xx xx xx xx xx xx 
GPCog xx xx xx xx xx xx xx 
Geriatric Depression Score xx xx xx xx xx xx xx 
HADS xx xx xx xx xx xx xx 
CFT PSP: Part 1  xx xx xx xx xx xx xx 






Table 8: Frequency of type of referrals made at intervention time points 
Number (n) of referrals 















General Practitioner xx xx xx xx xx xx xx 
Geriatrician xx xx xx xx xx xx xx 
Physiotherapy xx xx xx xx xx xx xx 
Occupational Therapy xx xx xx xx xx xx xx 
Speech Therapy xx xx xx xx xx xx xx 
Dietician xx xx xx xx xx xx xx 
Intermediate Care xx xx xx xx xx xx xx 
Adult Social Care xx xx xx xx xx xx xx 
Continuing Care xx xx xx xx xx xx xx 
District Nurses xx xx xx xx xx xx xx 
Falls Clinic xx xx xx xx xx xx xx 
Dementia Services xx xx xx xx xx xx xx 
Voluntary Sector xx xx xx xx xx xx xx 




Table 9: Number of referrals per participant at intervention time points 
 
Number (n) of referrals 
 
Visit 1 (n) Visit 2 (n) Visit 3 (n) Visit 4 (n)  Visit 5 (n) Visit 6 (n) Overall (n) 
Median (IQR) 
Participant number xx xx xx xx xx xx xx (xx.x) 
 
Table 10: Participant Outcome Data 
Variable  Intervention Group Control Group 
 
Timepoint  T1 T2 T3 T1 T2 T3 
SF-36 
 
       
Physical functioning:  












xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 






xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 
















 Median (IQR) 













xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 































xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 







































xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 
Number of deaths Mean (SD) 
[range]  
Median (IQR) 
xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 
Cause of death Mean (SD) 
[range]  
Median (IQR) 
xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 





xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 





xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] xx.x(xx.x)[x-x] 
Total number of days 
















Table 11: Numbers and proportions reporting levels within EQ-5D-5L dimensions by intervention and control 
 
  
 Mobility Self-care Usual activities Pain Anxiety/depression. 
Level n (%) Intervention Control Intervention Control Intervention Control Intervention Control Intervention Control 
01 No problems  
 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
02 Slight problems  
 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
03 Moderate problems  xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
04 Severe problems  
 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
05 Extreme problems 
 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
Number reporting some 
problems (02-05) 
 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
Change in number reporting 
problems 
 
+/-xx +/-xx +/-xx +/-xx +/-xx +/-xx +/-xx +/-xx +/-xx +/-xx 
% difference in number 
reporting problems- control-
intervention) 




Table 12: Assessment of missing outcome measures by group 
Variable Intervention Group (n=) (%) Control Group (n=) (%) 
Timepoint T1 T2 T3 T1 T2 T3 
SF-36       
Physical functioning:  
Items 3a, 3b, 3c, 
3d,3e,3f,3g,3h,3i,3j 




xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Bodily pain:  
Items 7,8 
 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 








xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Social functioning:  
Items 6,10 
 




xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Mental health:  
Items 9b,9c,9d,9f,9h 
 




Variable Intervention Group (n=) (%) Control Group (n=) (%) 




xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
LTC-6 
 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
UCLA-3 
 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Barthel Index 
 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
EQ-5D-5L 
 
      
Mobility  
(levels1-5) 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Self-care  
(levels1-5) 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Usual activities 
(levels1-5) 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Pain/discomfort 
(levels1-5) 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Anxiety/depression 
(levels1-5) 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
EQ-5D-5L VAS 
 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Number of deaths xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
 
Number of hospital 
admissions 
xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) xx.x(xx.x) 
Number of hospital 
readmissions 




Variable Intervention Group (n=) (%) Control Group (n=) (%) 
Timepoint T1 T2 T3 T1 T2 T3 
Total number of days 
spent in hospital 






















AE classification (%) 
 
Xx(xx.x) 
AE classification (%) 
 
Xx(xx.x) 
AE classification (%) 
 
Xx(xx.x) 




Table 14: Harm by Group (Serious Adverse Events) 














Significant disability or incapacity* 
 
Xx(xx.x) Xx(xx.x) 
Congenital anomaly or birth defect* 
 
Xx(xx.x) Xx(xx.x) 
Considered by the investigator to be 
an important medical event* 
Xx(xx.x) Xx(xx.x) 
Details of SAE   
Details of SAE   
Details of SAE   
 
*related to the intervention only. 
  




Appendix 14: Case Report Forms  
GP CRFs and adverse events CRFs were identical for baseline, three-month follow-
up and six month follow-up. Only the baseline CRFs are included to avoid repetition. 




















































































































Appendix 15: Outcome Measures Questionnaire Booklets 
Outcome measures questionnaire booklets were identical at baseline, three and six 












































Appendix 16: Skewness, kurtosis and z-values all outcome 
measures 
Table 1a: SF-36 (Intervention)
  
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 0.547 0.427 1.28 0.662 0.448 1.48 0.745 0.456 1.64
Kurtosis -0.808 0.833 -1.65 0.015 0.872 0.02 -0.620 0.887 -0.70
Skewedness 0.11 0.46 0.24 0.02 0.46 0.04 0.29 0.46 0.63
Kurtosis -1.42 0.90 -1.58 -1.33 0.90 -1.48 -1.38 0.90 -1.53
Skewedness 0.61 0.46 1.35 0.77 0.46 1.69 0.37 0.46 0.81
Kurtosis -0.25 0.89 -0.28 0.25 0.89 0.28 -0.99 0.89 -1.12
Skewedness 0.18 0.47 0.38 0.75 0.47 1.58 0.85 0.47 1.80
Kurtosis -1.19 0.92 -1.29 -0.28 0.92 -0.31 0.09 0.92 0.09
Skewedness 0.49 0.47 1.03 0.53 0.47 1.13 1.17 0.47 2.48
Kurtosis -0.58 0.92 -0.63 -0.63 0.92 -0.68 0.48 0.92 0.53
Skewedness -0.40 0.46 -0.88 -0.58 0.46 -1.28 1.24 0.46 2.72
Kurtosis -1.32 0.89 -1.49 -1.17 0.89 -1.33 6.83 0.89 7.70
Skewedness -0.56 0.46 -1.24 -1.14 0.46 -2.51 -1.53 0.46 -3.35
Kurtosis -1.31 0.89 -1.48 0.36 0.89 0.41 1.42 0.89 1.60
Skewedness -1.21 0.47 -2.57 -1.00 0.47 -2.11 3.84 0.47 8.13
Kurtosis 1.17 0.92 1.27 0.56 0.92 0.61 17.28 0.92 18.83
Skewedness 0.13 0.46 0.28 0.43 0.46 0.94 0.65 0.46 1.42















Table 1b: SF-36 (Control)   
 
  
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 0.78 0.46 1.67 0.84 0.47 1.77 1.23 0.48 2.56
Kurtosis -0.39 0.90 -0.43 0.70 0.92 0.77 1.04 0.93 1.11
Skewedness -0.32 0.48 -0.67 0.21 0.48 0.43 0.14 0.48 0.28
Kurtosis -1.12 0.93 -1.19 -1.53 0.93 -1.64 -1.54 0.93 -1.65
Skewedness -0.17 0.48 -0.36 -0.10 0.48 -0.20 0.24 0.48 0.51
Kurtosis -1.23 0.93 -1.32 -1.74 0.93 -1.87 -1.48 0.93 -1.59
Skewedness 0.18 0.50 0.36 0.66 0.50 1.32 0.14 0.50 0.28
Kurtosis -0.63 0.97 -0.65 -1.08 0.97 -1.12 -0.77 0.97 -0.79
Skewedness -0.09 0.48 -0.18 0.35 0.48 0.72 0.45 0.48 0.94
Kurtosis 0.26 0.93 0.28 -0.81 0.93 -0.87 -0.50 0.93 -0.53
Skewedness -0.57 0.48 -1.18 -0.59 0.48 -1.22 -1.32 0.48 -2.74
Kurtosis -0.55 0.93 -0.59 -0.28 0.93 -0.30 1.18 0.93 1.26
Skewedness -0.90 0.48 -1.87 -0.93 0.48 -1.94 -1.33 0.48 -2.76
Kurtosis -0.67 0.93 -0.72 -0.73 0.93 -0.79 0.73 0.93 0.78
Skewedness -0.62 0.49 -1.27 -2.18 0.49 -4.43 -0.83 0.49 -1.69
Kurtosis -0.83 0.95 -0.87 7.27 0.95 7.63 0.46 0.95 0.48
Skewedness 0.78 0.48 1.63 0.36 0.48 0.75 0.22 0.48 0.45















Table 2: LTC-6 (intervention and control) 
  
Table 3: UCLA-3 (intervention and control) 
  




Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness -1.42 0.48 -2.95 -1.74 0.48 -3.62 -1.17 0.48 -2.44
Kurtosis 0.95 0.93 1.02 2.75 0.93 2.95 0.15 0.93 0.16
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness -1.25 0.49 -2.54 -2.22 0.49 -4.53 -1.71 0.49 -3.48





Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 0.04 0.47 0.09 -0.65 0.47 -1.37 -0.22 0.47 -0.46
Kurtosis -1.00 0.92 -1.09 -0.57 0.92 -0.63 -0.90 0.92 -0.98
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness -0.72 0.48 -1.50 -0.75 0.48 -1.55 -0.98 0.48 -2.03





Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 1.19 0.46 2.61 1.17 0.46 2.56 1.17 0.46 2.56
Kurtosis 0.30 0.89 0.34 -0.12 0.89 -0.13 -0.12 0.89 -0.13
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 1.53 0.48 3.18 0.88 0.48 1.83 0.88 0.48 1.83








Table 5: EQ-5D-5L (intervention and control) 
 
  
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness -1.05 0.46 -2.26 -1.49 0.46 -3.22 -0.67 0.46 -1.44
Kurtosis 2.05 0.90 2.28 3.32 0.90 3.68 1.10 0.90 1.22
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness -0.54 0.46 -1.16 -0.93 0.46 -2.00 -0.48 0.46 -1.04
Kurtosis -0.33 0.90 -0.37 1.12 0.90 1.24 0.01 0.90 0.02
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness -1.20 0.49 -2.44 -1.11 0.49 -2.27 -0.20 0.49 -0.40
Kurtosis 0.95 0.95 0.99 0.94 0.95 0.98 -0.02 0.95 -0.02
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 0.44 0.49 0.89 -0.76 0.49 -1.55 -0.83 0.49 -1.69















Table 6: Site-reported outcome measures (intervention and control) 
  
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 3.37 0.46 7.40 3.37 0.46 7.40 2.04 0.46 4.47
Kurtosis 10.16 0.89 11.46 10.16 0.89 11.46 2.33 0.89 2.63
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 0.0 0.0 0.0 0.0 0.0 0.0 5.10 0.46 11.19
Kurtosis 0.0 0.0 0.0 0.0 0.0 0.0 26.00 0.89 29.33
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 3.373 0.456 7.404602 4.442 0.456 9.749767 2.941 0.456 6.455479
Kurtosis 10.156 0.887 11.45646 20.482 0.887 23.10381 8.327 0.887 9.392804
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 1.30 0.46 2.84 0.66 0.46 1.45 0.86 0.46 1.88
Kurtosis 1.33 0.89 1.50 -0.53 0.89 -0.60 0.61 0.89 0.69
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 2.28 0.49 4.64 2.39 0.49 4.88 2.19 0.49 4.47
Kurtosis 3.50 0.95 3.67 5.46 0.95 5.73 4.78 0.95 5.02
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 0.0 0.0 0.0 0.0 0.0 0.0 3.06 0.49 6.23
Kurtosis 0.0 0.0 0.0 0.0 0.0 0.0 8.09 0.95 8.49
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 3.059 0.491 6.229968 2.394 0.491 4.876507 2.590 0.491 5.274347
Kurtosis 8.085 0.953 8.485696 5.459 0.953 5.729893 6.055 0.953 6.35461
Statistic Std. Error z-value Statistic Std. Error z-value Statistic Std. Error z-value
Skewedness 0.02 0.49 0.04 2.31 0.49 4.70 0.20 0.49 0.40
Kurtosis -0.90 0.95 -0.95 6.80 0.95 7.13 -0.48 0.95 -0.50
Number of hospital re-admissions
Total number of days spent in hospital
Number of prescribed medications
Control
Number of hospital admissions
M00 M03 M06
Number of hospital re-admissions
Total number of days spent in hospital
Number of prescribed medications
Intervention
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